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ABSTRACT 
 
Leishmaniasis is a vector-borne neglected tropical disease endemic to 98 countries 
worldwide. Twenty Leishmania species are capable of establishing intracellular infection within 
human macrophages, causing different clinical presentations. Vaccine development against 
leishmaniases is supported by evidence of natural immunity against infection, mediated by a 
dominant cellular Th1 response and production of IFN-γ, IL-2 and TNF-α by polyfunctional TCD4+ 
and TCD8+ cells, ultimately leading to macrophage activation and parasite killing.  
Excreted-secreted proteins are important virulence factors present throughout Leishmania 
life stages and are able to induce durable protection in dogs, a good model for human infection. We 
aim to develop a second generation vaccine from the Leishmania secretome, with the potential for 
large scale dissemination in a cost-effective, reproducible approach. 
The secretome of six main pathogenic species (plus L. tarentolae) was analysed by Mass-
Spectrometry and conserved candidate antigens were searched in the complete dataset. A total of 52 
vaccine antigen candidates were selected, including 28 previously described vaccine candidates, and 
an additional 24 new candidates discovered through a reverse vaccinology approach. 
 In silico HLA-I and –II epitope binding prediction analysis was performed on all selected 
vaccine antigens, with world coverage regarding HLA restriction. To select the best epitopes, an 
automated R script was developed in-house, according to strict rational criteria. From thousands of 
potential epitopes, the automated script, in combination with optimal IC50, homology to host and 
solubility properties, allowed us to select 50 class I and 24 class II epitopes, synthesized as individual 
peptides. In vitro toxicity assays showed these selected peptides are non-toxic to cells. 
The peptides’ immunogenicity was evaluated using immunoscreening assays with immune 
cells from human donors, allowing for the validation of in silico epitope predictions and selection, and 
the assessment of the peptide’s immunogenicity and prophylactic potential. Healed individuals, which 
had active infection and received treatment, possess Leishmania-specific memory responses and are 
resistant to reinfection, being considered the gold standard of protective immunity. On the other 
hand, the naive population is extremely important to include in the experimental validation step since 
it is the target population to vaccinate with a prophylactic vaccine. Importantly, a minimum specific 
T-cell precursor frequency is needed to induce long-lasting memory protective responses. 
Furthermore, there is also a positive correlation between immunodominant epitopes and a high 
frequency of specific T-cell precursors. Peptides able to induce Th1 and/or cytotoxic immune 
responses in both background are promising candidates for a vaccine formulation. Altogether, 
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experimental validation exclusively in human samples will provide us a very strong base for a vaccine 
formulation and allow to accelerate translation to the field. 
Results show Leishmania-specific peptides successfully induce IFN-γ production by total 
PBMC from healed donors, and by specific T cells amplified from the naïve repertoire. Preliminary 
evidence exists for peptides which are immunogenic in both immune backgrounds (eight HLA-class I 
9-mer peptides and five class II 15-mer peptides) which are, for now, the most promising candidates 
to advance for the multi-epitope peptide design. 
Through the combination of proteomic analysis and in silico tools, promising peptide 
candidates were swiftly identified and the secretome was further established as an optimal starting 
point for vaccine development. The proposed vaccine preclinical development pipeline delivered a 
rapid selection of immunogenic peptides, providing a powerful approach to fast-track the deployment 
of an effective pan-specific vaccine against leishmaniases.  
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RESUMÉ 
 
La leishmaniose est une maladie tropicale négligée à transmission vectorielle qui est 
endémique dans 98 pays dont les plus pauvres. Vingt espèces de Leishmania sont capables d’établir 
une infection intracellulaire au sein des macrophages humains, provoquant différentes 
manifestations cliniques.  Le développement d'un vaccin contre les leishmanioses est étayé par des 
preuves d'immunité naturelle contre l'infection, induite par une réponse à médiation cellulaire de 
type Th1 dominante associée à la production d'IFN-γ, d'IL-2 et de TNF-α par des cellules T 
polyfonctionnelles TCD4+ et TCD8+, conduisant à l'activation classique des macrophages entrainant 
la destruction des parasites. Induire une protection robuste et durable et déterminer les épitopes 
immunodominants responsables de la protection naturelle représente un véritable défi. 
Les protéines sécrétées sont des facteurs de virulence jouant un rôle important dans le cycle 
de vie des leishmanies et sont capables d’induire une protection durable chez le chien, un bon modèle 
pour l’infection humaine. Notre objectif est de développer, à partir du sécrétome de Leishmania, un 
vaccin de seconde génération reproductible et facile à produire à bas prix dans les zones d’endémie, 
avec des rendements de production rendant possible son utilisation à grande échelle.  
Les sécrétomes des six espèces les plus pathogènes de leishmanie (plus L. tarentolae) ont été 
analysés et comparées par spectrométrie de masse. Les antigènes candidats ont été recherchés dans 
l'ensemble des données protéomiques disponibles. 52 antigènes candidats vaccin ont ainsi été 
sélectionnés, dont 28 avaient déjà été décrits dans la littérature et 24 sont nouveaux et découverts 
grâce à une approche de vaccinologie réverse. 
 Une analyse de la prédiction de liaison des épitopes in silico HLA-I et –II a été réalisée sur tous 
les antigènes candidats vaccin, prenant ainsi en compte le polymorphisme HLA de la population 
mondiale. Pour sélectionner les meilleurs épitopes parmi des milliers d’épitopes potentiels, un script 
R automatisé a été développé en interne, selon des critères rationnels stricts. Ainsi, 50 épitopes de 
classe I et 24 épitopes de classe II ont été sélectionnés et synthétisés sous forme de peptides 
individuels. Des essais de toxicité in vitro ont montré l’absence de toxicité cellulaire de ces peptides.  
Les individus guéris par chimiothérapie généralement développent des réponses 
immunitaires protectrices à Leishmania. Des tests de stimulation des PBMC ont donc été réalisés avec 
des échantillons biologiques provenant de donneurs guéris de Tunisie et la production d'IFN-γ a été 
évaluée par ELISpot. De plus, il était important d'inclure dans l'étape de validation expérimentale des 
peptides des échantillons provenant d’individus naïfs, population cible à vacciner avec un vaccin 
prophylactique. Les résultats montrent que des peptides spécifiques de Leishmania induisent avec 
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succès la production d'IFN-γ par les PBMC totaux provenant de donneurs guéris et par les 
lymphocytes T spécifiques amplifiés à partir du répertoire naïf.  
Globalement, la validation expérimentale des peptides réalisée exclusivement sur des 
échantillons humains nous fournira une base préclinique très solide pour développer un vaccin 
efficace capable de protéger les populations touchées par ces maladies. Elle constituera un moyen sûr 
et rentable de mieux sélectionner les candidats retenus pour le vaccin et d'éliminer ceux qui 
présentent un risque d'échec élevé au tout début du processus de développement du vaccin.  
Grâce à la combinaison de l'analyse protéomique et d'outils in silico, des candidats 
peptidiques prometteurs ont été rapidement identifiés pour le développement d'un vaccin. Le 
« pipeline » de développement préclinique du vaccin proposé fournit une sélection rapide de peptides 
immunogènes, offrant une approche puissante pour accélérer le déploiement d'un vaccin pan-
spécifique efficace contre les leishmanioses. 
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RESUMÉ DETAILLÉ 
 
Les leishmanioses sont des maladies parasitaires à transmission vectorielle liées à l’infection 
par plus de 20 espèces de parasites protozoaires flagellés appartenant au genre Leishmania. Parmi 
les parasitoses, la leishmaniose est le deuxième plus grand tueur dans le monde après le paludisme, 
avec 50 000 décès estimés par an. Signalées dans 98 pays (dont 72 sont des pays en voie de 
développement), elles exposent 1 milliard de personnes au risque d’être infecté et de développer une 
des 4 formes cliniques de la maladie : la leishmaniose viscérale (LV), forme la plus sévère aussi connue 
sous le nom de kala-azar ; la leishmaniose cutanée (LC), forme la plus fréquente ; la leishmaniose 
cutanéo-muqueuse (LCM), forme la plus mutilante et défigurante; ou la leishmaniose cutanée post-
kala-azar (LDPKA), pouvant présenter des complications graves après une LV.  
Le contrôle de la leishmaniose repose principalement sur la lutte anti-vectorielle et le 
traitement, qui présentent plusieurs inconvénients, notamment la toxicité, le prix et le manque 
d'efficacité. A l’heure actuelle, aucun vaccin contre les leishmanioses humaines n’est disponible sur le 
marché. La vaccination est pourtant le moyen le plus adapté pour interrompre la transmission des 
leishmanies et contribuer à l’élimination des leishmanioses. 
Des recherches menées par mon laboratoire d’acceuil sur les antigènes d’excrétion-sécrétion 
(AES) purifiés de leishmanies, est né CaniLeish® : le premier vaccin antiparasitaire Européen contre 
la leishmaniose viscérale canine, commercialisé par la société Virbac depuis 2011. C’est une 
innovation majeure en immunologie parasitaire et un atout essentiel dans la prévention de la 
leishmaniose canine mais aussi humaine, le chien étant le principal réservoir de parasites 
potentiellement transmissibles à l’homme. CaniLeish® est capable de déclencher une réponse à 
médiation cellulaire protectrice de type Th1 par immunisation avec des AES purifiés de cultures de 
promastigotes de Leishmania infantum. La résistance à Leishmania chez l'Homme est également basée 
sur une réponse Th1 et des réponses cytotoxiques (production d'IFN-γ, d'IL-2 et de TNF-α par les 
lymphocytes T CD4 + et CD8 + polyfonctionnels), conduisant à l'activation des macrophages et à la 
destruction des parasites intracellulaires. Par contre, la progression de la maladie est associée à des 
réponses cellulaires de type Th2 (prédominance d’IL-10 et d’IL-4). 
L'objectif principal de mon projet de thèse est de développer un vaccin de deuxième 
génération contre les leishmanioses humaines. Fort du succès du vaccin CaniLeish®, les AES de 
leishmanies ont été choisis comme source d'antigènes pour le développement d'une stratégie de 
vaccination prophylactique à visée humaine, à base de peptides multi-epitopiques, réunissant "les 
meilleures parties des meilleurs antigènes" en un seul candidat vaccin polyvalent. Notre objectif est 
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de concevoir et de synthétiser des peptides avec des épitopes immunodominants multiples (poly-
épitopiques) et appropriés dérivés de protéines excrétées / sécrétées identifiées à partir de données 
protéomiques provenant de 6 espèces pathogènes de leishmanies: L. infantum, L. major, L. tropica, L. 
amazonensis, L. braziliensis et L. donovani). Des études de phase préclinique ont été réalisées 
exclusivement sur des cellules humaines afin d'évaluer l'immunogénicité des peptides sélectionnés. 
La validation expérimentale des peptides synthétiques a consisté à évaluer les profils immunitaires 
après stimulation peptidique de cellules d'individus exposés ayant développé une immunité à 
l'infection par Leishmania (individus guéris) par rapport à des sujets naïfs. D'autre part, il est 
extrêmement important d'inclure dans l'étape de validation expérimentale de l’immunogénicité des 
peptides des échantillons provenant d’individus naïfs car il s'agit de la population cible à vacciner 
avec un vaccin prophylactique. De manière importante, une fréquence minimale de précurseur 
spécifique de cellules T est nécessaire pour induire des réponses protectrices mémoire. 
D’autres résultats étaient attendus des données protéomiques comme la caractérisation 
détaillée du sécrétome et la découverte d’éventuelles corrélations entre la distribution géographique, 
les manifestations cliniques, l'immunomodulation et la pathogenèse. Nous avons également inclus 
dans notre étude les données du sécrétome d'une espèce de Leishmania non pathogène : L. tarentolae. 
Nous espérons aussi contribuer à accroître nos connaissances sur la variabilité interspécifique des 
leishmanies et éventuellement à identifier et caractériser de nouveaux facteurs de virulence pouvant 
contribuer au diagnostic de ces maladies et/ou à la mise au point de médicaments contre les 
leishmanioses. 
Les tâches accomplies dans ce projet de recherche comprennent : 
·  l’identification exhaustive et la caractérisation des AES présents dans le sécrétome de six 
espèces pathogènes de Leishmania par spectrométrie de masse (L. infantum, l’espèce utilisée 
pour la production de CaniLeish ®, et aussi L. major, L. tropica, L. amazonensis, L. braziliensis 
et L. donovani) ainsi qu’une espèce non pathogène pour l’homme, L. tarentolae; 
· la sélection de 52 antigènes vaccinaux les plus pertinents sur l'ensemble des données 
protéomiques générées. Ceux-ci comprennent 28 protéines déjà décrites dans la littérature 
scientifique comme des candidats vaccins (Set A), et 24 nouvelles protéines sélectionnées, en 
utilisant une approche de vaccinologie reverse (Set B) selon un critère de « non-homologie de 
séquences protéiques avec celles de l'hôte » ; 
· l’identification d’épitopes T (séquences peptidiques qui se lient spécifiquement aux molécules 
HLA-I et -II, et qui activent le système immunitaire adaptatif) les plus affins pour l’ensemble 
des molécules HLA majoritairement représentées dans les populations humaines (36 allèles 
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HLA-I, correspondant à 11 supertypes et 98% de la population mondiale, et 21 allèles HLA-II, 
correspondant à 95% de la population mondiale), à l’aide de plusieurs serveurs de prédiction 
d’épitopes hautement performants; 
· la seléction des épitopes le plus immunogènes, avec l’aide d’un script R automatisé, que j’ai 
développé pour ce projet (Pissarra J et al, publication en cours de révision), permettant de 
sélectionner facilement les épitopes les plus pertinents en intégrant différents critères 
prédéfinis. Les critères utilisés pour la hiérarchisation des épitopes sont : la forte affinité de 
liaison, la conservation entre les espèces, la prédiction par au moins 2 algorithmes différents, 
et la faible homologie des séquences peptidiques avec celles de l'hôte. Le script R applique ces 
critères aux données brutes collectées à partir des algorithmes de prédiction pour filtrer 
rapidement un nombre extrêmement important d’épitopes potentiels (stratégie "best of"). Le 
script est très polyvalent et applicable à d'autres prédicteurs, à d'autres protéines, mais aussi 
à d'autres pathogènes. Ainsi, nous avons sélectionné 50 épitopes HLA-I (9-mer) et 24 épitopes 
HLA-II (15-mer). Les peptides HLA-I proviennent de 23 protéines différentes (11 du Set A 
et12 du Set B), et les peptides HLA-II proviennent de 15 protéines (7 du Set A et 8 du Set B). 
 
L’originalité et la pertinence de notre stratégie vaccinale réside aussi dans l’utilisation de tests 
fonctionnels précliniques comme voie d’exploration de l’efficacité de nos candidats vaccins : 
l’utilisation ex vivo de cellules humaines pour développer un vaccin humain. En effet, les modèles 
murins sont inappropriés pour étudier les réponses immunitaires humaines contre Leishmania. Il est 
difficile et dangereux d’extrapoler des résultats obtenus chez la souris à des hôtes naturels de 
l’infection. Globalement, la validation expérimentale des peptides réalisée exclusivement sur des 
cellules humaines devait fournir une base préclinique très solide pour développer un vaccin humain 
efficace capable de protéger les populations touchées par ces maladies. Elle constituait un moyen sûr 
et rentable de mieux sélectionner les candidats retenus pour le vaccin et d'éliminer ceux qui 
présentaient un risque d'échec élevé au tout début du processus de développement du vaccin.  
Grâce à la combinaison de l'analyse protéomique et d'outils in silico, des candidats 
peptidiques prometteurs ont été rapidement identifiés pour le développement d'un vaccin. Le 
« pipeline » de développement préclinique du vaccin proposé fournit une sélection rapide de peptides 
immunogènes, offrant une approche puissante pour accélérer le déploiement d'un vaccin pan-
spécifique efficace contre les leishmanioses. Les individus guéris d’une infection leishmanienne 
possèdent des réponses immunitaires mémoires contre les parasites qui les rendent résistants à la 
réinfection, et sont considérés comme le gold standard de l'immunité protectrice. La validation 
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expérimentale des peptides doit également être effectuée sur des échantillons provenant de sujets 
ayant d'autres statuts immunitaires : individus asymptomatiques et naïfs. Les individus 
asymptomatiques sont infectés par le parasite mais ne développent pas la maladie, ce qui signifie que 
leur système immunitaire parvient à contrôler l'infection sans pour autant éliminer le parasite. De 
plus, la population naïve est extrêmement importante à inclure dans la validation expérimentale, car 
elle représente la population cible pour un vaccin prophylactique. En effet, une fréquence minimale 
de précurseurs de cellules T spécifiques est nécessaire pour induire une réponse protectrice de 
longue durée. Il existe également une corrélation positive entre les épitopes immunodominants et la 
fréquence élevée de précurseurs de cellules T spécifiques, ce que nous chercherons dans notre étude. 
Les peptides sont validés pour leur capacité à induire des réponses mémoires préexistantes 
spécifiques à Leishmania sur des échantillons provenant d’individus guéris (en collaboration avec 
l’Institut Pasteur de Tunis). L’efficacité des peptides à stimuler ex vivo des cellules mononuclées du 
sang périphérique humain (PBMC) et à produire des cytokines de type Th1 comme l’IFN-γ (cytokine 
associée à la protection) a été évaluée. 
Pour tester l’efficacité des peptides à activer le répertoire naïf d’individus sains, des essais de 
co-culture de cellules T sont réalisés avec plusieurs cycles d'amplification cellulaire (en raison de la 
rareté des cellules spécifiques), et la production d'IFN-y spécifique est recherchée par la technique 
ELISpot. Le typage HLA des donneurs naïfs permet une sélection « sur mesure » pour l’optimisation 
des immuno-essais, et aussi la conclusion effective sur les résultats de prédiction d’épitopes et la 
restriction HLA associée. 
Ce projet aura aussi des répercussions importantes sur la connaissance de la biologie du 
parasite, grâce notamment au jeu de données protéomiques et à l’identification des régions 
d’immunogénicité des antigènes choisis (epitope-mapping). Ainsi, cela permettra d'augmenter nos 
connaissances sur la variabilité inter-espèces, et de révéler potentiellement de nouveaux facteurs de 
virulence importants et utiles pour le diagnostic de la leishmaniose ou le développement de nouveaux 
médicaments. 
Nous pensons que ce projet contribuera à la découverte de peptides immunogènes pouvant, 
sous forme de peptides multi-épitopes, entrer dans la composition d’un vaccin efficace contre les 
leishmanioses humaines. Notre stratégie devrait concourir à minimiser les risques d’échec à un stade 
précoce du développement du vaccin et lors de la réalisation de futurs essais cliniques. Enfin, elle 
offre aussi les bases méthodologiques nécessaires aux suivis immunologiques des individus vaccinés 
lors d’essais cliniques de vaccination en zone d’endémie. 
  
x 
 
THESIS OUTLINE 
 
The present thesis describes the preclinical development of a peptide-based vaccine against 
human leishmaniasis and preliminary experimental validation on the proposed peptide candidates.  
Chapter I provides a contextualization of Leishmania biology, the problematic of 
leishmaniasis control and the importance of vaccine development. Particularly, it reviews current 
epidemiologic information on Leishmania spp. parasites, host-pathogen interactions and host 
immune responses against the parasite, as well as current vaccine pipeline and peptide-based 
vaccines.  
Chapter II describes the proteomic analysis of the secretome of seven Leishmania species, 
responsible for the main clinical forms of leishmaniasis, and characterization of the secretome as an 
important source of virulence factors and of vaccine antigen candidates. Also, the results of this 
section provide the dataset used for vaccine antigen selection. 
Chapter III exposes the strategies selected for vaccine antigen selection. A total of 52 protein 
candidates were selected from the secretome proteomic datasets through two parallel approaches: 
searching peptide candidates previously described in the literature (set A) and through a reverse 
vaccinology approach (set B). 
Chapter IV describes the immuno-informatic tools available and used in this study, in silico 
epitope human leukocyte antigen (HLA)-binding predictions and epitope selection, including the 
development of a semi-automated R script to select the best epitopes from the vast HLA-binding 
prediction data corresponding to the selected 52 protein antigens. The selected HLA class-I and -II 
epitopes were synthesized as 9- and 15-mer peptides, respectively, for experimental validation. 
In Chapter V, current methods to assess T-cell mediated peptide immunogenicity are 
reviewed, and cellular immune responses against the peptide candidates are evaluated through 
immunoassays with samples from humans with different immune status regarding Leishmania 
infection (naive and healed individuals).  
Finally, Chapter VI comprehends a synthesis of main findings of this thesis work, general 
discussion and conclusions, as well as future perspectives. 
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1. Leishmaniasis is a Neglected Tropical Disease 
 
Leishmaniasis is a term that refers to any form of a complex group of diseases caused by 
protozoan parasites of the genus Leishmania (belonging to the Trypanosomatida order: 
Trypanosomatidae family) and are transmitted by sand flies, phlebotomine vectors. Over 20 different 
Leishmania (L.) species are known to cause disease in humans and other mammals. Despite being 
closely related and sharing a common lifecycle and an invertebrate host, different Leishmania species 
are transmitted by different vector species, have different epidemiological features, namely, zoonotic 
or anthroponotic transmission, and cause quite different clinical presentations. The main four clinical 
forms of leishmaniasis are: cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), 
visceral leishmaniasis (VL) also known as kala-azar, and post-kala-azar dermal leishmaniasis (PKDL).  
Neglected Tropical Diseases (NTDs), also known as Neglected Infectious Diseases (NIDs), 
englobe several communicable diseases caused by diverse infectious organisms. They prevail in 149 
tropical and subtropical countries causing a massive economic and development burden to the 
affected societies (http://www.who.int/neglected_diseases/diseases/en/). Poor and/or rural 
populations are the most vulnerable to these infections, and the least likely to have access to 
healthcare services. NIDs share features that advocate both for Public Health initiatives that 
successfully detect, prevent disease and treat patients, but also for the development of new and more 
effective control tools.  
Leishmaniasis is one of the most neglected tropical diseases as diagnostics and treatment 
tools are often ineffective or toxic, and improvement and development are impaired by the lack of 
funding and R&D (4–6). Leishmaniasis is endemic to the poorest countries in the world, and evidence 
shows that epidemics (or increases in incidence) are closely associated with socio-economic 
conditions, war and conflicts, malnutrition and food insecurity, and access to healthcare (7–10). 
Leishmaniasis surveillance is seldom based on passive case detection which further contributes to 
the underestimation of its burden and impairment of control efforts, whilst contributing to active 
parasite transmission (11,12). 
In the last decades, efforts towards controlling NIDs have increased, notably since the World 
Health Organization’s 2012 Roadmap on NTDs, which calls for enhanced control, prevention, 
elimination and eradication of NTDs, namely the regional elimination of VL in the Indian subcontinent 
by 2020 (13). Shortly after, the London Declaration on NTDs was signed 
(www.who.int/neglected_diseases/London_Declaration_NTDs.pdf), wherein several pharmaceutical 
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companies, donors, endemic countries and non-government organisations declare their commitment 
to contribute to NIDs elimination through R&D and control programme implementation. The latest 
Report of the WHO’s Strategic and Technical Advisory Group for Neglected Tropical Diseases 
(www.who.int/neglected_diseases/NTD_STAG_report_2017.pdf) further cements the commitment 
towards NIDs elimination and shows the progress achieved so far. Regarding leishmaniasis 
specifically, the Resolution WHA60.13 was adopted by the 60th World Health Assembly in 2007 to 
promote the awareness of the burden of leishmaniasis, and to monitor of progress of leishmaniasis 
control programmes (11,14).  
Leishmaniasis prevention needs an integrated approach targeting both human and animal 
hosts (One Health approach). Measures that aim at reducing the incidence of leishmaniasis are 
directed: i) to people, e.g. diagnosis and treatment of cases (15); ii) to the reservoir, e.g. applying 
protective insecticide treatment to dogs (16); and iii) to vector, e.g. insecticide spraying. Since no 
effective vaccine against human leishmaniasis exists, the most effective method of controlling 
Leishmania transmission to date is vector control (17,18).  
A large VL elimination campaign was launched in 2005 in South Asia, relying heavily on indoor 
residual spraying, long-lasting insecticidal bed nets, and environment management, has contributed 
to the reduction of reported cases (12,19,20). However, success longevity depends on continuous 
application of control measures, which may not be assured once targets have been achieved, and/or 
given the cyclical and geographical shifts in leishmaniasis transmission (12,20). As most sand fly 
species bite mostly outdoors, there is no strong argument for insecticide spraying – in this scenario, 
and for L. infantum- and L. major-endemic areas, reservoir control may prove to be a more useful tool. 
The main milestones concerning leishmaniasis, since the implementation of the objectives set 
in 2012’s Roadmap for NTDs, are i) the improvement of surveillance and case management (‘District 
Health Information System’ platforms), and ii) the introduction of standardized tools for the 
collection of indicators from all member states, some accessible through the Global Health 
Observatory website (http://apps.who.int/gho/data/node.main.NTDLEISH), and others limited to 
high-burden countries (11,12). Regarding reservoir control, three canine vaccines are licensed and 
currently available in Europe and Brazil, Canileish® and Letifend®, and Leish-Tec®, respectively. 
Overall, current existing tools can greatly contribute to decrease Leishmania transmission, 
however, the need for investment in new diagnostics, treatment and prevention tools still stands (21–
23). Alternative approaches such as immunochemotherapy or immunotherapy should also be further 
explored (12,21), and beyond innovation, product accessibility must also be taken into account 
(24,25).  
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Particularly, the introduction of vaccines in endemic areas remains a primary objective in the 
context of leishmaniasis control (26–28), either a prophylactic vaccine preventing infection, disease 
progression and transmission, and/or an immunotherapeutic vaccine (12).  
A few cost-effectiveness studies on the impact of the introduction of human leishmaniasis 
vaccines were performed, and these have demonstrated that vaccines remain the most cost-effective 
tool for leishmaniasis control programmes. A vaccine against VL in the endemic Bihar state in India 
with conferring only 50% protection during 5 years is highly cost-effective compared with current 
treatments, as well as a vaccine against CL deployed in American countries with providing 70% 
protection during 10 years (29,30). 
 
2. Leishmania parasites and leishmaniases 
 
2.1. Leishmania spp. life cycle  
 
The general life cycle is common to all Leishmania species (Figure I.1 panel A), and the 
vertebrate host stage begins when an infected female sand fly takes a blood meal from a naive host. 
The main reservoirs for Leishmania spp. are dogs, rodents and humans.  
Sand flies from the genus Phlebotomus (Old World) or from the genus Lutzomyia (New World) 
are modified pool feeders, meaning they bite superficially multiple times and feed on pooled blood. 
Less competent flyers than mosquitoes, sand flies breed in walls, rubbish or rubble, or rodent 
burrows (31–33). Other transmission routes, which remain exceptional, include congenital 
transmission, blood transfusion, sharing of infected needles, or (rarely) sexual transmission (31,34–
36). 
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Figure I. 1 Leishmania parasites and lifecycle. A) Leishmania parasites general lifecycle (37). B) Microscopy images 
of Leishmania promastigotes cultured in vitro. Left image, contrast microscopy (© IRD Lemesre, Jean-Loup); right 
image, parasite DNA stained with red fluorescence dye (© IRD Vergnes, Baptiste). C) Microscopy images of Leishmania 
amastigotes inside human macrophages (© IRD Vergnes, Baptiste). Top image, overlap between green-labeled 
parasites and DNA stained with red fluorescence dye. 
 
Once inside the sand fly midgut, the parasite differentiates into a motile extracellular 
promastigote, firstly to a proliferative procyclic promastigote, and subsequently, to a non-
proliferative infectious metacyclic promastigote within approximately one week (Figure I.1 panel B). 
The infected sandfly takes a bloodmeal from a naive host, injecting metacyclic promastigotes that 
invade phagocytes (mostly macrophages and neutrophils), where they differentiate into intracellular 
amastigotes and establish infection (Figure I.1 panel C). The sand fly saliva enhances promastigote 
infectivity as it contains vasodilator and immunomodulatory molecules (38,39).  
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Once in the vertebrate host, these parasites have developed key strategies that allow them to 
thrive in drastic conditions destined to kill them, inside acidic phagolysosomes. Phagolysosomes are 
cytoplasmic organelles formed after the fusion of the phagosome with one or more lysosomes, that 
become acidic and contain antimicrobial peptides and hydrolytic enzymes, killing intracellular 
pathogens (40). The complex Leishmania lifecycle is highly adapted to the host’s immune system, 
which is actively manipulated to the parasite’s benefit.  
 
2.2. Leishmaniasis distribution 
 
Leishmaniases are distributed worldwide across the tropical, subtropical, and temperate 
regions in 98 countries, 72 of which are in developing areas of the world (Figure I.2) (12).  350 million 
people are at risk worlwide and an estimated 12 million people suffer from leishmaniasis (11). There 
are an estimated half a million new VL cases per year, and 1 to 1.5 million new CL cases per year, with 
2.4 million disability-adjusted life-years (DALYs), but these numbers are likely underestimated. Over 
90% of all cases of VL are found in seven countries (Brazil, Ethiopia, India, Kenya, Somalia, South 
Sudan, Sudan) (11,12). Approximately 90% of all CL cases occur in Afghanistan in Central Asia; Iran, 
Saudi Arabia, and Syria in the Middle East; and in Brazil and Peru in Latin America. CL is also a 
substantial issue for travellers, and military personnel visiting endemic areas (31). Finally, 90% of 
the cases of MCL occur in three South American countries: Bolivia, Brazil, and Peru.  
Co-infection with HIV has emerged as an important public health threat in areas in southern 
Europe and other regions where the two diseases coexist, as well as for immunocompromised 
individuals, as is the case of organ transplants and other conditions affecting cell-mediated immunity 
(41). 
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Figure I. 2 Leishmania world distribution (31,42). A) World distribution of CL-causing Leishmania species. B) World 
distribution of VL-causing Leishmania species. 
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2.3. Clinical syndromes 
 
The main disease-causing Leishmania species and respective clinical syndromes are described 
in Table I.1. 
 
Table I. 1 Leishmania parasites and major clinical syndromes. Adapted from Burza S. et al 2018 and Magill A. 2015 
(12,31). ©WHO, World Health Organization campaign photos. 
Clinical 
Syndromes 
Leishmania spp. and location Natural Progression  
Visceral 
leishmaniasis (VL), 
also known as 
kala-azar: 
generalized 
involvement of 
the 
reticuloendothelial 
system (spleen, 
bone marrow, liver, 
lymph nodes) 
L. (L.) donovani causes classic VL in Asia; 
L. (L.) infantum causes infantile VL in the 
Old World.  
L. (L.) chagasi=L. (L.) infantum causes VL 
in the Americas; 
L. (L.) donovani and L. (L.) infantum in 
East Africa (Ethiopia, Kenya, Somalia, 
Sudan, Uganda); 
L. (L.)  amazonensis is an uncommon 
cause of atypical VL in the Americas; 
L. (L.) tropica is rarely associated with VL 
syndrome, often atypical. 
VL is fatal within 2 
years (natural 
progression) 
 
© WHO 
Post–kala-azar 
dermal 
leishmaniasis 
(PKDL) 
L. (L.) donovani (Indian subcontinent) 
L. (L.)  donovani, L. (L.) infantum (East 
Africa) 
PKDL develops in 
apparently 
cured VL individuals (5-
10% in India, 50-60% in 
Sudan); PKDL lesions 
self-heal in up to 85% 
of cases in Africa but 
rarely in India 
 
© WHO 
Old World 
cutaneous 
leishmaniasis (CL): 
single or limited 
number of skin 
lesions 
L. (L.) major (also known as moist or rural 
oriental sore) 
L. (L.) tropica (also known as dry or urban 
oriental sore) 
L. (L.)  aethiopica 
L. (L.) infantum=L. (L.) chagasi (rare) 
L. (L.) donovani, L. (L.) infantum 
Self-healing in over 
50% of cases within 8 
or 12 months (different 
ulcer morphology and 
scarring/species); L. 
(L.) infantum healed 
lesions confer 
individual immunity 
 
© WHO/C.Black 
New World 
cutaneous 
leishmaniasis (CL): 
single or limited 
number of skin 
lesions 
L. (L.) mexicana (chiclero’s ulcer) (Central 
and South America) 
L. (L.) amazonensis (Brazil and Amazon 
Basin) 
L. (V.) braziliensis (Central and South 
America)  
L. (V.) guyanensis (Guyana, Surinam, 
Amazon basin) 
L. (V.) peruviana (uta) (Western Andes) 
L. (V.) panamensis (Central America) 
L. (V.) colombiensis (Central America) 
L. (L.) infantum/L. (L.) chagasi (Central 
and South America) 
Ulcerating lesions; 
often self-healing 
lesions within 3-4 
months (L. mexicana) 
or within 6 months (L. 
guyanensis) 
 
(31) 
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Table I.1 (continued) 
Clinical 
Syndromes 
Leishmania spp. and location Natural Progression  
Leishmaniasis 
recidivans (LR) 
L. (L.) tropica (North Africa, Middle East) May last for many 
years (Tuberculosis-like 
presentation) 
 
(31)  
Diffuse cutaneous 
leishmaniasis 
(DCL) 
L. (L.) amazonensis (Brazil, Amazon 
basin) 
L. (L.) mexicana (Central and South 
America) 
L. (L.) aethiopica (East Africa) 
Slow to heal lepra-like 
lesions (within 2 to 5 
years); 
DCL and HIV co-
infection seldom 
reported 
 
(43) 
Disseminated 
leishmaniasis 
L. (V.) braziliensis and L (V.) amazonensis 
(Brazil) 
Not well described  
Mucocutaneous 
leishmaniasis 
(MCL) 
L. (V.) braziliensis (espundia) (Central and 
South America)  
Other Leishmania (V.) spp. (guyanensis, 
panamensis) are rare 
Ulcerating lesions 
(palpable lymph nodes 
before and early on in 
the onset of lesions; 
Possible self-healing) 
2-5% of patients 
infected by these 
species develop MCL 
 
(31) 
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Depending on the infecting species and host immunity, different clinical syndromes develop. 
However, most infected individuals remain asymptomatic, indicative of the development of an 
effective immune response, even if incomplete. Evidently, the ratio between asymptomatic:active 
infection varies widely according to the infecting species and endemic region (Table I.2). 
 
Table I. 2 Ratio between number of asymptomatic and active disease cases, according to geographical region. 
Adapted from Singh OP et al 2014 (44). 
Country 
Ratio 
(asymptomatic:active infection) 
Reference 
Sudan 1:2,4 (45) 
Kenya 4:1 (46) 
Ethiopia 5,6:1 (47) 
Brazil 18:1 (48) 
Spain 50:1 (49) 
Bangladesh 4:1 (50) 
India and Nepal 8,9:1 (51,52) 
 
In patients where immune responses are inadequate to control parasite proliferation, the 
infection progresses to active disease. Leishmaniasis encompasses a spectrum of clinical syndromes 
(Table I.1 and Figure I.3), from self-healing CL, to chronic, or disseminated visceral disease, indicative 
of both parasite diversity and variable host responses (31,53,54). 
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Figure I. 3 Spectrum of Leishmania infection and disease (31). DCL, diffuse cutaneous leishmaniasis; DTH, 
delayed-type hypersensitivity; LCL, localised cutaneous leishmaniasis; LR, leishmaniasis recidivans; ML, mucosal 
leishmaniasis; PCR, polymerase chain reaction; VL, visceral leishmaniasis.  
 
Polyparasitic active leishmaniasis (DCL, PKDL or VL) presents with heavily parasitized 
macrophages in the dermis, with few lymphocytes present, and peripheral PBMC that do not 
proliferate upon antigenic stimulus, do not produce IFN-γ or IL-2, and patients do not produce any 
DTH reaction and show high levels of IL-10 (31). Oligoparasitic active leishmaniasis is characterised 
by the slow progression of chronic lesions, with high PBMC recruitment and infiltration, and can 
progress to granuloma formation as in the case of L. donovani liver infection, a site of chronic 
inflammation usually triggered by persistent infectious agents which have a central area of 
macrophages, often fused into multinucleate giant cells, surrounded by T lymphocytes (31,55). 
 
Asymptomatic and subclinical infections are not yet well defined. Cases can be detected by a 
positive serological test, PCR or Leishmanin skin test (LST) in individuals otherwise healthy. 
However, currently available serological tests were developed to detect active VL, and PCR positivity 
fluctuates greatly over time (low parasitemia, different target sequences, and short DNA half-life in 
the body). The LST is useful to detect cellular-mediated responses in patients or exposed individuals, 
but it is seldom negative in active VL patients. Recovered / healed individuals can usually be identified 
by a positive LST, as well as positive responses against Leishmania antigens in vitro stimulation, 
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although with lower sensitivity (56). Recovered and self-resolving individuals present long-term 
protection against disease, in the absence of immunosuppression (57,58). Despite no technique is 
really adapted and developed for asymptomatic case detection, it is common to use two or more 
markers for asymptomatic infection detection, seldom serology and PCR (59).  
 
It is still not possible to known which patients will progress to active disease, remain 
asymptomatic carriers or achieve parasite clearance (44,60). Factors that contribute to the spectrum 
of Leishmania infection and disease are associated to complex interactions between environmental 
factors, parasite and host-related factors (Figure I.4). The main risk factors for developing human 
leishmaniasis include environmental or behavioural risks (migration, urbanisation, deforestation, 
irrigation, lack of bed nets, open houses, house dampness), vector-associated factors (proximity to 
sand fly breeding sites, proportion of infected vectors, preferred sand fly feeding behaviour), host 
factors (malnutrition, immune status including HIV infection, other co-infections, age, genetic 
background), and parasite-associated factors (infecting species, tropism, virulence, co-infections with 
Leishmania RNA virus) (23,41). 
 
 
Figure I. 4 Risk factors for the development of active or asymptomatic leishmaniasis (44). DAT, direct 
agglutination test; SLA, soluble leishmania antigen; ELISA, enzyme-linked immunosorbent assay; CMI, cellular-
mediated immune response; LST, leishmanin skin test; IGRA, Interferon-gamma release assay.  
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3. Leishmania spp. pathogenesis and host immunity  
 
3.1. Innate immunity against Leishmania spp. infection 
 
The first immune barriers for the parasite to overcome are the complement system and innate 
immune cells (neutrophils, innate lymphoid cells, antigen-presenting cells) (Figure I.5). Leishmania 
parasites initially interact with skin-resident cells – dermal macrophages, Langerhans cells, and 
keratinocytes (61). Interestingly, keratinocytes provide a mechanical obstacle against infection, but 
may also have an important role in the immune response, since they secrete effector cytokines, 
namely IL-6 which is associated to protection in mice (61–63).  
 
 
Figure I. 5 Overview of the acute phase of inflammation (64). Tissue damage causes mast cell degranulation in the 
tissues thereby releasing histamine and chemotactic factors. This increases the expression of adhesion molecules, 
enabling phagocytic neutrophils to adhere and cross into the tissue. Innate immune responses are triggered first. 
Neutrophils, guided by chemotactic factors, ingest microorganisms by phagocytosis. Increased permeability allows 
complement components to enter, generating a variety of antimicrobial and pro-inflammatory molecules. Meanwhile, 
tissue macrophages ingest any microorganisms, releasing simultaneously inflammatory cytokines. These cause 
vasodilation, increased permeability and expression of adhesion molecules. Inflammatory cytokines also cause 
Langerhans cells (not represented) to migrate to draining lymph nodes where they activate T lymphocytes to initiate an 
adaptive immune response.  
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a) First obstacles: the complement system 
The complement system comprises a large number of plasma proteins which interact among 
themselves and react with other components of the immune system, enhancing antibody and 
phagocyte function and inducing inflammatory responses against infection (65). There are three 
complement activation routes – alternative, lectin, or classical pathways (65). All pathways culminate 
with the activation of C3 convertase which generates C3b and C3a from C3 (complement component 
3). C3b is deposited on the surface of the pathogens allowing for parasite killing through opsonisation 
and subsequent phagocytosis by neutrophils and macrophages, or through the formation of the 
membrane attack complex (MAC) complex and cell lysis (66) (Figure I.6).  
All three pathways seem to be important for Leishmania clearance, and undoubtedly the 
alternative complement activation is critical for parasite elimination (67). Between 85% to all 
promastigotes are killed by complement within a few minutes in human blood (L. donovani, L. 
infantum, L. major, and L. amazonensis), so parasites must quickly establish infection inside 
phagocytes, namely inside macrophages, their definitive host cell (67,68).  
 
Leishmania parasites found elegant solutions to not only overcome targeting by the 
complement system, but also to exploit host opsonins to invade host cells and modulate their 
response in its favour, mostly through the interaction with glycocalyx molecules and other virulence 
factors (62,69,70). The major parasite surface proteins involved in initial first host-pathogen 
molecular interactions are: lipophosphoglycan (LPG), a glycoconjugate; the GP63 metalloprotease, 
also known as promastigote surface protease (PSP) or leishmanolysin, present only in promastigotes; 
and glycosyl-inositol phospholipids (GPI), present in large numbers in both promastigotes and 
amastigotes (63,69).   
Both LPG and GIPLs bind to the mannan-binding serum protein (MBP), which can activate the 
complement system in an antibody-dependent manner through the lectin activation pathway (63). 
LPG is the major acceptor of C3b. Simultaneously, LPG and GP63 are involved in promastigote 
complement resistance. The LPG on the parasite surface prevents the complement membrane attack 
complex insertion: when the C5b-MAC complex binds, it does not affect the parasite membrane, and 
is released as soluble C5b-9 complex (63,71). GP63 can inactivate C3b and totally inhibit the 
formation of the C5b convertase complex (63,68). In addition, Leishmania promastigote membrane 
kinases (LPK-1 and potentially others) phosphorylate the C3, C5 and C9 components of the 
complement, inhibiting complement activation (63,72) (Figure I.6).  
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Moreover, GP63 cleaves C3, and resulting iC3b opsonises promastigotes promoting 
macrophage through the interaction with surface C3 receptor, also known as CR3 or MAC-1 
(68,73,74). The CR3-dependent entry route is important for establishing infection inside 
macrophages, favouring parasite development and persistence (73,75) due to associated IL-12 
downregulation (63,76). GP63 also cleaves host tyrosine phosphatase SHP1 preventing IFN-γ-
mediated classical macrophage activation (63). LPG interacts with the early inflammatory C-reactive 
protein, triggering phagocytosis (77) (Figure I. 6).  
C3b-coated parasites can be internalized by macrophages via the CR1 receptor (complement 
receptor 1) (73). Promastigotes can also invade macrophages through interactions with host 
macrophage Fc-γ, mannose or fibronectin receptors (68,74). FcγR-dependent Leishmania 
phagocytosis is required for clearance and protection from disease (78) (Figure I. 6).  
 
 
Figure I. 6 Receptor-mediated phagocytosis of Leishmania parasites (73). A) GP63-mediated entry via interaction 
with CR3 receptor. CR3 may also mediate direct binding to promastigotes via a yet unknown surface epitope on 
promastigotes. GP63 also binds fibronectin, which then bridges the parasite to fibronectin receptors (FnRs). B) LPG 
expression on amastigotes is absent, possibly allowing the low levels of GP63 to become opsonized with iC3b protein 
and subsequently ligate CR3. Antibody and fibronectin detection of amastigotes leads to ligation of Fc gamma receptors 
(FcγRs) and FnRs, respectively. B) Immediately following inoculation by the sand fly, promastigotes parasitize 
predominantly Polymorphonuclear Neutrophils (PMN). Promastigotes enter PMN via CR3 and then enter macrophages 
or DC while contained in the short-lived granulocyte. Promastigotes and amastigotes may also directly enter DC via 
DC-specific DC-SIGN. 
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b) Neutrophils and macrophages, evasion and exploitation of host innate immune 
responses 
Shortly after parasites are injected in the skin, neutrophils are the first cells to be recruited to 
the inflammation site (79). Because of the sand fly’s natural pool feeding behaviour, the tissue damage 
caused and the injection of saliva proteins together with the promastigote gel and Leishmania-
produced exosomes, create a highly inflammatory environment through the release of alarmins 
(signal for tissue damage), cytokines, and chemokines (63,80). Neutrophils can act against the 
intracellular Leishmania parasites through reactive oxygen species (ROS), neutrophil elastase (NE), 
and neutrophil extracellular traps (NETs) (79,81–87). Nevertheless, neutrophils become infected by 
promastigotes during the first 18 hours post-infection, providing a transient shelter allowing for 
parasite development and immunomodulation of subsequent response cascades (79,88).  
The parasite has evolved to both evade and exploit host innate immune responses, reviewed 
in Geiger et al 2016 (1). There is evidence that Leishmania infection prolongs neutrophil survival in 
vitro and in vivo, as parasites delay the onset of apoptosis in infected neutrophils (68,89). This delay 
provides the time needed for the recruitment of antigen-presenting cells (macrophages and DC) to 
the infection site. As neutrophils undergo apoptosis, the parasites take advantage of a Trojan horse 
strategy, where phagocytosis of apoptotic neutrophils by dermal macrophages or dendritic cells 
triggers anti-inflammatory signal pathways (high TGF-β, IL-10 and low IL-12), providing an optimal 
route for intracellular development, while simultaneously impairing subsequent adaptive immune 
responses (90–93).  
Furthermore, Leishmania disease development depends on the presence of apoptotic 
promastigotes in the virulent inoculum, which expose phosphatidylserine (PS) also enabling a silent 
cell invasion and inducing the production of anti-inflammatory cytokine TGF-β (68,94,95).  It is 
interesting to note that neutrophils readily phagocytized promastigotes, but amastigotes are not 
uptaken by these cells, rather by macrophages through endocytosis (CR3- or clathrin- and caveolae-
mediated) (63,94). 48 hours after infection, the majority of infected cells are macrophages (96). 
Parasite are also capable of escaping pre-apoptotic macrophages in membrane blebs that are uptaken 
by bystander macrophages (68). 
During promastigote internalization, the parasite transforms the phagolysosomal 
microenvironment and survives inside an adapted parasitophorous vacuole (PV) allowing a 
successful differentiation to amastigote form, by either delaying phagolysosomal fusion (L. major, L. 
infantum, L. donovani, with or without LPG), or producing large vacuoles that dilute and impair 
hydrolytic enzymes (L. mexicana and L. amazonensis) (97,98).  
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The production of reactive nitrogen and oxygen species (RNS, ROS) by macrophages is tightly 
controlled by the balance between energy metabolism and cell redox state (2). The enzyme arginase 
produces either ornithine, used for polyamine synthesis, or it produces RNS and ROS (namely, O2-, 
NO, H2O2, and peroxynitrite ONOO-), responsible for intracellular parasite killing. Leishmania 
parasites actively modulate this balance, skewing arginase function towards glycolysis, and ensuring 
parasite intracellular survival. These mechanisms are reviewed in Holzmuller et al 2018 (2). 
Neutrophils and macrophages have concerted activities: neutrophils augment macrophage 
function to quickly neutralise early inflammatory stimulus, and apoptotic neutrophils signal 
macrophages to decrease inflammation and promote healing (99,100). In the context of non-healing 
lesions, neutrophils contribute to the development of chronic infection through the impairment of the 
recruitment of inflammatory monocytes and monocyte-derived DC and of subsequent Th1 response 
(92,99,101–104). 
 
c) Sensing danger – TLR signalling 
In addition to receptor-mediated phagocytosis, macrophages and other antigen-presenting 
cells (APC) possess receptors responsible for sensing danger and reacting accordingly through the 
production of cytokines and chemokines. In this context, danger is perceived as any molecule able to 
harm the host, from pathogens (Pathogen-Associated Molecular patterns, PAMPs) or from cell stress 
and injury (Damage-Associated Molecular Patterns, DAMPs). The main PAMPs are microbial nucleic 
acid, lipoproteins, surface glycoproteins, and other membrane components, and are recognised by 
Pattern Recognition Receptors (PRRs), including toll-like receptors (TLRs) (66).  
Humans have ten different membrane-bound TLRs, most use MyD88 for intracellular signal 
transduction, except TLR3 that uses MyD88-independent mechanisms (TRIF, TIR-domain-containing 
adapter-inducing interferon-β; TIRAP, TIR domain containing adaptor protein; or TRAM, TRIF-
related adaptor molecule), and TLR4 that uses both. Among them, TLR2 and TLR4 can recognize 
extracellular promastigotes, TLR3 and TLR9 can recognize parasites in intracellular vacuoles 
(66,105).  
Studies have shown a major role for TLR activation in anti-Leishmania immunity, namely 
TLR4 and TLR9 (106). TLR9 activation has been linked to protective adaptive responses (107). TLR 
recognition results in the activation of transcription factors (NF-κb and IRFs) and the production of 
inflammatory cytokines and promotion of NO production (68). TLR4 inhibition results in a M2b 
macrophage phenotype, high IL-10 production contributing to Th2 responses, whereas TLR4 ligands 
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are shown to induce IL-12 and NO production, with low concomitant IL-10 production, suggesting a 
protective effect by the TLR4/MyD88/IL-12 pathway (108,109).  
TLRs are crucial for the coordination of the type and magnitude of the innate response, with 
a dual role in protection against Leishmania parasites. Albeit a non-decisive role in infection outcome, 
TLRs contribute towards an early Th2 bias, promoting parasite survival (108). TLR signalling and 
control of early innate responses becomes particularly relevant for Leishmania immunity since 
PAMPs are conserved and expressed constitutively across pathogenic species, and they are key 
virulence factors, suggesting their inclusion when designing vaccine formulations against Leishmania 
(108).  
 
d) Innate lymphoid cells – NK cells 
Natural killer (NK) cells belong to the group of Innate lymphoid cells (ILCs), immune cells that 
mirror T cell phenotypes and functions, yet ILCs do not express antigen receptors not do they undergo 
clonal selection and expansion upon activation (110). According to cytokine production patterns and 
associated transcription factors, ILCs can be divided in 3 groups. NK cells belong to group 1 ILCs 
(ILC1s) that predominantly express interferon-γ (IFN-γ) and depend on the transcription factor T-
bet, associated with Th1 T-cell development (111).  
NK cells are an important source of IFN-γ in early host parasite interactions, driving TCD4+ 
cell differentiation into a Th1 phenotype. This secretion can be dependent on IL-2 produced by 
specific TCD4+ cells and IL-12 secretion by DC, as in the case of L. infantum infection, where NK cell 
activation depends on IL-12 production and TLR9 expression by myeloid DC, emphasising the 
complex interactions that will eventually lead to either infection control or progression (61,112). LPG 
interacts with TLR2 and activates NK cells, triggering IFN-γ and TNF-α production, contributing for 
host protection in the mouse model, possibly through TLR9 activation (108,113). In L. major infection, 
NK cells produce IFN-γ, which can amplify IL-12 production by DC and induce Th1 differentiation 
(protective role). Pathology-associated functions have also been described – NK cells (NKp46+ 
CD49b+) are recruited to the spleen and hepatic granulomas where they secrete IL-10 and impair 
protective immunity in experimental VL models (114,115). During L. donovani infection, extensive 
activation of NK cells induces IL-10 secretion (negative immunoregulatory role of cell-mediated 
immunity) (114). 
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3.2. Bridging the gap – innate and adaptive immune response coordination 
 
The early innate immune effector mechanisms described above, namely phagocytosis, 
cytokine and chemokine production, expression of co-stimulatory molecules on APC, are essential for 
T cell differentiation. Early Leishmania infection is marked by a ‘silent phase’ during which parasites 
replicate inside host cells without any associated symptoms for about 4 to 5 weeks  (116,117). The 
development of a protective immune response requires the coordinated action of cells of the innate 
and adaptive immune response (63,117,118) (Figure I.7). The complex early innate immune 
responses and induced adaptive immune responses are summarised in Figure I.7. 
 
 
Figure I. 7 Crosstalk between innate and adaptive immune responses (119). Macrophages, neutrophils and NK 
cells are attracted to the site of pathogen entry. Dendritic cells take up antigen and migrate to regional lymph nodes. 
Here antigen presentation to T cells takes place, and these differentiate into helper T cells (Th1 or Th2 T CD4+ cells) 
and cytotoxic T cells (T CD8+ cells). Activation of B cells and immunoglobulin production are also initiated.  
 
Skin-resident DC, Langerhans cells and dermal DC can efficiently uptake and present parasite 
antigens in a pro-inflammatory environment, migrate to the lymph nodes where they can activate 
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specific naive T cells (120). Most DC become infected after contacting with infected neutrophils. 
However, some weeks post-infection, the number of DC in the lesion site is higher due to increased 
recruitment, and these infected DC can prime naive T cells locally, an effector function essential for 
acquired resistance against Leishmania (120) (Figure I.7). 
After antigen recognition, naive T cell precursors differentiate into effector cells (priming) 
(Figure I. 8). Naive TCD8+ cells recognise specific peptides presented by major histocompatibility 
complex (MHC)-class I molecules on the surface of nucleated cells, and differentiate into cytotoxic 
CD8+ T lymphocytes which kill infected cells. On the other hand, CD4+ T lymphocytes are activated by 
APC and differentiate into different effector subsets – T helper 1 (Th1), Th2, Th17 or follicular TFH 
which activate the target cells; or regulatory T cells (Tregs), which inhibit cell activation (121). Naive 
T cell activation depends on i) antigen recognition of specific pMHC by the T-cell receptor (TCR); ii) 
expression and interaction of co-stimulatory molecules and, iii) the cytokine environment which 
determines the differentiation pathway (121). T cell activation will be further discussed below (3.2 b 
Immunological synapse between APC and T cells). 
 
 
Figure I. 8 Naive T cell priming. Interaction between antigen-presenting cells and naive T cells (represented here: 
TCR/pMHC interaction and costimulatory molecules) leading to the differentiation into effector cells (122).  
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a) Antigen presentation and the Major Histocompatibility Complex (MHC) 
Two classes of MHC molecules, membrane-associated glycoproteins, present antigens to 
TCD4+ and TCD8+ cells: 
- MHC-class I exist on the surface of all nucleated cells, and present 8-12 amino-acid peptide 
epitopes to TCD8+ cells, acting against intracellular pathogens. Briefly, short peptides from 
intracellular antigens are processed in the proteasome, transported to the endoplasmatic 
reticulum by the transporter associated with antigen processing (TAP protein), where they 
are trimmed and loaded onto nascent MHC-class I molecules (123,124). 
- MHC-class II exist only on the surface of APC (B cells, macrophages, DC, epithelial thymus 
cells), and they present 13-25 amino-acid epitopes to TCD4+ cells, acting against extracellular 
pathogens as well as inducing differentiation of other T helper phenotypes thereby regulating 
the immune response. Briefly, endocytosed extracellular antigens or antigens from intra-
vesicular pathogens inside macrophages are degraded in endocytic vesicles and presented by 
MHC class II molecules to TCD4+ cells resulting in APC activation (123).  
 
Soluble antigenic peptides of the correct length and sequence can directly bind to MHC-class 
I molecules. Although artificial, this direct binding can be exploited in the context of immunoassays, 
when peptides cannot be presented via endogenous class I presentation (123–125).  
Exogenous peptides can be presented by MHC class I molecules through cross-presentation 
(126), and it has been described to occur during Leishmania infection (127,128).  
In humans, MHC molecules are named Human Leukocyte Antigen (HLA) (Figure I.9). 
 
 
Figure I. 9 HLA class I and class II molecules (©STEMCELL Technologies Inc. 2017). 
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The HLA molecules are encoded in a cluster of closely linked genes at chromosome 6 
comprising 6 class I loci and 13 class II loci (Figure I.10). There are two components to HLA diversity: 
i) gene families, encoding HLA-class I heavy chains and -class II alpha and beta chains; and ii) genetic 
polymorphism, responsible for multiple alternative forms of a given gene (alleles), and respective 
encoded protein (allotype). HLA gene polymorphism corresponds to variability at a gene locus in 
which all variants occur at a frequency greater than 1% (55). HLA gene expression is codominant, the 
two alleles are expressed in roughly equal amounts in the heterozygote, and each individual expresses 
a unique set of HLA alleles, specific to a unique set of antigenic peptides (123,124). 
A given isoform is the product of an individual HLA allele (123). There are monomorphic 
genes and oligomorphic genes, for which different alleles have been described (Figure I.10). Six HLA-
class I isotypes: A, B, C, highly polymorphic genes, and with a role in antigen presentation to TCD8+ 
cells; F, monomorphic gene, intracellular; E and G genes, oligomorphic and important for NK-
mediated responses. Also, there are five HLA-class II isotypes: DM, DO, oligomorphic genes encoding 
proteins involved in the loading of other class II molecules; DR, DQ, DP, highly polymorphic genes, 
encoding proteins responsible for presentation to TCD4+ cells (123).  
 
 
Figure I. 10 Genetic loci in chromosome 6 encoding for all HLA proteins (©STEMCELL Technologies Inc. 2017). 
 
HLA gene nomenclature describes this diversity (Figure I.11), e.g. HLA-A*02:101:01:02N 
corresponds to: “HLA” prefix for human genes; “A” genomic locus; “02” allele group; “02:101” is the 
encoded protein, the specific HLA protein numbered by order of discovery; “01” is the allele variant, 
a silent/synonymous polymorphism within the coding region; “02” is a SNP number, denotes 
differences in a non-coding region; “N” is a suffix to denote additional information. For example, 
alleles that have been shown not to be expressed - 'Null' alleles - have been given the suffix 'N'. Alleles 
that have been shown to be alternatively expressed may have the suffix 'L', 'S', or 'Q'. (Figure I.11) 
(129).  
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Figure I. 11 HLA gene nomenclature (130). 
 
The peptide-binding cleft or groove is the longitudinal cleft in the top surface of an MHC 
molecule into which the antigenic peptide is bound (55). Each allele has a unique binding groove that 
defines its specificity, and many of the MHC polymorphisms change the pockets affecting peptide 
binding specificities (123). The bonds between MHC molecules and the peptidic epitope are 
determined by their molecular structure and main anchor binding positions, respectively. The 
peptides insert their amino-acid side chains (anchor residues) into pockets in the peptide binding 
groove.  For MHC-class I molecules, the peptide binding groove is formed by the α1 and α2 domains, 
and the 9-mer peptide anchor residues are often determined by the B and F pockets (peptide’s P2 and 
P9 residues)  (124) (Figure I.12). On the other hand, the peptide binding groove of MHC-class II 
molecules is formed by the α1 and β1 domains and, contrarily to MHC-class I, they are open at both 
ends, presenting longer peptides of variable length (123). Also, MHC-class II molecules present higher 
binding pocket variability, which hinders the identification of anchor residues, although four main 
pockets were identified which interact with peptide’s P1, P4, P6 and P9 residues (131) (Figure I.12). 
The MHC-class II binding pockets accommodate a 9-mer core region which determines binding 
affinity and specificity (131) (Figure I.12).  
 
CHAPTER I – GENERAL INTRODUCTION 
23 
 
 
Figure I. 12 MHC binding cleft and interacting residues along the peptide sequence (124). A) MHC-class I binding 
groove. B) MHC-class II binding groove. 
 
HLA supertypes are allele groups with shared binding specificities (supermotifs), meaning 
that if a peptide is able to bind to an allele within a supertype, it will bind to other alleles in the same 
supertype (132,133). From binding data, structural analysis and motif identification, nine HLA-class 
I supertypes were described - HLA-A1, -A2, -A3, -A24, -B7, -B27, -B44, -B58, -B62 (134). Lund et al 
further defined three new HLA-class I supertypes (HLA-A26, -B8, and -B39) (135). Sidney et al 
proposed a revised version of these groups, and found that 80% of the 945 alleles evaluated were 
classified into one of the nine supertypes previously identified (133). However, some alleles were 
found to have binding specificities pertaining to different supertypes (9 alleles A01A03, and 10 alleles 
A01A024) and some alleles were ‘unclassified’ (133). MHC-binding motif information is readily 
accessible (www.iedb.org) and MHC sequence data are also available in the IMGT, the international 
ImMunoGeneTics information system database (www.imgt.org). Allele classification in supertypes 
allows to reduce their inherent complexity, assisting experimental design and validation of potential 
epitopes (132). Evidently, despite the practical advantages, oversimplification of the HLA allele 
complexity may introduce unwanted bias.  
Moreover, 62% of all EBV- and HIV-derived peptides have motifs associated to two or more 
supertypes and include 21% of peptides with supermotifs bound with an affinity of maximum 100nM 
(133). 95% of all epitopes were recognized by individuals expressing different alleles and even other 
supertypes (133), and this feature is referred to as epitope promiscuity (136). 
 
Although evidence is scarce, some HLA polymorphisms have been associated with 
leishmaniasis susceptibility. Genome-wide association studies in Indian and Brazilian populations 
found polymorphisms in the HLA-DRB1–HLA-DQA1 class II region contributes to visceral 
leishmaniasis susceptibility, suggesting that genetic risk factors for visceral leishmaniasis are shared 
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despite differences in geography and infecting parasite species (137).  Another study in the Sri Lankan 
population, found a high heterogeneity in detected alleles, but provides preliminary evidence for 
some alleles associated with protection (the B*07 allele and the DRB1*15 DQB1*06 haplotype which 
are over represented in controls; and the haplotypes DRB1*04 DQB1*02 and DRB1*07 DQB1*02 
which were absent in patients) or susceptibility (DRB1*15 allele which is over represented in 
patients), suggesting a role for certain class I and class II HLA genes in LCL susceptibility. However, 
another study with 110 Peruvian individuals, which also focussed on HLA class II loci, did not find any 
association between the different alleles and haplotypes detected, and susceptibility to CL or MCL 
(138). Another study focusing in HLA class I genes showed a statistical significance between HLA-A26 
expression and susceptibility to disease in VL patients (139).  
 
b) Immunological synapse between APC and T cells 
Naive T cells recognise specific peptide:MHC complexes (pMHC) in the APC surface, in 
combination with co-stimulatory signals, which triggers T cell proliferation (IL-2 mediated) and 
differentiation (122). Briefly, naive T cell priming depends on 3 consecutive signals (Figure I.13): 
i) stable interaction between the pMHC and the TCR and CD4 or CD8 (activation signal);  
ii) the interaction between costimulatory molecules CD28 on the T cell with B7.1/B7.2 (also 
known as CD80/CD86), and between CD40L on T cells and CD40 on the APC surface 
(survival or costimulatory signal); the lack of costimulary molecules inhibits cell maturation 
and activation; 
iii) cytokine signalling, namely IL-2, IL-6, IL-12, IL-4, TGF-β (differentiation signal). 
Once cells are in contact, when T-cell receptors bind to an antigen and cell-adhesion molecules 
bind to their counterparts on the two cells, the immunological synapse is formed, a highly organised 
interface between a T-cell and the target cell, and the adaptive response ensues. 
Specifically, macrophages and dendritic cells need two signals for activation and 
differentiation from Th1 cells – IFN-γ signalling, and CD40 ligand (CD40L) interaction on the T cell 
surface. These signals further increase expression of CD40 and TNF-α receptors, produced by APC 
themselves, functioning in synergy with IFN-γ to raise and maintain activation (Figure I.13). Secreted 
or receptor-mediated costimulatory signals are essential for cell activation and for the generation 
of protective immunity (Figure I.13). 
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Figure I. 13 Interactions between T cells and antigen-presenting cells. A) TCD4 cell interaction with MHC-class II 
molecules on the surface of a dendritic cells and intracellular signalling. B) TCD8 cell interaction with MHC-class I on 
the target cell surface (122). 
 
After cell proliferation, the interaction with infected macrophages or dendritic cells, results in 
the differentiation and acquisition of Th1 or Th2 effector functions: naive TCD4+ cells activated in 
presence of IL-12 and IFN-γ commit to differentiate into Th1 cells, whereas naive TCD4+ cells 
activated in the presence of IL-4 commit to a Th2 differentiation (Figure I.14). The main factors that 
influence the differentiation fate are the cytokine environment, the type of APC, the abundance of 
pMHC and the binding affinity with the TCR receptor. Molecules produced by activated macrophages 
are toxic to the host as well, so Th1 responses are tightly controlled by Th2 responses (IL-4, TGF-β, 
IL-10, IL-13) and regulatory T cells (122) (Figure I.14).  
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Figure I. 14 Naive T cell differentiation in Th1 or Th2 effector cells and cross-regulation, adapted from (121). A) 
Th0 cells differentiate into Th1 or Th2 effector cells according to cytokine environment. B) Th1/Th2/Treg cross-
regulation. 
 
Leishmania parasites actively prevent macrophage activation and interfere with the development 
of adaptive immune responses through several mechanisms (69,140,141):  
i) impairing cell function, by decreasing MHC class-I and -II expression through direct parasite 
internalization or targeted vacuolar fusion; or by changing TCR interaction through increased 
membrane fluidity, or by interfering with adhesion molecules and co-receptors;  
ii) Leishmania cathepsin-B-like protease induces TGF-β production, activating macrophage 
arginase, and resulting in high ornithine, low NO levels, which favour parasite survival; 
iii) anergy induction, in active VL TCD8+ cells typically do not produce IFN-γ, and express high 
levels of CTLA-4 and PD-1, negative regulators of T cell activity associated with T cell anergy 
and exhaustion.   
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3.3. Adaptive immunity mechanisms 
 
a) Primary and secondary immune responses 
 The human adaptive immune system includes both naive T cells (with randomly assigned 
TCR specificity by genetic recombination during thymic development) and memory T cells (selected 
and differentiated from effector cells after initial antigen encounter into long-lasting specific T cells).  
 Each TCR is uniquely arranged and randomly selected from over 1010 possible combinations. 
TCR expression is clonal, meaning each mature lymphocyte has a single type of receptor of unique 
specificity (Figure I.15). The overall diversity of T cell clones in an individual comprises at least 108 
different lymphocyte specificities, providing the ability to recognise virtually all possible epitopes 
from a given pathogen and the basis for the complexity of the adaptive immune system. Upon antigen 
recognition, specific T cells become activated, undergo clonal expansion and become effector cells 
(Figure I.15). However, lymphocyte diversity and the unique TCR specificity per clone also imply that 
few antigen-specific T cell clones for a given epitope are present, which poses a problem for response 
detection.  
 
 
Figure I. 15 T cell clonal selection model (142). 1) during development, thousands of cell clones bearing unique TCR 
are generated in central lymphoid organs. Clones that bind self-antigens with high affinity are deleted and the remainder 
colonise the secondary lymphoid tissues (primary immune repertoire). 2) The introduction of foreign antigen induces 
activation, proliferation and differentiation of the specific T cell clones.3) a proportion of these antigen-specific T cells 
differentiates into memory T cells responsible for stronger and faster responses upon re-exposure.  
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During a primary response against infection, specific naive T cells proliferate and differentiate 
into effector T cells that eliminate the pathogen or infected cells. As the immune response enters the 
resolution phase, some T cell clones differentiate into long-lasting memory cells and remain in 
circulation (Figure I.14). Activated memory T cells will proliferate more rapidly and produce higher 
amounts of effector cytokines. Re-stimulation of these cells results in another proliferation cycle, 
followed by a new resting phase (Figure I.16). The expansion and maintenance of the antigen-reactive 
cell populations provide the basis for immunological memory, which translates into enhanced and 
prolonged secondary responses (Figure I.16). The T-cell clonal selection model applies to both 
humans and mice. 
 
 
Figure I. 16 Characteristics of primary and secondary cellular responses (143). The figure represents the cellular 
responses (TCD8 lymphocytes) in mice against an Influenza A virus-specific peptide. Mice were immunized twice 
intranasally, 8 months apart; rechallenge 8 months after initial challenge induces a faster and greater cytotoxic TCD8 
response in the lungs. 
 
b) T cell activation - from peptide presentation to T cell effector functions  
  Besides peptide- and MHC-related features, T-cell activation depends TCR signalling and 
TCR-pMHC binding parameters, namely binding affinity and avidity (144). 
 The TCR-peptide-loaded MHC (pMHC) binding strength is referred to as affinity, the sharing 
of a monovalent interaction, or, the binding strength of one molecule to its ligand at a single site 
(55,125). Antigen-presentation dictates the fate of developing T cells. In the periphery, unlike in the 
thymus or bone marrow, T cells are activated if they recognise antigens with high affinity. The T cells 
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recognising antigens with low affinity generally become nonresponsive or anergic (145). Chronic 
infections, such as leishmaniasis, can induce high or chronic doses of antigen, in which case, T cells 
can become anergic, exhausted or apoptotic. 
Affinity by itself cannot directly describe the activation extent of a given TCR-pMHC 
interaction. A high TCR-pMHC dissociation time and serial TCR triggering are more stimulatory than 
a strong affinity (125,144).  
Binding avidity refers to all multivalent interactions involved in cell-cell interaction, i.e. the 
sum of the strength of binding of two molecules or cells to another at multiple sites (55). Avidity-
based mechanisms mediate antigen sensitivity in T cells, which results in different binding and 
activation parameters in naive versus memory cells with the same TCR specificity (146). Throughout 
the immune response, primed T cells acquire greater sensitivity to pMHC signalling than naive T 
cells, undergoing avidity maturation (147). Avidity maturation may be related to decreasing antigen 
levels during the resolution phase, in preparation for the generation of specific memory T cells, more 
effective against secondary infection (148).  
Although TCD8+ cells are undoubtedly important for host immune responses against 
Leishmania parasites (see below), some controversial results were observed in animal models, 
namely, CD8-knockout mice which are resistant to infection (149). These differences may be 
attributed to the antigen dose, as evidenced by the fact that TCD8+ cells are effective against low 
parasite doses, but not against high parasite loads (150). In turn, these observations further 
strengthen the need for optimal T cell priming for the generation of long-lasting T-cell memory.  
 
Requirements for the successful induction of an effective adaptive immune response: 
- Magnitude of response, a sufficient number of specific T cells is needed; 
- Breadth of response, broader diversity of T cell specificity is more effective than responses 
targeting one epitope; 
- Avidity, infection control mediated by high avidity T cells is more effective; 
- Cell function, the induction of adequate effector phenotypes is needed (e.g. Th1 and cytotoxic 
responses) 
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c) Adaptive immunity against Leishmania spp. infection – lessons from mice 
Two pivotal aspects regarding adaptive immunity make it an intrinsic mechanism for 
immunization – response specificity, through the use of highly variable and specific receptors, and 
memory generation, allowing for a stronger secondary immune response (151).  
Generally, protective immunity against leishmaniasis is associated with a predominant 
inflammatory Th1 response, while disease is associated with a predominant anti-inflammatory Th2 
response (63,152). During the initial ‘silent phase’, immune cells in the infection site secrete IL-4, 
promoting a Th2 response and thereby an environment that favours parasite development (116).  
Interestingly, the Th1/Th2 dichotomy observed in L. major mouse infection was incorporated 
in the first description of Th1 and Th2 helper T cell populations by Mosmann TR et al 1988 (153).  
 
The correlation of Th1 responses and protection against Leishmania originates from 
landmark discoveries from experimental infection studies in mice: 
i) L. major infection in mice produces different outcome according to genetic background – 
BALB/c mice develop a Th2 immune response (IL-4-mediated) and are susceptible; C57BL/6 
mice develop a Th1 response (with IFN-γ and IL-12 production) and are resistant (121,154); 
ii) Leishmania spp. immunomodulation of IL-12 production – the decreased IL-12 production by 
infected macrophages, prevents IFN-γ production by NK cells, and Th1 differentiation and 
function favouring parasite development (121,155,156); 
iii) Leishmania spp. induces IL-10 production by regulatory T cells, preventing parasite clearance 
– the increased IL-10 downregulates MHC-II expression, TNF-α and NO production, leading to 
reduced parasite clearance and suppressed activation of Th1 cells (157–159);  
iv) Passive T cell transfer from resistant C57BL/6 mice to irradiated BALB/c susceptible mice 
generates protection against L. major infection (160). 
 
More recent studies in L. major mouse infection (in resistant C57BL/6), CCL2/MCP-1 
production resulted in the recruitment of Ly6C+ inflammatory monocytes, capable of capturing and 
killing parasites by oxidative burst and migration to lymph nodes where they differentiate into 
specialized DC subsets (161). These CCR2+ monocytes capture L major parasites, produce IL-12 and 
differentiate into iNOS-expressing DC in the lymph nodes, promoting Th1-mediated protection, 
making them an interesting target cell population for vaccine formulations (161). Also, studies have 
found that in experimental VL and CL (mice), resistance needs anti-parasitic Tbet+ IFN-γ producing 
TCD4+ cells (161,162).  
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d) Adaptive immunity – pathogenesis and human-specific mechanisms against 
Leishmania spp. infection 
Human leishmaniases often exhibit a mixed type 1 and type 2 cytokine profiles, so the 
Th1/Th2 dichotomy observed in mouse models does not apply (163–165). Although mouse models 
are extremely useful to detail the molecular mechanisms involved in immunopathology, these only 
offer an incomplete assessment human-specific mechanisms (163,166,167). Notwithstanding, the 
complex immune responses observed in dogs against canine leishmaniases bear a much closer 
resemblance to human responses (168).  
 
During active VL and DCL (diffuse cutaneous leishmaniasis), the host immune response is 
dysfunctional, and in human CL and MCL immune-mediated tissue pathology is observed. Active VL 
patients possess weak T-cell mediated responses unable to control infection – Th1 responses are 
balanced with immunosuppressive mechanisms, i.e. specific Th1 cells are activated but not enough to 
prevent disease development.  
 In human CL, the cell-mediated responses at the lesion site are crucial for disease outcome. 
Human CL caused by L. major induces high levels of IFN-γ, IL-10, IL-12 mRNA in lesions, indicative of 
mixed TCD4+ responses. IFN-γ-producing cells are definitely predominant in healing cutaneous 
lesions, but in chronic cutaneous lesions and mucocutaneous lesions we observe both Th1 and Th2 
cytokines, with high levels of IL-4 and IL-10 (169).  
In human VL, no clear correlation exists with increased IL-4 levels (169). However, IL-10 has 
been implicated with the development of active disease in infected patients (169,170). In active VL, 
high levels of IL-4 and IFN-γ are detected in the spleen, but these levels decline after cure, and the 
same profile is observed upon antigenic in vitro PBMC stimulation (165,169). IL-10 is produced by 
different cell types (Tregs, Th2, Th1 and other cells) and differences between CL and VL are still not 
clear.  
The anti-inflammatory cytokine IL-10 plays a key role in the regulation of host immune 
responses (121). There is a consensus regarding the suppressive effect of IL-10 on the immune 
response in VL and its association with disease severity, since this cytokine is an important 
immunosuppressant and inhibitor of macrophage microbicidal activity in both mice and humans with 
VL (63,152,171). In human VL, IL-10 is increased in plasma, as well as increased mRNA levels in the 
spleen, bone marrow and lymph nodes (170). Total PBMC from healed VL patients stimulated with 
Leishmania soluble antigens co-produce IFN-γ and IL-10 (172). On the other hand, IL-10 blockade in 
VL patient sera or splenic aspirate cultures results in suppressed parasite replication in macrophages 
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and enhanced Th1 responses (170,173). IL-10 immunomodulation may also involve the induction of 
T cell exhaustion and anergy (174). It is interesting to note that while in VL patients IL-10 is detected 
in the plasma (170), this is not the case for patients infected with L. major and L. aethiopica (175). 
However, IL-10 mRNA is detected in lesions caused by L. major and L. tropica (176). This is most likely 
due to the immune response compartmentalisation, and possibly due to different sources of IL-10 
production. 
The mechanisms behind Th1/immunosuppression regulation during Leishmania infection 
are not fully understood, however, the cytokine IL-10 has a crucial role in these processes. T cell-
derived IL-10 is mostly produced by IFN-γ-producing TCD4+ cells, Type 1 regulatory cells (Tr1, 
conventional T cells that convert to FoxP3+ regulatory cells) and, to a lesser extent, by thymus-
derived Tregs (CD4+CD25+FoxP3+) (177). The Treg cell subpopulation has an important dual role in 
immunosuppression and promotion of concomitant immunity in CL. Treg-produced IL-10 modulates 
APC functions and suppresses TCD4+ effector functions against L. major and L. braziliensis and helps 
maintain a stable infected macrophage reservoir.  Tregs bind IL-2 (high levels of CD25 = IL2R) and 
deprive other cells from this growth factor, causing apoptosis (176,178). Ambiguous and little 
evidence for Treg involvement in human or experimental VL needs further development 
(173,179,180). 
 
PKDL pathogenesis remains mostly unknown, there is consensus that immune suppression 
allows the multiplication of latent parasites from the viscera or residing in the skin. PKDL is 
characterised by increased IFN-γ and TNF-α, and IL-10 and TGF-β at lesion sites (181). In Indian 
PKDL, a low expression of receptors is observed, a high number of TCD8+ cells in circulation and in 
lesions, as well as increased antigen-induced IL-10 production by TCD8+ cells, impaired antigen-
induced proliferation and increased Th17 responses (IL-17A, IL-23, RORyT) (182). The presence of 
Tregs at the skin (FoxP3+CD25+CTLA4+) is correlated with parasite burden in Indian PKDL (183). In 
Sudanese PKDL, some susceptibility-associated polymorphisms in the IFN-γ receptor have been 
described, and immune responses similar to cured VL patients (184). PBMC from Sudanese PKDL 
patients proliferate in response to Leishmania antigens and TCD4+ cells secrete IL-10 and IFN-γ, 
similarly to responses observed in cured VL patients. Th17 cells may have a role in parasite clearance 
in PKDL: PBMC from Indian PKDL patients stimulated with Leishmania antigens produce IL-17A and 
IL-23, and PBMC stimulated with IL-17A show enhanced production of TNF-α and NO (182). 
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MCL is characterised by the chronic inflammation of the nasal mucosa and a hyperactive T 
cell response (high levels of IFN-γ and TNF-α, decreased levels of IL-10 and TGF-β). In this case, 
pathogenesis is caused by a poorly regulated T cell response (174,185). In human MCL patients, the 
number of TCD8+ cells in the lesion site increases as disease progresses. These cells express high 
levels of granzymes and perforin (cytolytic activity), contributing to inflammation and disease 
pathology via perforin-mediated cytotoxicity (186). Th17 cells is also associated with pathogenesis 
in MCL patients: MCL lesions have increased IL-17A mRNA levels, and TGF-β, RORyT, IL-23 
(associated with Th17 differentiation), and IL-17 is produced by not only TCD4+ but also TCD8+, 
CD14+ and CCR6+ cells (187). High IL-17 increases neutrophil recruitment, suggesting it promotes 
inflammatory response making it a potential target for immunotherapy (187). 
 
DCL is a severe manifestation of CL, characterised by high antibody titers, TGF-β in 
circulation, and a defective cellular immune response against Leishmania antigens which is restricted 
to anti-parasitic responses, as responses to unrelated antigens rest intact (188). Human DCL patients 
have increased parasite numbers in skin lesions, as well as low levels IFN-γ, IL-2 mRNA, and high 
levels of IL-10, IL-4, IL-5. Therapeutic cure enhances IFN-y production with low IL-10, further 
suggesting the need for Th1 responses. In DCL, high antigen exposure may be responsible for T cell 
unresponsiveness, alternatively, T cell responses may promote localized parasite growth in the skin 
(189). DCL patients respond poorly to drug treatment and better results are obtained in combination 
with immunomodulation (IFN-γ and BCG plus antimonial treatment) (189).  
 
 
3.4. Generation of immunological memory is essential for vaccine development 
  
a) Human immunological memory  
Immunological memory is defined as the ability of the immune system to respond more 
rapidly and more effectively on a second encounter with an antigen; immunological memory is 
specific for a particular pathogen and is long-lived (55).  
Memory T cells are identified by the expression of CD45RO isoform, and by the lack of CD45RA 
isoform expression (CD45RO+CD45RA-) (190) (Figure I.17). CD45RA is considered a marker for naive 
T cells (CD45RO-CD45RA+). They are also categorized according to the expression of lymph node-
homing molecules, such as CCR7 – central memory T cells (TCM) express CCR7 and traffic to lymphoid 
tissues, and effector memory T cells (TEM) do not express CCR7 and migrate to peripheral tissues 
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(191). Both subsets produce effector cytokines in response to infection and other stimuli, yet TCM cells 
produce more IL-2, and TEM have higher proliferative capacity (191). Stem cell memory T cells (TSCM) 
are CD45RO-CD45RA+, similarly to naïve T cells, they also express co-receptors CD27 and CD28, IL-
7Rα, CD62L and CCR7, and most importantly, can differentiate into other subsets, including TCM and 
TEM, hence the designation. Current consensus lies in a differentiation lineage between the different 
T cell subsets, based on signal strength and degree of activation, from precursor to effector functions. 
TCM, TEM and TSCM all produce IFN-γ, TNF-α and IL-2 but vary in the proportion of cells producing these 
effector cytokines (191,192) (Figure I.17).   
 
 
Figure I. 17 T cell subset populations and differentiation (193). A) Memory TCD8+ cell differentiation. B) Memory 
TCD4+ cell differentiation. 
Overall, memory TCD4+ or TCD8+ memory cells in blood circulation rapidly produce IFN- γ 
and IL-2 upon non-specific stimulation with phorbol 12-myristate 13-acetate (PMA)/ionomycin and 
can produce multiple cytokines in effector responses. The presence of polyfunctional memory T cells 
is associated to strong recall and protective responses (191,194).  
Initial T cell recruitment site following an infection dictates the generation of memory cells 
and even a compartmentalization of pathogen-specific memory T cell responses, as observed by 
studies with canine leishmaniasis models (195), other viral infections (196,197), or Mycobacterium 
tuberculosis PPD intradermal administration (191) .  
The distribution is an important aspect regarding memory T cell populations, as most subsets 
were described in peripheral blood but there is evidence for memory T cell presence in tissues in mice 
and humans (191,192). Tissue-resident memory T cells (TRM), described initially in mice, have been 
shown to be present throughout the human body, with TCD4+ subsets persisting in either the mucosa 
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(CCR7-) or lymph nodes (CCR7+), and TCD8+ cells persisting mostly as CCR7- cells in peripheral tissue. 
Most of these cells express a putative marker CD69, absent in circulating memory T cells. Tissue-
specific properties have also been described – skin TRM express cutaneous lymphocyte antigen (CLA) 
and skin-associated homing chemokine receptors CCR4 and CCR10; TRM in the intestinal mucosa 
express gut-homing chemokines CCR9 and integrin α4β7 – suggesting tissue-specific mechanisms for 
memory generation (191,192). Most human TRM cells (bone-marrow, lung, mucosal) are 
polyfunctional for effector and cytolytic cytokines and produce IL-17, whereas skin-specific TRM 
produce IL-22.  
Immunological memory responses against Leishmania after drug treatment or self-healing 
involves central and effector memory TCD4+ and TCD8+ cells (57,80,198–200). 
 
b) Cell populations involved in immune responses against Leishmania parasites 
The Leishmanin skin test (LST), or Montenegro test, evaluates delayed-type hypersensitivity 
(DTH) reactions, a form of cell-mediated immunity elicited by an antigen in the skin stimulating 
sensitized Th1 CD4 and CD8 lymphocytes are methods used to evaluate infected individuals’ immune 
response to Leishmania (55). To detect Leishmania-specific responses, Leishmania antigen 
(Leishmanin) is injected intradermally in the skin, and induration is measured 48 to 72 hours after 
(generally indurations>5 mm are considered positive). While active VL patients are generally LST-
negative due to cell anergy, six months after successful chemotherapy, around 80% of patients 
become LST-positive. Hence, while the LST has little value for diagnostic purposes, it may prove useful 
to detect asymptomatic infections and/or previous exposure in epidemiological studies. 
Nevertheless, LST is rarely performed nowadays due to supply issues and lack of standardization in 
antigen production (12,201). 
In individuals with history of CL (L. major or L. tropica), studies have shown the presence of 
both TEM cells (CD4+CD45RO+CD45RA−CCR7−) that produce IFN-γ, and TCM cells 
(CD4+CD45RO+CD45RA−CCR7+) that produce IL-2, and their role in protective recall responses (202). 
An important role was also found for memory CD8+ TEM cell subsets (CD8+CD45RO+CD45RA-CCR7-) 
in recall responses in healed CL individuals after L. major or L. tropica infection (200). 
Similarly, it was shown that individuals who recovered from L. infantum infection, or who are 
asymptomatic, possess effective and specific memory responses against Leishmania (57). Stimulated 
PBMC from healed individuals showed increased CD69+ expression, a T cell activation marker, in both 
TCD4+ and TCD8+ cells, increased CD25 expressing in TCD8+ cells, and increased percentage of TCD4+ 
cells expressing memory marker CD45RO when compared with controls and individuals with 
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symptomatic disease (57). Asymptomatic individuals can control L. infantum infection through the 
presence of IFN-γ producing TCD8+ cells (53,203).  
Furthermore, studies with cured individuals after L. braziliensis infection have shown that 
while both CD8+ and CD4+ specific T cells are present, with the number of TCD8+ cells increasing after 
cure, CD4+ TEM cells are the main source of IFN-γ produced after antigenic stimulation (204,205). Also, 
cured CL patients show increased lymphoproliferative potential and higher IFN-γ production, while 
asymptomatic individuals infected with L. braziliensis have higher levels of IL-10, probably involved 
in the balance between immunoregulatory and effector responses responsible for parasite control 
without associated tissue damage (205).  
After therapy, parasite burden decreases along with Leishmania-specific immune responses, 
an equilibrium that appears to be essential for long-term protection – constant antigenic stimuli (due 
to reinfection or parasite persistence) can induce and maintain specific memory T cells but also 
contribute to a chronic activation of effector cells and T cell exhaustion.  
There is evidence that time after cure may influence host responses since a reduction in TCD4+ 
and TCD8+ cell activation is observed two years after the initial L. braziliensis infection and cure, and 
this is again consistent with increased regulatory responses (206). Differences between early lesions 
and late lesions (L. braziliensis) positively correlate the duration of illness with increased CD4+CD69+ 
T cells, and negatively with CD4+CD25+ T cells (207).  Furthermore, again during active CL caused by 
L. braziliensis, both CD4+ and CD8+ TEM cells (CD45RO+CCR7–) are present in lesion sites, in much 
higher frequency than TCM cells, and this enrichment in effector cells can be associated with 
immunopathology and tissue damage (207). Nevertheless, the recall responses present in healed 
individuals persist, and CD4+ and CD8+ TEM cells proliferate and produce IFN-γ after secondary 
stimulation, whilst having regulatory mechanisms that prevent immunopathology without the loss of 
protective immunity (206).  
Humans immunized with a whole crude vaccine (prepared from promastigote antigens from 
New World Leishmania species) are resistant to reinfection and mount similar responses to those 
found in recovered patients after L. braziliensis infection, showing IFN-γ production without IL-4 as 
well as a higher proportion of TCD8+ cells, consistent with a long-lasting protective role of TCD8+ 
cells (53,175,208,209). IL-4 production is only detected during active MCL infection (175).  
It is important to note, most human studies are performed with peripheral blood, and 
additional tissue-specific memory responses cannot be excluded.  
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c) Memory maintenance and concomitant immunity 
Memory T cell maintenance mechanisms remain unclear, and no successful human vaccine 
targeting cellular-mediated immunity exists, but there is evidence of long-lasting memory T cells. 
Even for antibody-based vaccines, as is the case of individuals vaccinated against the vaccinia virus, 
there are specific memory T cells in circulation 25 to 70 years after immunization (191,210). 
Moreover, a study has found a direct correlation between influenza-specific memory TCD4+ cells and 
reduced disease severity after challenge (211), and circulating memory TCD4+ cells are associated 
with non-progression of HIV infection (194).  
In mice, the cytokines IL-17 and IL-15 have been implicated in the maintenance of TCD8+ 
memory T cells, whereas TCD4+ memory cells need TCR and/or MHC-II signalling for their functional 
maintenance (191,192). In humans, these differences may be associated with tissue distribution 
where memory cells in the bone marrow, lymphoid tissue, spleen and blood can be maintained by IL-
17 and IL-15, and memory T cells in the mucosa are maintained by TCR cross-reactions due to the 
high antigen density (191,212–214). 
Interestingly, healed and asymptomatic individuals continue to carry viable parasites, in 
roughly constant numbers throughout their life (215,216). This is a very important aspect for 
infection transmission (217) and for potential relapse in immunosuppressive conditions (44), but 
also for memory generation and maintenance. Persistent parasites may be necessary for memory 
maintenance, as revealed by the fact that sterile cure of persistently infected mice makes them 
susceptible to secondary infection, and the prominent role of TEM cells in anti-Leishmania recall 
responses (218). As previously referred in 2.3, asymptomatic infection is much more common than 
active disease and even more than sterile cure, and these infections show low parasite levels, no 
pathology, and protective immunity against reinfection and/or disease severity.  
Persistent parasites appear to include two subpopulations: i) quiescent non-replicative 
parasites which can resist host immune responses; and ii) persistent replicative parasites, similar to 
acute infection parasites, maintained through a numbers game between active parasite replication 
and immune clearance (215,218) (Figure I.18). HIV-Leishmania co-infection case studies, wherein an 
underlying Leishmania infection becomes active upon immunosuppression (219–221), and the 
reactivation of latent infection after administering iNOS or IFN-γ inhibitors in mice (222), further 
support this model. Also, constant parasite replication and killing help maintain the effector memory 
T cells, and agrees with the loss of immune protection after sterile cure (57,198,215,223,224).  
This process of memory maintenance is named concomitant immunity. Immune memory 
against Leishmania is mediated through continuous cell priming that maintains memory cells in 
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circulation and in the skin, allowing for a small number of parasites to develop and replicate inside 
APC and maintain the memory cell populations responsible for protective immunity (53,215) (Figure 
I. 18). In mouse models, protection against L. major reinfection is associated to parasite persistence 
mediated by CD4+CD25+ Treg cells that produce IL-10 (218,225,226).  
 
 
Figure I. 18 Model for the maintenance of concomitant immunity against Leishmania parasites (227). 
In humans, there is evidence for TEM and TCM cells participation in maintaining immunity 
against CL, and only TEM require persistent parasite antigens (80,202). After treatment, parasites 
persist in original site of infection, partly due to IL-10 mediated mechanisms. Persistent parasites 
maintain CD4+ TEM cells that protect against reinfection (161,218). Alternatively, long-lasting central 
memory TCD4+ cells (TCM) develop in the absence of persisting antigens and acquire effector 
functions upon reinfection (223). TCM require additional IL-12 signals to fully develop into functional 
Th1 cells. In the absence of IL-12, they can convert into IL-4 producing cells. These cells are generated 
early in infection and are responsible for clearance of primary infection and control of secondary 
infections (174). Lastly, skin-resident memory TCD8+ cells (TRM) are also maintained in the absence 
of persistent parasites and provide protection against L. major in the mouse model (198,228). In mice, 
TRM induce the recruitment of inflammatory monocytes, which produce ROS and NO, contributing to 
the control of parasite growth (228). CD69+CCR4+CCR10+CLA+ skin TRM cells may be important targets 
in anti-Leishmania vaccination (198). 
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- Early immune responses greatly impact subsequent adaptive response; 
- Both TCD8+ and TCD4+ cells mediate protection or susceptibility to Leishmania infection; 
- IFN-γ is absolutely required to control the parasites sufficiently and control the disease; 
- IL-4 is associated with the development of a non-protective Th2 phenotype; 
- Human memory subsets involved in long-lasting protection are not very well described, but 
an important role for TEM and TCM was described; 
- Memory maintenance against Leishmania is associated with parasite/antigen persistence. 
 
 
3.5. Leishmaniasis is a vaccine-preventable disease 
 
Overall, the main observations supporting vaccine feasibility are: i) protection against 
reinfection following spontaneous or drug-induced recovery; ii) protection can be induced through 
leishmanization; iii) Th1 cells are essential for resistance; iv) TCD4+ and TCD8+ cells are involved in 
immune memory.  
The strongest evidence supporting the idea of inducing protection against Leishmania 
infection comes from leishmanization (LZ), the deliberate inoculation with live, virulent L major 
parasites (229,230). The intradermal inoculation of naive individuals with live promastigotes mimics 
a natural cutaneous infection, inducing self-resolving lesions, typically smaller than by natural 
infection, which in turn protect the individual from secondary infection (229,230). The outcomes of 
LZ reflect the natural host response diversity observed in natural infection, with most of the 
individuals developing a self-healing lesion and some being able to control infection and never 
develop a lesion. LZ was used in large scale control programs in endemic countries in Asia and Middle 
East (namely in Uzbekistan, Iran, Iraq) until the 80‘s, and has proven to be efficacious against Old 
World CL (231).  
LZ-induced protection is associated with parasite persistence and development of 
concomitant immunity (see 3.4.c). This protection is T cell-mediated: IFN-γ-producing TCD4+ cells are 
recruited to dermal site of infection, where they perform effector functions including activating 
microbicidal mechanisms in infected macrophages (232–234).  
This protection depends on high parasite virulence and infectivity, as low virulence parasites 
stimulate DTH responses but do not provide protection (174,232). LZ has also been proposed as an 
assay to measure vaccine candidates’ efficacy, as it stands as the gold-standard regarding correlates 
of protection (231). LZ was abandoned due to logistical and safety issues related to dose control, 
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strain and virulence standardization, and also the occasional development of persistent lesions and 
associated ethical concerns (229,230).  
LZ can provide cross-protection against VL and there is further evidence for cross-species 
protection:  
i) L. major-infected CL patients seem to be protected against L. infantum infection (235,236);  
ii) longitudinal studies have shown that humans in L. major endemic areas in Sudan are 
protected against L. donovani VL (237);  
iii) a CL-causing L. donovani clinical isolate from Sri Lanka protects mice against visceral disease 
(238);  
iv) in experimental VL, C57BL/B6 mice infected with L. major are protected from L. infantum VL, 
associated with the recruitment of IFN-γ producing Ly6C+ CD4+ cells to skin and visceral 
organs (162). 
 
Also, several parasite-related factors support the development of a vaccine against leishmaniases 
(239,240): 
i) No significant antigenic variation is observed between Leishmania spp. life stage forms 
(detailed in chapter II);  
ii) The preferential host target cell is the macrophage, and current tools allow for modulation 
of macrophage intracellular killing and functional enhancement; 
iii) High level of antigenic conservation among pathogenic species (detailed in chapter II); 
iv) New suitable Th1-inducing adjuvants are today under development (see Table I.3);  
v) Parasite – and vector-associated antigens can be used to induce protection. 
 
The three available canine vaccines (CaniLeish®, LeishTec® and Letifend®) provide additional 
evidence that it is possible to induce protection against leishmaniasis through immunisation in the 
dog model.  
Thus far, no major breakthroughs in the development of a second-generation vaccine were 
observed. There are many gaps in the knowledge about immune responses against Leishmania, 
correlates of protection and even knowledge on the number of natural challenges after the first 
inoculation. From 11 published studies testing first generation vaccines (fractions of the parasite or 
whole killed Leishmania with or without adjuvants), only 4 showed a decrease in human infection, 
measured by LST or Montenegro skin test (MST) seroconversion, highlighting the need for better 
methods to assess of T-cell mediated responses and correlates of protection (241).  
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Several inactivated/killed and subunit vaccines have all shown to be quite ineffective in 
human hosts, despite promising results in animal studies (242). Also, vaccines tested in endemic 
regions have not performed as well as when tested in healthy volunteers (226,242). There seem to be 
several underlying issues at play: the use of mouse models to validate antigen candidates (golden 
hamsters as promising alternative as an experimental VL model); intravenous challenges instead of 
natural challenge used in the experimental designs; the ability of the immune system to effectively 
recognize live, but not killed, parasites (242); and the methods to test and measure protective 
immune responses (226). 
 
Vaccine feasibility:  
- Natural protective immunity after recovery from infection;  
- Leishmanization; 
- Cost-effectiveness studies; 
- Parasite-related features. 
 
Main challenges for leishmaniasis vaccine development: 
- No cellular immunity-inducing vaccine available; 
- Lack of approved Th1-inducing adjuvants for human vaccine development; 
- Lack of reliable correlates with immune protection; 
- Poor translation from animal models; 
- Undefined optimal administration route. 
 
3.6. Immune correlates of protection against leishmaniasis  
 
Specific immune correlates of protection, defined as measurable immune responses that are 
responsible for and statistically interrelated with protection (243), are largely unknown and non-
standardised in vaccine development against Leishmania. The mechanisms behind protection, and 
their evaluation, must be understood so that an effective vaccine is developed.  
 
As detailed above, the resolution of human CL depends on Th1 cells that secrete IFN-γ and 
activate macrophages for intracellular parasite killing. Similarly for VL, if Th1 cells are absent, or if 
Th2 cells are predominant, patients develop chronic progressive VL (160,244).  
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The major role attributed to TCD8+ cells during anti-Leishmania immune responses is via IFN-
γ secretion that, in turn, will induce nitric oxide production and resistance against reinfection, as well 
as cytotoxic activity towards infected macrophages (244–246). TCD8+ cell-produced IFN-γ has been 
implicated in both resistance and immunopathology (247).  
The known role of TCM and TEM populations in long-lasting protective responses should be 
explored to assess the quality of induced responses after immunisation and evaluate protection 
throughout time. 
 
 Antibody production, used as a correlate of protection for currently available antibody-based 
vaccines, does not provide quality evidence of protective responses against Leishmania. .  
VL and DCL are associated with high parasite burdens and, as infection progresses, DTH responses 
become poor and total antibody titres rise (248). The anti-Leishmania antibodies detected by the 
diagnostic tests rK39 (India) or rK28 (Africa) persist many years after cure, which can be due to 
repeated exposure or parasite persistence, and cannot distinguish between asymptomatic, previous 
or current infection (248). The presence of IgG2 antibodies is detected in healed patients, however, 
they are not actively functional in infection control (60). On the contrary, there are reports showing 
a deleterious effect by IgG antibodies in animal models, through the production of IL-10 by 
macrophages after binding to the Fcγ receptor (249).  
 
Da-Cruz et al performed studies with healed patients infected by L. braziliensis, and suggested 
two markers for protective immunity: i) cure is correlated with high, but decreasing, numbers of 
Leishmania-specific TCD4+ cells, in the absence of IL-4; and ii) decreasing levels IL-5 are associated 
with long-term cure (175). These data are confirmed by studies with healed patients after L. major 
infection (250). In MCL long-term healing, 1 to 17 years after treatment, there is a slight increase in 
TCD8+ subpopulation for a final ratio TCD4+/TCD8+ of around 1 (175). After treatment and parasite 
elimination, it is expected that the population of effector TCD8+ specific cells will retract. The 
maintenance of specific TCD8+ cells in circulation, and that can re-expand and differentiate upon 
restimulation, is probably mediated by the TCD4+ cell population. Interestingly, although MCL healed 
patients showed increasing IFN-γ levels, these were variable, with high and low responders. Probably, 
persistent Th1 CD4+ cells, together with decreasing proportions TCD4+ and TCD8+ specific 
populations in the absence of IL-4 production, are important for infection control and prevention of 
relapse (175).  
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Polyfunctional T cells produce several effector cytokines simultaneously and often in higher 
amounts, particularly pro-inflammatory cytokines IFN-γ, TNF-α, and IL-2. Polyfunctionality broadens 
the range of effector functions, and has been implicated in the development of vaccines against 
intracellular pathogens, i.e. targeting cellular-mediated immunity (251–253). Polyfunctionality 
correlates with T cell efficacy and can be used during vaccine development, for the design of 
candidates that target such responses and to analyse vaccine-induced responses (254).  
The magnitude of response, as in the number of antigen-specific effector cells, is used for 
humoral responses as a correlate of protection (253). However, the quality of a given immune 
response, determined by the effector functions (proliferation, cytotoxicity, cytokine and chemokine 
production) and associated with polyfunctionality, is a better determinant for protection than the 
magnitude of response (253). Considering this, a high-quality response is one that specifically 
balances different effector functions to produce an effective and long-lasting protective immune 
response. Also, the diversity of antigens targeted by specific T cells (breadth of response) can be used 
as a correlate of protection – in studies with HIV patients, broader antigenic diversity correlates with 
protective immune responses (255).  
Leishmania-specific Th1 cells that produce IL-2 and/or TNF-α are mostly CCR7+ TCM cells; 
(256). It is possible that polyfunctional cells differentiate into IFN-γ-producing (only) T cells due to 
chronic antigen exposure (257), so vaccines must induce adequate Th1 responses, neither too low 
nor too high, to assure both effector functions and memory maintenance. These responses depend of 
antigen dose, stimulation duration, antigen-presenting cells targeted, and the early cytokine 
environment induced by the vaccine formulation (253,258).  
 
Second and third generation vaccines typically do not induce antigen persistence, which is 
probably required to maintain anti-Leishmania immunity (157,218), as it occurs in natural infection 
or whole-organism vaccines. In highly endemic areas, natural boosts may occur, nevertheless, this is 
an important aspect to consider and include during vaccine design and preclinical development, and, 
for example, adapt vaccination schedules to include boost immunizations. 
 Finally, it has been demonstrated that memory responses in vaccinees correlate with the 
number of precursor cells in the naïve repertoire (259–261). This crucial feature should be exploited 
during the preclinical development of vaccine candidates through the comparison of immunogenicity 
profiles induced by the antigens in different immune backgrounds – naïve, healed VL, healed CL, etc. 
Antigens that correlate both with the presence of memory responses and the existence of naïve 
precursor cells are strong candidates for a successful vaccine formulation, able to induce memory in 
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naive individuals (prophylactic vaccine) or boost existing responses to help control infection 
(therapeutic vaccine). 
 
In summary, the most important markers of immunity against leishmaniasis are: a 
predominant Th1 response and with the presence of polyfunctional TCD4+ cells (IFN-γ, IL-2, TNF-α), 
and with low IL-10 (80). This immune environment will ultimately favour the production of effector 
anti-leishmanial molecules such as reactive nitrogen and oxygen intermediates for parasite control 
(63,68,141). Also, a relevant aspect for the induction of immunity against Leishmania seems to be the 
need for a balanced ratio between IFN-γ/IL-12 and IL-10/IL-4 (159), which should be preserved to 
prevent immunopathology and assure memory generation and maintenance. 
 
The lack of well-established correlates of protection hinders vaccine development against 
leishmaniasis: 
- Mouse models are of limited extrapolation to human disease and should not be used to 
screen potential candidates designed for human vaccine formulations; 
- Protective responses against Leishmania are characterised by mixed Th1/Th2 responses 
with predominant IFN-γ and low IL-10; 
- Memory T cells (CD45RO+) present in healed individuals are expected to proliferate and 
acquire effector functions after vaccine antigen stimulation; 
- Vaccine candidates should induce Th1 cellular responses, and respective associated 
cytokines, maintaining the balance high IFN-γ/IL-12 and low IL-10/IL-4; 
- Cell surface phenotype should be performed to identify the cell populations involved in the 
induced responses; 
- It is advisable to include a complete panel of induced cytokines (Th1, Th2, Th17 and Treg) to 
assess polyfunctionality and to better elucidate the immune mechanisms induced by the 
vaccine candidates. 
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4. Vaccines against human leishmaniasis 
 
Since the end of leishmanization, several attempts were made to develop other first 
generation vaccines (killed or live attenuated Leishmania parasites), as well as second generation 
(recombinant proteins or peptide-based vaccines) or third generation vaccines (DNA-based vaccines) 
(106,262,263).  
Several first generation vaccines using crude antigens from Leishmania promastigotes, 
prepared with or without BCG as the adjuvant, were tested in human clinical trials. These candidates 
were found to be safe but generally ineffective, as is the case of autoclaved L. major (ALM) vaccine 
which showed results comparable to BCG injection alone (169). Highly variable efficacy levels were 
reported against CL (0-75%) and very low efficacy against VL (169). Three other first generation 
vaccine candidates have been tested: 'Mayrink vaccine‘; 'Convit vaccine’ and 'Razi Institute vaccine‘ 
with inconclusive or negative results for prophylaxis potential, but somewhat encouraging for 
therapeutic indications (264). These studies, although unsuccessful in launching a vaccine against 
leishmaniasis, further established the vaccine feasibility. Moreover, they paved the way for the 
development of second and third generation vaccines. Second and third generation vaccines need to 
be formulated with an adjuvant to increase immunogenicity and response specificity.   
 
 
4.1. Current vaccine pipeline 
 
In the last decades, several antigens have been explored as candidate antigens for both 
prophylactic and therapeutic second-generation vaccines against leishmaniasis. These antigens will 
be further characterised in chapter II.  
 
The most advanced vaccine candidates are described below. 
 
The vaccine candidate Leish-111f (also named LEISH-F1 or MML) was the first subunit 
vaccine to progress to human phase I and II clinical trials, safety and immunogenicity testing in 
healthy subjects (265). Leish-111f consists of a chimeric recombinant protein containing three 
antigens in tandem (Leishmania elongation initiation factor, LeIF; L. major stress-inducible protein, 
LmSTI1; and thiol-specific antioxidant, TSA), combined with monophosphoryl lipid A-stable emulsion 
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(MPL-SE), and induces a potent Th1-type immune response (265). This formulation was tested in five 
clinical trials:  
i) Phase I trials in 2005, “Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults 
Not Previously Exposed to Leishmania Parasite” and “Safety Study to Evaluate the Leish-111f 
+ MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects 
Previously Exposed to the Leishmania Parasite” in Colombia (ClinicalTrials.gov Identifiers: 
NCT00121862 and NCT00121849, respectively);  
ii) Phase I trials in 2005-2007, “Study to Evaluate the Leish-111F + MPL-SE Vaccine in the 
Treatment of Mucosal Leishmaniasis” in Peru, and “Study to Evaluate the Leish-111F + MPL-
SE Vaccine in the Treatment of Cutaneous Leishmaniasis” in Brazil (ClinicalTrials.gov 
Identifiers: NCT00111514 and NCT00111553, respectively);  
iii) Phase I trial in 2005-2006, “Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the 
Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the 
Leishmania Parasite” (ClinicalTrials.gov Identifier: NCT00121849);  
iv) Phase I trial in 2007-2015, “Open-Label Safety Study of Three-Antigen Leishmania Polyprotein 
with Adjuvant MPL-SE in Healthy Adults in India” (ClinicalTrials.gov Identifier 
NCT00486382).  
 
The LEISH-F1+MPL-SE vaccine was partially protective in experimental VL, but ineffective 
against canine leishmaniasis in phase III field trials (266). In human trials, this formulation was found 
to be safe and well tolerated, and immunogenic against VL and CL (230). Furthermore, LEISH-F1 
showed therapeutic efficacy against MCL, in terms of accelerated time to cure, when used in 
combination with chemotherapy (267). 
Researchers at the Infectious Disease Research Institute (IDRI) redesigned Leish-111f into a 
new construct Leish-110f (also named LEISH-F2), to better comply with regulatory and manufacture 
concerns – the 6-Histidine tag near the amino terminus was removed, and the residue Lys274 was 
replaced by glutamine, so to eliminate an apparent proteolytic site (230,268). The safety, 
immunogenicity and efficacy of the LEISH-F2+MPL-SE candidate were tested in a phase I clinical trial 
with promising results, and in a phase II trial to assess its immunotherapeutic potential against CL in 
comparison with standard chemotherapy with SSG (showing very limited success): 
i) Interventional Phase I trial in 2009-2011, “Safety and Immunogenicity of the LEISH-F2 + MPL-
SE Vaccine with sodium stibogluconate (SSG) for Patients with PKDL” in Sudan 
(ClinicalTrials.gov Identifier NCT00982774); 
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ii) Interventional Phase II trials in 2009-2013, “A Study of the Efficacy and Safety of the LEISH-
F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis” in Peru (ClinicalTrials.gov 
Identifier NCT01011309). 
 
A third vaccine candidate was developed by IDRI, LEISH-F3. From previously identified 43 
antigen candidates recognised by VL patients’ serum from Sudan, researchers applied rational 
criteria (sequence conservation among species, low homology with human proteins, and proved 
efficacy in animal models) and selected two proteins - L. infantum/donovani nonspecific nucleoside 
hydrolase (NH) and sterol 24-c-methyltransferase (SMT). These proteins were combined to form the 
recombinant protein LEISH-F3 and adjuvanted with either MPL-SE, glucopyranosyl lipid A 
formulated as stable emulsion (GLA-SE), or second generation lipid adjuvant stable emulsion (SLA-
SE) (269). 
 
The LEISH-F3 vaccine candidate was tested in three clinical trials to assess safety and 
immunogenicity of the different formulations (270):  
i) Interventional Phase I trial in 2011-2013, “Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult 
Volunteers” in USA (ClinicalTrials.gov Identifier NCT01484548);  
ii) Interventional Phase I trial in 2012-2016, “LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE 
Vaccine” in USA (ClinicalTrials.gov Identifier NCT01751048);  
iii) Interventional Phase I trial in 2014-2016, “Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy 
Adult Volunteers” in USA (ClinicalTrials.gov Identifier NCT02071758).  
 
Later, the LEISH-F3 candidate was slightly modified with the addition of the cysteine protease 
B (CPB) to increase antigen recognition and extend the geographical affectation of the vaccine (271). 
This new candidate was formulated with GLA-SE and is called LEISH-F3+. This vaccine has evaluated 
in experimental infection models (hamsters) and has shown to provide robust immunity, similar to 
LEISH-F3 (271). The LEISH-F3+GLA-SE vaccine candidate was also proven to be safe, and induced 
strong and specific immune responses, measured by cytokine production and immunoglobulin 
subclass information. This candidate should, therefore, be tested in additional clinical trials in 
endemic countries, in populations susceptible to Leishmania infection (269). 
 
Another promising candidate in the pipeline is the ChAd63-KH vaccine candidate, also named 
Leish2a, developed by researchers at York University. It consists of a chimpanzee adenovirus-based 
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vaccine (ChAd63) carrying a synthetic HASPB gene linked to a KMP11 gene with a viral 2A sequence 
(272). This candidate progressed to a Phase I clinical trial where the safety profile was confirmed, 
and strong TCD8+ cellular responses were observed (273). The Leish2a vaccine was also assessed in 
a Phase II clinical trial in Sudan to test safety and induced immune responses in individuals with 
persistent PKDL infection (ClinicalTrials.gov Identifier: NCT02894008, “A Study of a New Leishmania 
Vaccine Candidate ChAd63-KH (Leish2a)”).  
 
In earlier stages of development, there is also a new candidate developed by the European 
FP7 network MuLeVaClin, which is based on defined Leishmania antigens KMP11 and LeishF3+, and 
sand fly saliva antigen LJL143, formulated into Influenza virus-like particles (VLP) and adjuvanted 
with GLA-SE, a TLR-4 agonist (274). Pre-clinical studies in the mouse model show this candidate is 
safe and immunogenic, particularly against the vector-derived antigen (274). 
 
Furthermore, other polypeptidic/chimeric vaccines against leishmaniasis are in pre-clinical 
stages of development, and were validated in human samples.  
The protein Nucleoside Hydrolase NH36 is the main component of the Leishmune® vaccine, 
once commercialised in Brazil. The immunogenicity of three NH36 polypeptides (N-terminal, central, 
C-terminal domains) was tested pre-clinically with samples from cured CL and VL patients, from areas 
endemic to L. infantum in Spain (275). Recombinant NH36 and the N-terminal domain (F1) induced 
lymphoproliferation in samples from cured and asymptomatic individuals, accompanied by increased 
IFN-γ, TNF-α and granzymeB production. Also, F1 induced IL-17 production cured CL patients and 
asymptomatic patients. Additional studies were performed with samples from healed and 
asymptomatic individuals, from areas endemic to L. braziliensis in Brazil (276). Here, the F1 domain 
induced Th1 and Th17 responses in cured/exposed patients infected with L. (L.) infantum (chagasi).  
The polyprotein KSAC includes fragments of the proteins KMP11, SMT (24-c-
methyltransferase), A2 (A2 amastigote-specific protein), and CPB (cysteine protease B) (277). KSAC 
formulated with monophosphoryl lipid A (MPL-SE) induced antigen-specific multifunctional Th1 cells 
and conferred protection against L. infantum and L. major challenge in mice. Post-challenge responses 
in the KSAC/MPL-SE-vaccinated mice show higher IFN-γ/IL-4 ratios and decreased IgG1 responses 
to SLA (268,277).  
 
A recombinant chimeric protein composed by T cell epitopes specific to human and mice MHC 
alleles and derived from 4 Leishmania infantum proteins (LiHyp1, LiHyp6, LiHyV and HRF proteins) 
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was formulated with saponin and tested in BALB/c mice. Vaccinated mice and challenged with L. 
amazonensis were protected against infection. The candidate induced a specific IFN-γ, IL-12 and GM-
CSF production, lower IL-4 and IL-10 levels, as well as high IgG2a isotype antibody levels. In addition, 
antileishmanial nitrite production by splenocytes was detected. Interestingly, the recombinant 
protein administered alone induced a partial protection against challenge (278). 
 
4.2. Leishmania Excreted-Secreted Antigens as promising vaccine candidates 
and the successful canine vaccine CaniLeish®  
 
Leishmania excreted-secreted proteins (ESP or ESA) are important virulence factors, and are 
implicated in early host-parasite interactions, establishment of infection and in the regulation of host 
immune responses (279–281). Their role in the modulation and evasion of the host immune 
responses is reviewed in Holzmuller et al 2018 (2).  
In the last decades, particularly after the completion of genome and proteome annotation of 
several pathogenic Leishmania species, these excreted-secreted proteins were further characterised. 
Additionally, ESP have been shown to be processed and presented by antigen-presenting cells (127), 
as well as, to trigger protective cellular immune responses (282–285). Gour et al described the 
fractions F1 (11, 13 and 16 KDa) and F3 (26, 29 and 33 KDa) from Leishmania ESA, which contained 
Th1-inducing proteins (283). Interestingly, several of the antigens used in the most advanced vaccine 
candidates are found in the Leishmania secretome, such as KMP11, nucleoside hydrolase, thiol-
specific antioxidant (TSA) or translation initiation factors (detailed in chapter III – Vaccine Antigen 
Selection).  
 
The Lemesre lab (UMR177, IRD, France) developed a method for the production of naturally 
excreted-secreted antigens from culture supernatants of L. infantum promastigotes, and evaluated 
their potential use in a vaccine formulation. Notably, LiESAp were shown to provide significant 
protection in dogs by inducing a strong and long-lasting Th1 response, leading to the development of 
the european canine vaccine Canileish® (284,286). The adaptation and scaling-up of this vaccine for 
human use is impossible due to elevated costs, and because the active principle remains undefined, 
although likely to contain a plethora of different protein antigens, which may induce non-specific 
responses and/or response variability. Also, this vaccine is formulated with QA-21 (purified extract 
of Quillaja saponaria) as adjuvant, which is currently not approved for human use. However, QA-21 
is derived from the QS-21 adjuvant which has been approved for human use by the FDA. 
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The canine vaccine is well-tolerated and safety studies did not show any significant adverse 
effects (286,287). However, a study in Spain has revealed a high rate of adverse yet mild reactions in 
vaccine users included in the survey (82%), the most frequent being local reactions, apathy, fever and 
gastroenteritis (288). Still, one often overlooked aspect is that each vaccine dose contains a fixed 
amount of QA-21 adjuvant, which is not adapted to the dog’s weight. This highlights the need for 
optimal selection and dosage of the adjuvant used human vaccine formulations. An epitope-based 
approach and new Th1-inducing adjuvants will greatly mitigate these concerns. 
 
Some attempts were made to identify the protective antigens contained in total ESP 
preparations. From Leishmania excreted/secreted proteins, research developed at the Lemesre Lab 
showed that soluble Promastigote Surface Antigens (PSA) is an immunodominant component of L. 
amazonensis and L. infantum secretome, and highly conserved among Leishmania species (289). 
Moreover, the vaccinated dogs with recombinant PSA (rPSA) of L. amazonensis or its carboxy-
terminal part, both combined with QA-21 as adjuvant, were protected at 78.8% and 80%, respectively 
(290). This cross-protection was associated with hallmarks of a dominant Th1-type immune 
response. In L. infantum and L. major-protected humans (healed individuals), it was also clearly 
demonstrated that the rPSA induced a dominant Th1 response associated to cytotoxicity in vitro. 
During the FP7-funded RAPSODI project (2009-2012), the Lemesre Lab and collaborators developed 
a vaccine candidate containing the Promastigote Surface Antigen (PSA) from L. amazonensis, whose 
immunogenicity was validated on human cells (282). However, the very low productivity of 
recombinant LaPSA would result in an expensive vaccine, which is unfeasible for human mass 
vaccination. As peptide production is far less expensive, the adopted approach was to select only 
peptides derived from proteins of interest for vaccine development. 
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4.3. Peptide-based vaccines 
 
 The final formulation is of extreme importance for the development of an effective vaccine to 
be deployed in low-resource settings. The ideal target product profile (TPP) for a vaccine against 
leishmaniasis englobes: 
i) good safety profile;  
ii) a minimum number of immunizations and boosts needed;  
iii) the absence of animal products and impurities;  
iv) cost-effectiveness;  
v) a prophylactic and therapeutic effectiveness;  
vi) optimal delivery;   
vii) preferably, the lack of cold-chain supply (169,270).  
 
A peptide-based vaccine formulation would answer many of these requirements (291). 
Peptide-based vaccines explore the minimal immunogenic units necessary to induce protective 
immune responses (epitopes) and have become an increasingly important tendency in vaccine 
development  (291,292). Peptide-based approaches allow for a highly specific stimulation of host 
immune responses, while decreasing the risk of unwanted cross-reactions and other adverse 
reactions (292).   
 
Several epitope discovery strategies have been exploited in peptide-based vaccine design 
(293,294), particularly: 
i) in silico epitope mapping through HLA-binding epitope prediction, selection of 
conserved antigens by phylogenetic analysis, protein localization prediction or 
through reverse vaccinology approaches;  
ii) phage display assays; 
iii) immunodominance assays and peptide competition assays. 
 
An epitope-based approach, in contrast to subunit recombinant protein or inactivated live 
vaccines, offers several advantages, namely: i) easiness of production, ii) superior stability and no 
need for cold-chain supply; iii) higher purity and absence of potentially harmful substances; iv)  lower 
antigen complexity; v) low scaling-up costs; vi) high response specificity; and vii) ability to combine 
epitopes to design multi-epitopic and/or multi-specific vaccines (292,295).   
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From the CaniLeish® and recombinant PSA development studies, our lab has identified the 
main immunogenic portion from carboxy-terminal region of rPSA, representing 19.4% of the rPSA 
sequence. Vaccinated dogs with three peptides derived from this region, combined with QA-21 as 
adjuvant, were protected at 60% (Petitdidier E. et al. submitted). This protection level is significant 
given the small size of the immunogenic peptides used in this vaccine formulation, in comparison to 
total rPSA (78.8% of protection) or PSA carboxy-terminal region (80% of protection).  This study 
clearly demonstrates peptide-based vaccines are a promising approach for the design of vaccines 
against leishmaniases. 
In human leishmaniases, we need to consider the diversity of Leishmania species and HLA 
diversity due to population variability from numerous endemic areas.  
Altogether, peptide-based vaccines are a promising approach for the design of vaccines 
against leishmaniases, through the ability to include multiple immunogenic and conserved epitopes 
from various protein antigens, increasing the chances of immunogenicity and both parasite strain and 
target population coverage.  
However, short peptides are known poor immunogens when administered alone. The main 
associated challenges are the avoidance of inactivation or degradation by the host immune system, 
and the enhancement of peptide immunogenicity. This low immunogenicity can be overcome with 
the addition of adjuvants in the final vaccine formulation that direct and boost the induced responses. 
There is the need to improve adjuvants for the final vaccine formulations, adjuvants that are more 
efficacious, less toxic, and approved for human use (226). Some new promising adjuvants are being 
developed, particularly Th1-inducing adjuvants and TLR agonists, which can be used in anti-
Leishmania vaccine formulations (Table I.3.) 
 
Table I. 3 Toll-like receptor agonists and Th1-inducing adjuvants for use in vaccine formulations, adapted from 
(239). 
Adjuvant Class Mechanism of action Type of immune response 
Lipid A analogues 
(e.g., MPL, GLA) 
Immunomodulatory 
molecule 
Toll-like receptor 4 Antibody, Th1 
Imidazoquinolines 
(e.g.,Imiquimod, R848) 
Immunomodulatory 
molecule 
Toll-like receptor 7 / 8 Antibody, Th1 
CpG ODN 
Immunomodulatory 
molecule 
Toll-like receptor 9 
Antibody, Th1, Th2, TCD8+ 
cells 
Saponins (e.g., QS21) 
Immunomodulatory 
molecule 
Unknown 
Antibody and cell-mediated 
immune responses 
Virosomes Particulate formulation Antigen delivery Antibody, Th1, Th2 
GLA-SE Combination Toll-like receptor 4 Antibody, Th1 
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In summary, the most important bottlenecks in peptide-based vaccine design are the epitope 
choice, the adjuvant selection and availability; and vaccine administration. Despite vaccines targeting 
cellular immunity are not yet available, recent advancements human Th1 inducing adjuvants make 
this objective are a closer reality. 
Moreover, synthetic peptides present great versatility for adaptation to innovative delivery 
systems (292,295). The exploitation of innovative approaches should also be considered for anti-
Leishmania vaccine development, such novel devices for optimal intradermal delivery (i.e. dermal 
patches, nano-delivery systems, etc) that ensure proper immune response priming throughout time 
(296). Also, chimeric proteins combining peptides, polyproteins and delivery vectors are promising 
formulations. 
 
4.4. Leishmania-specific peptides tested in human cells 
 
Potential peptides are tested for immunogenicity in mice or human PBMC. Most 
immunogenicity testing of candidate proteins and peptides in leishmaniasis vaccine development 
have been performed in mouse models. Although these models provided important insights into 
Leishmania pathogenesis and host immunity, they are inconclusive in terms of vaccine antigen design. 
Many vaccine candidates under development fail in early stages of clinical development probably due 
to weak antigenicity and lack of predictive animal models. Promising candidates against 
leishmaniasis developed with animal studies often were unsuccessful in human trials (297,298). The 
failure of protective vaccines in human trials may be because of differences in peptide processing 
(TAP binding) and presentation between murine H-2 and human HLA systems. In which case, 
humanized animal models may provide a useful tool for vaccine preclinical development. 
 
Still, some peptide vaccine candidates against Leishmania were tested in human PBMC. These 
studies used mostly samples from LST+ or healed patients, and lymphoproliferation and cytokine 
production by ELISA as readout. Briefly, studies testing Leishmania-specific peptide immunogenicity 
in human immune cells are:  
 
i) Russo 1993 (299): peptides from L.major GP63 (13 peptides with 14 a.a.) (300), three of 
which increased PBMC proliferation, and IFN-γ production. Epitope prediction was 
performed with an algorithm developed by Rothbard and Taylor (301) based on sequence 
motifs based on known human, mouse and guinea pig epitopes. 
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ii) Delgado G 2003 (302): peptides from L. panamensis KMP11 (6 peptides with 20 a.a. 
spanning the whole protein sequence) induced lymphoproliferation and IFN-γ production 
by T-cells. Authors assess peptide binding to HLA molecules with binding assays 
performed with four purified HLA-DR molecules (DRB1* 0101, 0401, 0701 and 1101). 
Donors were HLA-typed (PCR to amplify the exon 2 of the DRB gene) and the correlation 
between in vitro immune response and peptide binding assay predictions was 
ascertained. 
iii) Basu R 2007 (303): peptides from L. donovani KMP11 (84 octamers spanning the whole 
protein sequence), some of which induced IFN-γ, IL-10 and IL-17 production by TCD8+ 
cells and increased splenocyte proliferation. Authors propose potential HLA restriction 
according to the experimental data and donor HLA typing (HLA-A, -B and –C alleles). 
iv) Seyed N 2011 (304): peptide pools from L. major antigens (18 nonamers from CPB, CPC, 
TSA, LeIF, LmSTI, LPG) increased IFN-γ production by TCD8+ cells. The six protein 
antigens were examined for epitopes restricted to the HLA-A*0201 allele using in silico 
HLA-binding prediction algorithms (see Chapter IV). Authors used a 2-step epitope 
selection pipeline using 2 prediction algorithms (SYFPEITHI and BIMAS) and 5 five other 
algorithms (EpiJen, Rankpep, nHLApred, NetCTL and Multipred) which further filtered 
the peptide list and, finally, analysed with NetMHCpan1.1 to check for the possibility of 
binding to different alleles of HLA-A2 supertype (HLA- A*0202-A*0206 and A*0209). 
BLAST was then used to reject peptides that were 100% identical with mice and human 
proteins. 
v) Elfaki ME 2012 (305): peptides from L. donovani GP63 (4 peptides with 15-21 a.a.), two 
of which increased IL-10 production, while another peptide and peptide pools decreased 
IL-10 production, with no significant IL-4 production. Epitope prediction was performed 
with EpiMatrix (www.immunome.org/iVAX/) for alleles DRB1*1101 and DRB1*0804 and 
a panel of 8 HLA-DR “supertype” alleles (> 90% of human populations worldwide). 
Peptide hydrophobicity analysis and BLAST against the human genome were performed.  
vi) Naouar I 2016 (306): peptides from L. major antigens (78 nonamers from 33 proteins), 
six of which induced cytotoxicity, assessed by granzyme B production, but low IFN-γ and 
IL-10 levels were found in PBMC culture supernatants. Epitope prediction was performed 
for the HLA-A*0201 allele and proteasomal cleavage prediction (RANKPEP algorithm, 
imed.med.ucm.es/Tools/rankpep.HTML). Affinity to HLA-0201 alleles was assessed with 
stabilisation assays. 
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vii) Freitas e Silva R 2016 (307): ten peptides (15-mer) conserved in L. braziliensis, L. major 
and L. infantum discovered with a reverse vaccinology approach using proteomic 
datasets, five of which induced PBMC proliferation. Linear epitope prediction was 
performed for 9 HLA-class I supertypes (HLA-A1, -A2, -A3, -A24, -A26, -B7, -B27, -B44 and 
-B58) and for 4 HLA-class II supertypes (HLA-DPA, HLA-DPB, HLA-DQA, HLA-DRB). The 
algorithms NETMHC and NETCTL were used to predict HLA-class I-binding epitopes, and 
NETMHC Class II was used for a MHC II prediction. Additionally, the linear peptides were 
structurally modelled to MHC molecules to find the most stable in silico epitope + allele 
complexes. Structures from 33 different alleles of MHC I (21) and MHC II (12) were used. 
viii) Mahantesh V 2017 (308): peptides from L. donovani 3’-nucleotidase (5 nonamers) 
induced IFN-γ and IL-2 production, increased T-cell proliferation in PBMC culture and CTL 
activity. Epitope prediction was performed for HLA-A*02 and HLA- B40 alleles with six 
HLA-binding prediction algorithms (SYFPEITHI, BIMAS, RankPep, NetCTL1.2, IEDB 
tools.iedb.org, and ProPredI). In the last epitope selection step, the selected peptides were 
analysed by NetMHCpan3.4 to check the binding affinity to other HLA class I alleles, and 
promiscuous epitopes that bind to at least 10 HLA-A*02 or 5 HLA-B40 were selected. 
 
These studies are further detailed in Table I.4. 
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Table I. 4 Leishmania-specific peptide vaccine candidates validated using human samples. ‘Ref’, bibliographical references.  
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5. Project objectives and approach 
 
The present doctoral project was part of the Marie Sklodowska-Curie Innovative Training 
Network EUROLEISH.net (project 2.1 - Development of a multiepitope peptide-based vaccine against 
human leishmaniasis). Project 2.1 is integrated within the 15 EUROLEISH.net projects as a basic 
sciences project focused on leishmaniasis prevention. 
 
The project’s main objective is the development of a human-compatible second-generation 
peptide-based vaccine against leishmaniasis, with global coverage, and based on 
immunogenic epitopes conserved among several pathogenic Leishmania species. 
 
The major aims are:  
• To identify the antigenic proteins present in the Leishmania secretome; 
• To design and elaborate species-conserved peptides with multiple and appropriate 
immunogenic epitopes to be used as vaccine antigens; 
• To perform preclinical phase studies in human cells to evaluate the predictive peptide’s 
immunogenic and immunoprotective properties; 
• to evaluate the immunoprotective profiles of exposed individuals who have developed 
immunity to Leishmania infection. 
 
Considering the limitations of previous candidates and restrictive budgets associated with NTD 
research, the proposed strategy aims combine several data and methods to increase cost-efficiency 
and shorten development time to maximise late-stage success of a vaccine against human 
leishmaniases (Figure I.19). 
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Figure I. 19 Overview of the project’s work plan, the key challenges or bottlenecks and how these will be 
addressed. 
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1. Introduction 
 
In summary, the principal Leishmania species causing cutaneous leishmaniasis (CL) in the 
Mediterranean Basin, Africa, Middle East, and India are L. (L.) major (zoonotic CL, ZCL), L. (L.) tropica 
(anthroponotic CL); whereas in Central and South America, the main CL-causing species are L. (L.) 
mexicana, L. (L.) amazonensis, and L. (V.) braziliensis (1). VL is caused by L. (L.) donovani parasites in 
the Indian and African regions, and L. (L.) infantum parasites in the Mediterranean Basin, Central and 
South America and China (1–3). Other Leishmania species infect non-human vertebrate hosts, as is 
the case of L. tarentolae whose natural host is the lizard (4). For pathogenesis and epidemiological 
aspects see Chapter I – General Introduction.  
The term “co-evolution” was actually used for the first time to describe the relationship 
between Leishmania parasites and host sand fly species (5). Environmental cues lead to the 
differentiation from procyclic promastigote to metacyclic promastigote inside the sand fly, and to 
intracellular amastigote in the vertebrate host (temperature, pH, exposure to reactive oxygen and 
reactive nitrogen species, extracellular proteolytic activity, or nutritional requirements) (6,7). 
Leishmania parasites have co-evolved with vertebrate hosts since the Jurassic period, and have 
adapted to diverse epidemiological scenarios divergently for 20-100 million years, and yet still share 
very high levels of genomic homology and synteny (6).  
The first full genome sequence of a Leishmania parasite was published in 2005 (8) marking 
the beginning of the post-genomic era for these parasites. L. major parasites have a 32,8 megabase 
haploid genome, containing over 8200 protein-coding genes, and over 94% of all mRNA molecules 
are constitutively expressed between promastigotes and amastigotes (9,10). Since then, three other 
Leishmania species genomes have been sequenced and annotated – L. (L.) infantum (11), L. (V.) 
braziliensis (11), and L. (L.) mexicana (12). Comparative analysis showed a high level of genetic 
conservation among species (7392 common genes), but quite remarkable large-scale genetic 
differences in terms of ploidy and gene copy number (12).  
The high level of conservancy observed among Leishmania genomes, with minor changes in 
mRNA levels between promastigotes and amastigotes, suggests that differentiation, virulence and 
pathogenesis depend on post-transcriptional and post-translational expression control mechanisms 
(6,9,13–18). Predicted genes are expressed as polycistronic units present on the same DNA strand, 
much alike bacterial operons. However, genes grouped in a common orientation are not regulated by 
common mechanisms nor are they functionally related (19,20). Regulation of single gene expression 
does not rely in RNA polymerase (RNApol) promoter control – control of gene expression is 
performed at multiple levels (trans-splicing, mRNA polyadenylation, mRNA stability, transcript 
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elongation, and protein stability) (19–21). Accordingly, very few RNApol promoters were identified, 
none for RNApol II, except for the splice leader RNA promoter and RNApol I promoter sites in the 
rDNA locus (10).  
Post-translational modifications (PTM) are proposed to be a major mechanism in Leishmania 
control of gene expression (6,22,23). Over 200 different types of PTM have been generally described, 
and Leishmania proteins can be cleaved eliminating signal sequences, pro-peptides and initiator 
methionines, or cleaved by specific proteases to generate final functional protein forms (10). 
Leishmania protein modifications include methylation, acetylation, phosphorylation, hexosylation, 
fucosylation; the addition of complex molecules such as lipids, sugars or glycolipids; ubiquination, 
nytrosylation and hyperoxidation of sulfhydryl group (6,10,22). 
Proteomic studies are therefore optimal tools to study Leishmania pathogenesis since gene 
expression is for the most part regulated post-transcriptionally (6). The first proteomic studies 
compared promastigote and amastigote forms and were performed for L. (L.) infantum (24), L. (L.) 
donovani (25), L. (L.) mexicana (26), and L. (V.) panamensis (27).  
The main pathways upregulated in amastigotes are fatty acid oxidation and gluconeogenesis, 
mitochondrial respiration, proteins with basic pH, and some specific proteins such as tryparedoxin 
peroxidase, methylthioadenosine phosphatase, required for survival under oxidative conditions in 
the host cell (6,25,26,28). By contrast, Leishmania promastigotes rely mostly on glycolysis and amino-
acid metabolism for energy generation and are also capable of hydrolysing dissacharides. In 
promastigotes, the glycolytic pathway is upregulated, and in metacyclic promastigotes the proteins 
PFR1D, alpha- and beta-tubulin, cysteine protease B, trypanoredoxin, GP63, and GP46 show higher 
expression levels (6,25,26). Other differentially expressed proteins are associated with diverse 
metabolic functions – cytoskeleton components, stress responses, amino acid and carbohydrate 
metabolism, detoxification and proteolysis (6,25,26). Likewise, some modest differences were found 
between cutaneous- and visceral-adapted L. donovani strains, the latter having increased translation, 
biosynthetic processes, antioxidant protection and signalling functions (29).  
The specific activities of some glycolytic enzymes are slightly decreased (hexokinase, 
phosphofructokinase and glucose-6-phophate dehydrogenase) or greatly reduced (pyruvate kinase) 
in amastigotes. In the amastigote form, parasites use mostly fatty acids and amino-acid metabolism 
for energy generation, as access to glucose and other sugars is limited (6,25,30). The capacity for 
sugar uptake is also reduced in amastigotes in comparison to promastigote forms, so glycolytic and 
pentose-phosphate pathways are present and functional but with lower activity levels. Also, glucose 
degradation results in succinate production (instead of pyruvate) through the action of 
phosphoenolpyruvate carboxykinase/malate dehydrogenase enzymes (6,25,30). 
CHAPTER II – THE LEISHMANIA SECRETOME 
88 
 
Sugar residues required by Leishmania amastigotes are generated de novo through 
gluconeogenesis (6,30). Both metacyclic promastigotes and amastigotes accumulate β-mannan, a 
complex polyssacharide, as intracellular energy storage. However, contrary to promastigotes, this 
molecule is essential for amastigote survival and replication and is dependent on hexose uptake 
(6,30). 
The term ‘secretome’ was firstly defined by Tjalsma et al 2000 as a subset of the proteome 
comprising both all secreted proteins and the pathways and machinery required for protein 
transport/secretion (31). There is increasing interest in the secretome and excreted-secreted 
proteins as they play a pivotal role in virulence and interaction with the host, in this case, for 
Leishmania establishment of infection and immunomodulation (32–40). These early secreted 
proteins allow Leishmania parasites to survive in an otherwise lethal environment, inside the 
phagolysosome, as well as to modulate host response by suppressing host cell signalling and 
macrophage activation, while deviating the host’s immune response towards a permissive anti-
inflammatory phenotype (32–40).  
Proteomic analysis of the secretome of L. (L.) donovani promastigotes (41), L. (L.) mexicana 
promastigotes (42), L. (V.) braziliensis promastigotes (43), and L. (L.) major promastigotes inside the 
sand fly midgut (44) were performed, contributing to an increased knowledge about the function of 
these proteins. These studies show the main secretion pathway in Leishmania parasites is through 
exosome/micro-vesicle production, which are crucial for parasite virulence (37,40,45). Only a small 
proportion of proteins possesses a N-terminal secretion signal peptide or is non-classically 
(ER/Golgi-independently) secreted (46). Interestingly, amastigotes continue to secrete exosomes to 
the cytoplasm of infected and neighbouring cells (46). Exosomes are increasingly implicated in host-
pathogen interactions and are determinant for the promotion or inhibition of host immunity (36,47). 
 
A plethora of candidate virulence factors has been identified in the Leishmania secretome, 
meaning functional characterization is extremely difficult. It is generally accepted that the Leishmania 
pathogenesis depends on parasite-mediated early immune priming and continuous 
immunomodulation, as well as maintenance of the parasitophorous vacuole conditions (30,32,48,49). 
Molecules found in the secretome can be associated to any of these essential functions.  
 
Furthermore, other than virulence factors necessary for parasite survival, many interesting 
molecules have been identified in the secretome, namely drug and vaccine candidates. As referred in 
Chapter I – General Introduction, Leishmania secreted antigens have been shown to trigger Th1 
responses in several disease models (39,50–52) and several antigen candidates in the human vaccine 
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development pipeline are known to be secreted. However, the total content of the naturally secreted 
LiESAp, the active principle of the CaniLeish® canine vaccine, remains largely undefined. The 
development of a second-generation vaccine based on antigens present in the Leishmania secretome 
requires the comprehensive characterisation of the antigenic proteins responsible for the observed 
immune responses. The present analysis aims to fill this knowledge gap, to identify all the proteins 
present the L. infantum secretome produced in aseric conditions. Furthermore, we provide the first 
simultaneous analysis of five other major pathogenic Leishmania. 
The present chapter describes the identification of the total secretome of six Leishmania 
species, exclusive human pathogens, as well as L. tarentolae, non-pathogenic to humans. The 
secretome was prepared according to the method used to produce LiESAp from promastigote cultures 
growing in aseric medium, used in the CaniLeish® vaccine.   
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2. Material and Methods 
 
2.1. Leishmania parasite cultures in aseric medium, generation and purification 
of total excreted-secreted proteins 
 
The in vitro culture of Leishmania promastigotes (Table II.1) was performed in a completely 
chemically defined medium (CDM/LP) free of serum, macromolecules, proteins and peptides as 
previously described (53,54).  When parasite concentration reached 2–3×107 promastigotes per ml 
in a 6-days period, culture was centrifuged (2000×g, 20 min, 4 ◦C) to remove parasites. The 
supernatant was collected, filtered (0.2-μm-pore-size filter, Millipore) to eliminate removal 
promastigotes, concentrated approximately 100-fold and dialysed by ultrafiltration with a 3-kDa-
cutoff filter unit (Pall). Protein concentration was determined according to Bradford method (Bio-
Rad Laboratories). The purified naturally excreted secreted antigens from Leishmania promastigotes 
are designated as ESAp (LiESAps are used as the CaniLeish® vaccine antigen). Leishmania ESAps were 
stored at -80°C until use. 
 
Table II. 1 Leishmania spp. strains cultured for the generation of ESAp. 
Leishmania spp. strains cultured for the generation of ESAp 
Leishmania infantum MHOM/MA/67/ITMAP-263 
Leishmania major MHOM/SY/91/LEM-2420 
Leishmania tropica MHOM/SY/90/LEM-2067 
Leishmania donovani MHOM/IN/80/DD8 
Leishmania braziliensis MHOM/BR/75/M-2904 
Leishmania amazonensis MHOM/BR/76/LTB-012 
Leishmania tarentolae WT commercial strain 
 
 
Figure II. 1 General workflow for the preparation of the Leishmania promastigote secretome. 
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2.2. Protein separation 
 
Proteins were separated on 1D SDS-PAGE gels (12 % polyacrylamide, Mini-PROTEAN® TGX™ 
Precast Gels, Bio-Rad, Hercules USA). Gels were stained with PageBlue Protein Staining Solution 
(Fermentas) and scanned using a computer-assisted densitometer (Epson Perfection V750 PRO). Gel 
lanes were cut into 12 gel pieces (11 bands plus the well fraction) and destained with three washes 
in 50% acetonitrile and 50 mM triethylammonium bicarbonate buffer (TEABC). After protein 
reduction (with 10 mM dithiothreitol in 50mM TEABC at 56 °C for 45 min) and alkylation (55 mM 
iodoacetamide TEABC at room temperature for 30 min) proteins were digested in-gel using trypsin 
(800 ng/band, Gold, Promega, Madison USA) as previously described (1). Desalting and pre-
concentration of samples were performed with a ZipTip C18. Digest products were dehydrated in a 
vacuum centrifuge and reduced to 3 µL. 
 
2.3. High-performance liquid chromatography and MS measurements 
 
 Peptide samples were dehydrated in a vacuum centrifuge, solubilized in 3 µl of 0.1% formic 
acid-2% acetonitrile. Three µL were analyzed online by nano-flow HPLC-nanoelectrospray ionization 
using a LTQ Orbitrap XL mass spectrometer (LTQ Orbitrap XL, Thermo Fisher Scientific, San Jose, CA) 
coupled with an Ultimate 3000 HPLC (Dionex). Desalting and pre-concentration of samples were 
performed on-line on a Pepmap® precolumn (0.3 mm x 10 mm). A gradient consisting of 0-40% A in 
30 min, 80% B in 15 min (A = 0.1% formic acid, 2% acetonitrile in water; B = 0.1 % formic acid in 
acetonitrile) at 300 nl/min was used to elute peptides from the capillary (0.075 mm x 150 mm) 
reverse-phase column (Pepmap®, Dionex). LC-MS/MS experiments comprised cycles of 5 events; an 
MS1 scan with orbitrap mass analysis at 60000 resolution followed by CID of the five most abundant 
precursors. Fragment ions generated by CID were detected at the linear trap. Normalized collision 
energy of 35 eV and activation time of 30 ms were used for CID. Spectra were acquired with the 
instrument operating in the information-dependent acquisition mode throughout the HPLC gradient. 
The mass scanning range was m/z 400-2000 and standard mass spectrometric conditions for 
experiments were: spray voltage, 1.9 to 2.4 kV; no sheath and auxiliary gas flow; heated capillary 
temperature, 200°C; capillary voltage, 40 V and tube lens, 120 V. For all full scan measurements with 
the Orbitrap detector, a lock-mass ion from ambient air (m/z 445.120024) was used as an internal 
calibrant as described (55).  
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Figure II. 2 General workflow for the mass spectrometry analysis of the Leishmania promastigote secretome.  
 
2.4. Bioinformatics analysis 
 
Raw MS spectra were processed using the MaxQuant environment (56) and Andromeda for 
database search with iBAQ algorithm enabled (57). The MS/MS spectra were matched against the 
Leishmania entries of UniProtKB SwissProt and TrEMBL sections (release 2017_01; 
http://www.uniprot.org) and 250 frequently observed contaminants (MaxQuant contaminants 
database) as well as reversed sequences of all entries. The following settings were applied for 
database interrogation: mass tolerance of 7 ppm (MS) and 0.5 Th (MS/MS), trypsin/P enzyme 
specificity, up to two missed cleavages allowed for protease digestion, minimal peptide length at 7, 
cysteine carbamidomethylation as fixed modification and oxidation of methionine as variable 
modification. FDR was set at 0.01 for peptides and proteins. 
A representative protein ID in each protein group was automatically selected using in-house 
bioinformatics tools (leading v2.2 and multi-species script), developed by Oana Vigy (Plateforme de 
Proteomique Fonctionnelle de Montpellier), and the Perseus software (version 1.5.3.0). First, proteins 
with the most numerous identified peptides are isolated in a “match group” (proteins from the 
“Protein IDs” column with the maximum number of “peptides counts (all)”). For the match groups 
where more than one protein ID is present after filtering (no specific tryptic peptides), the “leading” 
protein is firstly chosen as the best annotated protein in UniProtKB (reviewed SwissProt entries 
rather than automatic TrEMBL entries) corresponding to the ‘Leading_AUTO’ identification status. In 
case of ambiguous peptide identifications, proteins are identified by a given species and group-
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species order preference, corresponding to a ‘Leading_SPECIES’ identification status (Table II.2). If 
ambiguous identifications cannot be distinguished with specific peptides or taxonomy, these remain 
identified as a match group (‘MultiSpecies’ identification status). 
 
Table II. 2 Ordered species and group-species list established to define a "leading" protein based on the 
taxonomy criteria (only for match groups cases where more than one protein ID are present after filtering). 
Taxonomy Group Species Order 
Leishmania infantum  1 
Leishmania chagasi  2 
Leishmania donovani (strain BPK282A1)  4 
Leishmania donovani  3 
Leishmania donovani donovani  4 
Leishmania donovani archibaldi  4 
Leishmania donovani complex sp. CR-2013  4 
Leishmania major  5 
Leishmania gerbilli  6 
Leishmania turanica  6 
Leishmania arabica  6 
Leishmania tropica  7 
Leishmania tropica complex sp. CR-2013  8 
Leishmania aethiopica  8 
Leishmania killicki  8 
Leishmania mexicana (strain MHOM/GT/2001/U1103)  10 
Leishmania mexicana  10 
Leishmania amazonensis  9 
Leishmania mexicana mexicana  10 
Leishmania mexicana venezuelensis  10 
Leishmania pifanoi  10 
Leishmania braziliensis  11 
Leishmania braziliensis complex EV-2015  12 
Leishmania guyanensis  12 
Leishmania peruviana  12 
Leishmania panamensis  12 
Leishmania shawi  12 
Leishmania lainsoni  13 
Leishmania naiffi  13 
Leishmania utingensis  13 
Leishmania lindenbergi  13 
Leishmania sp. MHOM/BR/2002/NMT-RBO004  14 
Leishmania sp. CR-2014  14 
Leishmania sp.  14 
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2.5. Secretion pathway analysis (SecretomeP) 
 
SecretomeP is a sequence-based method for the prediction of eukaryotic secreted proteins 
targeted to a non-classical secretory pathway, i.e. proteins without an N-terminal signal peptide (58). 
SecretomeP queries other feature prediction servers to obtain information on various post-
translational and localisational aspects of the protein, which are integrated into the final secretion 
prediction. This method is also capable of predicting (signal peptide-containing) secretory proteins 
where only the mature part of the protein has been annotated, or cases where the signal peptide 
remains uncleaved. 
The SecretomeP 1.0 standalone version was downloaded (http://www.cbs.dtu.dk/cgi-
bin/nph-sw_request?secretomep) and fasta files with protein sequences corresponding to total 
identifications per sample were retrieved from UniProtKB. Each sample list was analysed with 
SecretomeP 1.0 (Signal-P and non-classical eukaryotic secretion predictions were performed). 
Proteins with NNscore > 0.5 were considered non-classically secreted. 
 
2.6. Exosome marker analysis 
 
The secretome datasets were screened for exosome cargo protein markers, from two different 
sources: i) ExoCarta, an exosome database, which includes the contents that were identified in 
exosome cargo in multiple organisms (59); and ii) Silverman et al 2008 (41) describes 26 Leishmania-
secreted proteins associated with exosome-like and glycosomal vesicles. 
To find the Leishmania genes ortholog to the most common exosome markers described by 
the ExoCarta database, a search strategy in OrthoMCL database was performed (Figure II.3). Briefly, 
100 exosome markers (GenBank gene accessions) were downloaded from the Exocarta database (59). 
Firstly, a text search (‘Identify Sequences based on text terms’) was performed at OrthoMCL database 
web server with the 100 Gene Symbols. This search retrieved 3631 sequences (step 1), 83 of which 
correspond to human-specific proteins (step 2). These sequences were transformed to groups (step 
3) to compare with four Leishmania phyletic ortholog groups in the database (step 4). These 
Leishmania phyletic groups were then retransformed into sequences (step 5), and 72 sequences from 
L. infantum, L. mexicana, L. major and L. braziliensis were retrieved (step 6) (Figure II.3 panel A). In 
parallel, 2140 accessions identified in the secretome proteomic datasets were converted to GeneDB 
IDs in the UNIProtKB database web server. 1860 out of 2140 identifiers from UniProtKB accessions 
identified in the secretome were successfully mapped to 1988 GeneDB Ids. This list was then 
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compared (list intersection) with the 72 Leishmania ortholog exosome marker genes in TriTrypDB 
(Figure II.3 panel B).  
 
 
Figure II. 3 Exosome marker analysis of 100 exosome protein markers from ExoCarta. A) OrthoMCL search 
strategy for Leishmania ortholog genes of exosome cargo markers from ExoCarta. B) Intersection between 72 
Leishmania ortholog genes and 1981 GeneDB IDs identified in the secretome proteomic analysis. 
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3. Results 
 
3.1. Proteins found in the secretome correspond to 12-17% of total Leishmania 
proteins 
 
The method used for the preparation of the secretome is analogous to the large-scale 
production of LiESAps for the CaniLeish® vaccine, which allows the production and analysis of 
naturally excreted-secreted proteins. Leishmania promastigotes are cultured in a completely defined 
aseric medium until the growth stationary phase (day 6). 
To identify the proteins present in the Leishmania secretome, 11 bands (plus the well fraction) 
from the 1D gel were carefully isolated and analysed per sample, covering all proteins per lane (Figure 
II.4 panel A). A total of 2140 unique proteins were identified (UniProtKB database release 2017_01), 
between 909 and 1357 total accessions per sample (Figure II.4 Panel B), considering all identification 
categories defined by the bioinformatics identification script. Amongst the identified proteins, only a 
portion correspond to characterised proteins with SwissProt annotation (2.8%). Remaining proteins 
correspond to transcripts with an in silico characterisation in the TrEMBL database.  
 
 
Figure II. 4 Leishmania secretome protein identifications. A) Synthetic images of one-dimensional gel 
electrophoresis of total secretome of different Leishmania species. B) Total number of protein accessions identified. 
Total number of accessions identified per sample, according to the bioinformatic script: ‘Leading_AUTO’ (accessions 
unique to the tested species), ‘Leading_SPECIES’ (ambiguous identifications assigned according to tested species), 
and ‘Multi_species’ (ambiguous identifications, impossible to distinguish between species).  
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All six human pathogenic species analysed share a high number of common accessions (326), 
corresponding to 24% up to 35.9% of total identifications per sample (Figure II.5 panel A). The 
number of commonly identified proteins decreases to 306 accessions when considering all seven 
Leishmania species, meaning 20 proteins were not identified in the L. tarentolae sample.  
The 20 accessions identified only in human pathogenic species are: beta-fructofuranosidase-
like protein (EC 3.2.1.26); chaperonin HSP60, mitochondrial; cystathionine beta-synthase (EC 
4.2.1.22); putative cytochrome c; GDP-mannose pyrophosphorylase (EC 2.7.7.22); GDPMP protein 
(EC 2.7.7.13); mannose-1-phosphate guanyltransferase (EC 2.7.7.13); paraflagellar_rod_component_-
_putative; putative 2-hydroxy-3-oxopropionate reductase (EC 1.1.1.60); putative ribosomal protein 
S6; putative small GTP-binding protein Rab1; S-methyl-5'-thioadenosine phosphorylase (EC 2.4.2.28) 
(MTA phosphorylase); superoxide dismutase (EC 1.15.1.1); three uncharacterised proteins (A4HIL9; 
E9AZC3; E9B159) and one hypothetical conserved protein (A4I5W4).  
As expected, the L. braziliensis and L. major samples, two species with reference proteomes in 
UniProtKb (LEIBR and LEIMA), have the highest number of specific proteins (Figure II.2 panel B). 
Interestingly, LEIAM and LEITA, although underrepresented in the databases, show a high number of 
specific proteins, respectively, 66 and 63 accessions. Also, shared proteins between LEIIN and LEIDO 
samples are more numerous than LEIIN-specific proteins (Figure II.2 panel B). 
Considering the reference proteomes available in UniprotKB, an average total of 8034 
proteins are encoded in the Leishmania genome. The proteins identified in the secretome correspond 
to 12% up to 17% of total proteins (Table II.3).  
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Figure II. 5 Comparison of protein identification lists. A) Venn diagram comparing proteins identified in six human 
pathogenic species. B) Intersection lists between all Leishmania species, individual unique lists, and relevant groups: 
human pathogens (all except L. tarentolae), VL-causing species (LEIIN+LEIDB), Old World CL-causing species 
(LEIMA+LEITR), Mediterranean species (LEITR+LEIIN+LEIMA), New World CL-causing species (LEIAM+LEIBR), CL-
causing species (LEIAM+LEITR+LEIBR+LEIMA). 
 
Table II. 3 Leishmania reference proteomes, respective protein counts, and proteins found in the secretome. 
Proteome ID Organism 
Organism 
ID 
Protein 
count 
Secretome 
protein 
counts 
% of 
total 
proteins 
UP000000542 Leishmania major (Strain: MHOM/IL/81/Friedlin) 5664 8038 1290 16,1 
UP000008153 Leishmania infantum (Strain: JPCM5) 5671 8045 1241 15,4 
UP000007258 
Leishmania braziliensis (Strain: 
MHOM/BR/75/M2904) 
5660 8084 981 12,1 
UP000008980 Leishmania donovani (strain BPK282A1) 981087 7960 1357 17,1 
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3.2. The majority of Leishmania excreted-secreted proteins are non-classically 
secreted 
 
A bioinformatics analysis of the secretome protein lists was performed with SecretomeP to 
identify proteins containing secretion signal peptides and proteins which are non-classically secreted 
(also known as leaderless secretion, unconventional or non-conventional secretory pathway) (58).  
The consensus regarding protein secretion in eukaryotes is that membrane-associated or 
secreted proteins reach their final localisation via the classical secretory pathway. Proteins contain a 
signal peptide and/or transmembrane domain which targets them to the ER, from where they exit in 
vesicles, reaching the Golgi and eventually the membrane. Yet, there are extracellularly active 
proteins which do not enter the ER/Golgi pathway (60).  
Results show that only a few proteins identified in the Leishmania secretome contain a 
classical secretion signal peptide (from 4.8% up to 12.9%). These results agree with previous 
proteomic studies which have shown as well that classical secretion is not the main secretion pathway 
in Leishmania parasites (33,46).  
Over 42% of proteins are predicted to be secreted through non-classical pathways for all 
Leishmania species analysed. ‘Leaderless’ proteins are extracellularly active despite not having a 
signal peptide or a transmembrane domain. So far, four non-conventional mechanisms have been 
described in eukaryotes: i) pore-mediated translocation (type I); ii) ABC transporter-based secretion 
(type II or membrane flip-flop) of acylated proteins; iii) organelle-based translocation or 
autophagosome/endosome-based secretion (type III) by diverting endosomal and other membrane-
bound compartments from their normal function to become secretory (60). The fourth 
unconventional protein secretion mechanism occurs when  proteins containing signal peptides or 
transmembrane domains bypass the Golgi and are still secreted (type IV) (60). Interestingly, the type 
II membrane flip-flop mechanism (membrane translocation through N-terminus dual acylation) 
although not yet well-studied, has been demonstrated for Leishmania protein HASPB (61).  
Importantly, the proteins secreted via non-classical secretion are predicted to be 3 to 9 times 
more frequent than proteins containing signal peptides for classical secretion.   
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Figure II. 6 Secretion pathway analysis. Total accessions identified in each sample were analysed with SecretomeP 
1.0 (mammalian proteins). Percentage of proteins with NN score > 0,5 and no predicted signal peptide are predicted to 
be non-classically secreted (blue bars). SignalP analysis predicts the presence of signal peptides which target proteins 
for classical secretion (percentage of total proteins, red bars).
As indicated by the SecretomeP results, and as previous secretome studies have shown, 
Leishmania-secreted proteins are associated with exosome-like vesicles as well as glycosomal 
vesicles. In the latter case, either Leishmania parasites secrete whole glycosomes or glycosomal cargo 
into the extracellular moiety (41). Exosomes are 30-100 nm membrane vesicles of endocytic origin 
secreted by most cell types in vitro (47). 
Interestingly, in the present study we find 8 proteins associated with vesicle-based secretion, 
from the 26 proteins described by Silverman et al 2008 (Table II.4). Furthermore, several Leishmania 
proteins ortholog to exosome protein markers from other eukaryotic cell types were identified in the 
secretome datasets (Table II.5). The ExoCarta database describes the 100 most common proteins 
often associated with exosome cargo from different tissues and cell types, and across 10 different 
species, including humans (59). Remarkably, a high number of ortholog genes were found in 
Leishmania, 18 orthologs per species for a total of 72 genes identified. These correspond to 16 
different proteins, 9 of which are found in the secretome datasets (Table II.5).  
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Table II. 4 List of Leishmania-secreted proteins associated with exosome-like and glycosomal vesicles found 
in the secretome datasets (Silverman et al 2008). AP, adipocyte exosome (adiposome); GLY, Leishmania 
glycosome; BC, B-cell lymphocyte exosome; DC, dendritic cell exosome 
GeneDB 
accession number 
Protein name 
Microvesicle 
association 
LmjF28.2860 Cytosolic malate dehydrogenase, putative AP 
LmjF24.2060 Transketolase, putative GLY  
LmjF28.2770 Heat-shock protein hsp70, putative BC, DC, AP  
LmjF14.1160 Enolase BC, DC, AP 
LmjF05.0350 Trypanothione reductase GLY  
LmjF16.0540 Aspartate carbamoyltransferase, putative GLY  
LmjF31.1070 Biotin/lipoate protein ligase-like protein AP 
LmjF36.3210 14-3-3 Protein-like protein DC, AP  
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Table II. 5 List of exosome markers and genes found in the secretome. From the 100 most abundant proteins associated with 
exosome cargo (Exocarta database) (59), 72 Leishmania ortholog genes were found (18 per species), and 20 of these were found in 
this dataset through OrthoMCL and TriTrypDB searches, corresponding to 9 different proteins. Yellow = proteins with signal peptide 
prediction (SignalP). 
GeneIDs 
Found in 
Secretome 
[Gene Product] 
[PFam 
Domains] 
Domain name 
LbrM.15.1040; LbrM.33.0760; 
LinJ.15.1060; LinJ.33.0770; 
LmjF.15.1000; LmjF.33.0720; 
LmxM.15.1000; LmxM.32.0720 
LinJ.15.1060; 
LinJ.33.0770; 
LmjF.15.1000; 
LmjF.33.0720 
60S ribosomal protein 
L6, putative 
PF01159 Ribosomal protein L6e 
LbrM.30.0540; LinJ.30.0470; 
LmjF.30.0460; LmxM.29.0460;  
LinJ.30.0470; 
LmxM.29.0460 
aspartyl-tRNA 
synthetase, putative 
PF00152, 
PF01336 
tRNA synthetases class II 
(D, K and N),  OB-fold 
nucleic acid binding 
domain 
LbrM.32.0470; LinJ.32.0410; 
LmjF.32.0400; LmxM.31.0400; 
LinJ.15.1060 
LinJ.32.0410;  
LmxM.31.0400 
ATP-dependent RNA 
helicase, putative 
PF00270, 
PF00271 
DEAD/DEAH box 
helicase, Helicase 
conserved C-terminal 
domain  
LbrM.34.3140; LinJ.35.3280; 
LmjF.35.3230; LmxM.34.3230; 
LmxM.15.1000 
LbrM.34.3140; 
LinJ.35.3280 
cystathione gamma 
lyase, putative 
PF01053 
Cys/Met metabolism PLP-
dependent enzyme 
LbrM.29.2180; LinJ.29.2310; 
LmjF.29.2200; 
LmxM.08_29.2200; 
LmjF.35.3230 
LbrM.29.2180; 
LinJ.29.2310; 
LmjF.29.2200; 
LmxM.08_29.2200 
GTP-binding protein, 
putative 
PF00350, 
PF02212, 
PF01031 
Biotin-requiring enzyme 
LbrM.32.4110; LmxM.31.3870; 
LinJ.32.4020; LmjF.32.3870; 
LmjF.36.2660 
LinJ.32.4020;  
LmxM.31.3870 
myosin XXI PF00063 
Myosin head (motor 
domain) 
LbrM.11.0920; LinJ.11.1140; 
LmjF.11.1160; LmxM.11.1160; 
LinJ.32.4020 
LmjF.11.1160 
protein transport 
protein Sec31, 
putative 
PF00400 
WD domain, G-beta 
repeat 
LbrM.19.0760; LinJ.19.0440; 
LmjF.19.0440; LmxM.19.0440; 
LmjF.36.3660 
LbrM.19.0760 
nucleosome assembly 
protein, putative 
PF00956 
Nucleosome assembly 
protein (NAP) 
LbrM.31.1980; LinJ.31.1770; 
LmjF.31.1750; LmxM.30.1750; 
LmjF.11.1160 
LinJ.31.1770; 
LmjF.11.1160 
nucleosome assembly 
protein-like protein 
PF00956 
Nucleosome assembly 
protein (NAP) 
LbrM.14.0470; LinJ.14.0470; 
LmjF.14.0460; LmxM.14.0460; 
LmjF.30.0460 
 None found 
cystathionine beta-
lyase-like protein 
PF01053 
Cys/Met metabolism PLP-
dependent enzyme 
LbrM.24.1520; LinJ.24.1400; 
LmjF.24.1360; LmxM.24.1360; 
LmjF.14.0460 
 None found 
hypothetical protein, 
conserved 
null   
LbrM.20.2180; LinJ.34.2450; 
LmjF.34.2620; LmxM.33.2620; 
LmjF.29.2200 
 None found 
RNA helicase, 
putative,mitochondrial, 
putative 
PF00271 
Helicase conserved C-
terminal domain 
LbrM.35.3890; LinJ.36.3840; 
LmjF.36.3660; LmxM.36.3660; 
LmjF.24.1360 
 None found 
nudix hydrolase-like 
protein 
PF00293 NUDIX domain 
LbrM.29.2720; LinJ.13.0260; 
LmjF.13.0260; LmxM.13.0260; 
LmjF.34.2620 
 None found 
hypothetical protein, 
conserved 
PF00583 
Acetyltransferase (GNAT) 
family 
LbrM.31.2920; LinJ.31.2650; 
LmjF.31.2580; LmxM.30.2580; 
LmjF.13.0260 
 None found 
ubiquinol-cytochrome-
c reductase-like 
protein 
PF02320 
Ubiquinol-cytochrome C 
reductase hinge protein 
LbrM.20.0631; LinJ.34.0740; 
LmjF.34.0705; LmxM.33.0705; 
LmjF.19.0440 
 None found 
hypothetical protein, 
conserved 
PF09799 
Predicted membrane 
protein 
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3.3. Functionality of excreted-secreted proteins is conserved among 
Leishmania species 
 
To better elucidate the specialised functions performed by the Leishmania-secreted 
proteins, a Gene Ontology (GO) annotation analysis was performed. Gene Ontology provides a 
representation or categorisation of the properties assigned to different gene products, and covers 
three main domains which represent how individual genes contribute to organism biology: 
Molecular function, the molecular activities of individual gene products; Cellular component, 
where the gene products are active; and Biological process, the pathways to which the gene 
product’s activities contribute (62). 
Results show secreted proteins by all seven Leishmania species analysed have conserved 
functions, across all GO domains (Figure II.7).  
In all analysed Leishmania species, the vast majority of secreted Leishmania proteins 
possess, regarding molecular function pathways, either binding (GO:0005488, refers to the 
selective, non-covalent, often stoichiometric, interaction of a molecule with one or more specific 
sites on another molecule) or catalytic activity functions (GO:0003824, refers to the catalysis of 
a biochemical reaction at physiological temperatures; gene products possess specific binding sites 
for substrates, and are usually composed wholly or largely of protein). The remaining molecular 
functions identified are structural molecule activity (GO:0005198, refers to the action of a 
molecule that contributes to the structural integrity of a complex or its assembly within or outside 
a cell) or antioxidant activity (GO:0016209, refers to the inhibition of the reactions brought 
about by dioxygen (O2) or peroxides; usually the antioxidant is effective because it can itself be 
more easily oxidized than the substance protected) (Figure II.7 panel A). These results agree 
entirely with previous proteomic analysis of L. donovani and L. braziliensis secretomes (41,43). 
Regarding the biological process domain, a high number of proteins are involved in 
cellular (GO:0009987, refers to any process that is carried out at the cellular level, but not 
necessarily restricted to a single cell, for example, cell communication) or metabolic processes 
(GO:0008152, refers to the chemical reactions and pathways, including anabolism and catabolism, 
by which living organisms transform chemical substances), regulation (GO:0065007, refers to 
any process that modulates a measurable attribute of any biological process, quality or function.) 
and response to stimulus (GO:0050896, refers to Any process that results in a change in state or 
activity of a cell or an organism as a result of a stimulus in terms of movement, secretion, enzyme 
production, gene expression, etc.) (Figure II.7 panel B).  
Cellular compartment GO annotations are more disperse, but still conserved among 
Leishmania species (Figure II.7 panel C). Most gene products are described to be active in the 
cytoplasm (GO:0005737, refers to all of the contents of a cell excluding the plasma membrane 
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and nucleus, but including other subcellular structures) and nucleus (GO:0005634, refers to 
membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and 
replicated). The main gene products which possess these functions are: tubulin, elongation 
factors, proteasome-associated proteins and histones. 
 
 
Figure II. 7 Gene Ontology (GO) terms annotation as percentage of total identified proteins. A) Molecular 
function GO terms. B) Cellular component GO terms. C) Biological process GO terms. 
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Additionally, multifunctional proteins have been described, particularly, moonlighting 
proteins that perform multiple independent, and often unrelated, functions, in the absence of gene 
fusion, splicing variants or different catalytic domains (63). Several moonlighting proteins have 
been described in both eukaryotes and prokaryotes which were incorporated in the MoonProt 
Database, a Database for Moonlighting Proteins (64). This database includes four Leishmania-
specific proteins with described moonlighting functions (Table II.6). These four proteins were 
found in secretome datasets from all analysed Leishmania species. 
 
Table II. 6 Leishmania proteins with moonlighting functions in the MoonProt database (64). 
UniProt 
ID 
Protein Name Function 1 (primary function) 
Function 2 (moonlighting 
function) 
Species 
Name 
Q3HL75 Enolase 
enolase, enzyme reversible 
conversion of 2-phosphoglycerate to 
phosphoenolpyruvate 
binds plasminogen 
Leishmania 
mexicana 
E9BTJ1 
fructose-1,6-
bisphosphate 
aldolase 
aldolase, cleavage of fructose-1,6-
bisphosphate to glyceraldehyde 3-
phosphate and dihydroxyacetone 
phosphate, in glycolysis 
Activation of mouse (host) macrophage 
protein tyrosine phosphatase-1 (SHP-1), 
causes macrophage disfunction 
Leishmania 
donovani 
Q95VF2 
elongation 
factor 1-alpha 
translation elongation factor, the rate 
and fidelity of protein translation 
binds to and activates Src homology 2 
domain containing tyrosine phosphatase-
1 (SHP-1) in host macrophages, inhibits 
activity of infected macrophages 
Leishmania 
donovani 
Q95U89 
mitochondrial 
2-cysteine 
peroxiredoxin 
peroxidase activity, detoxification of 
reactive oxygen species (ROS), 
removal of peroxide, use redox 
active cysteine residue (peroxidatic 
Cys) to reduce substrates like H2O2 
chaperone and activators of signal 
transduction cascades, prevents thermal 
aggregation of citrate synthase in vitro, 
lack of expression makes promastigoes 
more sensitive to temperature in the 
mammalian host (37°C) 
Leishmania 
infantum 
 
3.4. Several important virulent factors are found among the most abundant 
proteins (iBAQ analysis) 
 
The analysis of the proteomic data (UniProtKB database release 2017_01) resulted in a 
total of 2140 accessions identified, from all identification status (Leading_AUTO, 
Leading_SPECIES, Multispecies = LEADING_CHECK). A normalised iBAQ value of 1 corresponds to 
the overall iBAQ average (absolute iBAQ average 1,81x107; Log10 iBAQ average 6,195). 582 
accessions with normalised iBAQ values over 1,1 were considered as abundant (see Appendix 
II.1). 
The most abundant protein overall is nucleoside diphosphate kinase, the only identified 
accession with a normalised iBAQ value over 1,5 (Figure II.8). This enzyme is required for the 
synthesis of nucleoside triphosphates (other than ATP) and catalyses the reaction transforming 
ATP and nucleoside diphosphate in ADP and nucleoside triphosphate. The generated nucleoside 
triphosphates are then used for nucleic acid, lipid or polyssacharide synthesis, protein elongation, 
signal transduction and microtubule polymerisation. It is likely this protein possesses additional 
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moonlighting functions such as protein binding, similarly to other kinases described in the 
MoonProt database.  
Several important well-documented virulence factors were identified in the Leishmania 
promastigote secretome. Leishmania parasites secrete virulence factors to the host cell cytoplasm 
where they actively modulate host signalling molecules and immune responses (33,65). 
There are fourteen highly abundant proteins in the secretome, with normalised iBAQ 
values over 1,4, including well-known virulence factors (Figure II.8, dark orange). By descending 
order: soluble promastigote surface antigen PSA-38S, tubulin beta chain (2 accessions), 
tubulin alpha chain, putative small myristoylated protein-3, ubiquitin-60S ribosomal protein 
L40, an uncharacterized protein, infective insect stage-specific protein, peroxidoxin 2, 
soluble promastigote surface antigen PSA-34S (Fragment), adenosylhomocysteinase (2 
accessions), putative heat-shock protein hsp70, and elongation factor 1-alpha (Appendix II.1). 
Among the most abundant proteins, we wish to highlight HSP70, a protein chaperone with 
key function for parasite’s adaptation to higher temperatures in vertebrate hosts; and ubiquitin-
60S ribosomal protein L40 involved in gene regulation. Also, the promastigote surface antigen 
is a major surface glycoprotein, related to glycoprotein 46 (gp46), whose functions are not fully 
understood, but is associated to the evasion of complement lysis (66) and parasite virulence, as 
evidenced by its upregulation in PKDL-causing Leishmania parasites (67). Furthermore, the 
elongation factor 1-alpha contributes to parasite persistence by inhibiting macrophage function 
through SHP-1-mediated disruption of JAK1, JAK2, STAT1 phosphorylation (68). Additionally, 
EF1alpha interacts with ribosomal subunits, for example, the 60S subunit also identified here, 
associated with protein translation (65). In turn, ribosomal subunits also interact with S-
adenosylhomocysteine hydrolase, also very abundant in the secretome (65).  The infective 
insect stage-specific protein expressed by gene META1 is specific to infective metacyclic 
promastigotes (69).  
Several of these proteins have also been described as important antigens, namely, the 
protein PSA-38S (51) and elongation factor 1-alpha (70). Interestingly, the enzyme 
adenosylhomocysteinase, involved in amino-acid biosynthesis (synthesis of L-homocysteine 
from S-adenosyl-L-homocysteine) was found to be highly abundant, which is expected for 
Leishmania promastigotes, and it has also been shown to be immunogenic in hamsters and human 
PBMC stimulation assays (71). The uncharacterised protein (A4H3U0) identified among the 
most abundant proteins is actually the most abundant in the LEIBR sample. This protein is 
predicted to have a metalloendopeptidase activity with cell adhesion functions and could be 
analysed further as a potential antigen candidate. 
Moreover, heat-shock proteins, other cytoplasmic and cytoskeleton proteins, such as 
tubulin and actin, as well as membrane-associated proteins are ubiquitous proteins identified as 
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exosome cargo. Indeed, among the most abundant proteins identified (normalised iBAQ value 
over 1.4) the proteins tubulin (alpha and beta chains), heat-shock protein 70 and surface antigens 
are found. The high abundance of these proteins further supports the importance of exosome-
based secretion in Leishmania parasites. 
 
 
Figure II. 8 Log-transformed iBAQ values normalised to overall average. The iBAQ values from 2140 
accessions identified in the Leishmania secretome were analysed. A normalised iBAQ value superior to 1,1 is 
associated to abundant proteins. 
 
Among the second most abundant accessions with normalised iBAQ values above 1,3, the 
main virulence factors identified were promastigote surface antigens and soluble forms of the 
two major Leishmania virulence factors, glycoprotein 63 (GP63) or leishmanolysin. GP63 is a 
zinc-dependent surface metalloprotease with a major role in promastigote evasion of the immune 
system, as well as adhesion and invasion of host macrophages (72).  Other important virulence 
factors include several cysteine proteases, enzymes involved in the Leishmania antioxidant 
system (superoxide dismutase, trypanothione reductase, tryparedoxin peroxidase, and thiol 
specific antioxidant); and other enzymes such as peptidyl-prolyl cis-trans isomerase 
(cyclophilin), and enolase with probable key roles in tissue invasion and virulence (73,74). The 
protein aldolase (putative 2,4-dihydroxyhept-2-ene-1,7-dioic acid aldolase) binds host tyrosine 
phosphatase SHP-1, inducing macrophage dysfunction and promoting parasite persistence (75). 
The putative histidine secretory acid phosphatase is found on the parasite’s surface and is 
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continuously secreted by all species analysed to date and, although its role in pathogenesis is for 
the most part unknown, it is implicated in nutrient scavenging as well as modulation of host 
environment (72). 
 
The identification of histone proteins in stationary phase samples can be associated with the 
release of apoptotic vesicles.  Indeed, several histone proteins are found in all datasets - Histone 
H4 and Histone H2B are the most abundant (normalised iBAQ values between 1.37 and 1.38). 
Furthermore, we also found Histone H3 (1.29), Histone H2A (1.22), and Histone H2A.1 (1.18). The 
histones are core components of the nucleosome, the DNA packaging unit in eukaryotes consisting 
of histones bound to the DNA strands (chromatin). In the MoonProt database, the only histone 
described to have a moonlighting function is mouse histone H1 which acts as a thyroglobulin 
receptor.  
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4. Discussion 
 
To our knowledge, this is the first proteomic analysis of the secretome comparing multiple 
Leishmania species, pathogenic and non-pathogenic to humans (publication in preparation). 
Furthermore, the method used to produce naturally secreted proteins using aseric in vitro growth 
conditions is recommended to analyse such proteins. Seldom the secretome analysed in 
proteomic studies is prepared from cultured parasites with medium containing serum, which 
negatively affects protein secretion. The lack of duplicates for each sample was due to cost 
constraints and it can pose some limitations to the present study. However, previous experiments 
from the development of the canine vaccine show limited variability between secretome batches 
(vaccine quality control, unpublished data). 
The present study focuses on the Leishmania promastigote secretome, a critical player in 
early stage host-pathogen interactions. Leishmania parasites do undergo differentiation to 
amastigotes inside the vertebrate host, however, previous studies show low levels of differential 
gene expression, with a big role for post-translational regulation of the stage-specific gene 
expression and survival in the intracellular environment. As gene and protein annotation improve, 
so will our understanding of all players involved in host-parasite interactions. The key to 
potentially discover targets or markers and develop the much-needed improved treatments and 
diagnostics. 
As expected, classical secretion mediated by N-terminal signal peptides is the least 
important secretion mechanism in Leishmania parasites and most proteins are predicted to be 
secreted through non-conventional pathways. Still, a large portion of the proteins are not 
predicted to be secreted despite being identified in the secretome. Despite its usefulness in 
deciphering the protein secretion pathways, it has been demonstrated that the SecretomeP 
prediction algorithm presents some limitations in predicting non-classical secretion for plant 
proteins and other eukaryotic organisms (76,77). These limitations may also apply to Leishmania 
proteins because of the algorithm training data. Possibly, Leishmania proteins possess unexpected 
features or share features with proteins from both eukaryotes and prokaryotes which are not 
considered by the algorithm. To evaluate this possibility, an additional bioinformatics analysis 
with SecretomeP predictions for gram-negative/gram-positive bacteria non-classical secretion 
will be performed and included in the publication. 
Nevertheless, the results presented here are completely aligned with previous studies on 
Leishmania secreted proteins and the importance of vesicle-based secretion in Leishmania 
parasites (33,37,40,45). Exosome cargo is increasingly studied and implicated in host-host and 
host-pathogen interactions (35,47,78), and in this database we find proteins that are identified 
often in exosomes. We found many exosome marker proteins in the Leishmania secretome (9 
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different proteins out of 16 Leishmania orthologs to genes described in the Exocarta). This 
suggests a highly conserved cell communication mechanism across eukaryotic organisms, to 
which the parasites perfectly adapted to interrupt and manipulate so to enable their replication 
and continued transmission.  
 
Several important and well-described virulence factors are among the most abundant 
proteins (PSA, leishmanolysin, HSP70, and others). Some of these proteins have not only been 
described to be key players in early establishment of infection but also as potential vaccine antigen 
candidates (79–81). 
The biological reason for the presence of certain proteins or protein families remains 
elusive. We expect to find a mix of virulence factors, immunomodulators, and excretion products.  
Interestingly, Leishmania proteins with moonlighting functions have been described, all of which 
are found in the secretome. Considering the existence of these moonlighting functions, the 
remaining proteins and virulence factors identified in the secretome are probably performing 
additional functions which remain unidentified. 
Importantly, the functions attributed to the secreted proteins are highly conserved among 
Leishmania species. L. braziliensis is the most divergent species among the human infective species 
analysed and L. tarentolae which is non-infective to human. Still, they share gene product 
functions across all Gene Ontology domains. The secretome data generated deserves further in-
depth analysis to evaluate if certain GO terms are enriched in this biological compartment. This 
analysis will be performed and discussed in the manuscript in preparation, aiming at unravelling 
the essentiality of excreted-secreted proteins in host-pathogen interactions. Nevertheless, we 
provide evidence of the high degree of Leishmania species conservation on the proteomic level 
(active end products of genome expression) which further supports the discovery of conserved 
virulence factors and/or antigens.  
The datasets generated with the proteomic analysis constitute an ancillary expected 
outcome of the present project. Hopefully, the detailed characterization of the secretome will 
contribute to novel discoveries on potential connections between geographical distribution, 
clinical presentation, immunomodulation and pathogenesis. Also, by including a non-pathogenic 
Leishmania species (L. tarentolae), we hope to contribute to increase our knowledge about 
interspecies variability and possibly reveal novel important virulence factors that can contribute 
to leishmaniasis diagnosis or drug development. 
The high conservation of the proteins identified in the Leishmania secretome datasets 
further corroborates the proposed strategy of using promastigotes secreted proteins as a source 
for antigen discovery and pan-Leishmania vaccine development. The following chapter will 
explore these datasets to highlight relevant vaccine antigen candidates.  
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Objective: to search for Leishmania-specific vaccine antigens that will advance for epitope 
prediction analysis for the development of a human vaccine formulation against human 
leishmaniases. 
 
Aims: 
- To screen a maximum number of antigens, so to fully explore the potential of the 
secretome proteomic datasets and increase the chances of finding strong binding 
epitopes; 
- To list and search previously described antigens in Leishmania secretome, which will 
allow the identification of known vaccine candidates, according to the literature;  
- To perform a reverse vaccinology (RV) approach which will allow the identification of 
novel protein antigen candidates based on (low) homology with human host proteins. 
 
 
1. Introduction 
 
An antigen is a molecule that can bind specifically to an antibody or generate peptide 
fragments that are recognised by a T cell receptor, both produced by adaptive immune responses 
(1). Immunogens are molecules that, on their own, can elicit an adaptive immune response on 
injection into a person or animal (1). All antigens have the potential of binding specific antibodies 
or TCR, however, not all antigens are immunogenic, as they can be recognised by specific 
antibodies or TCR without inducing an immune response. In this sense, all immunogens are 
antigens, but not all antigens are immunogens, and vaccine candidates must be immunogenic. 
As mentioned in the previous chapter, there is a high level of antigenic conservation 
among pathogenic species, as all species share high genome homology and synteny. Also, there is 
not a significant antigenic variation among Leishmania parasite forms (promastigote and 
amastigote). 
Over the last decades, Leishmania vaccine antigens have been increasingly detailed, from 
non-defined crude antigen mixtures to the generation of recombinant proteins. Several factors 
have greatly contributed to these advances: i) the availability of pathogen- and host-specific 
genome and proteome information; ii) increased knowledge on mechanisms behind antigen 
recognition, presentation and subsequent immune activation cascades; and iii) the improvement 
of computational tools for epitope mapping and prediction. 
  
CHAPTER III – VACCINE ANTIGEN SELECTION 
119 
 
2. Methods 
 
2.1. Bioinformatic analysis of proteomic datasets 
 
Raw MS spectra (AESLMTS_110414, AESLMTS_151026, AESLMTS_160115) were 
processed using the MaxQuant environment (version 1.5.5.0), as in Chapter II. The MS/MS spectra 
were matched against the Leishmania entries of UniProtKB SwissProt and TrEMBL sections 
(release 2016_05: 50997 entries with 229 SwissProt + 50768 TrEMBL). Again, a representative 
protein ID in each protein group was automatically selected using in-house bioinformatics tools 
(leading v2.2 and multi-species scripts) developed by Oana Vigy (Plateforme de Proteomique 
Fonctionnelle de Montpellier), and the Perseus software (version 1.5.3.0).  
All Leishmania entries available in UniProtKB (UniProtKB release 2016_05) were used for 
tryptic peptide identification: four reference proteomes from Leishmania infantum strain JPCM5 
(RefProteome_LEIIN-all_2016_01.fasta), Leishmania major strain MHOM/IL/81/Friedlin 
(RefProteome_LEIMA-all_2016_01.fasta), Leishmania braziliensis strain MHOM/BR/75/M2904 
(RefProteome_LEIBR-all_2016_01.fasta), Leishmania mexicana strain MHOM/GT/2001/U1103, 
Leishmania donovani strain BPK282A1 (Proteome_LEIDB-all_2016_01.fasta). Also, all L. 
amazonensis and L. tropica proteins in the UniProtKB were included (Uniprot_LEIAM-
all_2016_01.fasta; Uniprot_LEITR-all_2016_01.fasta). 
 
2.2. Protein set A – previously described vaccine antigen candidates 
 
The complete list of previously known antigen candidates (Table III.1) was retrieved from the 
following publications:  
i) Singh B, Sundar S. 2012. Leishmaniasis: Vaccine candidates and perspectives. Vaccine 
30:3834– 3842 (2);  
ii) Kumar R, Engwerda C. 2014. Vaccines to prevent leishmaniasis. Clinical & Translational 
Immunology 3, e13 (3);  
iii) Lakshmi BS, Wang R, Madhubala R. 2014. Leishmania genome analysis and high-
throughput immunological screening identifies tuzin as a novel vaccine candidate against 
visceral leishmaniasis. Vaccine 32:3816–3822 (4);  
iv) Sundar S, Singh B. 2014. Identifying vaccine targets for anti-leishmanial vaccine 
development. Expert Rev Vaccines. 13(4): 489–505 (5);  
v) Alvar J, Croft S, Kaye P, Khamesipour A, Sundar S, Reed SG. 2013. Case study for a vaccine 
against leishmaniasis. Vaccine 31S B244–B249 (6);  
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vi) Mou Z et al. 2015 Identification of broadly conserved cross-species protective Leishmania 
antigen and its responding CD4+ T cells. Sci. Transl. Med. 7, 310ra167 (7). 
 
Table III. 1 Initial list of vaccine antigen candidates found in the literature. 
Reference Leishmania vaccine antigen candidates 
(2) Heat-shock proteins | PSA-2 and GP46 (surface glycoproteins) | A2 & HASPB | 
Cysteine proteases | LACK | CRK (creatine kinase) & MAPK (mitogen-activated 
protein kinase) | Histones | Glycolytic enzymes & SMT (sterol 24-c-
methyltransferase) | 
Recombinant antigens (Leishmune/fucose mannose ligand, MML-MPL) | 
PFR | LPG | Initiation factors | GSH (glutathione) & TSH (trypanothione 
reductase) | LmSTI1 | TSA 
Topoisomerase and RIC (RNA import complex) | Lcr | Ldp23 
KMP11 | Purine salvage system & nucleoside hydrolase (NH) 
(3) fucose mannose ligand (leishmune) | KMP11 | SMT | A2 | cysteine protease B | 
Lb EIF | HASPB | LACK | PSA | NH | GP63 | Leish-111f (TSA::STI1::EIF) 
(4) Tuzin | FGP | phospholipase A1-like protein (PLA1) | potassium voltage-gated 
channel protein (K VOLT) 
(5) Leish-111f |Leishmune (FML vaccine) | Leish-Tec (adenovirus with L. donovani 
A2 protein) | H1 | CPa+CPb | LACK | P0 | A2 | HASPB | LPG | LiESA/QA-21 
(6) LACK | Leishmanolysin (GP63) | TSA | STI1 | EIF | HASPB | SMT | KMP11 | A2 | 
Cysteine protease B | NH | Methionine aminopeptidase 45 | Protein disulfide 
isomerase | Elongation Factor-2 
(7) Glycosomal phosphoenolpyruvate carboxykinase (gPEPCK) 
 
After listing all vaccine antigen candidates cited in the selected publications, a manual search 
was performed in the secretome datasets, either by protein accession or by protein name, as 
follows: 
i) A word search by protein name was performed on the 3 already available secretome 
proteomic datasets from experiment AESLMTS_110414 (L. infantum, L. major and L. 
tropica datasets analysed with the UniProtKB database release 2011_04 
(SwissProt_TrEMBL_2011_04: 15,082,690 sequences; 4,872,194,356 residues / 
Leishmania 42,035 sequences). All associated identifiers (protein entry numbers) were 
retrieved from all match groups and respective identified tryptic peptides, so that each 
protein contains at least 3 species-specific sequences (protein x = ID1 + ID2 + ID3 + …). 
ii) The identified tryptic peptides were aligned with the UniProtKB protein sequences 
(through ClustalOmega alignments) to check if all peptides are found and to check for 
unique residues or peptides.  
iii) For L. tropica, with less annotated proteins in UniProtKB, proteins are often identified as 
one of the species with complete or reference proteome in UniProtKB. To include the 
maximal number of species-specific sequences and include L. tropica-specific sequences, 
the coding genes were searched in the TriTrypDB. The corresponding translated proteins 
were retrieved and aligned with identified tryptic peptides – if the sequences contained 
the tryptic peptides, they were included as L. tropica species-specific sequence.  
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iv) The ortholog sequences for the remaining 3 species datasets (L. donovani, L. braziliensis, 
L. amazonensis) were retrieved with a UniProtKB BLAST search. Briefly, the L. infantum 
accession for each protein of interest was ‘blasted’ to find other Leishmania-specific 
sequences through sequence similarity. All ‘Leishmania’ accessions were retrieved, 
including protein accession numbers, organism, and sequence identity (%).   
v) All accession numbers per protein of interest were searched in the secretome proteomic 
datasets generated by the analysis with the UniProtKB release 2016_05, including the 
additional species L. infantum, L. donovani, L. braziliensis, L. amazonensis and L. tarentolae 
(experiments AESLMTS_110414, AESLMTS_151026, AESLMTS_160115). All identified 
tryptic peptide counts per sequence were retrieved, as well as respective identification 
status assigned by the script leading v2.2 (LEADING_AUTO / LEADING_SPECIES / 
Multispecies). Species-specific sequences with higher homology levels and containing the 
highest number of identified peptides were included. 
vi) The final list for protein Set A contains 4 to 6 species-specific sequences per protein 
antigen, meaning only proteins present in all studied species were selected; 
 
2.3. Protein set B - reverse vaccinology approach for antigen selection 
 
A total of 618 accessions were identified in all 6 proteomic datasets from pathogenic 
Leishmania species (UniProtKB release 2016_05) (Figure III.1 panel A).  
All 618 protein sequences were submitted to BLASTp analysis against the human 
proteome (Homo sapiens taxid:9606 RefSeq protein database from 
ftp.ncbi.nlm.nih.gov/genomes/H_sapiens/protein/). This analysis was performed using the 
standalone BLAST tool for Windows™, with imported search parameters from the online version, 
to keep standard alignment parameters (Figure III.1 panel B). Briefly, to import the default 
BLASTp search strategy, one random accession was run on the BLASTp online tool, against Human 
RefSeq proteins, with standard algorithm parameters. The search strategy was saved to a local 
directory as an “.asn” file and used in the standalone BLAST analysis (Figure III.1 panel B). 
The alignment results were retrieved using the tabular output format is a “.csv” file 
(outfmt=6), containing the columns (Figure III.1 panel B): query sequence name (qseqid), length 
(qlen), sequence (qseq); subject sequence name (sseqid), alignment length (length), start of 
alignment in query (qstart), end of alignment in query (qend), expect value (evalue), bit score 
(bitscore), percentage of identical matches (pident), number of identical matches (nident), 
percentage of positive-scoring matches (ppos), number of positive-scoring matches (positive).  
All accessions with “no hits found” were included in the protein set B.  
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Sequences were retrieved from UniProtKB and aligned to identify protein groups. In order 
to complete the protein groups with species-specific sequences, accessions per protein group 
were ‘blasted’ in UniProtKB. Species-specific sequences with higher homology levels and 
containing the highest number of identified peptides were included, resulting in 4 to 6 species-
specific sequences per protein. 
 
 
Figure III. 1 A reverse vaccinology approach to find novel excreted-secreted Leishmania antigen 
candidates. A) Venn diagram comparing total identified proteins from 6 Leishmania species – L. infantum (LEIIN), 
L. major (LEIMA), L. donovani (LEIDB), L. braziliensis (LEIBR), L. tropica (LEITR) and L. amazonensis (LEIAM) 
showing 618 accessions were identified in all samples. B) Standalone blastp code (MS-DOS) used to blast 618 
common accessions against the human proteome (RefSeq proteome) using default parameters from the online 
BLASTp server. 
 
2.4. Evaluation of protein relative abundance with iBAQ 
 
To rank the relative abundance of different proteins, an intensity-based absolute 
quantification (iBAQ) algorithm was used. Raw data files were analysed with the MaxQuant 
software package (version 1.5.5.0). As detailed in the previous chapter, the iBAQ value is obtained 
by dividing peptide intensities by the number of theoretically observable peptides of the protein 
(all fully tryptic peptides with 6 to 30 amino acids calculated by in silico protein digestion).  
The iBAQ values corresponding to 2333 LEADING_CHECK accessions were retrieved. In 
order to estimate relative antigen abundance of protein sets A and B, absolute iBAQ values (2333 
total LEADING_CHECK accessions, 88 set A accessions and 68 set B accessions) were log-
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transformed (log10) and normalised to overall iBAQ average (average iBAQ value 2,4x107; log10 
average iBAQ value = 6,3302).  
 
3. Results 
 
3.1. Around 40% of previously described Leishmania vaccine antigens are 
found in the secretome (protein set A)  
 
All previously described vaccine antigens were manually searched in the secretome 
datasets, either by protein accession or protein name (Table III.1). Only proteins present in all 
studied species were included in protein set A.  
An initial list of 72 protein antigens was retrieved from the literature (Table III.2). These 
candidates include kinases, translation initiation factors, several proteases and other virulence 
factors. 
The 72 proteins listed from the database (Table III.2) were manually searched in the 
proteomic datasets. From these, 36 were found in the secretome, and 28 are present in all tested 
species which corresponds roughly to 40% of the initial list (Table III.3). 
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Table III. 2 A total of 72 protein antigens listed from the selected publications was searched in the secretome 
proteomic datasets (2–7). 
Antigen 
category 
Individual proteins to search in 
proteomic datasets 
Description 
Heat-shock 
proteins 
HSP70 Heat-shock proteins (HSP) were one of the first proposed antigen 
candidates. These proteins are encoded by a single copy gene, and the 
temperature shift the parasites undergo increases HSP expression, to adapt 
to survival in the vertebrate host. HSP90 is the most abundant form, with 17 
tandem gene copies. HSP70 has been identified has the immunodominant 
antigen in antibody responses against Leishmania and has shown to 
stimulate DC maturation and cytokine production. HSP90 and HSP70 are B-
cell mitogens. 
HSP71 
HSP60 mitochondrial 
HSP90  
Enzymes 
involved in the 
trypanothione 
antioxidant 
system 
Trypanothione reductase  
A recombinant L. donovani trypanothione reductase (LdTPR) induces 
lymphoproliferation and NO production in vitro, and protects hamsters 
against challenge, but also, in human samples from active and cured VL 
patients. LdTPR induces PBMC lymphoproliferation, even if slightly milder. In 
cured VL samples, LdTPR also induced IL-12 and IFN-γ production, 
accompanied by low IL-10 levels, contrary to soluble L. donovani antigens, 
which induce a mixed Th1/Th2 response with higher IL-10 levels and low 
IFN-γ.  
Peroxidoxin 1 and 2  
Pxn1 and Pxn2 tested in mice exhibit differences in the elicited response. 
Both are immunogenic, however Pxn1 induced a predominant Th2 response 
and high IgG1 whereas Pxn2 induced a mixed Th1/Th2 response with high 
IgG2a antibody levels. 
Tryparedoxin peroxidase (also 
known as TSA, thiol-specific 
antioxidant antigen) and 
mitochondrial tryparedoxin 
peroxidase  
3 forms in L. infantum with different immunological properties: cytosolic 
tryparedoxin peroxidase (LicTXNPx), mitochondrial tryparedoxin peroxidase 
(LimTXNPx), and tryparedoxin (LiTXN1). LiTXNPx elicits strong humoral 
response and has no influence on cytokine production. LmTXNPx, non-
secreted, decreases IL-4 secretion both in vitro and in vivo. LiTXN1 is poorly 
immunogenic and promotes induces IL-10 secretion both in vitro and in vivo 
favouring parasite internalization and survival.  
TSA elicits strong Th1 responses in infected BALB/c mice infected by L. 
major, and there is evidence for its immunogenicity in humans. TSA is 
abundantly present and homogeneously distributed on the promastigote 
surface. TSA-based DNA vaccine induced cytotoxicity and increased levels 
of IgG1 and IgG2a. 
Surface 
glycoprotein 
GP46  
GP46, also known as M-2, is a promastigote surface membrane glycoprotein. 
When administered with adjuvant, it induces protective cellular immune 
responses.  
Promastigote surface antigen-2  
Promastigote Surface Antigen (PSA) exists in soluble and membrane-
anchored form, and contains a leucine rich repeat (LRR) region which is an 
immunogenic epitope after protein fragmentation, inducing IFN-γ production 
and Th1 responses. Sequence analysis between PSA molecules from 9 
different Leishmania species revealed highly conserved segments in the N-
terminal region, while the central LRR domain and C-terminal regions are 
more divergent 
Putative surface antigen protein 2  
Putative surface antigen protein  
Flagellar and 
flagelle-
associated 
proteins 
PFR-2C (paraflagellar rod 
protein)   
Flagelar proteins are upregulated in promastigote forms.  
PFR-2 is a highly conserved immunogen inducing a Th1 immune response in 
dogs and mice.  
FPG was identified in a high-throughput in vitro immunological screening 
(with mouse splenocytes) and induced a predominant Th1 response (IL-12 
and IFN-γ). 
Lcr1 is present in L. infantum amastigotes, it stimulates Th1 cytokines (IFN-γ) 
and antibodies, partially protecting BALB/c mice.    
PFR-1D (paraflagellar rod 
protein)   
Flagellar glycoprotein-like protein 
(FPG)  
Lcr1 peptide (T-cell proliferation 
stimulating peptide)  
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Table III.2 (continued) 
Antigen 
category 
Individual proteins to search in 
proteomic datasets 
Description 
Histones 
H2A  Histones are evolutionary conserved DNA-binding nuclear proteins. In 
Leishmania, these present relatively low homology with human proteins and 
are stably expressed by both amastigotes and promastigotes.  
H2B has been shown to be a promising candidate, inducing PBMC 
proliferation, IFN-γ production, promoting a Th1 protective immune 
response.  
H1 from L. infantum and L. braziliensis induce humoral responses 
H2B  
H3  
H4  
Translation 
initiation factors 
LeIF (Leishmania elongation 
initiation factor) 
LeIF protein belongs to the DEAD box protein family, it is homologous to 
eIF4A. There is evidence LeIF functions as a Th1-type natural adjuvant, 
mimicking IL-12-mediated downregulation of IL-4 production in lymph node 
cultures. 
Putative eukaryotic translation 
initiation factor 2 subunit  
Putative eukaryotic translation 
initiation factor 3 subunit 8  
Putative eukaryotic translation 
initiation factor 3 subunit 7  
Probable eukaryotic initiation 
factor 4A; Short=eIF-4A; 
EC=3.6.4.13 
Eukaryotic initiation factor 5a  
Glycolytic 
enzymes 
Hexokinase (EC=2.7.1.1) 
Leishmania glycolytic enzymes are compartmentalized in glycosomes, 
unique trypanosomatid organelles, and are phylogenetically distant from 
mammalian host enzymes, making them useful vaccine antigen candidates. 
Glucose-6-phosphate isomerase 
Phosphofructokinase 
Fructose-biphosphate aldolase 
Triosephosphate isomerase 
Glyceraldehyde-3-phosphate 
dehydrogenase 
Phosphoglycerate kinase and 
mutase 
Phosphopyrvate hydratase 
(Enolase) 
Pyruvate kinase (EC=2.7.1.40) 
Other kinases 
mitogen activated protein (MAP) 
kinase (Putative MAP kinase)  
 
CRK (creatine kinase)  
Putative fucose kinase; 
EC=2.7.1.52; 
Glycosomal 
phosphoenolpyruvate 
carboxykinase (EC=4.1.1.-) 
Putative nima-related protein 
kinase; EC=2.7.11.1;  
Enzymes 
involved in the 
purine salvage 
pathway 
Nucleoside diphosphate kinase; 
EC=2.7.4.6; 
Leishmania parasites depend upon the purine salvage system to utilize 
purine bases from their mammalian hosts; for this purpose they utilize a 
variety of nucleoside transporters that can be the potent targets for vaccine 
development. 
During parasite-delayed macrophage apoptosis, Leishmania nucleoside 
diphosphate kinase can inhibit ATP binding to P2X receptors thereby 
preventing apoptosis. 
The nucleoside hydrolase (NH) is a glycoprotein, part of the Leishmania 
fucose-mannose ligand (FML) complex, and essential for early infection 
establishment. NH is a known vaccine antigen, known to induce protective 
immune responses in mice and dogs against experimental infection. 
Putative adenosine kinase; 
EC=2.7.1.20; 
Nucleotide hydrolase 
Topoisomerases 
and other 
isomerases 
DNA topoisomerase  
DNA topoisomerases in the kinetoplastid parasites are mainly involved in 
kDNA replication, essential for the survival of parasite. These are, however, 
distinct from other eukaryotic counterparts, making them interesting antigen 
candidates. 
Protein disulfide isomerase (PDI) 
PDI catalyses thiol-disulfide interchange to prevent cell toxicity associated 
with ER stress and protein misfolding.  
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Table III.2 (continued) 
Antigen 
category 
Individual proteins to search 
in proteomic datasets 
Description 
Cyclophilins 
(peptidyl-prolyl-
isomerases) 
Peptidyl-prolyl cis-trans 
isomerase; EC=5.2.1.8;  
Cyclophilins possess peptidyl-prolyl cis-trans isomerase activity, can 
perform different functions and are known receptors for cyclosporine, an 
immunosuppressive drug. Leishmania presents different cyclophilin 
isoforms, not fully characterized.  
Immunization with the L. infantum recombinant cyclophilin protein-1 confers 
partial protection in mice and generates specific memory T cells.
Peptidyl-prolyl cis-trans 
isomerase; EC=5.2.1.8; 
(Cyclophilin-40) 
Sterol 24-c 
methyltransferase 
and other 
transferases 
SMT (sterol 24-c-
methyltransferase)  
SMT is involved in the final step of the sterol biosynthetic pathway in 
Leishmania, leading to the production of ergosterol. 
arginine methyltransferase  
Putative carnitine/choline 
acetyltransferase; EC=2.3.1.-  
Aspartate aminotransferase  
serine hydroxy methyl 
transferase  
Proteases 
Cysteine protease A and B 
Leishmania cysteine protease is the major protease involved in survival 
and adaptation to the host cell. Cysteine proteases have been shown to 
stimulate Th2 responses (IL-4 and IL-1). However, L. mexicana cysteine 
protease is a T-cell immunogen causes the development of protective Th1 
responses (IL-12 and IFN-γ).  
GP63 or major surface protease (MSP) is a zinc protease and a key 
virulence factor responsible for evasion of the immune system, and 
degradation of fibronectin enhancing movement within the connective 
tissue (see chapter I).  
The cpL and cpB cysteine proteases are responsible for the lack of MHC-II 
invariant chain, therefore, modulating the cytokine production (increased IL-
4 and IL-1) to the parasite’s benefit. Also, the human host’s papain-like 
cysteine proteases cathepsin A-like and B-like proteases, are targets of 
Leishmania immunomodulation and induction of Th2 responses.  
Ldp45 is involved in protein maturation. It is recognized by human T-cells 
and protects hamsters when formulated with BCG.  
GP63 (surface metalloprotease) / 
MSP (major surface protease) / 
leishmanolysin 
Cathepsin B-like (cpB) and 
cathepsin L-like (cpL) cysteine 
proteases 
Ldp45 (Methionine 
aminopeptidase 45) 
Putative aminopeptidase 
(Metallo-peptidase, clan mf, 
family m17; EC=3.4.11.) 
Putative aminopeptidase; 
(Metallo-peptidase, clan ma(E), 
family m1; EC=3.4.-.-) 
Putative aminopeptidase P 
(Metallo-peptidase, clan mg, 
family m24)  
Putative carboxypeptidase 
(Metallo-peptidase, clan ma(E), 
family 32)  
Putative thimet oligopeptidase 
(Metallo-peptidase, clan ma(E), 
family m3; EC=3.4.24.15) 
Putative dipeptidyl-peptidase III 
(Metallo-peptidase, clan m-, 
family m49; EC=3.4.14.4)  
Putative peptidyl dipeptidase 
(Metallo-peptidase, Clan MA(E), 
Family M3,putative, partial)  
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Table III.2 (continued) 
Antigen 
category 
Individual proteins to search 
in proteomic datasets 
Description 
Other antigens 
KMP11 (kinetoplastid membrane 
protein-11)  
KMP11 is a widely known amastigote and promastigote antigen, non-
covalently bound to LPG, and conserved in trypanosomatids. B and T cell 
immunogen. There is evidence it is processed by DCs and presented by 
MHC-II molecules, activating specific T cells. The IFN-γ produced is 
enough to foster TNF-α and NO production resulting in parasite death 
inside macrophages. In susceptible individuals, KMP11 induces IL-4, IL-10 
and IL-13 production perpetuating macrophage infection. 
LACK (Leishmania analogue of 
the kinase receptor C) 
LACK is present in both amastigotes and promastigotes, and is highly 
conserved among Leishmania species. It is homologue of mammalian 
RACK1. LACK belongs to the WD repeat protein family. It is important for 
DNA replication, RNA synthesis, signal transduction and cell cycle, and 
also in the differentiation from metacyclic promastigote to amastigote, as 
there is a minimum threshold of this protein to establish infection. LACK is 
known to induce Th2 responses (IL-4 and IL-10 production).  
Elongation factor 2  EF-2 is recognised by human T cells and provides protection in hamsters. 
Ldp23 or 23 kDa cell surface 
protei  (probable 60S ribosomal 
protein)  
Ldp23 is present on the surface of L.donovani and L. major amastigotes 
and promastigotes, it accelerates IFN-y production and inhibits IL-4 
production. 
 A-2  
A2 is the major antigen in the Leishmune® canine vaccine, it is only present 
in amastigotes. It contains multiple copies of a 10 amino-acid repeat, and is 
known to induce Th1 responses and provide partial protection against 
Leishmania species. 
HASPB and HASPA (hydrophylic 
acylated surface proteins A and 
B)  
Leishmania HASPB is a lipoprotein that is exported via an unconventional 
secretory pathway. Recombinant HASPB1 confers protection against 
experimental challenge in mice. 
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Table III. 3 Protein description of the 28 selected antigen candidates (Set A). In yellow, the antigens used in current vaccine formulation. Significant differential expression information from 
Alcolea P. et al 2010. Transcriptomics throughout the life cycle of Leishmania infantum: high down-regulation rate in the amastigote stage. Int J Parasitol. 40(13):1497-516 (8). 
Protein name REFS 
differential 
expression in 
stationary phase 
promastigotes VS 
amastigotes? 
Protein function (associated GO terms) 
Flagellar glycoprotein-like protein (FPG) 1, 3   
integral component of membrane [GO:0016021]; motile cilium 
[GO:0031514] 
Trypanothione reductase 1  -25,7 +- 1,4 
cell [GO:0005623]; disulfide oxidoreductase activity [GO:0015036]; flavin 
adenine dinucleotide binding [GO:0050660]; trypanothione-disulfide 
reductase activity [GO:0015042]; cell redox homeostasis [GO:0045454] 
Cysteine protease_cathepsinB-like 1, 4  - cysteine-type peptidase activity [GO:0008234] 
LmSTI1 (Lm stress-inducible 1) homolog  1 - 5  -  
TSA (thiol-specific antigen) / Tryparedoxin peroxidase  1 - 5  - peroxidase activity [GO:0004601]; peroxiredoxin activity [GO:0051920] 
LACK (leishmania analogue of the kinase receptor C)  1 - 5  - 
ribosome [GO:0005840]; kinase activity [GO:0016301]; regulation of 
cytokinesis [GO:0032465] 
Protein disulfide isomerase-2 4, 5  - 
endoplasmic reticulum [GO:0005783]; protein disulfide isomerase activity 
[GO:0003756]; cell redox homeostasis [GO:0045454] 
KINASES       
Nucleoside diphosphate kinase; EC=2.7.4.6; (Purine salvage system) 1 14+-0 
ATP binding [GO:0005524]; nucleoside diphosphate kinase activity 
[GO:0004550]; CTP biosynthetic process [GO:0006241]; GTP biosynthetic 
process [GO:0006183]; UTP biosynthetic process [GO:0006228] 
Putative adenosine kinase; EC=2.7.1.20; (Purine metabolism) 1  - 
adenosine kinase activity [GO:0004001]; purine ribonucleoside salvage 
[GO:0006166] 
Pyruvate kinase; EC=2.7.1.40; (glycolytic enzyme) 1  -  
kinase activity [GO:0016301]; magnesium ion binding [GO:0000287]; 
potassium ion binding [GO:0030955]; pyruvate kinase activity 
[GO:0004743] 
Putative glycosomal phosphoenolpyruvate carboxykinase; EC=4.1.1.-; 6 N.D. 
ATP binding [GO:0005524]; kinase activity [GO:0016301]; 
phosphoenolpyruvate carboxykinase (ATP) activity [GO:0004612]; 
gluconeogenesis [GO:0006094] 
Putative hexokinase; EC=2.7.1.1; (glycolytic enzyme) 1   
cell [GO:0005623]; ATP binding [GO:0005524]; glucose binding 
[GO:0005536]; hexokinase activity [GO:0004396]; cellular glucose 
homeostasis [GO:0001678]; glycolytic process [GO:0006096] 
INITIATION FACTORS       
Putative eukaryotic translation initiation factor 2 subunit 1, 2 N.D. 
GTP binding [GO:0005525]; GTPase activity [GO:0003924]; translation 
initiation factor activity [GO:0003743] 
CHAPTER III – VACCINE ANTIGEN SELECTION 
129 
 
Table III.3 (continued) 
Protein name REFS 
differential 
expression in 
stat.promast vs  
amastigotes? 
[Alcolea PJ 2010] 
Protein function (associated GO terms) 
Putative eukaryotic translation initiation factor 5a 1, 2 N.D. 
ribosome binding [GO:0043022]; translation elongation factor activity 
[GO:0003746]; translation initiation factor activity [GO:0003743]; positive 
regulation of translational elongation [GO:0045901]; positive regulation of 
translational termination [GO:0045905]; translational frameshifting 
[GO:0006452] 
eIF4A 1, 2, 5  - 
ATP binding [GO:0005524]; helicase activity [GO:0004386]; translation 
initiation factor activity [GO:0003743] 
HISTONES       
Histone2A 1, 4  - 
nucleosome [GO:0000786]; nucleus [GO:0005634]; DNA binding 
[GO:0003677] 
Histone H2B 1, 4 2,6 +- 0,2 
nucleosome [GO:0000786]; nucleus [GO:0005634]; DNA binding 
[GO:0003677] 
Histone H4 1, 4  - 
nucleosome [GO:0000786]; nucleus [GO:0005634]; DNA binding 
[GO:0003677] 
OTHER       
Triosephosphate isomerase 1  - 
triose-phosphate isomerase activity [GO:0004807]; gluconeogenesis 
[GO:0006094]; glycolytic process [GO:0006096]; pentose-phosphate shunt 
[GO:0006098] 
Nucleoside hydrolase 1, 2, 5  - hydrolase activity [GO:0016787] 
PFR-2C 1  - motile cilium [GO:0031514] 
HSP60    - 
cytoplasm [GO:0005737]; ATP binding [GO:0005524]; protein refolding 
[GO:0042026] 
GP63 5  - 
membrane [GO:0016020]; metalloendopeptidase activity [GO:0004222]; 
cell adhesion [GO:0007155] 
Metallo-peptidase, clan mf, family m17); EC=3.4.11.-;    - 
cytoplasm [GO:0005737]; aminopeptidase activity [GO:0004177]; 
manganese ion binding [GO:0030145]; metalloexopeptidase activity 
[GO:0008235] 
Putative aminopeptidase (Metallo-peptidase, clan ma(E), family m1); 
EC=3.4.-.-; 
   - 
aminopeptidase activity [GO:0004177]; metallopeptidase activity 
[GO:0008237]; zinc ion binding [GO:0008270] 
Putative dipeptidyl-peptidase III (Metallo-peptidase, clan m-, family m49); 
EC=3.4.14.4; 
   -  
cytoplasm [GO:0005737]; dipeptidyl-peptidase activity [GO:0008239]; metal 
ion binding [GO:0046872] 
Putative thimet oligopeptidase (Metallo-peptidase, clan ma(E), family 
m3); EC=3.4.24.15; 
    
metal ion binding [GO:0046872]; metalloendopeptidase activity 
[GO:0004222] 
Elongation factor 2 1  - 
GTP binding [GO:0005525]; GTPase activity [GO:0003924]; translation 
elongation factor activity [GO:0003746] 
KMP11  1 - 5     
Calpain-like cysteine protease 1     
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At times, because proteins were manually searched by protein name, redundant proteins 
and isoform sequences are found, as for the case of peroxidoxins. Through sequence alignment 
and gene IDs three groups for peroxidoxins were generated according to their function in the anti-
oxidation pathway – tryparedoxin peroxidase, peroxidoxin and tryparedoxin (Table III.4).  
 
Table III. 4 Deconvolution of peroxidoxin sequences annotated in the UniProt and Genbank databases. 
Underlined sequences were selected. 
Species Name UniProt Acc Nr UniProt GeneID Genbank ID 
L. major 
thiol-specific antioxidant antigen A9LJZ6_LEIMA TSA ABX11567.1. 
thiol-specific antioxidant antigen Q4QF68_LEIMA TRYP7 AAC31146.1 
tryparedoxin peroxidase Q4QF74_LEIMA TRYP4 CAJ03332.1 
tryparedoxin peroxidase Q4QF80_LEIMA TRYP1 CAJ03330.1 
tryparedoxin peroxidase Q4QF76_LEIMA TRYP3 CAJ03334.1 
tryparedoxin peroxidase A9LNR9_LEIMA TRYP6 ABX26130.1 
peroxidoxin Q9TZS4_LEIMA N/A AAC79432.1 
peroxidoxin Q4QBH2_LEIMA LMJF_23_0040 CAJ03825.1 
Tryparedoxin E9ADX3_LEIMA TXN2 / LMJF_29_1150 CBZ12452.1 
L. 
infantum 
thiol-specific antioxidant antigen Q8MU50_LEIIN N/A AAK58478.1 
tryparedoxin peroxidase A4HWK3_LEIIN TRYP / LINJ_15_1120 CAM66832.1 
tryparedoxin peroxidase A4HWK2_LEIIN TRYP / LINJ_15_1100 CAM66830.1 
cytosolic peroxiredoxin Q95NF5_LEIIN TRYP / LINJ_15_1140 AAL25847.1 
putative mitochondrial 
peroxiredoxin 
Q95U89_LEIIN mTXNPx / LINJ_23_0050 AAL25846.1 
Tryparedoxin Q6RYT3_LEIIN TXN1 / LINJ_29_1250 
AAS48350.1./ 
CAM69684.1. 
L. 
tropica 
peroxidoxin 1 Q07DU6_LEITR Pxn1 AAZ23600.1 
peroxidoxin 2 Q07DU5_LEITR Pxn2 AAZ23601.1 
 
Each protein antigen in set A includes 4 to 6 species-specific sequences (Table III.5). The 
proteins with 5 and/or 6 species-specific sequences include proteins specific to L. tropica and/or 
L. amazonensis samples, which are automatically identified as one of the reference proteome 
species by the bioinformatics analysis. The gene search in TriTrypDB and respective translated 
proteins allowed the inclusion of species-specific sequences.  
Finally, the total 28 protein antigens from protein set A include 3 protein antigens with 4 
species-specific sequences, 14 protein antigens with 5 species-specific sequences, and 11 protein 
antigens with 6 species-specific sequences (Table III.5). 
In summary, the protein set A includes i) potential vaccine antigens; ii) antigens present in the 
secretome; and iii) antigens common to six pathogenic Leishmania species. 
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Table III. 5 Protein Set A includes 28 antigenic proteins (A1 to A32) described in the literature as potential 
vaccine antigens against Leishmania spp. Each protein antigen includes 4 to 6 species-specific sequences. The 
peptide counts allowing the identification of each sequence in the several samples are shown, as well as the protein 
length, percentage of identity among sequences and the identification (ID) status according the bioinformatic script 
used (see chapter II). L. braziliensis (LEIBR), L. donovani (LEIDB), L. infantum (LEIIN), L. amazonensis (LEIAM), 
L. major (LEIMA) and L. tropica (LEITR). 
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Table III.5 (continued) 
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3.2. A reverse vaccinology approach allowed the identification of 24 novel 
antigen candidates, including 3 antigens previously described in the 
literature  
 
The BLASTp analysis of the common 618 accessions generated a total of 15720 alignment 
results for 542 unique protein sequences. Proteins with no significant homology with human 
proteins were selected – a total of 76 accessions with “no hits found”. The 76 accessions include 
43 annotated sequences, corresponding to 14 proteins, and 33 accessions corresponding to 
uncharacterised proteins (UP). These 33 UP sequences were aligned with the ClustalOmega 
alignment tool, and 10 clusters were identified (Table III.6).  
Considering 14 proteins and 10 UP, protein set B contains 24 protein antigen candidates. 
The protein set B includes 7 protein antigens with 4 species-specific sequences, 16 proteins 
antigens with 5, and one protein antigen with 6 species-specific sequences (Table III.7). 
Among the proteins selected through this approach, 4 accessions were already included in 
the protein set A. These accessions correspond to 3 different proteins: i) L. infantum nucleoside 
hydrolase-like protein and L. major putative inosine-guanine nucleoside hydrolase; ii) L. infantum 
paraflagellar rod protein 2C; and iii) L. infantum kinetoplastid membrane protein 11C.     
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Table III. 6 ClustalOmega alignment results (percent identity matrix) for 33 uncharacterized proteins identified with the reverse vaccinology approach 
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Table III. 7 Protein set B includes 14 annotated proteins and 10 uncharacterised proteins (B1 to B24). Each 
protein antigen includes 4 to 6 species-specific sequences. The peptide counts allowing the identification of each 
sequence in the several samples are shown, as well as the protein length, percentage of identity among sequences 
and the identification (ID) status according the bioinformatic script used (see chapter II). L. braziliensis (LEIBR), L. 
donovani (LEIDB), L. infantum (LEIIN), L. amazonensis (LEIAM), L. major (LEIMA) and L. tropica (LEITR). 
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Table III.7 (continued) 
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3.3. Most protein antigens selected are well represented in the secretome  
 
Normalisation of iBAQ values allowed the determination of the relative abundance of a 
given protein, providing a rough estimation of overall antigen abundance. The absolute iBAQ 
values for the 2333 LEADING accessions identified with the proteomic analysis range from 2524,8 
(103) to 3526300000 (109). Nine protein accessions have iBAQ values of 0, including 4 
uncharacterized proteins, Calpain-like cysteine peptidase (Fragment), Putative ubiquitin 
conjugation factor E4 B; Tubulin binding cofactor A-like protein; Serine/threonine-protein 
phosphatase and DNA-directed RNA polymerase subunit beta. The null iBAQ values imply the 
detection of specific tryptic peptides but with very low intensity, still, these values were included 
in the analysis. After normalisation, iBAQ values range from 0,537 to 1,508, and proteins with 
normalised iBAQ values over 1 can be considered abundant in the secretome. 
  
 
Figure III. 2 Normalised iBAQ values show most of the selected protein antigens are more abundant than 
average. Absolute iBAQ values were log-transformed (log10) and normalized to overall log10-iBAQ average value. 
Total identified proteins (yellow), 88 set A protein antigen sequences (purple), and 68 set B protein antigen 
sequences (green).  
 
From 147 unique protein accessions in the protein set A, 88 iBAQ values are available for 
the LEADING_CHECK accessions, with absolute values ranging from 32613 (104) to 3526300000 
(109). The normalised iBAQ values for protein set A range from 0,713 to 1,508, including one 
highly abundant protein with a normalised iBAQ value above 1,5. The protein set A contains 67 
accessions with normalised iBAQ values above 1, which corresponds to 76% of total accessions, 
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indicating most set A proteins are well represented in the secretome (Figure III.3). The protein 
set A normalised iBAQ average is 1,117 (1,06x108).  
The most abundant protein in set A is also the most abundant protein in the overall 
proteomic analysis. The nucleoside diphosphate kinase (Q9GP00; LEADING_SPECIES) is the only 
protein with normalised iBAQ value superior to 1,5. There are 10 other very abundant proteins in 
protein set A with normalised iBAQ values superior to 1,319 (trypanothione reductase; 
triosephosphate isomerase; elongation factor 2; probable eukaryotic initiation factor 4A; 
leishmanolysin; histone H2B; histone H2B; nucleoside diphosphate kinase; histone H4; putative 
small myristoylated protein-3). The least abundant protein in set A, with normalised IBAQ value 
under 0,8, is a putative aminopeptidase (E9ALJ9; LEADING_AUTO). 
The protein set B includes 114 unique accessions, 68 of which correspond to 
LEADING_CHECK identifications with iBAQ values. The absolute iBAQ values range from 86138 
(104) to 604490000 (108). The normalised iBAQ values for protein set B range from 0,78 to 1,39. 
73,5% of all accessions in protein set B are abundant, with 50 accessions presenting normalised 
iBAQ values above 1 (Figure III.3). The protein set B normalised iBAQ average is 1,077 (4,1x107). 
The most abundant proteins in set B have normalised iBAQ values above 1,35 (putative 
aldolase; putative beta-fructofuranosidase; putative small myristoylated protein-1). The least 
abundant proteins in the set B, with normalised iBAQ values under 0,8, are a putative eukaryotic 
translation initiation factor 3 and glutamate dehydrogenase.  
 
 
Figure III. 3 Estimation of selected protein antigens’ abundance with normalised iBAQ values. 
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4. Discussion  
 
A potential limitation of the overall analysis of the promastigote secretome is to overlook 
amastigote-specific proteins, potentially very important in a vaccine formulation. Some 
amastigote-specific proteins have been described and are discussed in the selected publications 
from which antigens were listed, notably the A2 protein. These proteins evidently were not found 
present in the promastigote secretome. However, there is evidence that antigens present in the 
promastigote secretome can provide immunity against intracellular forms and that many secreted 
antigens are continuously secreted during intracellular life stages.  
The simultaneous high of conservation between Leishmania species, long-term co-
evolution and selective pressure by the immune system suggests the parasite relies on early 
immune responses to establish infection. The vertebrate hosts are exposed to metacyclic 
promastigote forms in early infection, when the immune response cascade is activated. This 
provides a unique opportunity for antigen discovery since early immune responses against 
promastigotes will dictate the fate of the adaptive immune response. Moreover, gene expression 
remains stable after parasite differentiation into intracellular amastigote forms, providing the 
advantage of targeting the parasites in early stages of infection as well as intracellular replicative 
forms (9–12).  Additionally, it is established from the dog infection model that the Leishmania 
promastigote secretome is a great antigenic source for Leishmania recognition and induction of 
protective immune responses (13) (see Chapter I).  
In this light, it is not surprising that multiple known candidates are found in the secretome. 
Precisely, 36 proteins out of 72 potential antigen candidates are excreted-secreted proteins. These 
include several protein antigens currently in use by the most advanced vaccine candidates against 
leishmaniasis – initiation factors, cysteine proteases; TSA (thiol-specific antigen); LACK; protein 
disulfide isomerase-2; Putative glycosomal phosphoenolpyruvate carboxykinase; nucleoside 
hydrolase; GP63; and KMP11, among others. 
 
The second-generation vaccine LEISH-F3, the most advanced human vaccine in clinical 
trial, is based on a fusion recombinant protein combining the Nucleoside hydrolase from L. 
donovani, Sterol-24-c-methyl-transferase from L. infantum; delta cysteine protease “B” from L. 
infantum. Interestingly, both nucleoside hydrolase and cysteine protease B antigens are found in 
the Leishmania secretome. Furthermore, the other antigen candidates included in vaccines LEISH-
F1 and -F2, the Leishmania elongation initiation factor (LeIF) and thiol-specific antioxidant (TSA) 
are also present in the Leishmania secretome.  
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In eukaryotic organisms, glutathione (GSH) is an antioxidant that works as a redox buffer 
during the glutathione redox cycle, protecting the cells from reactive oxygen species. GSH reduces 
disulfide bonds of cytoplasmic proteins becoming oxidized (GSSG) and the ratio between GSH and 
GSSG is a measure of cell toxicity. Instead, Leishmania parasites have trypanothione (TSH), 
trypanothione reductase (TryR), tryparedoxin, tryparedoxin peroxidase also known as TSA (thiol-
specific antigen), peroxidoxin, and mitochondrial peroxiredoxin. These proteins make-up their 
anti-oxidant system for protection against reactive oxygen and nitrogen species, and are therefore 
essential for parasite survival inside the phagolysosomal vesicles. Two of these were found in the 
secretome of all 6 species – trypanothione reductase and tryparedoxin peroxidase, also known as 
TSA (thiol-specific antigen). These proteins are important virulence factors and targets 
particularly for drug development, but little information exists on protein immunogenicity and 
sequence annotation is still incomplete for the many existing isoforms. 
 
Proteases are ubiquitous enzymes that catalyse the hydrolysis of peptide bonds and are 
important in several biological activities. There are at least 6 classes of proteases classified 
according to the nucleophilic group responsible for the first step in the proteolysis: serine, 
cysteine, metallo, aspartate, glutamate, and threonine proteases. The two major types in 
eukaryotes are cysteine (papain-like) proteases and serine (trypsin-like) proteases. Cysteine 
proteases are categorized into 72 families, but not all are represented in protozoan parasites. The 
most abundant and well-characterized cysteine proteases are the clan CA papain-family enzymes. 
Cysteine proteases are vital virulence factors that ensure parasite survival and 
establishment of infection. Moreover, some proteases were described as potential vaccine antigen 
candidates, namely GP63, methionine aminopeptidase p45, and cathepsin-like proteases. 
Although not specifically described as potential candidates, other Leishmania proteases were also 
searched (aminopeptidases and metallo-proteases) to expand the protease antigens included in 
the protein set A.  
 
The antigens trypanothione reductase and glycosomal phosphoenolpyruvate 
carboxykinase (gPEPCK), although not used in vaccine formulation, are among the most studied 
vaccine antigens against Leishmania, showing very promising pre-clinical results (7). gPEPCK is 
upregulated in stationary phase promastigotes and L. donovani amastigotes probably due to 
gluconeogenesis activation (14).  
 
The recombinant fusion protein Q is the main component of the latest canine vaccine 
approved in Europe (Letifend®), shown to be effective in pre-clinical trials in dogs. This fusion 
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protein contains portions of L. infantum histone H2A and ribosomal proteins (p2a, p2b, and p0). 
Again, these proteins are found in the Leishmania secretome. 
 
To expand the antigen port-folio to proceed for in silico epitope prediction, we adopted a 
reverse vaccinology approach, using low human host homology as selection criterium. This 
approach allows the comprehensive exploration of the secretome proteomic analysis data thus 
allowing the screening of numerous protein antigen candidates.  
Results show there were 618 accessions common to six Leishmania species (UniProtKB 
release 2016_05). These 618 common protein accessions correspond to about a third of total 
identifications, indicative of the high conservation among pathogenic species, and in agreement 
with previous studies studying excreted-secreted proteins (see chapter II). Common identified 
accessions between the tested samples also imply that peptides that lead to each protein 
identification are found in all samples (peptide counts) and are from conserved regions. The total 
number of species-specific sequences per protein (4 to 6) takes into account sequence variability 
for all given antigens. 
The BLASTp alignments are a powerful tool to find interesting protein candidates which 
share little homology with host proteins. Several cut-off values have been suggested for selection, 
according to Evalue, Bit score, minimum alignment length, and/or minimum sequence identity 
(15,16). In the present analysis we selected only the proteins with no significant homology found, 
so no cutoff values were applied. The generated proteomic datasets could be further explored by 
including proteins with a related host protein but still with significant partial sequence 
divergence. 
 
Some candidates found with the RV approach were already described as Leishmania 
antigen candidates – KMP11, nucleoside hydrolase, paraflagellar rod proteins and calpain-like 
cysteine peptidase. We believe the identification of these proteins through the RV approach 
further supports the validity of the proposed approach. 
 
Some uncharacterised and hypothetical proteins have been proposed as Leishmania 
antigen candidates, such as the hypothetical protein LiHyR (XP_001568689.1), which 
corresponds to the protein A4HNR3 in the UniProtKB database (17). LiHyR induced Th1 
responses and reduced parasite burden in mice. More importantly, it is also immunogenic in 
human PBMC from healthy donors and cured VL patients. This protein not found in the secretome, 
nor any of its related proteins (A4ICT2, E9ASH2, E9BTB7, A0A088S1U1, Q4Q223). The high 
number of hypothetical proteins in the databases is a result of the lack of protein annotation and 
functional characterisation of Leishmania proteins. However, this should not deter the study of 
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their immunogenic properties. Accordingly, the 10 uncharacterised proteins identified with the 
reverse vaccinology approach were included in the protein set B. 
 
Antigen abundance is a pre-requisite for the induction of immune responses. the 
secretome as an antigen source contains over 1000 proteins, around 15% of total Leishmania 
proteins. The non-quantitative approach used does not allow to ascertain in absolute terms the 
amount of each identified protein. However, relative protein abundance across all tested species 
can be used as an indicator of overall abundance. We find most protein antigens are well 
represented in the secretome, 76% for set A and 74% for set B proteins. This analysis is merely 
descriptive, as antigen abundance was not used as an inclusion or exclusion criterion. However, 
this information may be useful in later stages, to favour or eliminate epitopes from more or less 
abundant proteins, respectively. Also, these proteomic datasets can be further explored to find 
new and highly abundant antigens (e.g. protein set C). 
 
The total number of protein antigens to proceed for in silico prediction analysis is limited 
by the lack of high-throughput epitope selection analysis tools. Still, a total of 52 protein antigen 
candidates from the Leishmania secretome were selected and will proceed for epitope prediction 
analysis (Figure III.4). 
 
 
Figure III. 4 Overall protein antigen selection results from the secretome proteomic data. 
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Objective: to discover T-cell epitopes present in antigens from the Leishmania secretome capable 
of inducing cellular immune responses mediated by TCD8+ and TCD4+ cells. 
 
Aims:  
- To select the best performing immunoinformatic tools; 
- To perform epitope prediction targeting world HLA coverage; 
- To select immunogenic epitopes according to in silico prediction data. 
 
1. Introduction 
 
An epitope, also called an antigenic determinant, is the site on an antigen recognised by an 
antibody or an antigen receptor – T-cell epitopes are short peptides bound to MHC molecules, and B-
cell epitopes are typically structural motifs on the antigen surface (1). Epitopes are amino-acid 
sequences characterised by a low level of similarity to the proteome of the immunoreacting host. 
 
The epitopes to include in epitope-based vaccine development should be (2): 
i) Conserved among pathogen species; 
ii) High affinity binders to HLA molecules; 
iii) Presentable in target host population (HLA restriction); 
iv) Immunogenic (able to induce T cell activation); 
v) Able to induce long-term protection (memory responses); 
vi) Not cross-reactive with self-proteins (autoimmunity). 
 
Immunodominant epitopes present in an antigen are preferentially recognised by T cells, 
such that T cells specific for those epitopes come to dominate the immune response (1). 
Immunodominance depends both on antigen-related factors and on T cell-related factors (Table IV.1). 
Discovering immunodominant epitopes is desirable in vaccine development, as these will elicit the 
strongest immune responses. However, in the case of mutation, a vaccine based only on 
immunodominant epitopes would be rendered ineffective.  Moreover, while the observed responses 
against dominant epitopes will be the strongest, they are more likely to present high response 
variability among individuals and, therefore, potentially generate an uneven vaccine performance. 
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Table IV. 1 Determinants of immunodominance. Adapted from (3). 
Antigen-related factors T cell-related factors 
Kinetics of transcription and translation; Timing of CTL clonal expansion; 
Antigen processing and transport; T cell precursor frequency; 
Antigen abundance; TCR repertoire; 
Affinity to MHC molecules; Signal strength; 
Stability and turnover of pMHC complexes; TCR affinity and avidity; 
Type of APCs Proliferative capacity; 
 Intrinsic ability to respond; 
 Pre-conditioning or priming; 
 Dwell time on APCs; 
 Elimination of APCs; 
 
Competition for resources (cytokines, 
antigens or physical niche). 
 
On the other hand, immunoprevalent T-cell epitopes are frequently immunogenic in the 
context of multiple MHC alleles. These epitopes can induce specific IFN-γ responses with high 
responding T-cell frequency within the repertoire and are common across individuals with different 
HLA types (4). In summary, while immunodominant epitopes will be recognised more vigorously, 
immunoprevalent epitopes will be recognised more frequently. Epitope-based vaccines should 
privilege immunoprevalent epitopes, particularly vaccines targeting large populations or against 
pathogens with multiple antigenic sources.  
Immunodominance and immunoprevalence are relative terms rather than absolute, as they 
always depend on the total composition of antigenic molecules and on competitive high-affinity 
binding to MHC molecules. Both should be considered when designing peptide-based vaccines. 
 
1.1. T cell epitope prediction and immunoinformatics 
 
The knowledge of immunogenicity determinants and immunogenic epitopes increased 
greatly in recent years, demonstrated by available databases such as IEDB (Immune Epitope 
DataBase) (5–8).  
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Table IV. 2 Available T-cell epitope databases. General epitope databases, and pathogen- and tumor-specific 
databases of T-cell epitopes (9). 
General 
Database 
Description Availability 
MHCPEP Database of MHC-binding peptides ftp://ftp.webi.edu.au/pub/biology/mhcpep 
SYFPEITHI Database of MHC ligand and peptide motifs http://www.syfpeithi.de 
AntiJen 
(JenPep) 
Quantitative immunology database http://www.ddg-pharmfac.net/antijen 
MHCBN 
Database of MHC/TAP-binding peptides and T-
cell epitopes 
http://www.imtech.res.in/raghava/mhcbn 
EPIMHC 
Database for customised computational 
vaccinology 
http://bio.dfci.harvard.edu/epimhc/ 
IEDB Immune epitope database http://www.iedb.org 
IMGT/HLA IMGT/HLA database http://www.ebi.ac.uk/ipd/imgt/hla/ 
Pathogen- and tumor-specific databases 
AntigenDB Database of pathogen antigens http://www.imtech.res.in/raghava/antigendb 
Protegen Database of protective antigens http://violinet.org/protegen 
HIV Molecular 
immunology 
database 
HIV database http://hiv.lanl.gov/content/immunology 
HCV 
immunology 
database 
HCV database  http://cancerimmunity.org/peptide/ 
TANTIGEN Database of tumor T-cell antigens http://cvc.dfci.harvard.edu/tadb 
 
The IEDB is the largest and most complete epitope database, capturing epitope information 
from 99% of all publications describing immune epitopes, all except HIV- and cancer-specific epitopes 
(10,11). The IEDB contains both epitope and assay information regarding epitopes from infectious 
diseases, autoimmune and allergic diseases, and alloantigens for humans, primates, mice and other 
host species (12).  
The IPD-IMGT/HLA (or IPD-IMGT/MH-DB) database is one of the seven databases from the 
the Immuno Polymorphism Database (IPD) (13). The IPD-IMGT/HLA database is part of the 
International Immunogenetics Information System® (www.imgt.org) and is the main specialised 
repository for the sequence data of polymorphic gene sequences (14). It contains allelic sequences of 
HLA genes and official sequences named by the WHO Nomenclature Committee for Factors of the HLA 
System (as of April 2019, release 3.36.0 contains 16,200 HLA Class I Alleles, 6,162 HLA Class II Alleles 
and 186 other non-HLA Alleles).  
The MHCPEP database contains both naturally processed and synthetic peptides (over 4000 
binder peptides) (15), whereas SYFPEITHI is a manually curated database from the published 
literature and exclusively contains naturally processed peptides (over 7000 MHC ligands, motifs and 
epitopes), but both these databases are no longer updated (16). The MHCBN is a curated database 
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containing binder and non-binder epitopes (over 25800 peptide entries) with information about TAP 
interactions and MHC-linked autoimmune diseases, last updated in 2006 (17). 
 
Parallel to databases, analysis resources allow the prediction of T cell epitopes. Several 
sophisticated immunoinformatics tools, of variable performance, are available to evaluate some of 
the characteristics associated with immunogenic epitopes (7,8,18,19). A determinant aspect for 
algorithm performance is the amount and quality of the training datasets. As epitope data increases 
and improves, so will the performance of epitope prediction algorithms.  
 
T-cell epitopes prediction can be performed through direct (predicting T-cell receptor, TCR 
recognition) or indirect methods (predicting epitope binding to MHC/HLA molecules), the latter 
extensively more accurate than the former (20).  
HLA-binding affinity has become the first criterion when trying to predict if a given peptide 
sequence constitutes an epitope, since it is the first requirement for T-cell activation and it correlates 
with peptide linear sequences (7,20). The first algorithms developed used basic motif listings to 
prediction T-cell epitopes. Subsequently, HLA-binding predictions based on machine-learning 
algorithms were developed, based on Artificial Neural Networks (ANNs) and Support Vector 
Machines (SVMs), which display better predictive performance (4,21–23) (Table IV.3). HLA-binding 
predictions are affected by two main issues – prediction accuracy and sensitivity, and the MHC-class 
I and -class II alleles for which predictions are available (10). 
The performance of the several predictors was performed through benchmark studies, using 
curated datasets different from the algorithm’s training datasets (24–27). The evaluated predictors 
show in general somewhat similar performance, but ANN-based and consensus predictions have the 
best overall performance (10,27). The IEDB analysis resource centre has the highest number of 
predictors, including consensus predictions, the most effective prediction algorithm (23,25,28). 
 
 
 
 
 Table IV. 3 The most commonly used sequence-based algorithms for T cell epitope prediction (29).  
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Table IV. 3 (continued) 
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Table IV. 3 (continued) 
 
 
 
 
 
 
 1.2. In silico epitope predictions and implications for vaccine development 
 
MHC-class II binding predictions must take into account the  high peptide length variability 
due to the conformation of the binding groove, and are currently slightly less accurate than class I 
binding predictions (25,30). Due to the longer length of class II epitopes (around 15 to 25-mer), 
several binding registers or cores may be present in the same peptide (29,31). 
 
 Proteasomal cleavage analysis and TAP-transport prediction, although very informative in 
theory, do not improve MHC-binding predictions (10,32). These algorithms often display low 
prediction efficiency, and there are still significant knowledge gaps regarding protein intracellular 
processing.  
Also, for the particular case of  parasite-delivered antigens, the mechanisms responsible for cross-
presentation remain poorly understood (32,33). Professional APC, namely DC are the main cells 
capable of cross-presenting antigens. However, due to the extensive modulation by Leishmania 
parasites and preference for macrophage infection these mechanisms remain largely unknown (33). 
In this case, the use of experimental data detailing peptide-specific immune responses is 
indispensable to ascertain which peptides are indeed associated with natural protection and can be 
used in a vaccine formulation. 
 
 Additional aspects related with immunogenicity assist in epitope prediction and selection. 
Analysis of subcellular localization, protein abundance and good expression dynamics are the filters 
with the highest selective power (32). Highly conserved epitopes are ideal for vaccine development 
because of pan-specific protection across multiple strains of a given pathogen (34). Furthermore, 
combinatorial approaches that use multiple predictors are beneficial since they increase the 
confidence level in the peptides’ predicted binding affinity/HLA restriction (31,35). 
 Using homology to host proteins as rejection criterion is an unreliable filter. Self-recognition 
depends on the TCR-pMHC interaction which allows a reasonable amount of molecular mimicry, and 
therefore difficult to predict (36–38). However, potential interferences resulting in auto-immunity 
are correlated with epitope conservancy. BLASTp alignments can be used to compare and describe 
similarities pathogen- and host-derived peptide sequences. 
The ability to analyse the vast amount of data generated by immunoinformatic algorithms is 
an additional challenge researchers must overcome (39–41).  
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Ultimately, in silico immunogenicity predictions on the epitope level should privilege:  
i) antigen abundance, subcellular localization and expression dynamics, as abundant and early 
expressed pathogen-specific epitopes have increased chances of being processed and 
presented (32,42);  
ii) peptide-MHC complex (pMHC) binding affinity and stability (2,43,44);  
iii) homology, either as positive selection criterium of conserved sequences among pathogenic 
species, or as negative selection criterium of sequences homologous to host proteins (20);  
 
Other biochemical properties can also be taken into account for optimal formulation and 
handling, such as solubility, since peptides should be soluble in aqueous solution (2,21).  
 
We propose an epitope selection pipeline that starts with HLA-binding affinity prediction 
analysis, by at least two different algorithms, of a strong antigen pool of conserved, exposed and 
accessible proteins, expressed from early infection (antigens present in the Leishmania secretome). 
Additional adjustable filters are homology to host proteins, promiscuity, binding affinity, and 
solubility, with which we can rank epitopes.  
 
2. Methods 
 
2.1. Selection of HLA allele lists  
 
The allele lists to include in the epitope prediction algorithms were defined from the IEDB 
reference sets with maximal population coverage. 
 
a) HLA-class I alleles 
 
The HLA-class I reference allele list includes 28 alleles from HLA-A and HLA-B genes 
corresponding to >97% world population coverage (file from IEDB: hla_ref_set.class_i.txt) (45,46).  
To the 28 alleles included in the IEDB HLA-class I reference list, 8 more were included, for a 
total of 36 alleles included in the HLA-binding prediction analysis. The IEDB reference stipulates 
epitopes with variable length, with 8 up to 11 amino-acid long epitopes. However, in the present study 
only 9-mer epitopes were searched.  
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The HLA-class I alleles selected are: IEDB MHC-I binding predictions for 36 alleles (11 
supertypes), SYFPEITHI predictions for 22 alleles (11 supertypes); and NetMHCpan predictions for 
11 alleles (11 supertype representatives) (Table IV.4). 
 
Table IV. 4 HLA-class I alleles included in T-cell epitope prediction (45). 
Supertype 
group 
Allele 
Predictor 
(I = IEDB/ 
N=NetMHCpan / 
S=SYFPEITHI) 
Population 
frequency of 
allele 
Allele specific 
affinity cut-off 
(IC50 nM) 
A1 A*0101 I + N + S 16.2 884 
A*3002 I 5 674 
A*3201 I 5.7 131 
A2 A*0201 I + N + S 25.2 255 
A*0203 I 3.3 92 
A*0206 I 4.9 60 
A*0211 I  500 
A3 A*0301 I + N + S 15.4 602 
A*1101 I + S 12.9 382 
A*3001 I 5.1 109 
A*3101 I 4.7 329 
A*3301 I 3.2 606 
A*6601 I  500 
A*6801 I + S 4.6 197 
A24 A*2301 I 6.4 740 
A*2402 I + N + S 16.8 849 
A26 A*2601 I + N + S 4.7 815 
B7 B*0702 I + N + S 13.3 687 
B*3501 I + S 6.5 348 
B*3503 I 1.2 888 
B*5101 I + S 5.5 939 
B*5301 I + S 5.4 538 
B8 B*0801 I + N + S 11.5 663 
B27 B*1402 I + S 2.8 700 
B*2705 I + N + S 2 584 
B*3801 I + S 2 944 
B*4801 I 1.8 887 
B44 B*1801 I + S 4.4 732 
B*4001 I + N + S 10.3 639 
B*4402 I + S 9.2 904 
B*4403 I 7.6 780 
B*4501 I + S  500 
B58 B*5801 I + N + S 3.6 446 
B*5701 I + S 3.2 716 
B*1517 I  500 
B62 B*1501 I + N + S 5.2 528 
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b) HLA-class II alleles 
 
The HLA-class II reference allele list includes 27 alleles from HLA-DRB, and -DQ and -DP 
(alpha and beta chain combinations) genes corresponding to >99% world population coverage (file 
from IEDB: hla_ref_set.class_ii.txt) (46). 
 The HLA-DQ alleles were excluded from this dataset due to their association with recognition 
of human epitopes and the induction of immune tolerance, to prevent a bias toward cross-reacting 
epitopes (47). The removal of these alleles does not greatly reduce population coverage, as only the 
eight common DR alleles (DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*0801, 
DRB1*1101, DRB1*1301, and DRB1*1501) cover around 97% of human populations worldwide (48). 
The HLA-class II alleles selected: IEDB MHC-II binding predictions for 21 alleles, and 
NetMHCIIpan predictions for 21 alleles (same allele lists) (Table IV.4). 
 
Table IV. 5 HLA-class II alleles included in T-cell epitope prediction (46). 
HLA-class II alleles 
HLA-DPA1*01:03/DPB1*02:01 
HLA-DPA1*01/DPB1*04:01 
HLA-DPA1*02:01/DPB1*01:01 
HLA-DPA1*02:01/DPB1*05:01 
HLA-DPA1*02:01/DPB1*14:01 
HLA-DPA1*03:01/DPB1*04:02 
HLA-DRB1*01:01 
HLA-DRB1*03:01 
HLA-DRB1*04:01 
HLA-DRB1*04:05 
HLA-DRB1*07:01 
HLA-DRB1*08:02 
HLA-DRB1*09:01 
HLA-DRB1*11:01 
HLA-DRB1*12:01 
HLA-DRB1*13:02 
HLA-DRB1*15:01 
HLA-DRB3*01:01 
HLA-DRB3*02:02 
HLA-DRB4*01:01 
HLA-DRB5*01:01 
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2.2. Selection and usage of in silico HLA-binding prediction algorithms  
 
The following publications were reviewed for algorithm selection: 
- Tung CW. Chapter 6 - Databases for T-Cell Epitopes. Immunoinformatics 2014, 2nd Ed (9); 
- Desai SV, Kulkarni-Kale. Chapter 19 - T-Cell Epitope Prediction Methods: An Overview.  
Immunoinformatics 2014, 2nd Ed (20);   
- Wang M, Mogens MH. Chapter 17 - Classification of Human Leukocyte Antigen (HLA) 
Supertypes;  
- Algorithm benchmarking studies – Lin HH et al 2008 (24), Wang P et al 2008 (25), Peters B et 
al 2006 (26), Trolle T et al 2015 (27); 
- Castelli M et al 2013 Clin Transl Immunology ID:521231 (29). 
 
To improve prediction sensitivity, the main criteria used for the epitope prediction and 
selection were i) to include at least 2 different epitope databases; ii) to include at least 2 non-
redundant algorithms; iii) to use ANN- and SVM-based algorithms (9,20).  
Some analysis tools were explored but not selected (data not shown). EPIBOT does provide 
consensus predictions (NetMHC, SYFPEITHII, BIMAS, SVMHC and IEDB) but revealed no advantage 
over IEDB_consensus since it is based in a very restricted database of mouse-restricted epitopes (831 
known epitopes from 397 proteins from IEDB). EPIMHC was excluded because it is based on a 
relatively limited database of 4867 distinct peptide sequences, that users must customise, and uses 
Position-Specific Scoring Matrices (PSSM) (RANKPEP). CTLPred is the only algorithm allowing 
predictions from the MHCBN database, but it was excluded because it does not preclude HLA 
restriction, and there are quite divergent results between the in-built ANN and SVM algorithms (data 
not shown). Although SYFPEITHI performs PSSM-based predictions, the associated epitope database 
is unique and valuable as it is manually curated and complementary to IEDB.  
 
HLA-class I binding predictions were performed with: i) NetMHCpan 3.0 predictions for 11 
supertype representative alleles (49), ii) IEDB MHC-I binding, prediction Method Version 2013-02-
22, recommended predictions (consensus > ANN > SMM > NetMHCpan > CombLib) for 36 alleles (50), 
and iii) SYFPEITHI predictions (default predictions for 22 alleles) (16) (Table IV.6). Allele-specific 
binding affinity cut-off valued were applied (Table IV.4), and when not available, the general cut-off 
value of 500 nM was applied.  
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Table IV. 6 Selected databases and HLA-class I binding prediction algorithms. 
Database Prediction algorithm Epitope selection 
IEDB 
MHC-I Binding 
IEDBrecommended 
ANN_IC50 below allele-specific 
cut-off 
IEDB + IMGT/HLA NetMHCpan (ANN) IC50 below allele-specific cut-off 
SYFPEITHI SYFPEITHI (PSSM) No cutoff applied 
 
HLA-class II binding predictions were performed with: i) NetMHCIIpan, pan-specific 
predictions for 21 alleles (51), and ii) IEDB MHC-II binding, recommended predictions (Consensus 
approach considers a combination of any three of the four methods, NN-align, SMM-align, CombLib 
and Sturniolo) for 21 alleles, and nn_align core and IC50 values (22,25) (Table IV.7). The top 10% of 
binding predictions was selected. 
 
Table IV. 7 Selected databases and HLA-class II binding prediction algorithms. 
Database Prediction algorithm Epitope selection 
IEDB 
MHC-II Binding 
IEDBrecommended Top 10% predictions 
IEDB + IMGT/HLA NetMHCIIpan (ANN) 
 
The sequences of all 52 protein antigens, including 4 to 6 species-specific sequences, were 
retrieved from UniProtKB in fasta format. HLA-binding predictions were performed separately for 
each protein from Sets A and B.  
HLA-binding predictions were performed through the online servers, where the fasta files 
were uploaded per protein. Results were downloaded as .csv or .html files. Result tables were further 
formatted to comply with the input data settings imposed by the epitope selection script developed 
in R (see below): 
- HLA-class I predictions files contain 4 columns (allele|peptide|seq_num|score), and are 
named as ‘proteincode_predictorcode.csv’, e.g. “a1_iedb.csv”. 
- HLA-class II prediction files contain 6 columns (allele|seq_num|full_peptide|rank|core|ic50) 
and are named as ‘proteincode_predictorcode.csv’, e.g. “a1_iedbii.csv”. 
The data generated by each algorithm for each protein antigen were saved as .csv files and integrated 
in the epitope selection script developed in R. 
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2.3. Integration of HLA-binding prediction data 
 
To merge and analyse protein-specific epitope prediction data, a selection script was 
developed in R (Figure IV.1 panel A). Briefly, the selection pipeline allows the integration of HLA-
binding prediction data from multiple algorithms, and a first selection of conserved peptides (100% 
conserved among the six Leishmania species tested) and predicted by at least 2 non-redundant 
algorithms.  
After this first selection step, short-BLASTp results are added (position-specific total 
mismatches and/or anchor position mismatches compared to host proteins). Briefly, in the BLASTp 
online server, the human RefSeq proteins were used as the host proteome (Homo sapiens Taxid:9606). 
The corresponding .txt result file was downloaded to the working directory and renamed 
“alignment_I.txt” or “alignment_II.txt” (Figure IV.1 panel A).  
The result file generated by the selection script after these 2 selection steps was further 
analysed with the help of spreadsheet analysis software Excel® (Figure IV.1 panel B). 
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Figure IV. 1 T-cell epitope selection pipeline. A) Epitopes were selecting through the application of relevant filters by 
a selection script in R. B) The result table containing conserved peptides was further analysed with spreadsheet software 
Excel®. 
 
The result table from the selection script contains the columns: peptide (epitope sequence), 
blastp results (middle; middle2; subject); position-specific mismatches (m_1 up to m_9), and protein 
supertype. Then, using Excel®, relevant physical-chemical properties were added (MW, 
hydrophobicity, pI) to the result table from the selection script after analysis of the peptide list with 
the ProPAS software (52). Moreover, epitope promiscuity and HLA restriction were calculated (Excel 
function ‘UniqueFromCell’ – Figure IV.2 panel A) and used to duplicate peptide information (Excel 
macro ‘Splt’ – Figure IV.2 panel B), so to generate a filterable table per supertype.  
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Figure IV. 2 Excel® software code (VBA code) for analysis of final peptide list, from the selection script in R. A) 
VBA code for the creation of the ‘UniqueFromCell’ function, that identifies common HLA restriction between IEDB and 
NetMHCpan predictions. B) VBA code for the ‘Splt’ macro that duplicates peptide rows according to predicted 
(consensual) promiscuity. 
 
2.4.  SILVI – an open-source pipeline for T-cell epitope selection 
 
The final selection steps performed in the spreadsheet analysis software were integrated in 
the R selection script for publication purposes. The package Peptides was used for the addition of 
physical-chemical properties (MW, pI and hydrophobicity). Also, promiscuity and HLA restriction are 
now automatically calculated by the script. The final development version of the SILVI epitope 
selection pipeline will be published in Pissarra J et al 2019 (under review for publication in PLoS One).  
 
2.5.  Peptide toxicity assays 
 
 Cytotoxicity assays were performed with the PrestoBlue® viability dye. Briefly, 2x105 human total 
PBMC were seeded per well in 96-well plates and incubated overnight at 37°C, 5% CO2. Individual 
peptides were added at 3 different concentrations in triplicate wells (1 or 5, 10 and 25 µM). After 4 
hours, 10% final PrestoBlue® (Life Technologies, Switzerland) was added to each well and the plates 
were returned to the incubator for 16 hours. The fluorescence intensity (bottom-read) was measured 
using a multiwell plate reader (EnVision 2105 Multimode Plate Reader, Perkin Elmer) excitation 560 
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nm, emission 595 nm. 560 nm absorbance values were normalized to the 595 nm values for the 
experimental wells. 
 
3. Results 
 
3.1. The T-cell epitope selection pipeline greatly reduced initial epitope lists 
 
A T-cell epitope selection pipeline was developed in-house to optimise the process of epitope 
selection from vast amount of data produced by available algorithms, and to add extra relevant 
information, thus helping to refine the search of the most relevant epitopes through the application 
of filtering criteria. The R script reads epitope binding prediction data from different predictors, 
processes and compares data, assimilates BLASTp alignment results (53). The selection script feeds 
a final table with all relevant information to perform the desired selections. Additional epitope-
specific information was added afterwards, in the spreadsheet analysis software Excel® (molecular 
weight, pI, hydrophobicity, NetMHCpan score).  
 
 The script successfully integrated epitope prediction information from all 52 proteins. 
Considering only one species-specific sequence per protein, these 52 proteins comprise 20712 9-mer 
overlapping peptides, and 20412 15-mer overlapping peptides (Figure IV.3). Peptides that are 100% 
identical in all species-specific sequences per protein were selected in the first selection step, so each 
peptide in the “blast_me.fasta” file are protein- and Leishmania-specific. 
The result file “3_blast_mismatches_I.csv”, after the second R script selection step, includes 
HLA-class I binding predictions for 1048 unique peptides from Set A proteins and 1069 unique 
peptides from Set B proteins. The total 2117 peptides correspond to 2277 predictions, after 
considering promiscuous peptides. These predictions are common between at least two algorithms 
(I+S, I+N, I+N+S). 
The result file “3_blast_mismatches_II.csv”, after the second R script selection step, includes 
HLA-class II binding predictions for 847 unique cores. These epitope core predictions are common 
among IEDB MHC-II binding and NetMHCIIpan (I+N).  
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Figure IV. 3 Summary of selection filters and list reduction for HLA-class I and –class II binding predictions. 
 
For HLA-class I predictions, the 20712 overlapping 9-mer peptides from 52 protein antigens 
were analysed. The allele-specific binding cut-off together with first script selection step reduced this 
list to 2117 unique peptides, conserved among species and predicted by three predictors (I+N+S) 
(Figure IV.3). The HLA-class I epitope list was reduced further with promiscuity and hydrophobicity 
filters (hydrophobity < 0,5; promiscuity > 0) after the first selection step. Moreover, we only selected 
peptides with at least 2 total mismatches and at least 1 anchor position mismatch. These filters 
reduced the list to 480 unique epitopes (Figure IV.3).  
 
For HLA-class II binding predictions, the 20412 overlapping 15-mer full-length peptides from 
52 protein antigens were analysed, each containing a 9-mer binding core. The top 10% predictions 
together with the first script selection step, conserved among species and predicted by two 
algorithms (I+N), reduced this list to 847 unique cores (Figure IV.3). The HLA-class II epitope list was 
further reduced to 121 unique cores with promiscuity, hydrophobicity and total mismatch filters 
(hydrophobity < 0,5; promiscuity > 0; and total mismatches > 2) after the first selection step (Figure 
IV.3). 
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3.2. Successful selection of 50 HLA-class I and 24 HLA-class II Leishmania-
specific epitopes  
 
The final epitope list containing 480 epitopes was ranked according predicted IC50, and 
selections were performed per supertype – most promiscuous and strongest binders per supertype. 
Finally, between 3 up to 6 epitopes per supertype were selected, for a total of 50 HLA-class I epitopes 
(Figure IV.4). 
 
 
Figure IV. 4 Stepwise HLA-class I binding prediction results per protein antigen and protein conservation. The 
first selection step (in blue) includes epitopes under allele-specific IC50 cut-off values, 100% conserved among species 
and predicted by at least 2 algorithms. These epitope lists were reduced in a second selection step (in green) with the 
application of filtering criteria (promiscuity>0; prediction by all 3 used algorithms; hydrophobicity<0,5; total mismatches 
> 1; anchor mismatches > 0). Epitopes were selected according to best predicted IC50 values per supertype (orange). 
 
The 50 HLA-class I restricted peptides come from 23 different protein antigens (11 from Set 
A; 12 from Set B). 20 epitopes are from Set A antigens and 30 are from Set B antigens.  
All peptides are predicted to be strong binders, with average predicted IC50 of 40 nM 
(minimum 3,5 nM; maximum 111,5 nM). Most peptides are not predicted to be promiscuous, 6 
epitopes are predicted to be promiscuous to 2 supertypes, and 2 epitopes are promiscuous to 3 allele 
supertypes. 
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The final HLA-class II epitope list containing 121 unique cores was ranked according 
predicted promiscuity, and selections were performed per allele. The most promiscuous epitopes 
were selected (20), and 4 other epitopes were selected according to best predicted IC50 for remaining 
alleles (not represented in the overall promiscuity prediction) (Figure IV.5).  
 
 
Figure IV. 5 Stepwise HLA-class II binding prediction results per protein antigen and protein conservation. The 
first selection step (in blue) includes the top 10% of predicted epitopes, 100% conserved among species and predicted 
by at least 2 algorithms. These epitope lists were reduced in a second selection step (in green) with the application of 
filtering criteria (promiscuity>0; prediction by 2 algorithms; hydrophobicity<0,5; total mismatches > 3). Epitopes were 
selected according to predicted promiscuity (orange). 
 
The 24 HLA-class II-restricted epitopes come from 15 different protein antigens (7 from Set 
A; 8 from Set B). 12 epitopes originate from Set A antigens and 12 from Set B antigens. The average 
prediction percentile is 1,49% (minimum 0.01%; maximum 7.32%; median 0.53). These epitopes are 
predicted to be promiscuous, from 3 to 13 alleles. Between 4 to 18 epitopes per allele were selected. 
For HLA-class II binding predictions, the total epitope size is 15-mer, however, the 
determining motif for HLA binding is the epitope core or register. The predictive power of different 
algorithms correlates better with the ability for core prediction (4). By comparing core predictions, 
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we compare different predictors and consider all potential cores within a 15-mer peptide, selecting 
the best core/full_peptide combination according to predicted IC50.  
 
 
3.3. HLA-class I peptides are mostly water-soluble 
 
From the 50 HLA-class I peptides ordered, one was never successfully synthesized (B44_2):  
 
peptide Charge Hydrophobicity pI Protein Supertype IC50 
Mismatches 
(Total/Anchor) 
B44_2 
0 
(neutral) 
-0.1999 5,99 b16 A2+B44+B44 N_18,6 4/1 
 
Upon peptide solubilisation, 43 peptides are soluble in water; 5 soluble in sodium bicarbonate 
0.5M solution; and 1 soluble only in DMSO. 
 
24 HLA-class II peptides were directly and successfully solubilised in 10% DMSO. 
 
3.4. Selected HLA-class I peptides are not toxic to human cells 
 
No toxicity towards human PBMC was detected for any of the 49 HLA-class I peptides tested, 
regardless of peptide concentration (Figure IV.6). 
Peptide toxicity assays confirm the synthetic peptides can be used for in vitro cellular 
stimulation of human peripheral immune cells, in subsequent experimental validation steps. Peptide 
toxicity assays were not performed with class II peptides because of reduced peptide availability.  
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Figure IV. 6 Peptide toxicity assay results. Peptide toxicity was assessed for 49 9-mer peptides in human total PBMC 
at three concentrations (1 or 5 µM, 10 µM and 25 µM) with PrestoBlue® Viability dye after 20-hour incubation. 
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4. Discussion  
 
 Experimental validation steps limit the number of peptide candidates to test, meaning that 
these candidates must be carefully selected to increase the chances of selecting immunogenic 
peptides. The addition of an initial in silico screening in the development pipeline greatly diminishes 
costs associated with epitope mapping experiments by decreasing the number of peptides to test. 
Nevertheless, current in silico epitope prediction tools still present some shortcomings (Figure IV.8). 
The lack of gene and protein annotations as well as an underrepresentation of protozoan-derived 
epitopes in the databases renders sequence-based prediction less accurate  (35). Similarly, protozoan 
proteins with different physicochemical composition are not represented in the databases (35). 
Leishmania-specific epitopes are underrepresented in epitope databases. To date, the IEDB database 
contains a total of 538,374 peptidic epitopes, which include only 965 Leishmania epitopes (IEDB 
search: any epitopes + Leishmania ID 5658, February 2019 annotation). Of these, only 555 are T-cell 
epitopes, and if we consider positive assays only this number decreases to 379, corresponding to less 
than 1% of total 448402 T-cell epitopes with positive results in the database. 
 
 
Figure IV. 7 Current challenges affecting reverse vaccinology approaches for vaccine design. 
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 The term reverse vaccinology was first described by Rappuoli R. (31) to designate approaches 
that screen entire genomes or proteomes to filter out proteins of interest (antigens) using 
bioinformatic tools. Subsequently, particular features associated with antigenicity are searched, 
namely, subcellular localisation or expression timing.  
 At the time of the present analysis, only four (true) reverse vaccinology studies had been 
performed for vaccine development against Leishmania, with modest success in identifying strong 
epitopes (54,55). Briefly, most studies used BLASTp alignment to eliminate peptides or proteins with 
significant homology to host proteins (human or mouse). Also, most studies used sequence-based 
HLA-binding predictions for T-cell epitope discovery. 
 In the first study, in 2009, Herrera-Najera et al analysed the complete L. major proteome 
(8272 annotated proteins) and performed class I epitope predictions for mouse alleles. The first 
epitope prediction round used the algorithm RANKPEP based on position-specific score matrices 
(PSSM), subsequently, proteins with top scoring peptides were re-analysed using multiple HLA-
binding prediction algorithms to generate consensus predictions (SYFPEITHI, BIMAS, ProPred-I, and 
MAPPP which are PSSM-based; ANNPred; SVMHC; ComPred which is combines ANN and QM; and 
Predep, a structure-based algorithm). The last analysis step involved a BLASTp analysis against 
human and mouse proteins, wherein epitopes showing over 80% of sequence identity were 
discarded, and epitopes conserved among kinetoplastids were prioritised. However, predictions were 
only performed for mouse alleles (H-2Kd andH-2Dd). Also, proteasomal cleavage filters were applied, 
potentially introducing a bias in epitope prediction. Experimental validation was performed in mice. 
This approach eliminated the known candidates GP63, LACK, histone 2B, LmSTI1, TSA, CPb, NH36 or 
beta-tubulin in the first selection step. 
 Similarly, Guerfali FZ et al also used the complete L. major proteome for epitope prediction. 
Again, predictions were performed only for mouse alleles (BALB/c and C57BL/6 alleles) and with 
redundant PSSM-based algorithms (SYFPEITHI, BIMAS, RANKPEP). BLASTp analysis was also used to 
exclude epitopes with high levels of similarity with host proteins, but only 100% identical sequences 
were excluded. Moreover, SignalP predictions were used to select secreted protein antigens for 
epitope prediction, which is extremely unsensitive for Leishmania excreted-secreted proteins since, 
as shown by the literature and in chapter II of the present thesis, only up to 10% of proteins in the 
secretome are classically secreted. 
 In 2012, John L. et al retrieved total protein sequences from L. major and L. infantum and 8122 
common proteins were identified through BLASTp analysis. Subcellular localisation analysis was 
performed with PSORT and TMHMM to select cell surface and secreted proteins (cytoplasmic 
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proteins, and proteins with more than one transmembrane domain were excluded), and BLASTp 
analysis was used to select non-homologous proteins to human and mouse. Finally, epitopes were 
predicted through HLA-binding algorithms for class I alleles (BIMAS, SYFPEITHI, ProPred1 
predictions for human alleles HLA_0201, HLA-A2, HLA-A 0205, HLA-Cw 0602, HLA- A2.1, HLA-A3, 
HLA-B14, HLA-B 5401, and HLA-B 5102) and for class II alleles (ProPred predictions for human 
alleles DRB1_0101, DRB1_0102, DRB1_1101, DRB1_1104, DRB1_1501, DRB1_1502, DRB1_0402, 
DRB1_0404, DRB1_0405, DRB1_1301, and DRB1_1302). All predicted peptides were again ‘blasted’ 
against the human and mouse proteomes, 19 peptides showed no similarity and were selected but 
not validated experimentally. 
 Overall, these RV studies focus on mouse alleles instead of human alleles (except John L et al), 
so extrapolation for human immune responses is very limited. Also, the filtering criteria used 
(proteasomal cleavage, SignalP and PSORT predictions) are likely to reject important Leishmania-
specific proteins and/or epitopes. Discovered peptides were either validated in the mouse model or 
not at all. 
 In 2016, Freitas e Silva et al performed a reverse vaccinology approach followed by peptide 
validation in human samples. This study is detailed in chapter I - Table I.4 (Leishmania-specific 
peptide vaccine candidates validated using human samples) and describes the most complete RV 
approach. It includes the proteomes of three Leishmania species (L. braziliensis, L. major, and L. 
infantum), it uses one of the best available HLA-binding prediction algorithms (NetMHC), BLASTp 
analysis and structure-based epitope prediction. However, the proposed pipeline uses intensive 
computational analysis, namely structural modelling to HLA molecules, which is difficult to reproduce 
due to its extensive computational resource requirements.  
   
 We believe the successful identification of immunogenic epitopes depends on both the quality 
of used immunoinformatic algorithms and on the rationality of epitope selection criteria. These 
criteria should be permissive enough not to falsely reject immunogenic epitopes, and restrictive 
enough to effectively filter HLA-binding prediction data. Hence, there is an optimal balance between 
the used tools and the criteria chosen to filter their results, which sought to optimise. Overall, our 
proposed reverse vaccinology pipeline uses proteomic information from six Leishmania species, the 
most clinically relevant ones (L. braziliensis, L. major, L. infantum, L. donovani, L.amazonensis and L. 
tropica), it makes use of BLASTp analysis and the best available HLA-binding prediction algorithms. 
Because our starting sample is the Leishmania secretome, an optimal antigenic source, no subcellular 
localization filters need to be applied.  
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 The best sequence-based HLA-binding prediction tools currently available were used in this 
study (24–27). Structure-based epitope prediction tools are also available, which combine binding 
data, sequence information, known crystallographic data of pMHC complexes, and computational 
modelling. However, structure-based prediction tools only apply to the few alleles with 
crystallographic data and PDB files (Protein Data Bank), thereby excluding alleles and affecting 
vaccine coverage or introducing bias in predictions for other alleles (56). Moreover, these tools 
require great computational processing power and time. Altogether, it is more practical and accurate 
to use sequence-based pan-specific methods and based on machine-learning algorithms for epitope 
prediction.  
 
 Some previously described Leishmania protein antigens were excluded from epitope 
prediction analysis. The antigen KMP11 was removed due to ambiguous results showing evidence of 
induced Th2 responses (57).  Also, the LACK antigen was excluded since it may have an important 
role in parasite immunomodulation of host immune responses. Interestingly, studies have shown that 
LACK-specific TCD4+ cells are present in individuals never exposed to Leishmania (4,5). These cells 
are primed in gut-associated lymphoid tissues by cross-reactive microbial antigens and are able to 
quickly secrete IL-4 (6). Finally, the promastigote surface antigen was not included in the present 
epitope prediction analysis because this analysis previously performed by our team, both soluble and 
membrane-associated isoforms (58–60). 
 
Furthermore, after performing in silico epitope prediction, the ability to compare different 
data sources and to synergistically combine diverse algorithms in the context of epitope prediction 
remains challenging. To this end, the selection script developed in R greatly assisted in data 
integration and epitope selection.  
 
 The binding affinity and peptide conservation filters applied to the result table allowed a 90% 
reduction of the initial epitope list. Despite this broad selection, testing over 2100 9-mer peptides or 
over 840 15-mer peptides is still an issue for the experimental validation assays and experiment costs. 
To further reduce this list, peptides were selected by relative comparison according to the predicted 
HLA restriction, promiscuity and binding affinity to select the best epitopes per supertype or allele. 
Binding affinity is a key characteristic of peptide immunogenicity and the general cut-off value of 500 
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nM has been extensively used in T-cell epitope selection. Allele-specific binding information allows 
the establishment of specific thresholds which correlate well with epitope prediction (61).  
Homology was used firstly as a positive selection filter for highly conserved epitopes among 
Leishmania species. Logically, epitopes from proteins that show higher homology are more likely to 
be 100% conserved and, therefore, more likely to be selected. However, the 52 antigens processed 
are generally conserved, with between 60% up to 99% homology levels. Still, because selections were 
performed according to predicted IC50, there are conserved epitopes selected from less conserved 
proteins – e.g. B3, A28 proteins for HLA class-I epitopes, and A1, A10 for class-II epitopes.  
Homology to host was then used as negative selection filter, not to exclude prediction data, 
but for epitope ranking and description. In this case, epitopes were aligned with human RefSeq 
proteome, and position-specific mismatches were counted. This allowed us to establish a low 
stringency threshold for homology with human proteins, (at least 2 amino-acids in 9-mer peptides or 
at least 3 amino-acid mismatches for 15-mer peptides). Although the mechanisms eliciting self-
recognition and autoimmune responses are not fully understood, and therefore difficult to predict, 
the selection of epitopes with lower homology to host proteins is likely to decrease the chances of 
unwanted cross-reactivity.  
The hydrophobicity filter, although not sensitive to immunogenicity, allows the discovery of 
soluble epitopes, which can be easily produced, solubilised and tested in vitro. After peptide synthesis, 
a vast majority of class I peptides was found to be water soluble, which facilitates handling. Solubility 
assays were not performed for class II peptides because of reduced peptide availability – HLA-class II 
peptides were directly solubilised in 10% DMSO to improve peptide stability upon freezing.  
 
After peptide selection, the selection script was adapted to accommodate the steps performed 
in the spreadsheet analysis software and will be published under the title “Exploring -omics datasets 
for epitope-based development of vaccines and therapeutics – SILVI, an open-source pipeline for T-
cell epitope selection”. This publication aims to make SILVI available to the community and, hopefully, 
assist future studies in epitope selection analysis. In the manuscript, an example protein was included 
(Hepatitis C Virus Genome polyprotein P26664) to illustrate the workflow and SILVI’s potential in 
assisting epitope selection. When compared to validated epitopes in the IEDB, the application of low 
stringency filters (promiscuity > 0 and scoreN under 1000 nM) to class I epitope predictions results 
in 81% sensitivity and 82% specificity (out of 614 peptides selected, 100 are P26664 validated 
epitopes in the IEDB). Notably, these results are not improved after proteasomal cleavage analysis. 
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Finally, the final epitope selections include proteins from both antigen datasets (Sets A and 
B). For the HLA-class I epitope list, Set A proteins correspond to 40%, with 20 epitopes compared to 
30 from Set B proteins. For HLA-class II epitope lists, both datasets are equally represented (12 each). 
It is noteworthy that the new antigen candidates in Set B are equally or even potentially more 
immunogenic than known protein candidates.  
 
We successfully selected 50 HLA-class I- and 24 HLA-class II-restricted epitopes, through an 
epitope selection pipeline using high-performing HLA-binding predictions (27), and homology 
alignments (53). Based on this information, together with conservation among species, physico-
chemical properties and target population HLA restriction, prediction data was filtered, thereby 
reducing the number of peptides to test experimentally while increasing the chances of identifying 
immunogenic peptides.  
  
 The final peptide list includes high affinity binders with high immunogenicity potential 
according to in silico predictions. The synthetic peptides, and respective predicted immunogenicity, 
will be validated with experimental assays, detailed in Chapter V.  
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Objectives: to assess T-cell-dependent peptide immunogenicity and discover Leishmania-specific 
epitopes restricted to HLA-class I and -class II alleles for vaccine development, using 
immunoassays exclusively with human samples. 
 
Aims: 
- to evaluate peptide in vitro immunogenicity in both naive and healed immune backgrounds; 
- to validate the in silico epitope predictions; 
- to select the most immunogenic peptides that will proceed for multi-epitope peptide design 
  
1. Introduction 
 
 Immunogenicity testing is a key aspect in the development of vaccines, immunotherapies or 
biological therapeutics, from both a regulatory standpoint and a preclinical development perspective 
(1). Researchers may seek unwanted immunogenic regions within therapeutic molecules, for 
instance, therapeutic antibodies, or, on the other hand, immunogenic epitopes to induce specific 
protective immune responses through vaccination or immunotherapy. In either case, immunoassays 
must be performed, during clinical development and post-marketing surveillance, to identify and 
assess the ability of a given molecule to induce humoral or cellular immune responses in exposed or 
naive individuals. 
 The mechanisms of immunogenicity include T cell-dependent and T cell-independent 
responses. In the context of T-cell dependent immune responses, T-cell epitope mapping can be 
performed initially through in silico methods, subsequently validated with in vitro and in vivo assays, 
to describe Th1, Th2, cytotoxic, or regulatory epitopes.  The most common marker associated with 
Th1-cell activation is IFN-γ, however, a maximum number of parameters should be included in the 
characterisation of induced responses.  
 There are currently several methods available to assess immunogenicity and T-cell responses 
in vitro, summarised in Figure V.1. Importantly, several tools exist to assess the magnitude and 
breadth of specific responses, as well as to describe cell function according to cytokine production or 
cell phenotype. 
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Figure V. 1 Summary of the current toolbox of cell-based assays to assess T-cell-dependent immunogenicity, 
adapted from (2). A) In vitro T cell assay methods and respective application and readout. B) Advantages and 
disadvantages regarding the different methods. 
 
 The CEF peptide pools are commonly used as positive control for peptide T cell activation in 
assays using total PBMC, both for HLA class I and class II peptide presentation (3). These pools contain 
well-defined epitopes capable of inducing memory cellular responses, from Cytomegalovirus (CMV), 
Epstein-Barr Virus (EBV) and Influenza virus (Flu) (CEF), which cause chronic infection with multiple 
reactivations or repeated acute infections. 
 There is, however, a lack of standardisation in immunogenicity testing protocols, specifically 
regarding the methods used, and the evidence needed regarding type, quantity and quality of the 
observed immune responses. For example, to address these issues in clinical studies using flow 
cytometry-based immunophenotyping assays, the Human Immune Phenotyping Consortium (HIPC) 
promoted standardisation guidelines, so that data could be compared across sites and studies (4). 
 For all mentioned techniques, the number of available cells is a limiting factor. Moreover, the 
time, cost and workload needed to perform the assays can be restrictive (5) (Figure V.1). High- or 
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medium-throughput approaches allow for the reduction of the number of cells needed and overall 
experiment costs (6). 
 
 Although in vitro lymphocyte cultures do not allow assessment of cell migration and 
systemic interactions, they provide extremely useful information on antigen recognition and cellular 
activation.  Still, the cell frequency in peripheral blood differs greatly between naive and memory T 
cell populations.  
 Naive T cells specific to any given antigen have been shown to constitute only 0.01 to 1% 
of total T cells – 1 in 105 up to 106 T cells (Figure V.2). Memory cells, on the other hand, constitute 
more than 1% of total T cells in peripheral blood (Figure V.2). These differences in cell frequency 
imply that detection of induced responses in both repertoires must be performed differently.  
 Recall responses in immunized or protected individuals can be readily detected using total 
PBMC since specific memory cells are present at high frequencies in circulation (Figure V.2). Usually, 
short-term cultures (5 to 10 days) are performed in triplicates of 2.105 total PBMC, for a total of 6.105 
cells tested per condition.  
 On the other hand, naive T cells clones are rare, which constitutes a limiting issue for detection 
sensitivity. A method based on peptide:MHC tetramers uses four specific peptide:MHC complexes 
bound to a single molecule of fluorescently labelled streptavidin (13). It has proven extremely useful 
to identify populations of antigen-specific T cells in the naive repertoire, for example, describing the 
number of T cell precursors specific to ovalbumin and viral-specific epitopes (14). However, this 
technique can only evaluate one epitope per experiment, it is not applicable to large numbers of MHC 
alleles and requires previous knowledge about the peptide sequences. Also, it is very expensive and, 
therefore, unsuited for epitope mapping or peptide screening experiments (12).  
 A suitable method to prime naive T cells in vitro is to use antigen-pulsed autologous DC, and 
several rounds of stimulation inducing T cell activation, proliferation and effector phenotypes (7–11). 
Cellular amplification allows the analysis and measurement of antigen-specific responses mediated 
by a single precursor cell or population (12). Also, the use of purified cell populations, enriched in 
lymphocytes, helps increase the level of detection of such responses (2). 
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Figure V. 2 Specific cell frequency in different immune repertoires (5). 
  
 Precursor frequency experiments use limiting dilution conditions to determine the relative 
frequency of antigen-reactive cells in each population. Cell suspensions are distributed with the goal 
of isolating one antigen-specific cell in each well of a 96-well plate. Specific T cells are then amplified 
through re-stimulations with peptide-pulsed antigen-presenting cells. Due to the low frequency of 
specific cells in circulation, not all wells seeded will contain specific T cells that will proliferate in 
response to antigen recognition. Therefore, a minimum of 2 million cells should be tested to maximize 
the chances of detecting specific naive T cells. Wells or cell lines with one or more specific T cell will 
be considered positive, whereas negative wells never contained antigen-specific T cells. Using this 
assay, it is possible to estimate the specific cell frequency through applying the Poisson distribution 
formula to the number of total positive and negative wells. This approach also reduces inter-assay 
variability. Yet, if there is a high number of peptides to test, this approach can be difficult to perform 
as it is extremely laborious. Methods using batch cell stimulation can provide a viable alternative, so 
long as response specificity is confirmed. 
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2. Experimental strategy: 
  
 Immunoassays will be performed exclusively in human cells and using two immune 
backgrounds or status relative to Leishmania infection – naive and healed individuals (Figure V.3). 
Most healed individuals after Leishmania infection possess specific memory T cells, responsible for 
immunity against reinfection. Importantly, peptides that successfully induce T cell activation in both 
backgrounds are promising vaccine candidates (see Chapter I). These candidates are associated with 
protective recall responses and will be able to induce long-lasting memory responses in naive 
individuals, the objective of prophylactic vaccines. 
 The primary focus is the experimental validation of Leishmania-specific peptides, in order to 
validate in silico predictions and pre-select the most immunogenic peptides (Figure V.3). To this end, 
the in vitro immunoassays with naive human samples were optimised, healed donor samples were 
collected from endemic areas in Tunisia, and the 49 HLA-class I- and 24 HLA-class II-restricted 
synthetic peptides were screened in both immune backgrounds. The main experimental readout for 
the proposed immunoassay screenings will be IFN-γ production, assessed by IFN-γ ELISpot assays. 
 
 
Figure V. 3 Proposed in vitro T-cell assays to assess immunogenicity of synthetic peptides containing HLA-
class-I and class-II Leishmania-specific epitopes. A) General view of in vitro assays with purified T cells from naive 
donors (naive repertoire). B) General view of the protocol used to assess immunogenicity in cells from healed individuals 
(memory repertoire).  
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3. Methods 
 
3.1. Ethics statement 
 
 The recruitment and sampling collection of different groups of volunteers were done in 
accordance with Good Clinical Practice (GCP). 
 In France, the Etablissement Français du Sang (EFS) is an established scientific partner of the 
Institut de Recherche pour le Développement (IRD), and performed the recruitment of blood donors 
and sample collection at the human blood bank of Toulouse.  
 In Tunisia, the recruitment of healed donors was based on the recommendations and approval 
of the local ethical committee from the Institut Pasteur de Tunis (IPT), the Comité d'éthique de l'Institut 
Pasteur de Tunis (convention de collaboration N°305256/00). A written informed consent was 
obtained from all subjects involved in this study. 
 
3.2. Preparation of total soluble Leishmania promastigote antigens 
(TSLA) 
 
 All antigen extracts were prepared from promastigote stationary phase parasite cultures of L. 
infantum. Briefly, TSLA were obtained from washed parasites in 1x phosphate-buffered saline (PBS), 
centrifuged at 1000×g/10 min at 4°C and supernatants were removed. The pellets were resuspended 
in lysis buffer (50 mM Tris/5 mM EDTA/HCl, pH7. 1 mL/1×109 parasites), subjected to three rapid 
freeze/thaw cycles followed and to three sonication pulses of 20 seconds/40W. Samples were 
centrifuged at 5000×g for 20 min at 4°C, and supernatants were collected, aliquoted and stored at 
−80°C until use. Protein quantification was performed using Bradford method. 
 
3.3. Synthetic Peptides 
 
 HLA-class I 9-mer peptides were synthesized by the Peptide Synthesis Platform from the 
Institut de Biologie Paris-Seine (UMPC-Sorbonne Universités, Paris, France), and HLA-class II 15-mer 
peptides by Proteogenix (Schiltigheim, France). The first peptide stocks were stored as 200 µM 
solutions in sterile MilliQ water, or Sodium Bicarbonate 0.2 mM (used in Tunisia and MN01-02), and 
the second peptide stocks were stored as 500 µM solutions in 10% DMSO and sterile MilliQ water 
(MN03-04). 
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 The CEF-I control peptide pool is comprised of 23 well-defined peptides derived from 
Cytomegalovirus (CMV), Epstein Bar virus (EBV) and Influenza viruses and is widely used as a 
positive control for CD8 T cell activation, designed to stimulate T cells with a broad array of HLA types. 
CEF-I stock solution (Mabtec) was diluted 1:100 in culture medium for a final well concentration of 2 
µg/mL. 
 
3.4. Matrix-based peptide pools 
 
 A matrix-based pool testing strategy was chosen to validate and select the most immunogenic 
epitopes among the initial 48 class I and 24 class II peptides (Figure V.4). Briefly, peptides are 
attributed a random peptide number (pi1 to pi48 for HLA-class-I peptides, and pii1 to pii24 for HLA-
class II peptides) and arranged in a matrix. Each peptide is included in two independent pools (1 
vertical and 1 horizontal), and double-positive peptides are considered immunogenic.  
 
 
Figure V. 4 Matrix-based pool design. A) 49 peptides restricted to HLA-class I alleles (pi) were randomly distributed 
in 14 pools, pools 1 to 7 and pools A to G. B) 24 peptides restricted to HLA-class II alleles (pii) were randomly distributed 
in 10 pools, pools 1 to 5 and pools A to E (15). Pools highlighted in yellow are example positive pools, leading to the 
identification of 2 immunogenic peptides. 
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3.5. Immunoassays with samples from naive donors 
 
a) Naive donor bank 
 Buffy coat samples from naive donors are collected in Toulouse by the EFS and shipped to 
Montpellier. Each naive donor was given an internal sample identification code – MPLn. PBMC were 
purified using Ficoll-Paque PLUS density gradients (GE Healthcare, Uppsala, Sweden). Briefly, buffy 
coat samples are diluted in PBS 1x 2mM EDTA, gently layered on top of the Ficoll gradient and 
centrifuged for 30minutes at 400g. After centrifugation, the interface ring layer is collected and 
washed in PBS 1x 2mM EDTA. Red blood cell lysis was performed with homemade ACK lysis buffer – 
0.15 M ammonium chloride (NH4Cl), 10 mM potassium bicarbonate (KHCO3), 0.1 mM Na2EDTA. Total 
PBMC are seeded in T175 flasks for 2 hours at 37°C for monocyte adherence. Non-adherent PBMC 
(PBMC NA) are collected and cryopreserved at -150°C for future use.  
  
b) Generation of monocyte-derived dendritic cells 
 Monocyte-derived dendritic cells (MoDC) were generated from plastic-adherent PBMCs (from 
500 million to 1 billion total PBMC), after 5-day culture in AIM-V medium (Invitrogen) supplemented 
with 1000 U/mL of interleukin-4 (rhIL-4, Miltenyi Biotec) and 1000 U/mL of granulocyte macrophage 
colony-stimulating factor (rhGM-CSF, Miltenyi Biotec).  
 To evaluate the in vitro generation of monocyte-derived immature DC, the differentiation 
status of MPL9 and MPL10’s immature DC was assessed with the Mo-DC Differentiation Inspector 
human (Miltenyi Biotec, ref. 130-093-567), according to manufacturer’s instructions. It comprises 
monoclonal antibodies recognizing CD14, CD83, and CD209 and corresponding isotype controls. After 
staining, samples were acquired by flow cytometry (FACSCanto, Becton Dickinson) and analysed with 
the BD FACSDivaTM software (version 6.2). 
 
c) Cell counting 
 Total PBMC were counted manually using a KOVATM GlassticTM slide, after Trypan Blue 0,4% 
staining (cell suspensions diluted in PBS1x). 
 Purified T cells were counted using the LUNA-FLTM Automated Cell Counter (Logos 
Biosystems, Annandale, VA), after Trypan Blue 0,4% staining (cell suspension diluted in PBS1X, 10 µL 
are added to the LUNA slide, focus is manually adjusted, and cells/mL are counted in the range 5x104 
to 1x107 cells/mL). 
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d) Immunoassays with samples from naive donors (MN01-MN04) 
  A total of four optimisation experiments with naive donor samples were performed, 
summarised in Table V.8. 
 
Table V. 1 T cell amplification assays performed. Four different protocols were tested and optimised: in experiment 
MN01, the Wolfl protocol described in (16) was used. In experiment MN02, the T cell amplification assay was adapted 
from the protocol for TCD4 cells described in (8,9). In experiment MN03, this protocol was further optimised through the 
addition of a third co-culture and different peptide concentrations, tested in two different formats (96-well plate format 
and 48-well batch stimulation format). Finally, experiment MN04 used a 48-well format, batch stimulation assay, with 
the long peptide protocol for APC stimulation (immature dendritic cells, matured and pulsed for 16 hours). 
 
 
· Naive T cell assay adapted from Wolfl et al (MN01): 
  
 Naive T CD8+ cells were isolated from total PBMC from donor MPL3, in a two step-procedure, 
firstly by depletion of non-naive T cells and NK cells (cocktail of biotin-conjugated human monoclonal 
antibodies against CD45RO, CD56, CD57, CD244), and, subsequently, by positive selection of TCD8+ 
naive cells using an anti-CD8 monoclonal antibody coupled to magnetic microbeads (Miltenyi CD8 
MicroBeads), as recommended by the manufacturer (Naive CD8+ T cell Isolation Kit, ref. 130-093-244, 
Miltenyi Biotec). Cell purity was not assessed due to technical problems with the flow cytometer. 
 Naive TCD8+ cells were plated in 96-well plate, 200.000 per well (200k/w), and 10 wells per 
condition (2 million TCD8 cells), in CellGro medium (CellGenix #0020801-0500) supplemented with 
Penicillin/Streptomycin 1X and 5% human serum type AB (SAB, Lonza lot#0000166597) 
(=complete CellGro). Autologous PBMC (50.000 per well) were seeded in 96-well plates in complete 
CellGro medium (for a APC:TCD8 1:4 ratio). PBMC were loaded with peptide pools (1 µM each 
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peptide), medium alone or CEF peptide control pool (2 µg/mL) and incubated for 4 hours at 37°C/5% 
CO2. Pulsed PBMC were washed and irradiated 6 minutes under 50 Hz, 312 nm UV light (VL-6.M lamp, 
Fischer BioBlock Scientific). Naive T CD8+ cells were added to pulsed PBMC and cultured in complete 
CellGro medium supplemented with human recombinant (rh) IL-7 (500 U/mL, Miltenyi Biotec) and 
rhIL-15 (75 U/mL, Miltenyi Biotec). Medium was changed after 3 days. Naive T CD8+ cells were re-
stimulated on day 7 and day 14, for a total of 3 co-cultures in the same conditions (d0, d7, d14).  
 The protocol recommended by Wolfl et al was adapted to use total PBMC as APC. The protocol 
compares several cell types as APC, including total PBMC, and suggests the use of monocyte-derived 
dendritic cells. Monocyte-derived DCs were not generated for donor MPL3 so the adapted protocol 
uses total PBMC, pulsed with peptides for 4 hours, without any differentiation or maturation factors. 
 IFN-γ production was assessed on day 21 by IFN-γ enzyme-linked immunospot assay 
(ELISpot). All cells from culture wells were seeded in the ELISpot plate and compared with 
unstimulated cells from the same individual. Naive TCD8+ cell lines were considered positive when a 
spot count was twofold higher in the presence of the peptides than in their absence, with a minimal 
difference of 44 spots, the highest NS spot count (STIM spot count > 2xNS spot count average+44 
spots). 
 
· T cell amplification protocol_v1 (MN02):  
  
 The T cell amplification protocol using total TCD8+ cells from the naive repertoire was 
adapted from the protocol for TCD4 cells developed by the Bernard Maillere Lab (Laboratoire 
d’immunochimie de la réponse immune cellulaire, Institut de Biologie et technologies, CEA – 
Saclay)(8,10,17). This protocol uses magnetically purified total TCD8 cells which are co-cultured with 
autologous peptide-pulsed mature DC.  
 Immune cell populations (monocytes, TCD8+ and TCD4+ cells) from MPL9 buffy coat sample 
were purified differently from other donors. This sample was used to test a semi-automatic cell 
separator and sequential cell isolation and assess the protocol feasibility for the generation of the 
naive donor bank. Monocytes, TCD8+ and TCD4+ cell populations were magnetically isolated with the 
use of a MultiMACS™ Cell24 Separator Plus (Miltenyi Biotec). Briefly, the buffy coat sample was 
diluted in PBS1x 2mM EDTA and the distinct cell populations were sequentially purified: i) CD14+ 
monocytes through positive selection with the StraightFrom®Buffy Coat CD14 MicroBead Kit, human 
(Miltenyi Biotec, ref 130-114-976); ii) total TCD8+ cells through positive selection with the 
StraightFrom® Buffy Coat CD8 MicroBead Kit, human (Miltenyi Biotec, ref. 130-114-978); and, 
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finally, iii) total TCD4+ cells through positive selection with the StraightFrom® Buffy Coat CD4 
MicroBead Kit,human (Miltenyi Biotec, ref. 130-114-980).  
 Monocytes were cultured in T175 flasks for the generation of monocyte-derived DC (see 3.5.b) 
and, subsequently, immature DCs were cryopreserved. All T cell populations were cryopreserved and 
kept at -150°C until use. Cell purity was assessed by surface marker staining with the following 
antibodies: mouse anti-CD8-PE antibody (BD Biosciences); mouse anti-CD4-PeCy7 antibody (BD 
Biosciences); mouse anti-CD14-FITC antibody (BD Biosciences); and mouse anti-CD45-PerCPCy5 (BD 
Biosciences).  
 Three cryovials containing total TCD8+ cells from donor MPL9 were gently thawed (vials with 
50 million, 25 million and 12.5 million TCD8+ cells). Total TCD8+ cells were seeded in 96-well plate, 
200.000 cells per well in Iscove Modified Dulbecco medium (IMDM) supplemented with 10% human 
AB serum, 1x non-essential amino-acids (Invitrogen), 50 U/mL of penicillin and 50 μg/mL of 
streptomycin (Invitrogen) (=IMDMc), for a total of 10 cell lines (2 million TCD8+ cells) per condition. 
Autologous DCs (20000 per well) were seeded in 96-well plates and pulsed with the different stimuli 
using the short peptide protocol – immature DCs are incubated in AIMV medium (Invitrogen) and 
matured with lipopolyssacharide (LPS, 1 µg/mL) and Resiquimod (R848, 10 µg/mL) for 16 hours, and 
then pulsed with either medium alone, peptide pools or positive controls for 4 hours at 37°C/5% CO2. 
After peptide stimulation, APC were washed and irradiated 6 minutes under 50 Hz, 312 nm UV light 
(VL-6.M lamp, Fischer BioBlock Scientific). 
 TCD8 cell lines were generated by adding total TCD8+ cells to the pre-pulsed DC wells and 
cultured in IMDMc supplemented with rhIL-21 (30 U/mL, Miltenyi Biotec) for cell priming. Medium 
was changed after 3 days to IMDMc supplemented with rhIL-7 (500 U/mL, Miltenyi Biotec) and rhIL-
15 (75 U/mL, Miltenyi Biotec). Cells were stimulated on day 0 and 7, for a total of 2 co-cultures, plus 
the ELISpot stimulation. 
 The specificity of the TCD8+ cell lines was analysed with ELISpot assays: 20.000 T cells from 
each cell line were incubated with autologous iDCs alone (cNS control) or with iDCs previously loaded 
with peptide pools (1 culture well = 2 ELISpot wells with 20.000 cells each). TCD8 cell lines were 
considered specific when a spot count was twofold higher in the presence of the protein than in its 
absence, with a minimal difference of 25 spots (STIM spot count > 2xNS spot count average+25 spots). 
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· T cell amplification protocol_v2 (MN03):  
  
 Three cryovials containing total TCD8+ cells from donor MPL9 were gently thawed (vials with 
50 milion, 25 million and 12,5 million cells each). Total TCD8 cells were counted and cultured in 
IMDMc medium in: i) 96-well plates, 200.000 TCD8 cells per well and 10 cell lines per condition, or 
ii) 48-well plates, 1 million TCD8 cells per well and 2 wells per condition. In both formats, TCD8 cells 
were co-cultured at 1:10 ratio with DC cells stimulated using the short peptide protocol with mature 
monocyte-derived DCs, and a total of 3 co-cultures were performed (d0, d7, d14) plus the ELISpot 
stimulation. Different peptide concentrations were tested – 1, 2,5 and 5 µM per peptide in each pool. 
After peptide stimulation, APC were washed and irradiated 6 minutes under 50 Hz, 312 nm UV light 
(VL-6.M lamp, Fischer BioBlock Scientific). 
 For the IFN-γ ELISpot, and for all peptide concentrations, total TCD8 cells were incubated with 
autologous DCs alone (control) or with DCs previously loaded with peptide pools at a ratio of 1:10 
(APC:TCD8). For cell lines cultured in 96-well plates, 20000 TCD8 cells were seeded in the ELISpot 
plate. For cells cultured in 48-well plates, 50.000, 100.000 or 150.000 TCD8 cells were seeded in the 
ELISpot plate. Responses were considered specific when a spot count was twofold higher in the 
presence of the protein than in its absence, with a minimal difference of 25 spots (STIM spot count > 
2xNS spot count average+25 spots). 
 
· T cell amplification protocol_v3 (MN04): 
  
 Total TCD4 and TCD8 cells were isolated using magnetic microbeads according to the 
manufacturer’s instructions. Briefly, cryopreserved non-adherent PBMCs (PBMC NA) from healthy 
donor MPL10 were gently thawed. Total TCD4+ lymphocytes were isolated by positive selection using 
an anti-CD4 monoclonal antibody coupled to magnetic microbeads (Miltenyi Biotec, ‘CD4 Microbeads 
kit’ ref 130-045-101), as recommended by the manufacturer, and cryopreserved at -150°C for future 
use. Total TCD8+ cells were isolated from the flow through by negative selection using magnetic 
microbeads (Miltenyi Biotec, ‘CD8+ T cell isolation kit’ ref 130-096-495) according to manufacturer 
instructions. 
  In this experiment, only the 48-well format (batch stimulation) was used, 1 million TCD8 cells 
were seeded per well and 2 wells per condition (2 million TCD8 tested). A total of 3 co-cultures were 
performed (d0, d7, d14) and monocyte-derived DCs stimulated with the i) short peptide protocol 
(see above), and ii) long peptide protocol (simultaneous maturation with LPS/R848 and peptide 
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stimulation during 16h at 37°C). After peptide stimulation, APC were washed and irradiated 6 
minutes under 50 Hz, 312 nm UV light (VL-6.M lamp, Fischer BioBlock Scientific). 
 The selected donor was MPL10, and a tailored peptide pool was designed according to the 
HLA-typing results. The peptide pool consists of 3 peptides per supertype (best predicted IC50), for a 
total of 12 peptides (poolGOOD). Autologous monocyte-derived DCs were stimulated with 2,5 µM 
per peptide.  
 TCD8 cells were considered specific when a spot count was twofold higher in the presence of 
the protein than in its absence, with a minimal difference of 25 spots (STIM spot count > 2xNS spot 
count average+25 spots). 
 
3.6. Immunoassays with samples from Healed Donors  
  
a) Healed donor samples from a Leishmania-endemic area in Tunisia 
 Human donor groups (cured individuals and healthy individuals with no history of 
leishmaniasis) were recruited from endemic areas for CL, based on the following defined inclusion 
criteria: i) individuals living in the Gadarif Region in Tunisia, endemic foci to L. major transmission, 
and who have not moved away in the last 10 years; and ii) the presence of typical scars for cured CL 
group. A complete medical questionnaire was completed during examination. Adult healthy 
individuals recruited in low or non-endemic areas (Tunis), and no or low IFN-γ response to SLA (<100 
pg/ml) will be considered as non-immune/naive. Exclusion criteria were immunosuppressive 
diseases other than leishmaniasis, long term treatment and pregnancy. Each donor was assigned an 
internal sample identification code – TUNn. 
 Heparinized blood was collected from a total of 20 healed donors and 10 healthy controls (1st 
healed series n=10, 2nd healed series n=10, naive series n=10).  
 
b) Total PBMC stimulation assays 
 Total PBMC were isolated from blood by density centrifugation through Ficoll-Hypaque (GE 
Healthcare Bio-Sciences AB, Uppsala, Sweden). Whole blood samples were transported at room 
temperature, in a cooler to keep temperature stability during the car trip from Gafsa Hospital to the 
Institut Pasteur of Tunis. Upon arrival in the lab, the cells were cultured in RPMI 1640 supplemented 
with 10% heat inactivated Human AB serum (SAB, Lonza), 100 IU/mL penicillin, 100 µg/mL 
streptomycin, 2 mM L-glutamin, 1 mM sodium pyruvate and 1X non-essential amino acids. Briefly, 
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cells were plated in 96-well plates (TPP, Switzerland), 200.000 PBMC/well, and were kept with media 
alone (NS) or stimulated with: i) Phytohemagglutinin 10 µg/mL (PHA, Sigma-Aldrich); ii) TSLA 10 
µg/mL; iii) CaniLeish® Antigen 10 µg/mL (GMP-produced LiESAp lyophilised without adjuvant) as 
positive controls; and iv) peptide pools (5 µM per peptide). Cells were cultured at 37°C, 5% CO2 for 
10 days. On day 1, 4 and 6, human recombinant IL-2 (100 U/mL, R&D systems) was added to the 
wells. 
 The peptide pool conditions tested were: i) one pool containing class I 9-mer peptides (pool 
ALL_I with 48 peptides); ii) fourteen matrix-based class I peptide pools 1 to 7 and pools A to G 
(containing 6 or 7 9-mer peptides each); iii) one pool containing class II 15-mer peptides (pool ALL_II 
with 24 peptides); iv) and ten matrix-based class II peptide pools 1 to 5 and pools A to E (containing 
4 or 5 15-mer peptides each). 
 
 
Figure V. 5 Experimental planning for immunoassays with samples from healed donors. 
 
3.7. Interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT) 
 
 Briefly, 96-well polyvinylidene difluoride (PVDF) plates (MSIP, Millipore) were coated 
overnight at 4°C with 2,5 ug/mL anti-human IFN-γ monoclonal antibody (mAb 1-D1K; Mabtech). Cells 
were cultured overnight (16-20h) with positive controls, peptide pools, or with culture medium as 
negative control, in triplicate. IFN-γ secretion was detected by addition of biotinylated anti-human 
IFN-γ mAb (7-B6-1; Mabtech) in PBS 1% bovine serum albumin (BSA) for 2 hours at 37°C. After 
washing, extravidin-phosphatase solution (dilution 1:3000 in PBS 1% BSA; Sigma-Aldrich) was added 
to the plate for 1 hour at room temperature, and spots were revealed with BCIP substate solution 
(tablets, Sigma-Aldrich) for 10 min (maximum revelation time of 20 min). IFN-γ spots were quantified 
using an AID Immunospot analyzer (C.T.L.). 
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3.8. Statistical Analysis 
 
 Statistical analysis was performed using GraphPad Prism version 6 software (GraphPad). For 
healed experiment series, the non-parametric Mann-Whitney test (one-tailed with confidence 
interval 95%) was applied to compare independent sample groups (STIM vs NS). A p-value ≤ 0.05 
was considered statistically significant. 
 
3.9. HLA-typing 
 
 All HLA-typing services were provided by DKMS Life Science Lab, an affiliated company with 
DKMS German Bone Marrow Donor Centre.  High resolution HLA typing (99%)  is performed by Next-
Generation Sequencing (Long Range Sequencing Service). Genomic DNA was extracted using the 
QIAamp DNA Blood Mini Kit (Qiagen, ref 51104) and shipped to DKMS Lab in Germany. Sequencing 
was performed for exons 2 and 6 for 6 HLA loci (HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1) leading to 
the 6-digit identification of twelve HLA alleles per donor.  
 In order to compare allele frequencies between the recruited donors and country-specific 
populations, allele frequency data was retrieved from the Allele Frequency Net Database (AFND). The 
AFND provides a central source, freely available to all, for the storage of allele frequencies from 
different polymorphic areas in the Human Genome. Currently, collected data are in allele, haplotype 
and genotype format. In the present analysis, only HLA studies were considered (18). Allele frequency 
information with two-digit level of resolution for the French Population was retrieved from the AFND 
(Table V.2). Allele frequency information with two-digit level of resolution for the Tunisian 
Population was retrieved from the AFND (Table V.3). 
 Allele frequency refers to the total number of copies of the allele in the population sample 
(Alleles/2n) in decimal format. Some studies present results as percentage of individuals that have 
the allele (% ind), and it refers to the percentage of individuals who have the allele in the population 
(heterozygous allele count / n). Since Tunisian studies use mostly allele frequency to present results, 
for consistency purposes, only studies with results expressed as allele frequency were included. 
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Table V. 2 Description and size of 17 French population studies from AFND with HLA data considered for HLA 
allele frequency analysis 
Population (Studies) Ethnicity Study 
Sample 
Size 
HLA Loci 
France Bordeaux Mixed HLA 990  -A, -B, -C, -DRB1 
France Ceph Caucasoid HLA 124  -DPA1, -DPB1, -DQA1, -DQB1 
France Corsica Island Caucasoid HLA 100  -A, -B, -C 
France Grenoble Mixed HLA 1  -A, -B, -C, -DRB1 
France Grenoble, Nantes and Rennes Caucasoid HLA 6,094  -A, -B, -C, -DRB1 
France Lille Caucasoid HLA 95  -DPB1, -DQA1 
France Lyon Caucasoid HLA 4,813  -A, -B, -C, -DRB1 
France Marseille Mixed HLA 1  -A, -B, -C, -DRB1 
France Reims Caucasoid HLA 102  -A, -B 
France Rennes Caucasoid HLA 200  -DPB1, -DQB1, -DRB1 
France Rennes pop 2 Caucasoid HLA 148  -DPB1 
France Rennes pop 3 Caucasoid HLA 200  -A, -B, -DQB1, -DRB1 
France Rennes pop 4 Mixed HLA 1  -A, -B, -C, -DRB1 
France South Caucasoid HLA 350  -DQA1, -DQB1, -DRB1 
France Southeast Caucasoid HLA 130  -A, -B, -C, -DPB1, -DQB1, -DRB1 
France West Caucasoid HLA 100  -C, -DQB1, -DRB1 
France West Breton Caucasoid HLA 150  -DPB1, -DQA1, -DQB1, -DRB1 
 
 
Table V. 3 Description and size of 8 Tunisian population studies from AFND with HLA data considered for 
HLA frequency analysis  
Population (Studies) Ethnicity Study 
Sample 
Size 
HLA Loci 
Tunisia Arab HLA 100  -A, -B, -C, -DPB1, -DQA1, -DQB1, -DRB1 
Tunisia Gabes Mixed HLA 95  -A, -B, -DQB1, -DRB1 
Tunisia Gabes Arab Arab HLA 96  -DQB1, -DRB1 
Tunisia Ghannouch Arab HLA 82  -A, -B, -DQB1, -DRB1 
Tunisia Jerba Berber Berber HLA 55  -DQB1, -DRB1 
Tunisia Matmata Berber Berber HLA 81  -DQB1, -DRB1 
Tunisia pop 2 Arab HLA 111  -DQB1, -DRB1 
Tunisia pop 3 Arab HLA 104  -A, -B, -DQB1, -DRB1 
 
   
 For the analysis of HLA allele frequency in different world populations affected by 
leishmaniasis, data was collected from the AFND for the following world regions: South and Central 
America, North Africa, Western Asia, South Asia (Appendix V.1). Data were retrieved from AFND 
through a ‘HLA allele freq (Classical)’ search with the following filters: i) region name; ii) level of 
resolution=2-digits; iii) Population standard=Gold and Silver (19); iv) show frequencies=only 
positives (Table V.4). 
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Table V. 4 Populations with HLA allele frequency data from four world regions most affected by leishmaniases. 
Data from AFND, world regions plus filters (level of resolution: 2 digits + population standard: Gold and Silver only + 
only positive results). “records” are all combinations of 2-digit allele/population per world region. 
World Region countries included 
FULL 
results 
(records) 
records 
WITH 
FILTERS 
allele 
list 
(filtered 
results 
rows) 
Western Asia 
Armenia, Gaza, Georgia, Iran, Jordan, Iraq, Israel, 
Lebanon, Oman, Turkey, Saudi Arabia, UAE 
8976 66 94 
South and Central 
America 
Argentina, Bolivia, Brazil, Chile, Colombia, Costa 
Rica, Cuba, Guatemala, Ecuador, Jamaica 
13700 411 96 
North Africa Algeria, Ethiopia, Morocco, Sudan, Tunisia 6210 53 83 
South Asia India, Bangladesh, Pakistan, Sri Lanka 4707 325 85 
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4. Results - Immunoscreenings with samples from naive donors 
 
4.1. The naive donor bank and respective HLA-typing results 
 
 A total of 21 buffy coat samples from naive individuals were processed (MPL1-21) (Table V.9). 
HLA-typing was performed for donors MPL3-21 included in the naive donor bank (Table V.10). 
Individual HLA-class I alleles sharing peptide binding properties were grouped in allele groups 
(supertypes) according to the classification by Sidney J et al 2008 – supertypes A01, A02, A03, A24, 
A26, B07, B08, B27, B44, B58, B62 (cf chapter IV). Whenever specific alleles possess B and F pocket 
specificities that are shared by different allele groups they can be classified, for example, as A01A24 
or remain unclassified. 
 
Table V. 5 Naive donor bank description. Buffy coat samples from 21 individuals from the French blood bank EFS 
(Établissement Français du Sang), in Toulouse, France. EFS code = collection site code/internal sample ID. Total PBMC 
were recovered using Ficoll density gradient. 
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Table V. 6 HLA-typing results for donors MPL3 to MP21. A) Six loci corresponding to HLA-class I and class II polymorphic regions (HLA-A, -B, -C, -DRB1, -DPB1, 
-DQB1) were sequenced by NGS (exons 2 and 3), leading to the 6-digit identification of the alleles expressed by each donor. Allele supertype classification by Sidney 
et al 2008 (20). B) Ambiguous identifications are given a multiple allele code (MAC, https://hml.nmdp.org/MacUI/).  
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 HLA typing results for the 19 individuals describe the diploid loci for HLA-A, -B, -C, -DRB1, -
DQB1 and -DPB1 genes corresponding to 12 alleles per donor. The only HLA class I genes analysed 
were the HLA-A and -B genes (4 gene loci per donor), and homozygous alleles were excluded from 
allele counts. The only HLA class II genes analysed were the HLA-DRB1 and -DPB1 genes (4 loci) and 
homozygous alleles were excluded from allele counts. 
 HLA-typing results for the 19 naive donors included in the naive donor bank show the most 
frequent HLA-A allele is HLA-A*03, with 42,1% of individuals expressing an A*03 allele (8 allele 
counts) (Figure V.6).  Almost 80% of individuals express an allele from the A03 supertype (15 in 19 
donors), which also includes the alleles HLA-A*11:01:01G, A*31:01:02G, A*33:03:01G, A*66:01:01G 
(Table V.10). 
 The most frequent HLA-B allele expressed by the naive donors is HLA-B*07, with 36,8% of 
individuals expressing HLA-B*07 alleles (7 allele counts) (Figure V.6). Almost 75% of individuals 
express an allele from the B07 supertype (14 in 19 donors), which also includes the B*35 alleles, 
namely HLA-B*35:01:01G (Table V.10). The individuals expressing alleles that belong to the B07 
supertype include 36,8% and 31,6% of individuals who express HLA-B*07 and -B*35 alleles, 
respectively. Even if these alleles share peptide binding specificities, the high frequency of B*35 
alleles in the human populations could justify a separate allele group to minimise bias in epitope 
selection. 
 Another common HLA class I allele expressed by naive donors is the HLA-B*44, with 26,3% 
individuals expressing HLA-B*44 alleles (5 allele counts) and 63,2% of individuals expressing an 
allele from the B44 supertype (12 in 19 donors) (Figure V.6). The other main alleles belong to 
supertypes A01 and A02, with 8 and 6 individuals expressing alleles from these supertypes, 
respectively (Figure V.6).  Three of the donors are homozygous for one of the HLA class I loci: donor 
MPL3 (HLA-A*23:01:01G, A24), donor MPL07 (HLA-B*07:02:01G, B07), and donor MPL14 (HLA-
B*44:03:01G, B44).  
 The HLA-class I supertype B62, with B*15:01 as the representative allele, is not represented 
in the donor bank, and the supertypes B58 (B*58:01) and A01A24 are only represented once. The 
only B*15 allele expressed is B*15:03:01G (donor MPL10) which is classified in the B27 supertype. 
 The supertype A01A24, according to Sidney J et al 2008, includes alleles with specificities that 
are compatible with multiple supertypes (i.e HLA-A*29:02) – B pocket specificity for small, aliphatic 
and aromatic residues, and F pocket specificity for aromatic and large hydrophobic residues. In this 
case, these features are compatible with both the A1 supertype (B pocket specificity for small and 
aliphatic residues, and F pocket specificity for aromatic and large hydrophobic residues), and the A24 
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supertype (B pocket specificity for aromatic and aliphatic residues, and a F pocket specificity for 
aromatic, aliphatic and hydrophobic residues). 
 
 
Figure V. 6 Percentage of individuals in the naive donor bank expressing HLA class I alleles according to allele 
supertypes. Results for HLA-class I alleles (HLA-A and -B genes) grouped in supertypes (allele groups with shared 
binding properties). 
 
4.2. HLA allele frequency of the naive donor bank matches the French 
population 
 
 Studies from the AFND describing allele frequency for HLA-A and -B alleles in the French 
population show that the most prevalent HLA-A class I alleles are, by descending order, HLA-A*02, 
HLA-B*44, HLA-A*01, HLA-A*03, HLA-B*35, HLA-A*24, HLA-B*07, and HLA-B*08 (Figure V.7).  
 The overall allele frequencies in the French population are similar to the results obtained for 
the naive donors included in the bank, as the most prevalent HLA-A genes expressed are also HLA-
A*02, HLA-A*01, HLA-A*03, HLA-A*24, and HLA-B genes expressed are HLA-B*44, HLA-B*35 and 
HLA-B*07 (Figure V.7).  
 Naive donors express mostly HLA-A*03 alleles (0,2105 frequency / 42,1% of individuals), 
HLA-B*07 alleles (0,1842 frequency / 36,8% of donors), HLA-B*35 alleles (0,1579 frequency / 31,6% 
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of individuals), HLA-B*44 alleles (0,1316 frequency / 26,3% of individuals), HLA-A*01 alleles (0,1316 
frequency / 26,3% of individuals), and HLA-B*08 alleles (0,079 frequency / 15,8% of individuals) 
(Figure V.7). 
 
 
Figure V. 7 HLA class I allele frequency in the French population and in the naive donor bank. Allele frequency 
for HLA-A and -B genes (allele / 2n). 
 
 Similar results were obtained for HLA-class II alleles, wherein the most prevalent alleles in 
the French population correspond to the most common alleles expressed by the naive donors. The 
main HLA class II alleles, for HLA-DRB1 and -DPB1 genes, are HLA-DPB1*04, HLA-DPB1*02, HLA-
DRB1*04, HLA-DRB1*07, HLA-DRB1*13, HLA-DRB1*15, HLA-DRB1*11, HLA-DRB1*01 and HLA-
DRB1*03 (Figure V.8). 
 The most expressed HLA-class II allele is HLA-DPB1*04 with 68,4% of all donors expressing 
this allele (allele count 13, frequency 0,342). The most frequent HLA-DRB1 allele, and the second most 
frequent DRB allele overall, is HLA-DRB1*07 expressed by 36,8% of individuals (allele count 7, 
frequency 0,184). 
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Figure V. 8 HLA class II allele frequency in the French population and in the naive donor bank. Allele frequency 
for HLA-DRB1 and -DPB1 alleles (allele / 2n). 
 
4.3. HLA allele frequency of the naive donor bank includes the most 
prevalent alleles in the populations affected by leishmaniasis 
 
 The regions included in the AFND that match the populations most at risk for Leishmania 
infection are South and Central America, North Africa, Western Asia, South Asia. All positive HLA 
frequency studies (with Gold and Silver population standards) were included, which present results 
either as percentage of individuals expressing a given allele and/or HLA frequency in decimals.  
 The most common HLA-class I alleles across all four world regions, for HLA-A genes are HLA-
A*02, -A*24, -A*68, -A*01 and -A*03. As for HLA-B genes the most common alleles are HLA-B*35, -
B*44, -B*51, -B*07.  All these class I alleles are consistently expressed by over 10% of the population 
in these regions (Figure V.9). 
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Figure V. 9 Average HLA-class I allele frequencies according to world region. Averaged results from the population studies considered (%individuals and allele 
frequency) for HLA-class II alleles HLA-A and HLA-B.  A) South and Central America populations. B) North Africa population. C) Western Asia populations. D) South Asia 
populations. 
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 The most frequent HLA-class II alleles across all four world regions, expressed by over 10% 
of individuals in all these populations are HLA-DRB1*03, -DRB1*04, -DRB1*07, -DRB1*08, -DRB1*11, 
-DRB1*13, -DRB1*15. The allele HLA-DRB1*01 is less prevalent is the western and south asian 
populations. Some alleles are often not included in the allele frequency studies, as for example the 
HLA-DPB1 locus, which impedes comparisons among populations. 
 Typing of the HLA-DQB1 loci was performed for the individuals in the naive donor bank 
(Table V.10), and data exists for some of the selected populations, however, these were not included 
in the analysis since epitope prediction was not performed to HLA-DQ alleles. 
 HLA allele frequencies for these four world regions match the most prevalent alleles in the 
naive donor bank, suggesting the allele frequencies of naive donors are representative of these human 
populations. 
 
 
Figure V. 10 Average HLA-class II allele frequencies according to world region. Averaged results from the 
population studies considered (%individuals and allele frequency) for HLA-class II alleles HLA-DRB1 and HLA-DPB1. 
A) South and Central America populations. B) North African populations. C) Western Asian populations. D) South Asia 
populations.  
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4.4. Monocyte-derived dendritic cells are efficiently generated in vitro 
 
 The surface markers CD14, CD209 (DC-SIGN) and CD83 were used to determine the 
phenotype of monocyte-derived dendritic cells, after differentiation from monocytes and, for MPL10, 
after maturation. CD14 is highly expressed by monocytes, and functions as a co-receptor for LPS and 
LPS-binding protein (LBP). CD14+ monocytes can differentiate into DCs in a IL-4/GM-CSF cytokine 
environment. CD209 (DC-SIGN) is a C-type lectin and enables TCR engagement by stabilisation of the 
DC-T-cell contact zone, and expression is limited to tissue DCs and monocyte-derived DCs. CD83 is 
regarded as a maturation marker for DCs, it regulates antigen expression presentation and is only 
expressed by DCs, Langerhans cells and B cells. Hence, immature DCs are CD14-CD209+CD83- and 
mature DCs are CD14- CD209+CD83+.  
 In vitro monocyte differentiation into immature DC induced by IL-4 and GM-CSF is highly 
efficient, resulting in the recovery of 99,1% for MPL9 and 98,1% for MPL10 CD14- cells, excluding 
debris and contaminant cells (Figure V.11). 
 For MPL9, immature DCs as defined by the expression of CD209 and the absence of CD83 are 
42,8% of total CD14- cells. Some mature DC expressing CD83 are found (2,3%) (Figure V.11 panel A).   
 For donor MPL10, the immature and mature DC populations were compared. Results show 
that after in vitro monocyte differentiation, immature DCs represent 17,9% of total CD14- cells, with 
2,3% also expressing CD83 (Figure V.11 panel B). For mature DCs, after overnight maturation with 
LPS and Resiquimod, the percentage of mature DC (CD14-CD209+CD83+) increases to 28,6%, while 
8,3% of cells remain in an immature state (CD14-CD209+CD83+) (Figure V.11 panel C). 
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Figure V. 11 Monocyte-derived DC phenotype analysis for donors MPL9 and MPL10. DC were stained in 
independent experiments with Mo-DC Inspector kit, human (Miltenyi) that detects CD14, CD209 (DC-SIGN), and CD83 
expression. A) immature DC from donor MPL9. B) immature DC from donor MPL10. C) mature DC from donor MPL10. 
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4.5. Leishmania-specific TCD8+ cells are present in the naive repertoire 
 
 The first peptide immunoscreening performed tested all 49 HLA-class I peptides in matrix-
based pools using the protocol adapted from Wolfl et al, with magnetically isolated naive TCD8+ cells 
from donor MPL3 (experiment MN01). 
 
 
Figure V. 12 IFN-γ ELISpot results for the MN01 experiment: T cell amplification assay with naive TCD8 cells 
from naive donor MPL3. A) number of positive cell lines per condition (14 class I peptide pools). B) control results 
(TCD8 NS, PBMC NS, CEF and PHA). C) Spot counts per cell line and the threshold mark for well positivity. D) ELISpot 
well pictures and respective spot counts. 
  
 In experiment MN01, we successfully generated and detected specific T cell lines against 
Leishmania-specific peptide pools (Figure V.12 panel A). A total of 17 positive cell lines (out of 140) 
specific to 9 different peptide pools were generated from donor MPL3. Results show that 5 (out of 14) 
peptide pools generated 1 positive cell line, and 4 pools generated between 2 and 5 specific cell lines. 
 ELISpot results for negative controls (never stimulated TCD8 cells) showed overall low 
background levels (NS spot counts: 25, 20, 44, 13, 39, 3) for an average of 24 spots (±15,5). The 
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highest NS value (44) was included in the empirical test to determine well positivity (2*NS 
average+44 spots). The PHA solution used in this experiment is thought to have been from on old 
stock, probably degraded, as only 2 wells showed high spot counts, and still much lower than expected 
(PHA spot counts plate A: 222, 196, 60, 56; plate B: 46, 36) (Figure V.12 panel B). 
 In this experiment, the CEF-stimulated naive TCD8 cells underwent three co-cultures plus the 
ELISpot stimulation. The spot counts of the CEF peptide pool are quite variable with some low values 
(47, 79, 30, 3), which is expected since this assay uses a purified population of naive T cells, and very 
few memory cells are present (Figure V.12 panel B). Memory T cells are responsible for long-term 
responses against the CEF peptide pool (CMV-, EBV-, influenza-specific epitopes), so low spot counts 
can be expected when using purified naive T cell populations. CD45RA+ cell enrichment after magnetic 
purification was not assessed due to technical problems with the flow cytometer, even though 
staining was performed. Although there are specific naive T cells in naive individuals against the CEF 
peptides which can be stimulated an amplified in vitro, only 600.000 naive TCD8+ cells (triplicate 
wells) were tested. Still, it is noteworthy that some Leishmania-specific peptide pools induced much 
higher number of IFN-γ-producing cells than the CEF control pool.  
 
 
Figure V. 13 Four peptide pools successfully generated over 2 positive cell lines. A) Cross-matching results with 
matrix peptide pool constitution leads to the identification of 4 double-positive, hence immunogenic peptides. B) Naive 
donor MPL3’s HLA-typing results for 6 HLA loci (HLA-A, -B, -C, -DRB, -DP, -DQ) 
 
 Peptide pool 2 induced 5 positive cell lines out of 10, the highest number overall, ranging from 
99 to 198 spots. Pool B had the second highest number of positive lines, 3 in 10, with spots counts 
ranging from 99 to 269. Pool D and Pool 6 induced 2 positive cell lines each, with spot counts of, 
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respectively, 124/360, and 142/218. Pools E and F induced only 1 cell line but with very high spot 
counts of 274 and 278, respectively (Figure V.12 panels C and D).  
 If we consider a minimum of 2 positive cell lines, 4 immunogenic peptide pools are identified 
– pools B and D, and pools 2 and 6 (Figure V.13 panel A). Cross-matching these results with the pool 
matrix, four double-positive immunogenic peptides are identified – B7_3, A24_3, B8_3, B58_3 (Figure 
V.12 panel A).  
 The donor MPL3 expresses the alleles HLA-A*23:01:01G (A24), HLA-A*23:01:01G (A24), 
HLA-B*44:03:01G (B44), HLA-B*49:01:01G (unclassified but probable B44) (Figure V.12 panel B). 
Considering this information, only one peptide (A24_3) corresponds to the donor’s HLA typing, 
implying peptides are more promiscuous than predicted by in silico algorithms.   
 If we consider all peptide pools with at least 1 positive well, there are 9 positive matrix-based 
peptide pools leading to the identification of 20 double-positive peptides. However, from these 20 
double positive peptides, only 2 correspond to the donor’s HLA-typing. The number of restricted 
peptides is not significantly increased as these do not include more donor-specific supertypes. 
Interestingly, peptide pool E which generated one cell line with high spot count (274) contains both 
A24- and B44-restricted peptides. 
 
 This assay constitutes preliminary evidence of the presence of T-cell precursors specific to 
Leishmania epitopes in naive individuals’ immune repertoire. Although the magnitude of response 
was assessed for in vitro stimulated cell lines, specificity was not absolutely confirmed because spot 
counts were compared to NS wells (never stimulated autologous TCD8+ cells). An ELISpot well 
containing culture-stimulated cells but unstimulated during the ELISpot (cNS) will demonstrate that 
IFN-γ production is dependent on peptide-stimulus and, therefore, specific.  
 The remaining issues with this experiment are i) that no cell counts were performed before 
seeding in ELISpot plate (in this experiment 1 culture well corresponds to 1 ELISpot well) which may 
introduce bias when comparing wells; ii) the use of an empirical rule for well comparison, because 
there are no triplicates no statistical test can be applied; iii) LiESAp or CaniLeish® antigen, the original 
antigenic mixture, were not included as positive controls; iv) finally, the high number of purified naive 
TCD8 cells needed per experiment and per individual (MINIMUM 200.000*10 wells/condition) is 
logistically unviable.  
 In this experiment total PBMC were used as APC, without supplementation with 
differentiation or maturation factors. We expect the antigen presentation protocol can be further 
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optimised using professional APC, such as monocyte-derived DCs for short peptide presentation in 
HLA class-I molecules.  
 
4.6. Total TCD8+ cell in vitro amplification needs at least three stimulation 
rounds 
 
 In experiment MN02, total TCD8 cells from donor MPL9 were used, and the same matrix-
based peptide pools were tested at 5 µM concentration per peptide. Cell populations from MPL9 were 
isolated differently from other donors using the MultiMACS™ Cell24 Separator Plus (see Material and 
Methods). Surface marker phenotyping shows that CD8+CD45+ cells were present at 88,2% purity 
(66,4% of total events excluding debris) (data not shown). Also, CD14+CD45+ monocytes were 
isolated with 93,9% purity (89,4% of total event excluding debris) and CD4+CD45+ cells were isolated 
with 96% purity (84,7% of total events excluding debris) (data not shown).  
 The protocol used was adapted from analogous TCD4+ cell amplification assays (8,21), and 
uses the total TCD8+ cell population and mature monocyte-derived DCs (mDC) as APC. Since the class 
I peptides are only 9-mer in length, and do not necessarily need processing, a short peptide 
stimulation protocol was adopted, where monocyte-derived immatured DCs are firstly matured with 
LPS and TLR-7/8 agonist Resiquimod/R848, and only after stimulated with peptides for 4 hours. 
 In this experiment, no specific cell lines were generated against any of the pools at 5 µM 
peptide concentration (Figure V.14 panel A) after two co-cultures.  
 Negative control background levels from never stimulated TCD8+ cells remained low (NS spot 
counts 15/6/20/20/17, average 16). As expected, since in this experiment total TCD8 cells were used, 
the CEF control pool results were higher than MN01, even with just one co-culture plus the ELISpot 
stimulation (CEF spot counts 138/49/153/51, CEF MN02 Elispot2: 34, 238 (Too Numerous To 
Count), 39, 186 (TNTC), with only 20.000 TCD8+ cells seeded in the ELISpot wells.  
 PHA stimulation results (spot counts 366, TNTC, 404, TNTC) and average cell viability of 77% 
(± 9.9%) assessed before ELISpot seeding, confirm cells were viable and responsive (Figure V.13 
panel B). We estimate viability is higher than calculated by LUNA reader, for there is some cellular 
debris from DC cells and SAB used for the co-cultures, considered as dead cells by the automatic 
counter (a cell size filter was not applied). 
 The positive controls LiESAp and CaniLeish® antigen were tested in this experiment, however, 
the observed negative results remain inconclusive since the DC stimulation protocol was not adapted 
for protein processing. The short peptide stimulation protocol was used for all conditions and we 
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estimate a 4-hour incubation time of matured DCs is not sufficient to process and present the full 
protein antigens, and subsequent T-cell activation is abrogated (Figure V.14 panel B). 
 
 
Figure V. 14 IFN-γ ELISpot results for the MN02 experiment (96-well format), T cell amplification assay with total 
TCD8+ cells from donor MPL9. A) Number of specific T cell lines generated per condition. B) Spot counts for control 
conditions. C) Spot counts per condition showing individual cell lines; cNS, culture-stimulated cells but unstimulated in 
the ELISpot plate. 
CHAPTER V – EXPERIMENTAL VALIDATION OF SYNTHETIC PEPTIDES 
210 
 
  In this experiment, response specificity per cell line was confirmed with culture-stimulated 
cells but unstimulated during the ELISpot (cNS). Overall, observed spot count values in stimulated 
wells (STIM) are sometimes higher than cNS, but not enough to consider as positive responses (Figure 
V.14 panel C). Otherwise, spot counts are similar to respective cNS unstimulated wells. Also, STIM and 
cNS are mostly similar to background levels for negative controls (never stimulated TCD8 cells – NS) 
but much more variable. All conditions and all cell lines show some variability in background levels 
(cNS spot counts), and even some cell lines present high background levels (e.g. pools 1, C, E, F and G) 
(Figure V.14 panel C). For peptide pool C, one cell line has cNS spot count of 93 and STIM spot count 
of 142, which if we compared with the never stimulated TCD8+ negative control would be considered 
a positive cell line (Figure V.13 panel C). This can be due to approximation errors when averaging cell 
counts to calculate 20.000 seeded cells in the ELISpot (3 in 10 wells measured per condition). Still, 
pools that successfully generated more than one cell line in MN01 – pools B, D, 2 and 6 – did not induce 
IFN-γ production/positive cell lines (maximum spot counts were 41, 43, 39 and 25, respectively).  
 The use of statistical analysis to assess positive responses is more reliable and recommended 
as they are based on a theoretical background, have a universal application across experiments, and 
even more suitable to detect weaker responses. Furthermore, the primary objective of the peptide 
immunoscreenings is to exclude non-immunogenic and unstable peptides, before inquiring about 
precursor frequency. Therefore, the following adaptations were made to the protocol: i) an additional 
total TCD8:DC co-culture (3 instead of 2); ii) testing different peptide concentrations and fresh 
aliquots diluted in 10% DMSO; and iii) testing a different assay format that allow the application of 
statistical tests to determine well positivity, the counting of all culture wells and show results as 
SFC/million, a widely accepted way to present ELISpot results.  
 
4.7. In vitro amplification of total TCD8+ cells depends on the antigen-
presenting cells and respective stimulation protocol  
  
 In experiment MN03, total TCD8 cells from donor MPL9 were used, and all peptides were 
tested in two pools at different peptide concentrations. At the time of this experiment, HLA-typing 
results of MPL9 donor were not yet available to design one personalised peptide pool, so all class I 
peptides were tested in two pools, containing 22 peptides with predicted restriction to HLA-A genes 
(pool22), and 27 peptides with predicted restriction to HLA-B genes (pool27). Furthermore, two 
assay formats were tested: 96-well plate format, establishment of cell lines and empirical rule to 
determine positive responses, and the 48-well plate format (batch stimulation), that allows for 
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statistical determination of well positivity and cell counting before seeding in the ELISpot plates, 
while still testing the same number of cells. 
 
 
Figure V. 15 IFN-γ ELISpot results for the MN03 experiment (96-well format), T cell amplification assay with total 
TCD8 cells from donor MPL9. A) Number of specific cell lines and IFN-γ ELISpot spot counts for 96-well plate format 
control conditions; B. all results per cell line, 7 seven lines per condition (1, 2.5 and 5µM peptide concentrations). 
  
 The addition of a third re-stimulation or different peptide concentrations did not improve 
results obtained with the 96-well format T cell amplification assay, and no specific cell lines were 
generated (Figure V.15 panel A). With this format, positive control CEF stimulation also yielded very 
low spot counts (16/8/11), when cells are responsive, since PHA-stimulation yielded high IFN-γ 
production (PHA_20k spot counts 784, 693, 715 in plate A, and 595, 589, 608 in plate B).  
 Background levels of culture-stimulated cells but unstimulated in the ELISpot wells (cNS) of 
all cell lines are less variable than in the previous experiment MN02, but spot counts of stimulated 
cells are very similar to background (Figure V.15 panel C). 
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Figure V. 16 IFN-γ ELISpot results for the MN03 experiment (48-well format), T cell amplification assay with total 
TCD8 cells from donor MPL9. A) IFN-γ ELISpot results for control conditions. B) Pool22 IFN-γ ELISpot results for all 
conditions tested: 1, 2.5 and 5µM peptide concentrations and 50.000 (50k), 100.00 (100k), or 150.000 (150k) TCD8 
cells per ELISpot well. C) Pool27 IFN-γ ELISpot results for all conditions tested: 1, 2.5 and 5µM peptide concentrations 
and 50.000 (50k), 100.00 (100k), or 150.000 (150k) TCD8 cells per ELISpot well. 
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 Likewise, in the 48-well batch stimulation format, no differences were found in IFN-γ 
productions were observed between unstimulated (cNS) and stimulated cells (STIM). Nevertheless, 
better results were obtained with the CEF peptide control pool (CEF_100k spot counts 72/72/62 in 
plate A, and 36/47/56 in plate B, large spots), and high IFN-γ responses PHA-stimulated wells 
(PHA_50k spot counts: TNTC) (Figure V.16 panel C). 
 
 The reference number of cells seeded in the ELISpot plate is 10% of the culture well, in 
accordance with the 96-well plate format assay (200.000 TCD8 per culture well and 20.000 TCD8 
seeded in the ELISpot well). To optimise response detection in the 48-well batch stimulation assay, 
we expect to use 100.000 TCD8 cells per ELISpot well (10% of 1 million TCD8 cells per culture well), 
but different cell numbers were tested – 50.000 TCD8 (50k), 100.000 TCD8 (100k), 150.000 TCD8 
(150k) per ELISpot well. Response specificity for all cell densities was assessed by including culture-
stimulated wells unstimulated in the ELISpot wells (cNS). 
 For some conditions, in the 48-well assay format, stimulated conditions had fewer spot counts 
than unstimulated cNS wells (Figure V.16 panels B and C). Also, there appears to be a dose-dependent 
effect between peptide concentration and decreased spot counts in stimulated wells, very noticeable 
at 5 µM per peptide (Figure V.15 panels B and C). This effect is probably not due to peptide toxicity 
since cell viability was assessed, but probably to peptide binding competition, as each pool contains 
a large number of peptides (22 and 27 peptides). 
 
 From this experiment, we realized that stimulation of monocyte-derived matured DCs is not 
optimal and should be further optimised. Even if class I peptides are 9-mer in length, apparently these 
were not successfully presented by MHC molecules and were unable to prime specific T cells in vitro 
under these conditions. Furthermore, the cells used in the MN01 experiment were highly immature 
and were successful for T cell activation and cell line generation.  Therefore, two different protocols 
for monocyte-derived DC stimulation were adopted: i) short peptide protocol, immature DC are 
matured (with LPS and Resiquimod/R848) for 16 hours, and then pulsed with peptides for 4 hours 
at 37°C/5% CO2; and ii) long peptide protocol, immature DC are matured (with LPS and 
Resiquimod/R848), and simultaneously pulsed with peptides for 16 hours at 37°C/5% CO2. 
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4.8. IFN-γ production by Leishmania-specific total TCD8+ cells was 
successfully induced and detected with adequate DC stimulation  
 
 In experiment MN04, total TCD8 cells from donor MPL10 were magnetically isolated and co-
cultured with mDC (short peptide protocol) or iDC (long peptide protocol).  
 Since we week to validate the proposed protocol for DC stimulation, only 12 peptides were 
used in one peptide pool, customised according to the naive donor’s HLA alleles, instead of testing all 
49 HLA-class I peptides. Naive donor MPL10 expresses the HLA-class I alleles HLA-A*03:01:01G, HLA-
A*02:05:01G, HLA-B*15:03:01G, HLA-B*07:02:01G, belonging to supertypes A3, A2, B27 and B7, 
respectively (Figure V.17). Accordingly, the peptide pool tested (poolGOOD) includes 3 peptides per 
supertype, each at a 2,5 µM concentration – peptides A3_1, A3_2, A3_3, A2_1, A2_2, A2_6, B27_2, 
B27_3, B27_5, B7_1, B7_2, B7_3 (Figure V.17). 
 
 
Figure V. 17 MPL10 HLA-typing for HLA-class I loci and peptides selected to compose the peptide pool. 
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Figure V. 18 IFN-γ ELISpot results for experiment MN04, T cell amplification assays with total TCD8 T cells from 
donor MPL10. A) TCD8+ amplified with the short peptide protocol (mDC stimulation). B) TCD8+ cells amplified with 
the long peptide protocol (iDC stimulation). C) ELISpot well images and respective spot counts for CEF and positive 
well. 
 
 Again, to confirm optimal cell density for the detection of the induced response after 
stimulation in the 48-well plates, different TCD8+ cell numbers were seeded in the ELISpot plate in 
duplicate wells, similarly to experiment MN03. For the same number of seeded cells (100.000 TCD8 
cells/well), iDC stimulation (long peptide protocol) with CEF control peptide pool yielded better 
results than mDC stimulation (short peptide protocol) – CEF 100k/iDC spot counts 60 and 83 and CEF 
100k/mDC spot counts 53 and 54 (Figure V.18). Background levels of cNS wells are low, maximum 
spot count of 10, but are proportional to cell density (Figure V.18). 
 In this experiment, stimulated cells with the short peptide protocol show low spot counts 
regardless of cell density, with a maximum of 13 spot counts (Figure V.18 panel A). On the contrary, 
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successful amplification and detection of specific TCD8 cells is observed when stimulated with pulsed 
iDC, (long peptide protocol) (Figure V.18 panel B).  The observed responses are highly specific, as cNS 
wells (culture-stimulated cells unstimulated in the ELISpot) show very low spot counts, meaning IFN-
γ-producing cells are primed through peptide-specific stimulus and become activated.  
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5. Discussion - Immunoscreenings with naive donor samples 
 
 The immunoassays with naive donor samples currently still present several challenges. The 
main limitation is the number of cells needed per condition, since specific cells are rare. These 
experiments are also extremely time-consuming (with over 20-day cultures), and resource-
consuming due to reagents’ costs. Also, in vitro cellular amplification occurs under non-physiological 
conditions, so analysis should be performed with care. Finally, a high number of individuals should 
be tested to assess the peptides’ overall immunogenicity in the naive repertoire. Specific approaches 
were adopted to mitigate some of these issues, namely: i) the generation of a naive donor bank and 
respective HLA-typing; and ii) the use of matrix-based peptide pools. 
 
 Peptide immunogenicity testing through immunoassays with samples from naive donors is 
rather innovative in the field of peptide-based vaccine development. Several laboratories, namely the 
Bernard Maillere Lab (CEA – Saclay), have developed techniques of in vitro cellular amplification that 
allow the analysis of specific T cell precursors in the naive repertoire (8–10,17,22–24). 
Immunogenicity testing is often focused on samples from exposed/healed individuals or animal 
models. We believe immunogenicity testing in the naive repertoire is essential to assess the 
prophylactic potential of peptide vaccine candidates, since there is a minimum threshold of specific 
naive T cells in circulation needed to generate specific effector and memory T cells. Also, the TCR-
specificity of responding naive T cells correlates with the specific memory T cells present in immune 
individuals. We propose to assess and compare the peptide immunogenicity profiles in the naive and 
memory repertoires to select immunogenic peptide candidates to use in a final vaccine formulation 
against leishmaniasis. Overall, this approach allows for the fast validation of peptide vaccine 
candidates with increased confidence in late-stage human in vivo immunogenicity and vaccine 
effectiveness.   
 
5.1. Naive donor bank 
 
 The generation of a naive donor bank and respective HLA-typing results allows the 
optimization of samples to use in the immunoscreening experiments. Donors can be selected 
according to HLA-typing results to maximise HLA coverage while testing a minimal number of 
individuals. 
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 The naive donor bank was generated with samples from the French Blood Bank in Toulouse. 
The HLA-typing results for HLA-A, -B, -DRB1, and -DPB1 alleles expressed by the naive donors match 
that of the French population. The HLA diversity represented in the naive donor bank also 
corresponds to the most common alleles expressed by populations in South and Central America, 
North Africa, Western Asia and South Asia. These regions include the populations most at risk of 
developing leishmaniasis and are the target populations for an anti-Leishmania vaccine. 
Unquestionably, the naive donor bank is an extremely small population compared with the 
populations considered for the allele frequency studies, but the most frequent alleles are nonetheless 
represented.  
 Ultimately, we aim at increasing the sample size of the naive donor bank and increase the 
number of represented alleles, particularly those which are currently underrepresented. However, 
the most prevalent HLA alleles in the world population, and particularly in populations in endemic 
leishmaniasis areas, already represented in the naive donor bank will provide a great HLA coverage 
for future experiments.  
 A peptide-based vaccine formulation that includes peptides restricted to nine HLA-class I 
alleles (HLA-A*02, -A*24, -A*68, -A*01, -A*03, -B*35, -B*44, -B*51, -B*07) will be effective in these 
world regions. Regarding HLA-class II alleles, although these are expected to be more promiscuous 
than class I peptides, peptides restricted to HLA-DRB1*03, -DRB1*04, -DRB1*07, -DRB1*08, -
DRB1*11, -DRB1*13, and -DRB1*15 should be included in the final vaccine formulation.  
 
5.2. Peptide immunogenicity testing with samples from naive donors 
 
 The naive T cell assay (experiment MN01) confirmed the presence of Leishmania-specific 
TCD8 cells in the naive repertoire, with 4 peptide pools generating at least 2 positive cell lines (in 10 
tested per condition, i.e. 2 million T CD8+ cells). This assay shall be repeated in the future, after pre-
selecting peptides, with fewer peptides further along the peptide validation pipeline and with some 
protocol changes (i.e. cell counting before ELISpot seeding, ELISpot triplicates and higher number of 
cell lines).  
 The protocol used in experiment MN01 was adapted from Wolfl et al, to a simplified version 
using total PBMC as APC. While the authors recommend the use of monocyte-derived dendritic cells, 
at the time of this experiment it was not possible to induce DC differentiation in vitro, and the use of 
autologous total PBMC as APC is commonly done as well (25). The B cells and monocytes present in 
this population are for the most part in an immature state. 
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 The donor MPL3 is homozygous for the HLA-A loci (HLA-A*23:01:01G alleles classified as A24 
supertype) and expresses HLA-B*44:03:01G (B44 supertype) and HLA-B*49:01:01G, an unclassified 
allele. Considering four double-positive immunogenic peptides that generated more than 2 specific 
cell lines, only one (A24_3) matches MPL3’s HLA typing results. Interestingly, the allele B*49:01 has 
ambiguous binding pocket specificities. This allele has a B pocket specificity matching to the B44 
supertype, and F pocket binding like the B*38:01 allele (hydrophobic), so it likely this allele shares 
binding specificities with other alleles in the B44 supertype, and perhaps even other supertypes.  
 
 Surprisingly, when the total TCD8 stimulation assay protocol was adopted, the use of mature 
DCs with the short peptide protocol no longer stimulated T cell proliferation and IFN-γ production.  
 The number of co-cultures performed (MN02: 2 co-cultures, MN03: 3 co-cultures), the peptide 
concentration (1, 2,5 or 5 µM), or the assay format do not seem to be as important as the DC 
stimulation protocol, since IFN-γ responses were not detected in both MN02 and MN03 experiments. 
Many factors may contribute to this and apparently these Leishmania-specific peptides, even if short 
(9-mer) may need intracellular processing. Furthermore, we estimate that, even for short peptides, 
optimal DC stimulation requires peptide processing and presentation with simultaneous DC 
maturation through TLR activation, due to peptides’ intrinsic weak immunogenicity. 
 In experiment MN04, when immature DCs were again used as APC, and stimulated during 16 
hours with both peptides and maturation factors, specific IFN-γ production was induced and 
detected. These results suggest APC’s immature state and the simultaneous peptide/TLR stimulation 
are key for proper peptide presentation and T cell activation.  
 During in vivo responses, immature DC uptake antigen in the periphery and migrate to the 
lymph nodes as mature cells where they prime responding T cells. Immature DCs are phagocytic and 
process and present exogenous antigens. TLR stimulation of immature DCs induces cell maturation 
process consisting of the upregulation of MHC and costimulatory molecules (CD40, CD80 and CD86) 
and migration to the lymph nodes. Mature DC become powerful APC, able to prime naive T cells and 
influence T-cell differentiation. TLRs are therefore a unique link between pathogen recognition and 
induction of T cell responses. The maturation conditions and stimulation by different pattern 
recognition receptors (PRR) influence DC’s costimulatory molecules and the ability to produce 
inflammatory cytokines, therefore impacting the observed T cell responses (26,27). 
 
 Notably, both immature and mature DC populations generated from donors MPL9 and MPL10 
include cells with intermediary phenotypes, not expressing any of the stained markers (CD14-CD209-
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CD83-). To describe these populations other markers should be included in the analysis. Also, some 
contaminant cells (probably non-adherent PBMC) and debris due to cell thawing prior to staining are 
observed (18 to 47% of total events). Nevertheless, the differentiation of monocytes into DCs is 
successful as CD14- cells correspond to over 98% of all cells.  
 For MPL9 over 40% of total CD14- cells are immature DCs (CD14-CD209+CD83-). The 
percentage of immature DCs after differentiation for MPL10 is much lower (18% of total CD14- cells). 
These results may result from a shorter differentiation time for monocytes from MPL10 (four-day 
stimulation instead of five). However, overnight maturation with LPS and Resiquimod greatly 
increased the number of mature DCs (from 2,3% to 28,6% of CD14-CD209+CD83+ cells). 
 
 The experiments MN02-04 used monocyte-derived DC as antigen-presenting cells. These 
were co-cultured with TCD8+ cells at a 1:10 ratio. Although no optimisation experiments were 
performed to improve this ratio, there is evidence that optimal APC:T-cell ratio can go up to 1:160, or 
be as low as 1:2, with lower ratios having potentially negative impact on T cell stimulation (28). The 
intermediary 1:10 ratio was adopted, same as in the total TCD4+ cell amplification protocol.  
 
 After experiment MN01, a total TCD8 amplification assay protocol was adopted due to the 
high number of conditions to test and to decrease the experiment-associated costs. Even though naive 
donors are expected to have never been exposed to leishmaniasis, there is an increased risk of 
triggering cross-reactive responses, potential cross-specific memory T cells in circulation against 
other pathogens or antigens. To assure no recall responses are being detected, short term total PBMC 
stimulation experiments will be performed with both TSLA and peptide pools to confirm, 
respectively, the naive donor status (TSLA-negative) and IFN-γ production by amplified specific naive 
T cells and not cross-specific memory cells. 
 
 Peptide concentrations in the peptide pools tested ranged from 1 to 5 μM. While the nature of 
the induced response to change remains unchanged regardless of the peptide concentration, a 
positive effect on T cell activation is expected in the range of 1-10 µg/mL of a 9-mer peptide (29). 
Nevertheless, the peptide pool composition may also influence the observed responses. Response 
specificity against a single peptide may be decreased if pools contain many peptides, and likewise, 
pool sensitivity may be increased if there are multiple positive peptides. On the other hand, peptide 
competition and low frequency responses may hinder response detection. We expect that the 
peptides tested present binding competition since they are all predicted to be strong binders. In 
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experiment MN03, peptide pools with over 20 peptides each were used and stimulated cells at 5 µM 
show decreased spot counts when compared with the other tested concentrations. Therefore, it is 
possible that increased peptide numbers and/or increased peptide concentration inhibit T cell 
activation, either through peptide competition or due to the absence of high avidity specific T cells. 
We believe peptide competition is higher in the tested peptide pools than expected for traditional 
epitope mapping experiments, where only a few immunogenic regions are found within a full protein, 
and many negative peptides are included in the peptide pools. The matrix-based pools contain 7 
peptides, and the poolGOOD used in MN04 contains 12 peptides at 2,5 µM each. Peptide pools 
containing up to 12 peptides at 2,5 µM do not seem to inhibit T cell activation, so this peptide 
concentration will be adopted for future experiments. 
 Peptide pools are an efficient and sensitive way to optimise epitope mapping experiments and 
even to detect low level responses while decreasing experiment-associated costs and sample size. The 
use of matrix-based pools provides additional advantages regarding the number of assays performed 
and cryovials needed (compared with single peptide testing or mini-pool peptide testing). However, 
some unclear results regarding double positive peptides argue for the need of a second ELISpot to 
confirm peptide specificity (two-stage matrix-based pool approach). 
 
 The CEF control peptide pool provides a good control for peptide processing and presentation 
to total TCD8+ cells. Although results were quite variable (from 16 spot counts up to TNTC), they 
were consistently positive and with large spots.  Evidently, the observed responses are mediated by 
memory T cells instead of naive T cells. While CEF-induced responses do not necessarily provide 
evidence for amplification of specific T cell populations through clonal expansion, they still provide 
evidence that antigen presentation mechanisms by peptide-pulsed APC are effective in priming 
specific T cells in vitro. True positive control peptides for the naive T cell repertoire should be 
included, however, universal control peptides for naive T cell stimulation do not exist. A few peptides 
were so far described to have specific naive T cells in the naive repertoire. The most studied are 
peptides from the Melan-A/MART-1 antigen (Melanoma-Associated Antigen) (30,31). Still, these are 
restricted to HLA-A*02 alleles and have an unusually high precursor frequency. We propose and 
expect to find the most immunogenic peptides with specific naive T cells through the optimisation of 
T cell amplification assays, which have been shown to be effective in detecting specific T cells in the 
naive repertoire. 
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 In experiment MN04, which used the long peptide stimulation and a tailored peptide pool 
containing 12 peptides (2,5 µM each), we successfully amplified and detected Leishmania-specific T 
cells from the naive repertoire. Only one culture well was positive (1 million TCD8 cells seeded) 
among two stimulated wells (2 million TCD8 cells tested), as expected for low frequency specific cells. 
 The 48-well batch stimulation assay format allows for the successful amplification of specific 
T cells present in the naive repertoire, as well as practical advantages that permit cell counting, 
ELISpot well triplicates, and therefore the application of statistical tests for well positivity 
determination. Although, in this experiment, only two wells per condition were seeded in the ELISpot 
plate due to the optimisation of peptide concentration and cell density.   
 We aim to use the 48-well batch stimulation assay with a higher number of donor samples 
(n=10) to screen the synthetic peptides and select the most immunogenic ones. Possibly, the number 
of total TCD8 cells tested per condition can be increased (3 or 4 million total TCD8 per condition). 
 However, the 48-well batch stimulation assay format eliminates the application of the Poisson 
distribution formula for the calculation of the specific T cell precursor frequency. Hence, we propose 
to use the batch stimulation assays to pre-select the (most) immunogenic peptides and, subsequently, 
to perform precursor frequency analysis experiments with a fewer number of pre-validated 
immunogenic peptides, and possibly bypassing polyclonal activation with peptide pools but 
performing co-cultures with DC pulsed with single peptides.  
 
 Because naive T cell amplification assays were performed in a limited number of individuals 
with all peptides, comparison is very limited. However, MN01 and MN04 clearly evidence the 
existence of a minimum number of naive T cells specific to Leishmania peptides in naive donors, 
hence, validating their predicted immunogenicity and the feasibility of using such peptides in an 
effective vaccine formulation. The naive donor bank, which will be augmented with additional naive 
donor samples, and the in vitro stimulation protocol, which is now optimised, will allow to screen all 
peptides and select the most immunogenic by serial routine experiments. 
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6. Results - Immunoscreenings in healed individuals from endemic areas 
(Tunisia) 
 
 The first peptide immunoscreenings performed with healed donors’ samples tested all 49 
class I peptides and 24 HLA-class I peptides in matrix-based pools, using a short term total PBMC 
stimulation protocol. 
 Two series of blood samples were received, both including 10 samples from healed donors – 
first series TUN1 to TUN10, and second series TUN11 to TUN20. In the first series (TUN1 to 10), one 
blood sample was hemolysed (TUN2) so no PBMC were purified. IFN-γ ELISpot was performed for 
both series and culture supernatants were collected and stored at -80°C. The series of blood samples 
with naive donors was performed in the Institut Pasteur Tunis, no IFN-γ ELISpot was performed for 
these samples. 
 Peptide immunogenicity or the capacity to prime in vitro specific recall responses was 
successfully assessed for 9 healed donors (see Appendix V.2 for individual data).  
 
6.1. Healed donors’ personal information and HLA-typing results 
  
 The average age for the first healed donor series was 43 years-old, ranging from 26 to 64 
years-old (Table V.7). Male healed donors are much more frequent than female donors in this series, 
with only one woman in nine donors (TUN4). The presence of CL lesions was inquired in the medical 
questionnaire. On average, healed donors in the first series presented 2 cutaneous lesions, between 
one up to five lesions per donor. Most cutaneous lesions were localised to the legs or arms, only a few 
CL lesions were localised in the face (two donors, 11%) (Table V.7). 
 HLA-typing results for the first healed donor series was performed (Table V.8) 
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Table V. 7 Personal information and medical history from recruited healed donors (TUN1-TUN20). 
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Table V.7 (continued) 
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Table V. 8 HLA-typing results for the first healed donor series (TUN1-TUN3 to TUN10). A) Six loci corresponding to HLA-class I and class II polymorphic regions (HLA-
A, -B, -C, -DRB1, -DPB1, -DQB1) were sequenced by NGS (exons 2 and 3), leading to the 6-digit identification of the alleles expressed by each donor. Allele supertype 
classification by Sidney et al 2008 (20). B) Ambiguous identifications are given a multiple allele code (MAC, https://hml.nmdp.org/MacUI/) 
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 The HLA-typing results for the healed donors, although the sample size is quite small, mostly 
match the most frequent alleles in the Tunisian population (Figure V.19 and V.20). The HLA-class I 
alleles HLA-A*02 are the most frequent. HLA-A*24 alleles, although very frequent in the Tunisian 
population, were not represented in the healed donor series. On the other hand, other alleles such as 
HLA-B*44, -B*35 and -A*01 were more frequent in the healed donor series (Figure V.19).  
 
 
Figure V. 19 HLA class I allele frequency in the Tunisian populations and in the healed donor series. Allele 
frequency for HLA-A and -B alleles (allele / 2n). 
 
 The HLA-class II allele HLA-DPB1*04 is the most frequent in the Tunisian populations yet 
poorly represented in the healed donor series (Figure V.20). On the other hand, the second most 
frequent allele HLA-DRB1*07 is also well represented. Other alleles such as HLA-DPB1*03, -DPB1*06, 
-DRB1*11 and -DRB1*03 were more frequent in the healed donor series (Figure V.20). 
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Figure V. 20 HLA class II allele frequency in the Tunisian populations and in the healed donor series. Allele 
frequency for HLA-DRB1 and -DPB1 alleles (allele / 2n). 
 
6.2. Healed status validated by positive responses against TSLA  
 
 As expected, most donors show positive TSLA reactivity, defined by IFN-γ production by 
ELISpot (Figure V.19). Four donors (TUN3, TUN4, TUN5 and TUN10) have significantly higher IFN-γ 
responses against TSLA (TSLA-positive donors). Donor TUN7 has almost statistically significant 
differences (p-value=0,0571). Statistical significance was impossible to determine for donor TUN6 
because only two ELISpot wells can be analysed due to an error during seeding (CaniLeish®-
stimulated cells were stimulated with TSLA), but 192,5 spot count average is considerably higher than 
autologous NS spot counts (28,83 ±22,07). Two other donors (TUN9, TUN10) were considered TSLA-
positive since ELISpot results show IFN-γ production during culture stimulation, evidenced by dark, 
highly saturated wells, even though spot counts are low or innumerable. In addition to TSLA, 
CaniLeish® was also used as positive control. Interestingly, CaniLeish® antigens induced vigorous 
IFN-γ responses in >75% of individuals (7 in 9 donors). Moreover, donors TUN1, TUN7, TUN8 and 
TUN9 had significantly higher responses against CaniLeish® but not TSLA (Figure V.21).  
 IFN-γ ELISpot results show donors have quite different background levels, from an average 
NS spot count of 14,5 (TUN7) up to an average spot count of 161,5 (TUN1) (Figure V.21). 
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Figure V. 21 IFN-γ ELISpot results for controls for 1st healed series (n=9). A) Spot counts for NS (never stimulated 
PBMC), for positive controls PHA, TSLA and CaniLeish®, and pools ALL_I (49 class I peptides), ALL_II (24 class II 
peptides) and ALL_I+II (all 73 Leishmania-specific peptides). B) Table with averaged spot counts for all controls (* 
significantly different from autologous NS with the Mann-Whitney statistical test, p-value ≤ 0.05). 
  
6.3. IFN-γ responses against Leishmania-specific peptides 
 
 To evaluate recall responses against Leishmania-specific peptides, total PBMC were 
stimulated in vitro in the absence or presence of peptide pools containing HLA-class I or -class II 
peptides. Positive IFN-γ responses were induced by multiple peptide pools and by most donors – 
seven responder donors for HLA-class I peptide pools, and nine responder donors for HLA-class II 
peptide pools (Figure V.22). The number of responders and the number of peptide-specific responses 
induced for each donor were different according to the peptide pool (Figure V.22).  
 Overall, all HLA-class II pools induced IFN-γ production in at least one individual (II_pool5 
and B), up to 7 individuals (II_pool4) (Figure V.22 panel B). On the other hand, three HLA-class I 
peptide pools did not elicit IFN-γ production in any of individuals tested (I_pool4, A and C), and the 
remaining 11 pools induced IFN-γ production in at least one donor (I_pool3 and 7), up to 4 donors 
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(I_pool1 and E) (Figure V.22 panel A). Individualised ELISpot results are included in Appendix V.2 
(donors TUN1, TUN3-10). 
 For HLA-class II peptide pools, two donors had only one positive peptide pool so single 
immunogenic peptides were not identified (TUN1, II_poolE and TUN6, II_pool1). Likewise, for HLA-
class I peptide pools, TUN6 had only one positive peptide pool (I_poolE) (Figure V.22). Results 
regarding classI peptide pools  I_pool5 and I_pool6 are inconclusive for donor TUN7 since results are 
not available (no revelation antibody added to row C during ELISpot revelation). 
  
 
Figure V. 22 Responder frequency per peptide pool for the 1st healed series (n=9). Number of responders, 
individuals with significantly increased IFN-γ production (responders) per peptide pool. A) Responder donors to class I 
peptide pools. B) Responder donors to class II peptide pools.  
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 TSLA-positive donor TUN3 showed positive IFN-γ responses against HLA-class II peptide 
pools only, but against a high number of pools (7 out of 10: II_pool1, 2, 3, 4, II_poolA, C, and D) (Figure 
V.23 panel A). Twelve double-positive HLA-class II peptides were identified (14_b12, 16_b13, 3_a11, 
22_b4, 7_a14, 12_a32, 21_b4, 17_b15, 4_a11, 5_a12, 9_a25, 13_b12). These peptides are predicted to 
be very promiscuous and bind to  four up to eleven HLA-class II alleles. 
 For TSLA-positive donor TUN4, HLA-class I peptide pools did not induce significantly higher 
responses, but two positive HLA-class II pools did (II_pool4 and D). One double-positive immunogenic 
class II peptide was identified (pii19/13_b12) (Figure V.23 panel B). The 13_b12 peptide is predicted 
to be highly promiscuous, predicted to bind to seven class II alleles: HLA-DPA1*01:03-DPB1*02:01, -
DPA1*01:03-DPB1*04:01, -DPA1*02:01-DPB1*01:01, -DPA1*03:01-DPB1*04:02, -DPA1*03:01-
DPB1*04:02, -DRB1*07:01, -DRB1*09:01, and -DRB1*13:02. These include  alleles expressed by 
TUN4 namely, HLA-DRB1*07:01 and -DPB1*01:01 (Table V.8).  
 TSLA-positive donor TUN5 had positive IFN-γ responses against four HLA-class I pools 
(I_pool2, 7, E, F) and three HLA-class II pools (II_pool4, A, C) (Figure V.23 panel C). The double-
positive HLA-class I immunogenic peptides B62_2, B8_4, B44_1 and B44_4 were identified. Yet, the 
donor TUN5 expresses HLA alleles which belong to A26 (A*26:01:01G), A03 (A*34:02:01), B07 
(B*07:02:01G), and B08 (B*08:01:01G) supertypes, meaning only one in four positive peptides match 
the donors's HLA typing (B8_4).Additionally, the double-positive immunogenic HLA-class II peptides 
22_b4 and 17_b15 were identified in donor TUN5. Peptide 22_b4 is predicted to be promiscuous and 
bind to five class II alleles (HLA-DPA1*01:03-DPB1*02:01, -DPA1*01:03-DPB1*04:01, -DPA1*02:01-
DPB1*01:01, -DPA1*03:01-DPB1*04:02, -DRB1*09:01). Peptide 17_b15 is predicted to be 
promiscuous and bind to seven class II alleles (HLA-DRB1*01:01, -DRB1*03:01, -DRB1*07:01, -
DRB1*09:01, -DRB1*11:01, -DRB3*01:01, -DRB5*01:01, -DRB5*01:01). Some of these allele 
specificities match donor TUN5 typing results for HLA-class II loci -DRB1 and -DPB1, namely HLA-
DRB1*03:01, -DPB1*04:01, and -DPB1*01:01 alleles (Table V.8).  
 TSLA-positive donor TUN10 responded to seven positive HLA-class I pools (I_pool1, 2, 5, 6, B, 
D, G) and five positive HLA-class II pools (II_pool1, 4, 5, A, D) (Figure V.23 panel D). The double-
positive immunogenic class I peptides identified were A1_1, A1_4, A3_2, A24_3, B7_3, B7_4, B8_3, 
B27_1, B44_5, B58_3, B58_4, B58_5. Given donor TUN10’s HLA typing results, 5 in 16 peptides match 
the donor’s HLA allele typing (B7_3, B7_4, B7_5, B44_5, A2_4) (Table V.8). The double-positive 
immunogenic HLA-class II peptides identified in donor TUN10 were 14_b12, 22_b4, 18_b15, 4_a11, 
13_b12, 10_a25. Again, all these peptides are predicted to be very promiscuous and bind to five up 
to eleven class II alleles. 
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Figure V. 23 IFN-γ ELISpot results for TSLA-positive donors TUN3 (A), TUN4 (B), TUN5 (C), and TUN10 (D). 
Highlighted pools (*) induced significantly higher IFN-γ production when compared with autologous NS (Mann-Whitney 
test, p-value < 0.5). 
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Figure V.23 (continued) 
 
 Donor TUN7 is also highly responsive. This donor shows the lowest background values out of 
all the donors which may influence the observed results. Positive responses may be overestimated 
since this donor also shows the weakest responses to TSLA and CaniLeish®. Nevertheless, from the 
positive HLA-class I pools and from the 8 immunogenic peptides identified (A1_1; A3_3; A24_1; A3_1; 
A2_4; B7_2; B58_5 and B8_1), three peptides correspond to the donor’s HLA-typing results who 
expresses HLA-class I alleles which belong to the A01 (A*32:02:01G), A01A24 (A*29:01:01G), B07 
(B*35:03:01G) and B44 (B*44:03:01G) supertypes – peptides A1_1, A24_1 and B7_2 (Table V.8) .  
 As expected, individuals with lower background correspond to higher magnitude of response, 
with TUN7 and TUN10 presenting the strongest IFN-γ responses (Figure V.24). Overall, HLA-class II 
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peptide pools induced stronger responses, with response magnitude ranging from 2-fold up to almost 
24-fold higher responses by peptide stimulated cells (Figure V.24). 
 
 
Figure V. 24 Magnitude of response against matrix-based peptide pools for all healed donors. Fold-change 
differences in IFN-γ production after peptide stimulation. A) Pools containing HLA-class I peptides. B) Pools 
containing HLA-class II peptides. 
  
 Cross-matching the matrix-based peptide pools with positive results for all donors, a total of 
25 HLA-class I and 14 HLA-class II peptides were identified as double-positive immunogenic peptides 
(Figure V.25). Although donors expressed different HLA-DR and -DQ molecules, the immunoprevalent 
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HLA-class II-restricted peptide pii19 (13_b12) was immunogenic for 6 donors, becoming 
undoubtedly the most promising peptide candidate so far (Figure V.25 panel B). HLA-class II peptides 
pii4 (22_b4) and pii16 (4_a11) were immunogenic for 3 donors. Two HLA-class II peptides 
(pii14/17_b15 and pii1/14_b12) and seven HLA-class I peptides (pi8/B27_1, pi12/B58_4, 
pi22/A1_1, pi29/A24_1, pi36/A2_4, pi37/b4_B8, pi43/B58_5) were immunogenic for two donors. 
The remaining nine double-positive HLA-class II peptides and eighteen HLA-class I peptides were 
immunogenic only for one donor (Figure V.25). 
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Figure V. 25 Double-positive immunogenic peptides (peptides present in two positive matrix-based pools). A) 
25 class I immunogenic peptides identified in 6 healed donors. B) 14 class II immunogenic peptides identified in 7 
healed donors. C) Selected class I and class II peptides per protein antigen and peptides found to be immunogenic in 
samples from healed donors.  
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 Only a fraction of observed responses is specific to HLA-class I-restricted epitopes, as most of 
the reactions were induced by peptides not necessarily predicted to bind to the donors’ HLA alleles. 
From the seven donors with positive responses to HLA-class I pools, only for TUN3 (1 in 4 peptides), 
TUN7 (3 in 8 peptides), and for TUN10 (5 in 16 peptides) correspond to the donor’s HLA-typing. The 
other immunogenic HLA-class I peptides do not match the donors’ allele specificity, and yet are not 
expected to be promiscuous. This observation agrees with the presence of unpredicted epitope 
promiscuity, the ability of peptides to bind to two or more different HLA alleles.  
 
 The analysis of cytokine production in response to Leishmania-specific peptides will help not 
only confirm, but also better characterise the immune responses and cellular functional activity 
induced by the peptide pools. Cytokine analysis of culture supernatants will be performed by 
Cytokine-Bead assays (CBA) for healed donors and the naive control donors, for which no results 
were presented here.  
 
  
 
  
CHAPTER V – EXPERIMENTAL VALIDATION OF SYNTHETIC PEPTIDES 
238 
 
7. Discussion - Assays with Healed donor samples 
 
 Healed LCL donors, patients who developed active CL and either self-cured or received 
chemotherapy, generally possess strong and specific immune responses to Leishmania parasites and 
resistance to reinfection or relapse. In Tunisia, there are endemic areas for CL-causing L. major and L. 
tropica transmission. Historically, the Gafsa region was always an endemic area for CL, with typically 
sporadic and occasionally epidemic transmission (32). The Gafsa region in Tunisia is estimated to 
include a population of almost 324000 people, of which almost 147000 are at risk of developing 
leishmaniasis (33). Although parasitological confirmation was not performed for all donors, we 
expect L. major to be the species responsible for the primary infection. 
  
 The ELISpot results for the first series of healed donors are available (n=9) and presented 
here. The conclusion of the CBA analysis of these samples will allow the definite confirmation of the 
ELISpot responses and identified immunogenic epitopes, and more importantly, characterise in more 
detail the induced immune response by including a complete Th1/Th2/Th17 cytokine panel. The 
assessment of the production of the immunoregulatory cytokine IL-10 will be particularly 
informative. It has been described that Tunisian LST-positive individuals produce IL-10, also, IL-10 
mRNA is detected in CL lesions caused by L. major. These observations further support the analysis 
of balanced Th1/Th2 responses in individuals with protective immune responses against Leishmania. 
 The second series of samples yielded no ELISpot results (data not shown), with few and faint 
spots in the control wells indicating very low cell viability before seeding in the ELISpot plates, 
although ELISpot revelation was successful after 20-minute incubation with substrate solution. These 
results are probably due to the change, at culture day 5, from commercial human AB serum to 
homemade serum. This change probably caused cell death, and cells were mostly unviable when 
seeded in the ELISpot plate. Still, the CBA analysis on the culture supernatants will still be performed 
to confirm this hypothesis. 
 
 The first immunoscreening assays performed with healed donor samples successfully 
identified IFN-γ responses specific to Leishmania peptides and have led to the identification of 25 
HLA-class I and 14 HLA-class II immunogenic peptides. Overall, HLA-class II peptides appear to be 
more immunogenic as they induced higher IFN-γ production and in more individuals. An ‘ELISA’ effect 
in the ELISpot plates is observed at times – a dark background and high well saturation due to leftover 
IFN-γ from the culture wells. Yet, the AID reader successfully read and count all plates (Appendix V.2). 
CHAPTER V – EXPERIMENTAL VALIDATION OF SYNTHETIC PEPTIDES 
239 
 
 Four donors had significantly higher IFN-γ production after TSLA stimulation (TUN3, TUN4, 
TUN5, TUN10). Some individuals (n=5) did not have significantly increased responses after TSLA 
stimulation by ELISpot. However, for two of these donors (TUN9, TUN10), although spot count may 
be low or innumerable, an ‘ELISA’ effect is observed, where secreted IFN-γ diffuses into the 
supernatant and is absorbed on the ELISpot plate membrane producing a color carpet. This effect was 
observed probably because cells were not washed before seeding the ELISpot plate (plate centrifuge 
unavailable in the laboratory), a simple media change was performed.  These individuals were 
considered as TSLA-positive since there is evidence of IFN-γ production during culture stimulation. 
Donor TUN1, who appears to not respond to TSLA stimulation, however, responds strongly to 
CaniLeish®. Curiously, the four TSLA-positive donors received different treatment regimens 
(respectively, cryotherapy plus antibiotherapy, arab traditional treatment, 15-day hospitalization 
with administration of intramuscular Glucantime® 60mg/Kg, or cryotherapy only). The time since 
diagnosis also differed greatly between donors (6 donors with date of parasitological confirmation), 
ranging from 1 to 12 years, and of 10 years for TUN4 and 2 years for TUN5. There appears to be no 
correlation with type of treatment or healing time and development of TSLA-specific immune 
responses in this healed donor sample series.  
 
 Two individuals did not respond to any HLA-class I peptide pool, and although there are 
peptides specific to all possible alleles present in the tested individuals. This may due to reduced 
peptide stability which prevents peptide processing or presentation and T cell activation, as class I 
peptides were solubilized in water. Peptide stability assays will be performed with pre-selected 
peptides. 
 
 Only one peptide concentration was tested for total PBMC stimulation in these experiments. 
A possible inhibitory effect on induced IFN-γ responses is observed when peptide pools contain 24 
or 49 peptides (peptide pools ALL_I, ALL_II, and ALL_I+II). The 5 µM concentration per peptide in 
these pools may inhibit T cell responses or induce apoptosis or anergy. This effect may also be due to 
a high dilution of culture medium, since stock peptide solutions were at 200 mM, depriving the cells 
from essential nutrients. For this reason, new peptide stocks were prepared at 500 mM concentration. 
 
 To establish if the peptide pools significantly increased IFN-γ production in total PBMCs from 
healed donors, the Mann-Whitney non-parametric statistical test compared the triplicate STIM wells 
and the 6 autologous NS wells. A high variability in the ELISpot background is observed, as well as 
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some discrepancies in the ELISpot triplicates, possibly because red blood cell (RBC) lysis was not 
performed before seeding (reagents unavailable in the laboratory), and the number of contaminant 
RBC can affect successful T cell activation in a given well. Furthermore, dividing each culture well in 
two ELISpot seeding wells, may affect the minimum number of 100.000 PBMC per well resulting in 
failure to detect the specific T cells. Cell viability was also not assessed prior to ELISpot seeding, 
however, PHA responses were extremely high indicating the cells were viable and responsive. 
 The unstimulated ELISpot wells containing cells that were stimulated in the culture (cNS) 
have often an intermediary spot count value between the individuals’ NS and the STIM wells. This 
may be because in a stimulated culture well there are cells in different activation stages, especially 
since culture is supplemented with rhIL-2, and some cells are still producing IFN-γ from the culture 
stimulation. In future experiments, cells should rested for at least 3 days after the last media change, 
washed and checked for viability before seeding in the ELISpot plate, and a minimum number of 
200.000 PBMC seeded per well.  
 
 There does not seem to be a clear correlation between in silico-predicted HLA-class I 
restriction and individuals’ HLA typing. There is increasing evidence of extensive promiscuity in HLA-
class I antigen presentation which the in silico HLA-binding prediction algorithms do not account for 
(34,35). It is possible that in silico HLA-binding algorithms can predict immunogenic epitopes from 
antigen sequence data but perform less well in predicting HLA-restriction for promiscuous peptides. 
This argues for the selection of epitopes predicted to be promiscuous by the immunoinformatic tools 
available but, likewise, to expect unpredicted peptide HLA restriction.  
 There is, however, a good overlap regarding the most frequent alleles between the Tunisian 
population and the healed donors. Furthermore, if we consider the HLA coverage of the 25 
immunogenic HLA-class I peptides, the most frequent alleles in the Tunisian and world population 
are covered (A*01, A*02, A*03, A*24, B*07, B*08, B*44), although only one peptide is restricted to 
A*02 alleles. 
 The cellular source of IFN-γ production was not assessed. TCD4+ cells are the most common 
origin for IFN-γ production in response to TSLA, and probably to HLA-class II peptide pools, but this 
remains to be confirmed. 
 
 Finally, positive immune responses are observed against several Leishmania-specific peptide 
pools, as PBMC from healed donors produced IFN-γ in response to in vitro stimulation. Also, it is the 
first time IFN-γ responses from human PBMC after CaniLeish® stimulation are observed. This 
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preliminary observation needs further characterisation. As expected from the dog immune responses 
and observed here through in vitro human PBMC stimulation, the Leishmania promastigote secretome 
contains promising vaccine antigen candidates, which are also immunogenic in humans and 
associated with memory responses. 
 
8. Conclusions 
 
 T cell activation in vitro occurs under non-physiological conditions, and factors influencing T 
cell activation should be controlled whenever possible, namely antigen-presentation, peptide dose, 
and stimulation conditions. Nevertheless, in vitro assays with human immune cells are still more 
conclusive on peptide immunogenicity than animal models. Cell-based immunoscreening assays to 
assess peptide immunogenicity in vitro are suitable and informative because they recreate the T cell 
responses induced after in vivo peptide administration, and allow the analysis of T cell populations 
involved. Furthermore, immunoscreening assays can be performed with cells from human donors of 
different immune status regarding leishmaniasis, allowing the evaluation of both correlations with 
protective responses and prophylactic potential of the peptide candidates. We expect to find peptides 
that are associated with protective T cell responses against Leishmania present in healed patients, as 
well as to find corresponding peptide-specific T cell precursors in the naive repertoire.  
 Although immunoscreenings in the naive repertoire were mostly optimisation experiments 
and only a few individuals were tested, preliminary evidence exists for peptides which are 
immunogenic in both immune backgrounds. Notably, the four double positive peptides identified in 
experiment MN01 from pool stimulations with more than one positive cell line (B7_3, A24_3, B8_3 
and B58_3) were immunogenic in one healed donor sample (TUN10). The peptide B7_3 is also 
included in the poolGOOD (experiment MN04) which induced specific IFN-γ production by T cells 
from the naive repertoire (Table V.9).  
 
 Other peptides included in the poolGOOD induced both one positive naive T cell line 
(experiment MN01) and higher IFN-γ responses in healed donors: peptides A3_1, A3_3, B7_2 were 
immunogenic in donor TUN7, and the peptide A3_2 was immunogenic in donor TUN10. The peptide 
A2_1, which induced one positive naive T cell line (experiment MN01) was included in the poolGOOD 
(Table V.9). 
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 Some of the peptides which induced one positive cell line in experiment MN01 were also 
immunogenic in healed donor samples. Namely, the peptide B8_1 was immunogenic in donor TUN7, 
also the peptides A3_2 and B7_4 were immunogenic for donor TUN10. The double-positive peptide 
B8_4 identified in experiment MN01 (one positive cell line) induced significant IFN-γ responses in 
TSLA-positive donors TUN5 and TUN10. Similarly, peptide B62_2 which induced one positive cell line 
in experiment MN01 was also identified in TSLA-positive donor TUN5 (Table V.9). 
 Some double-positive peptides inducing one positive T cell line in experiment MN01 did not 
induce significantly higher responses in healed donors (peptides A2_1, A2_2, A2_3, A2_5, B27_3, 
A26_1). Still, peptides B27_2, A2_1, and A2_2 were included in the poolGOOD that induced positive 
IFN-γ responses in naive donor MPL10 (Table V.9).  
 
Table V. 9 Double-positive immunogenic peptides identified in the naive and memory repertoires. 
HLA-class I peptides 
Positive results 
in the naive repertoire 
Positive results 
in the memory repertoire 
A24_3, B8_3, B58_3 MN01 (2 positive cell lines) 1 healed donor (TUN7 or TUN10) 
B7_3 
MN01 (2 positive cell lines) 
+ MN04 (poolGOOD) 
1 healed donor  (TUN10) 
A3_2 
MN01 (1 positive cell line) 
+ MN04 (poolGOOD) 
1 healed donor  (TUN10) 
A3_1, A3_3, B7_2 MN04 (poolGOOD) 1 healed donor (TUN7 or TUN10) 
B8_4 MN01 (1 positive cell line) 2 healed donors (TUN5 and TUN10) 
B8_1, B7_4, and B62_2 MN01 (1 positive cell line) 
1 healed donor (TUN7, TUN10 or 
TUN5, respectively) 
B27_2, A2_1, and A2_2 
MN01 (1 positive cell line) 
+ poolGOOD 
-  
B27_1, B58_4, A1_1, 
A24_1, A2_4, B58_5 
-  
2 healed donors (TUN1, TUN5, 
TUN7, TUN9, or TUN10) 
 
 Assays were not yet performed with TCD4+ cells from the naive repertoire, so no conclusion 
can be made on corresponding patterns for HLA-class II peptides. However, more healed individuals 
responded to the HLA-class II peptides, and 14 immunogenic HLA-class II peptides were identified. 
Some immunoprevalent peptides were identified which induced higher IFN-γ responses in over half 
the individuals tested (peptide 13_b12), and in three donors (22_b4 and 4_a11). Remarkably, two of 
these peptides come from new protein antigen candidates discovered through the reverse 
vaccinology approach. Due to intellectual property issues, peptide sequences and antigen names must 
remain confidential and cannot be divulged. 
  Overall, twelve HLA-class I 9-mer peptides (A24_3, A3_1, A3_2, A3_3, B58_3, B62_2, B7_2, 
B7_3, B7_4, B8_1, B8_3, B8_4) and five HLA-class II 15-mer peptides (13_b12; 22_b4; 17_b15; 4_a11; 
14_b12) are, for now, the most promising candidates to advance for the multi-epitope peptide design. 
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 We aim to re-test all the synthetic peptides in more immunoscreenings with samples from 
both naive and healed donors. Possibly, re-test the matrix-based pools and these pre-selected 
peptides, with some small protocol improvements. Also, we seek to include healed donors from more 
endemic areas, namely L. braziliensis, L. infantum and L. donovani endemic areas. 
 
 The present results provide evidence that the proposed peptide-based vaccine development 
pipeline, from the in silico epitope selection to the immunoscreenings exclusively in human samples, 
swiftly delivered some potentially interesting vaccine candidates.  
 
 Although still presenting some limitations, experimental validation with human samples from 
naive and healed individuals is conclusive regarding future in vivo immunogenicity of vaccine 
candidates, and it may accelerate clinical trial testing while preventing late-stage failure. This 
approach particularly benefits vaccine research against leishmaniases, since experience shows a 
development gap between promising vaccine candidates tested in animal challenge experiments and 
de facto candidate immunogenicity in humans living in endemic areas,  
 This evaluation model for preclinical development of peptide-based vaccines, especially in the 
context of NTDs, provides a powerful approach to fast-track the development and deployment of 
effective tools that will assist leishmaniasis control and improve Public Health programmes in 
affected areas. 
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The development of new or more effective tools for leishmaniasis control is challenging 
and is often not a priority for standard product development pipelines, as the market does not 
allow the recovery of development costs, similarly to other NTDs. Furthermore, leishmaniasis is 
associated with poverty, which implies that costs are determinant for the feasibility of any tool or 
product (diagnosis, treatment, prevention). Also, when new products are available, these will 
likely need government and/or philanthropic subsidisation, and access in endemic areas must be 
facilitated. 
Nevertheless, improving NTD control, including vaccine development against 
leishmaniasis, is part of the Millennium Development Goal 3, a United Nations initiative (target 
3.3: by 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and 
combat hepatitis, water-borne diseases and other communicable diseases), and has received 
increasing focus and resources by pharmaceutical companies and other stake-holders. 
Furthermore, peptide-based vaccines and therapeutics are a promising way of reducing 
production costs, rather than other expensive biologicals (purified recombinant proteins or 
antibodies). Additionally, peptide-based products do not need cold chain transport conditions, 
posing a great advantage particularly for low-resource settings. 
 
1. A vaccine as the most promising tool for leishmaniasis control 
 
The vaccine development pipeline proposed in this project helps mitigate some of the 
bottlenecks associated with product development for NTDs (Figure VI.1). Briefly, the exploitation 
of large proteomic datasets, comprising the most important pathogenic Leishmania species, 
allowed the selection of 52 relevant vaccine antigens from the Leishmania secretome, a known 
immunogenic antigen pool. Moreover, this screening approach was coupled to an HLA-based in 
silico epitope prediction and selection workflow leading to the synthesis of over 70 promising 
short peptide vaccine candidates. Then, these peptide candidates were tested exclusively in 
human samples, a key aspect that ensures peptide immunogenicity in human hosts and vaccine 
population coverage. Experimental validation with samples from both healed individuals from 
endemic areas and naive individuals is extremely important to effectively assess the vaccine 
candidate’s feasibility (Figure VI.1). 
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Figure VI. 1 Summary of major project outcomes. 
  
Most studies assessing Leishmania-specific peptide immunogenicity performed so far (see 
Chapter I) compromise on either the number of antigens tested or the number of alleles 
considered, when HLA restriction is analysed. Our selected approach eliminates a priori 
assumptions, considering the full antigenic repertoire of the parasite’s secretome and taking into 
account the vast HLA variability of the human host. The overall approach is decisive for the 
development of a pan-specific vaccine against multiple Leishmania species, and targeting multiple 
human populations. 
In a more general view, vaccine development against Leishmania is like playing card 
without a complete deck. Information on correlates of protection is lacking, and many studies 
performed with animal models may skew our understanding of human-specific immunity 
mechanisms. The basic knowledge of Leishmania-specific immunity is quite limited, particularly 
if we compare with other protozoan parasites such as Plasmodium. Studies like the present that 
focus exclusively in human immunity and propose reproducible strategies for Leishmania vaccine 
development and peptide immunogenicity testing will greatly benefit the field. 
Ultimately, the discovery of immunogenic epitopes in the Leishmania secretome 
associated with protective immune responses will fast-track the development of a peptide-based 
vaccine, which targets the main pathogenic Leishmania species and with worldwide HLA coverage 
(Figure VI.1). 
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2. Interest and limitations of using proteomics in a vaccine development 
pipeline 
  
Proteomics is the most suitable tool for the analysis of Leishmania antigens as these 
parasites regulate gene expression mostly at the post-translational level, even if databases still 
need further improvement.  
It is important to note that new protein annotations in the UniProtKB Database changed 
the proteomic analysis results due to a database update. The same raw data were used and the 
same bioinformatic analysis was performed, but the database was updated between June 2016 
(analysis used for antigen selection, Chapter III) and March 2017 (analysis used for the proteomic 
analysis, Chapter II). The database annotation updates increased the number of species-specific 
proteins, as a higher number of unique proteins are identified. This affects protein identification 
and the number of common accessions among species. Briefly, if the Reverse Vaccinology 
approach for antigen discovery would be applied to the datasets generated with the new analysis 
(March 2017), only 326 accessions would be included, instead of 618. After BLASTp against the 
human proteome, only 33 common accessions are identified as non-homologous to human 
proteins. This corresponds to a loss of selected protein antigens (33 accessions/11 proteins) from 
the initial 24 protein antigens (76 accessions). Overall, 9 in 50 selected HLA-class I epitopes, and 
7 in 24 selected HLA-class II epitopes are no longer identified. These peptides were already 
synthesised when the new analysis was performed, and they were included in subsequent 
experimental validation.  
Nevertheless, database updates are frequent in -omics analysis, so these changes are fairly 
expected. In our case, the decrease in the total number of protein antigens analysed is actually 
undesirable for a comprehensive vaccine antigen selection. The core objective of the proposed 
peptide-based vaccine development pipeline was to screen the highest number possible of 
secreted proteins as antigen candidates, in order to maximise the chances of discovering 
immunogenic epitopes. Nevertheless, the epitope conservation filter included in the epitope 
selection step ensures that the peptides are identical among Leishmania target species even if the 
species-specific protein sequences are different. Finally, the database updates improved the 
molecular analysis of the secretome of the different Leishmania species (Chapter II), but did not 
interfere with the overarching goal of epitope-based vaccine development (Chapter III). 
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3. Lessons from other fields (cancer immunotherapy) 
 
Importantly, although a prophylactic vaccine remains the gold-standard, a therapeutic 
vaccine (immunotherapeutic formulation) would also greatly advance leishmaniasis control. The 
proposed multiepitope peptides should also be tested for treatment, in combination and/or 
comparison with current chemotherapy. A peptide candidate that enhances treatment would be 
a major tool to help control leishmaniasis in endemic settings. 
Currently, cancer immunotherapy is harnessing patients’ immune system to recognize and 
kill cancer cells (1). Leishmaniasis chronic infection shares some immunoregulatory features with 
cancer, so it is possible to incorporate inhibitors of specific immune checkpoints into vaccine or 
immunotherapeutic formulations which can transiently reduce immunosuppression to allow the 
generation of robust vaccine-mediated anti-parasitic immunity. In this context, the CTLA-4/PD-1 
(Cytotoxic T-lymphocyte-associated-protein 4/Programmed cell death-1) blockade could be 
explored to improve drug treatment and enhance vaccine efficacy against leishmaniasis. There is 
preliminary evidence that CTLA-4/PD-1 blockade promotes parasite clearance and treatment 
efficiency in animal models (2–4). Much like cancer blockade therapies, it is expected that specific 
types and combinations of immune checkpoint blockade will work differently for different types 
of leishmaniasis (VL/CL/MCL/PKDL/DCL). Further research into Leishmania immune responses 
and immunoregulation must be performed. 
 
4. Considerations for the final peptide vaccine formulation 
 
The peptide vaccine candidate against leishmaniases that will stem from this research will 
consist of synthetic peptides which include multiple Leishmania-specific immunogenic epitopes 
with worldwide HLA coverage. Evidently, the assembly design of the multi-epitope peptides will 
be carefully performed to maximise antigen uptake and presentation without affecting the 
induced immune response. Altogether, a successful vaccine must integrate the safety, efficacy and 
cost requirements to be deployed in the field.  
Also, peptide dose and the administration regimen must be optimised, in order to ensure 
both large number of responding T cells and an appropriate quality of the induced response (5). 
Specific targeting of tissue-resident dendritic cells for the induction of protective responses and 
the presence of adjuvants to enhance memory generation should be included in vaccine design for 
improved in situ T cell memory generation (6). Dermal DC are the optimal target for the peptide 
vaccine formulations since they then migrate to the lymph nodes and provide the ideal antigen 
presentation to specific T cells inducing the desired immune response. Besides adequate 
adjuvantation, another important aspect to consider is the administration route, and how it affects 
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product dispersion in the dermis and the number of targeted dermal DC (7). The anatomic location 
for vaccine administration is essential for optimal efficacy (6). For example, the administration in 
the skin or nasal mucosa could boost the generation of TRM cells in vivo. Early life vaccination is 
also preferential since memory T cells generated early in life have been shown to be maintained 
in peripheral blood, and there are fewer memory T cell clones to occupy pre-existent tissue niche 
environments where they were shown to persist until adulthood (6). Another key aspect of the 
successful assessment of vaccine immunogenicity and safety is the inclusion of sand fly challenges 
instead of intravenous infection in the design of clinical trials. 
In this view, we believe the most well-suited final vaccine formulation against 
leishmaniases will include appropriate Th1-inducing and/or TLR agonist as adjuvant(s), and with 
optimised administration, possibly intradermally, with multiple or large injection sites, different 
prime-boost regimens or even novel administration devices, in order to maximise antigen uptake 
by DCs and ensure the ideal quality and quantity of the induced immune response.  
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Appendix II.1 
 
Proteins identified in the secretome datasets ranked according to abundance (normalised 
iBAQ values) - 582 protein accessions with normalised iBAQ values over 1,10. 
 
LEADING_CHECK CASE_CHECK DESC_CHECK iBAQ LOG10 
NORMALISED 
TO LOG10 
AVERAGE 
Q9GP00 
LEADING_SPECIES 
- DO NOT 
CHANGE! 
Nucleoside diphosphate kinase 2552100000 9,4069 1,5186 
D1GJ50 
LEADING_AUTO - 
DO NOT CHANGE! 
Soluble promastigote surface antigen 
PSA-38S 
1908300000 9,2806 1,4982 
A4I8U5 Multi SPECIES Tubulin beta chain 1456100000 9,1632 1,4792 
A4HTR1 Multi SPECIES Tubulin beta chain 1456100000 9,1632 1,4792 
A4H727 
LEADING_SPECIES 
- DO NOT CHANGE! 
Tubulin alpha chain 1090500000 9,0376 1,4590 
Q4QFP8 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative small myristoylated protein-3 664170000 8,8223 1,4242 
P69201 
LEADING_AUTO - 
DO NOT CHANGE! 
Ubiquitin-60S ribosomal protein L40 604610000 8,7815 1,4176 
A4H3U0 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 582400000 8,7652 1,4150 
Q25307 
LEADING_AUTO - 
DO NOT CHANGE! 
Infective insect stage-specific protein 579490000 8,7630 1,4146 
Q07DU4 
LEADING_AUTO - 
DO NOT CHANGE! 
Peroxidoxin 2 578140000 8,7620 1,4145 
D1GJ46 
LEADING_AUTO - 
DO NOT CHANGE! 
Soluble promastigote surface antigen 
PSA-34S (Fragment) 
532290000 8,7261 1,4087 
A4HPQ9 Multi SPECIES Adenosylhomocysteinase 485670000 8,6863 1,4023 
A4HPQ8 Multi SPECIES Adenosylhomocysteinase 485670000 8,6863 1,4023 
Q4Q7Y4 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative heat-shock protein hsp70 482920000 8,6839 1,4019 
E9ARD0 
LEADING_AUTO - 
DO NOT CHANGE! 
Elongation factor 1-alpha 481690000 8,6828 1,4017 
O02614 
LEADING_AUTO - 
DO NOT CHANGE! 
Peptidyl-prolyl cis-trans isomerase 458460000 8,6613 1,3982 
A4H3V1 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative beta-fructofuranosidase 452080000 8,6552 1,3972 
A4I058 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative endoribonuclease L-PSP 
(Pb5) 
427180000 8,6306 1,3933 
O43990 
LEADING_SPECIES 
- DO NOT CHANGE! 
Infective insect stage-specific protein 393100000 8,5945 1,3874 
P15706 
LEADING_AUTO - 
DO NOT CHANGE! 
Leishmanolysin 366080000 8,5636 1,3824 
A4I7Z7 
LEADING_SPECIES 
- DO NOT CHANGE! 
Superoxide dismutase 346670000 8,5399 1,3786 
A4HYX4 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative small myristoylated protein-1 345990000 8,5391 1,3785 
Q4QJ67 
LEADING_AUTO - 
DO NOT CHANGE! 
Peptidyl-prolyl cis-trans isomerase 329800000 8,5183 1,3751 
A4HW98 
LEADING_SPECIES 
- DO NOT CHANGE! 
Histone H4 327030000 8,5146 1,3745 
Q27673 
LEADING_AUTO - 
DO NOT CHANGE! 
Leishmanolysin 318890000 8,5036 1,3728 
Q4QDL6 Multi SPECIES Histone H2B 307890000 8,4884 1,3703 
Q9BJC7 Multi SPECIES Histone H2B 307890000 8,4884 1,3703 
Q4QHP1 Multi SPECIES Histone H2B 307890000 8,4884 1,3703 
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LEADING_CHECK CASE_CHECK DESC_CHECK iBAQ LOG10 
NORMALISED 
TO LOG10 
AVERAGE 
A4HKT8 Multi SPECIES Nucleoside diphosphate kinase 305540000 8,4851 1,3698 
A4HKT7 Multi SPECIES Nucleoside diphosphate kinase 305540000 8,4851 1,3698 
A4HW62 
LEADING_SPECIES 
- DO NOT CHANGE! 
Enolase 294720000 8,4694 1,3672 
A4I1P9 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative 2,4-dihydroxyhept-2-ene-
1,7-dioic acid aldolase 
252150000 8,4017 1,3563 
A4HSP4 
LEADING_SPECIES 
- DO NOT CHANGE! 
Histone H4 250580000 8,3989 1,3559 
A4I2J4 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 237210000 8,3751 1,3520 
E9AHM9 
LEADING_SPECIES 
- DO NOT CHANGE! 
Heat shock protein 83-1 218720000 8,3399 1,3463 
A4IDG6 
LEADING_SPECIES 
- DO NOT CHANGE! 
Inosine-guanosine transporter 216660000 8,3358 1,3457 
Q8MNZ1 
LEADING_AUTO - 
DO NOT CHANGE! 
Leishmanolysin 215660000 8,3338 1,3453 
Q25225 
LEADING_AUTO - 
DO NOT CHANGE! 
Probable eukaryotic initiation factor 
4A 
215380000 8,3332 1,3452 
Q4JI42 
LEADING_AUTO - 
DO NOT CHANGE! 
Promastigote surface antigen 204160000 8,3100 1,3415 
E9BU45 
LEADING_AUTO - 
DO NOT CHANGE! 
14-3-3 protein-like protein 197980000 8,2966 1,3393 
A4HQG6 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative histidine secretory acid 
phosphatase 
196730000 8,2939 1,3389 
Q4QEN5 
LEADING_AUTO - 
DO NOT CHANGE! 
Cytochrome c 185550000 8,2685 1,3348 
A4ICW8 
LEADING_SPECIES 
- DO NOT CHANGE! 
Elongation factor 2 180130000 8,2556 1,3327 
Q4Q412 
LEADING_AUTO - 
DO NOT CHANGE! 
Macrophage migration inhibitory 
factor-like protein 
156670000 8,1950 1,3229 
A4I1D2 
LEADING_AUTO - 
DO NOT CHANGE! 
Peptidyl-prolyl cis-trans isomerase 146240000 8,1651 1,3181 
A4I076 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative NADP-dependent alcohol 
dehydrogenase 
144480000 8,1598 1,3173 
E9B8C5 
LEADING_AUTO - 
DO NOT CHANGE! 
Trypanothione reductase 139940000 8,1459 1,3150 
A4ICA5 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative histidine secretory acid 
phosphatase 
139460000 8,1444 1,3148 
A4I0Y8 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative IgE-dependent histamine-
releasing factor 
134210000 8,1278 1,3121 
A1Y2D3 Multi SPECIES 
Prostaglandin f2-alpha synthase 
(Fragment) 
133050000 8,1240 1,3115 
A4I6Z4 Multi SPECIES 
Prostaglandin f2-alpha synthase/D-
arabinose dehydrogenase 
133050000 8,1240 1,3115 
Q5SDH5 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative calpain-like cysteine 
peptidase 
130000000 8,1139 1,3099 
A4HYX1 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative calpain-like cysteine 
peptidase 
128160000 8,1078 1,3089 
A4HU13 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative calmodulin 126090000 8,1007 1,3077 
Q4QF80 Multi SPECIES Tryparedoxin peroxidase 124200000 8,0941 1,3067 
Q4QF76 Multi SPECIES Tryparedoxin peroxidase 124200000 8,0941 1,3067 
Q4QF68 Multi SPECIES Thiol specific antioxidant 124200000 8,0941 1,3067 
E9AGG5 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative surface antigen protein 2 120010000 8,0792 1,3042 
A4ZZ66 
LEADING_AUTO - 
DO NOT CHANGE! 
Cytoplasmic tryparedoxin peroxidase 116510000 8,0664 1,3022 
Q6RYT3 
LEADING_SPECIES 
- DO NOT CHANGE! 
Tryparedoxin 111070000 8,0456 1,2988 
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LEADING_CHECK CASE_CHECK DESC_CHECK iBAQ LOG10 
NORMALISED 
TO LOG10 
AVERAGE 
Q4QAP8 
LEADING_AUTO - 
DO NOT CHANGE! 
Triosephosphate isomerase 100230000 8,0010 1,2916 
P40285 
LEADING_AUTO - 
DO NOT CHANGE! 
Histone H3 98197000 7,9921 1,2902 
A4HE26 
LEADING_AUTO - 
DO NOT CHANGE! 
Peptidyl-prolyl cis-trans isomerase 97628000 7,9896 1,2898 
A4HJ63 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative amino acid permease 97306000 7,9881 1,2895 
A4H7P0 Multi SPECIES 
Putative calpain-like cysteine 
peptidase 
96683000 7,9854 1,2891 
A4H7N9 Multi SPECIES 
Putative calpain-like cysteine 
peptidase 
96683000 7,9854 1,2891 
A4HVE5 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative carboxypeptidase 96330000 7,9838 1,2888 
Q4QGI0 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative surface antigen protein 95339000 7,9793 1,2881 
P48499 
LEADING_AUTO - 
DO NOT CHANGE! 
Triosephosphate isomerase 90700000 7,9576 1,2846 
A4H6I8 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative aminopeptidase 90500000 7,9566 1,2845 
A4HS26 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative beta-fructofuranosidase 89468000 7,9517 1,2837 
A4I784 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative ADP-ribosylation factor 88068000 7,9448 1,2825 
A4I8F6 
LEADING_SPECIES 
- DO NOT CHANGE! 
Dihydrolipoyl dehydrogenase 87918000 7,9441 1,2824 
J9XRQ3 
LEADING_SPECIES 
- DO NOT CHANGE! 
Activated protein kinase C receptor 86331000 7,9362 1,2812 
A4I4D6 
LEADING_SPECIES 
- DO NOT CHANGE! 
Cysteine peptidase C (CPC) 80992000 7,9084 1,2767 
A4I2G1 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 60S ribosomal protein L35 80572000 7,9062 1,2763 
Q9U5N6 
LEADING_AUTO - 
DO NOT CHANGE! 
Fructose-bisphosphate aldolase 79363000 7,8996 1,2753 
Q4Q740 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative heat shock 70-related 
protein 1,mitochondrial 
78529000 7,8950 1,2745 
A4HWX3 
LEADING_SPECIES 
- DO NOT CHANGE! 
Transaldolase 77296000 7,8882 1,2734 
A4IA34 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 76200000 7,8820 1,2724 
Q4QDM4 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 75509000 7,8780 1,2718 
A4IAQ1 
LEADING_SPECIES 
- DO NOT CHANGE! 
Pyruvate kinase 73487000 7,8662 1,2699 
A4ICP0 Multi SPECIES Putative 40S ribosomal protein S18 73320000 7,8652 1,2697 
A4ICP1 Multi SPECIES Putative 40S ribosomal protein S18 73320000 7,8652 1,2697 
E9B376 
LEADING_AUTO - 
DO NOT CHANGE! 
Nucleoside diphosphate kinase 73229000 7,8647 1,2696 
E9AN57 
LEADING_AUTO - 
DO NOT CHANGE! 
GP63, leishmanolysin 72288000 7,8591 1,2687 
E9ALV8 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative tryparedoxin 71414000 7,8538 1,2679 
E9BCF2 
LEADING_AUTO - 
DO NOT CHANGE! 
Tryparedoxin peroxidase 70641000 7,8491 1,2671 
A4H3T9 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 69862000 7,8442 1,2663 
A4HTI0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Superoxide dismutase 69739000 7,8435 1,2662 
Q5UDS8 Multi SPECIES Tryparedoxin peroxidase 2 69656000 7,8430 1,2661 
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LEADING_CHECK CASE_CHECK DESC_CHECK iBAQ LOG10 
NORMALISED 
TO LOG10 
AVERAGE 
A0A088RNK9 Multi SPECIES Tryparedoxin peroxidase 69656000 7,8430 1,2661 
Q71S90 
LEADING_AUTO - 
DO NOT CHANGE! 
Superoxide dismutase 68715000 7,8371 1,2652 
E9AH84 
LEADING_SPECIES 
- DO NOT CHANGE! 
Inhibitor of cysteine peptidase 67939000 7,8321 1,2644 
E9BPK5 
LEADING_AUTO - 
DO NOT CHANGE! 
Carboxypeptidase, putative 65230000 7,8144 1,2615 
D1GJ51 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative surface antigen protein 2 65151000 7,8139 1,2614 
A4HZI9 
LEADING_SPECIES 
- DO NOT CHANGE! 
Proteasome subunit alpha type 65126000 7,8138 1,2614 
A4HIL9 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 64451000 7,8092 1,2607 
A4I5W4 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 62531000 7,7961 1,2585 
A4HMB3 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative aspartate aminotransferase 61566000 7,7893 1,2574 
A4HUJ7 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative nuclear transport factor 2 58882000 7,7700 1,2543 
A4HHC8 
LEADING_AUTO - 
DO NOT CHANGE! 
TXN1 protein 58595000 7,7679 1,2540 
E9B701 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative glycine cleavage system H 
protein 
58571000 7,7677 1,2540 
A4ID05 
LEADING_SPECIES 
- DO NOT CHANGE! 
Adenosylhomocysteinase 58281000 7,7655 1,2536 
Q4QC13 
LEADING_AUTO - 
DO NOT CHANGE! 
Proteasome subunit alpha type 58068000 7,7639 1,2533 
A4HVP9 
LEADING_SPECIES 
- DO NOT CHANGE! 
Nucleobase transporter 57780000 7,7618 1,2530 
A4I0C0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 3-ketoacyl-CoA thiolase 56788000 7,7543 1,2518 
A4IDG8 
LEADING_SPECIES 
- DO NOT CHANGE! 
Phosphomannomutase 56592000 7,7528 1,2515 
A4I421 
LEADING_SPECIES 
- DO NOT CHANGE! 
Malate dehydrogenase 56273000 7,7503 1,2511 
Q95U89 
LEADING_AUTO - 
DO NOT CHANGE! 
Peroxidoxin 55334000 7,7430 1,2500 
A4I8S7 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 54538000 7,7367 1,2490 
A4HUU6 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 14-3-3 protein 54518000 7,7365 1,2489 
E9ACG7 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative delta-1-pyrroline-5-
carboxylate dehydrogenase 
54478000 7,7362 1,2489 
C6KJE0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Actin 53651000 7,7296 1,2478 
A4I218 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 40S ribosomal protein S16 52927000 7,7237 1,2468 
A4IB24 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative ubiquitin-conjugating 
enzyme e2 
52202000 7,7177 1,2459 
A4HUX3 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative aminopeptidase 50612000 7,7043 1,2437 
Q4Q7X1 
LEADING_AUTO - 
DO NOT CHANGE! 
Glutamate dehydrogenase 49710000 7,6964 1,2425 
E9B8I6 
LEADING_AUTO - 
DO NOT CHANGE! 
Dipeptidyl-peptidase III, putative 49125000 7,6913 1,2416 
Q4Q1R5 
LEADING_AUTO - 
DO NOT CHANGE! 
Proteasome subunit alpha type 48011000 7,6813 1,2400 
A4I7K4 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative ATP-dependent RNA 
helicase 
47890000 7,6802 1,2398 
A4ID39 
LEADING_SPECIES 
- DO NOT CHANGE! 
Cysteine synthase 47706000 7,6786 1,2396 
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LEADING_CHECK CASE_CHECK DESC_CHECK iBAQ LOG10 
NORMALISED 
TO LOG10 
AVERAGE 
E9ACZ6 
LEADING_AUTO - 
DO NOT CHANGE! 
Proteasome endopeptidase complex 47523000 7,6769 1,2393 
A4HSK5 
LEADING_SPECIES 
- DO NOT CHANGE! 
S-methyl-5'-thioadenosine 
phosphorylase 
47140000 7,6734 1,2387 
A4H399 
LEADING_AUTO - 
DO NOT CHANGE! 
Histone H4 46531000 7,6677 1,2378 
A4IA55 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 40S ribosomal protein S19 
protein 
44623000 7,6496 1,2349 
A4H3U1 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 44275000 7,6462 1,2343 
Q4QJ78 
LEADING_AUTO - 
DO NOT CHANGE! 
Histone H4 44221000 7,6456 1,2342 
E9BQW3 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 44193000 7,6454 1,2342 
E9AWJ0 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative uncharacterized protein 44191000 7,6453 1,2342 
A4H638 
LEADING_AUTO - 
DO NOT CHANGE! 
GP63, leishmanolysin 43860000 7,6421 1,2337 
A4IAX3 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative proteasome activator protein 
pa26 
43473000 7,6382 1,2331 
A4HMZ0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative cystathione gamma lyase 43360000 7,6371 1,2329 
Q4QEI9 
LEADING_AUTO - 
DO NOT CHANGE! 
Elongation factor 1-alpha 43095000 7,6344 1,2324 
A4I0S4 
LEADING_SPECIES 
- DO NOT CHANGE! 
Triosephosphate isomerase 42952000 7,6330 1,2322 
A4ICG5 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative membrane-bound acid 
phosphatase 2 
41589000 7,6190 1,2299 
A4HCN4 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative endoribonuclease L-PSP 
(Pb5) 
41346000 7,6164 1,2295 
A4HUD9 Multi SPECIES Isocitrate dehydrogenase [NADP] 40868000 7,6114 1,2287 
A2CIA0 Multi SPECIES Isocitrate dehydrogenase [NADP] 40868000 7,6114 1,2287 
A4I120 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 40548000 7,6080 1,2282 
A8I4U5 
LEADING_AUTO - 
DO NOT CHANGE! 
Cytosolic tryparedoxin 40238000 7,6046 1,2276 
A4HXS6 
LEADING_SPECIES 
- DO NOT CHANGE! 
Aconitate hydratase 40189000 7,6041 1,2275 
E9AGQ5 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative heat shock protein 39876000 7,6007 1,2270 
A4I4A3 
LEADING_SPECIES 
- DO NOT CHANGE! 
ADF/Cofilin 39746000 7,5993 1,2268 
E9AGR8 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative aminopeptidase 39564000 7,5973 1,2264 
A0A142BXV0 Multi SPECIES 
Glucose-6-phosphate isomerase 
(Fragment) 
39449000 7,5960 1,2262 
A0A142BXU6 Multi SPECIES 
Glucose-6-phosphate isomerase 
(Fragment) 
39449000 7,5960 1,2262 
Q3C165 Multi SPECIES Glucose-6-phosphate isomerase 39449000 7,5960 1,2262 
Q2PDE4 Multi SPECIES Glucose-6-phosphate isomerase 39449000 7,5960 1,2262 
Q2PDE2 Multi SPECIES Glucose-6-phosphate isomerase 39449000 7,5960 1,2262 
E9AE35 Multi SPECIES Histone H2A 38536000 7,5859 1,2246 
E9AE33 Multi SPECIES Histone H2A 38536000 7,5859 1,2246 
Q9N9V4 
LEADING_AUTO - 
DO NOT CHANGE! 
40S ribosomal protein S25 38350000 7,5838 1,2243 
A4I650 Multi SPECIES 40S ribosomal protein S14 37676000 7,5761 1,2230 
A4I3H3 Multi SPECIES 40S ribosomal protein S14 37676000 7,5761 1,2230 
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E9AF59 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative aminopeptidase P 37283000 7,5715 1,2223 
Q4QFX2 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative inosine-guanine nucleoside 
hydrolase 
37112000 7,5695 1,2220 
E9AHQ2 
LEADING_SPECIES 
- DO NOT CHANGE! 
Succinyl-CoA:3-ketoacid-coenzyme 
A transferase 
36958000 7,5677 1,2217 
P42556 
LEADING_AUTO - 
DO NOT CHANGE! 
Pteridine reductase 1 36905000 7,5671 1,2216 
E9AH20 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 36583000 7,5633 1,2210 
A4HXU4 
LEADING_AUTO - 
DO NOT CHANGE! 
Probable citrate synthase, 
mitochondrial 
36237000 7,5592 1,2203 
A4HUK1 
LEADING_SPECIES 
- DO NOT CHANGE! 
Peptidylprolyl isomerase 35893000 7,5550 1,2196 
E9AHH9 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative ribosomal protein S20 35723000 7,5529 1,2193 
Q25332 Multi SPECIES Secreted acid phosphatase 1 (SAP1) 35397000 7,5490 1,2186 
Q25336 Multi SPECIES Secreted acid phosphatase 2 (SAP2) 35397000 7,5490 1,2186 
E9AU82 Multi SPECIES 
Putative histidine secretory acid 
phosphatase 
35397000 7,5490 1,2186 
A4HW29 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative calpain-like cysteine 
peptidase 
33911000 7,5303 1,2156 
A4I212 
LEADING_SPECIES 
- DO NOT CHANGE! 
Glutathione peroxidase 33714000 7,5278 1,2152 
E9AXG9 
LEADING_AUTO - 
DO NOT CHANGE! 
Peptidyl-prolyl cis-trans isomerase 33389000 7,5236 1,2146 
A4HVS0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Ubiquitin-conjugating enzyme-like 
protein 
33161000 7,5206 1,2141 
E9BRR9 
LEADING_AUTO - 
DO NOT CHANGE! 
ATP-dependent DEAD-box RNA 
helicase, putative 
33156000 7,5206 1,2141 
A4HC04 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative RNA helicase 33023000 7,5188 1,2138 
Q9N856 Multi SPECIES Uncharacterized protein 32890000 7,5171 1,2135 
Q9N853 Multi SPECIES Uncharacterized protein 32890000 7,5171 1,2135 
Q9N852 Multi SPECIES Uncharacterized protein 32890000 7,5171 1,2135 
A4H7T6 
LEADING_AUTO - 
DO NOT CHANGE! 
ENOL protein 32754000 7,5153 1,2132 
A4IB88 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 60S ribosomal protein L5 32079000 7,5062 1,2117 
Q95PT4 Multi SPECIES Myo-inositol-1-phosphate synthase 31448000 7,4976 1,2104 
E9APY4 Multi SPECIES Myo-inositol-1-phosphate synthase 31448000 7,4976 1,2104 
A4HUY6 Multi SPECIES Putative 40S ribosomal protein S21 31231000 7,4946 1,2099 
A4HUY7 Multi SPECIES Putative 40S ribosomal protein S21 31231000 7,4946 1,2099 
A4H7V6 
LEADING_AUTO - 
DO NOT CHANGE! 
INO1 protein 30521000 7,4846 1,2083 
Q868G9 
LEADING_AUTO - 
DO NOT CHANGE! 
Inhibitor of cysteine peptidase 30102000 7,4786 1,2073 
A0A0G3EHC9 
LEADING_AUTO - 
DO NOT CHANGE! 
Trypanothione reductase 29692000 7,4726 1,2063 
E9BAX6 
LEADING_SPECIES 
- DO NOT CHANGE! 
Proteasome subunit beta type 29690000 7,4726 1,2063 
P83851 
LEADING_AUTO - 
DO NOT CHANGE! 
Inosine-uridine preferring nucleoside 
hydrolase 
29061000 7,4633 1,2048 
A4I971 
LEADING_SPECIES 
- DO NOT CHANGE! 
Macrophage migration inhibitory 
factor-like protein 
28576000 7,4560 1,2036 
A4HT65 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 3-hydroxyacyl-ACP 
dehydratase 
28388000 7,4531 1,2032 
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E9AK13 Multi SPECIES Putative beta-fructofuranosidase 28374000 7,4529 1,2031 
A0A0D3RKQ2 Multi SPECIES Secretory invertase 28374000 7,4529 1,2031 
Q4QGJ9 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative surface antigen protein 2 27751000 7,4433 1,2016 
E9AGU0 
LEADING_AUTO - 
DO NOT CHANGE! 
Phosphoglycerate kinase 27664000 7,4419 1,2014 
A4I307 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 27643000 7,4416 1,2013 
A4I1I6 
LEADING_SPECIES 
- DO NOT CHANGE! 
GTP-binding nuclear protein 27585000 7,4407 1,2012 
E9ADT5 
LEADING_AUTO - 
DO NOT CHANGE! 
Cysteine peptidase C (CPC) 27569000 7,4404 1,2011 
Q3HL75 
LEADING_AUTO - 
DO NOT CHANGE! 
Enolase 27224000 7,4350 1,2002 
Q25278 
LEADING_AUTO - 
DO NOT CHANGE! 
Probable 60S ribosomal protein L14 27119000 7,4333 1,2000 
Q07DU5 
LEADING_AUTO - 
DO NOT CHANGE! 
Peroxidoxin 2 27078000 7,4326 1,1999 
A4I9I3 
LEADING_AUTO - 
DO NOT CHANGE! 
Malate dehydrogenase 27077000 7,4326 1,1999 
Q25298 
LEADING_SPECIES 
- DO NOT CHANGE! 
Kinetoplastid membrane protein 11C 26979000 7,4310 1,1996 
Q4QI64 Multi SPECIES Cathepsin L-like protease 26855000 7,4290 1,1993 
K7PPA6 Multi SPECIES Cysteine protease 26855000 7,4290 1,1993 
K7PNP9 Multi SPECIES Cysteine protease 26855000 7,4290 1,1993 
K7PN53 Multi SPECIES Cysteine protease 26855000 7,4290 1,1993 
K7P5C3 Multi SPECIES Cathepsin L-like protease 26855000 7,4290 1,1993 
K7P522 Multi SPECIES Cathepsin L-like protease 26855000 7,4290 1,1993 
Q4QI61 Multi SPECIES Cathepsin L-like protease 26855000 7,4290 1,1993 
P90628 Multi SPECIES Cathepsin L-like protease 26855000 7,4290 1,1993 
Q4QBD1 
LEADING_AUTO - 
DO NOT CHANGE! 
Aldose 1-epimerase-like protein 26805000 7,4282 1,1992 
E9AKP0 
LEADING_AUTO - 
DO NOT CHANGE! 
Peptidyl-prolyl cis-trans isomerase 26448000 7,4224 1,1982 
O44012 
LEADING_SPECIES 
- DO NOT CHANGE! 
40S ribosomal protein S6 26281000 7,4196 1,1978 
Q4QDZ7 
LEADING_AUTO - 
DO NOT CHANGE! 
Carboxypeptidase 25952000 7,4142 1,1969 
Q4FX34 
LEADING_AUTO - 
DO NOT CHANGE! 
Aspartate aminotransferase 25771000 7,4111 1,1964 
E9AHZ7 
LEADING_SPECIES 
- DO NOT CHANGE! 
2,3-bisphosphoglycerate-
independent phosphoglycerate 
mutase 
25610000 7,4084 1,1960 
E9ADX3 
LEADING_AUTO - 
DO NOT CHANGE! 
Tryparedoxin 25411000 7,4050 1,1954 
E9BMG9 
LEADING_AUTO - 
DO NOT CHANGE! 
Cytoskeleton-associated protein 
CAP5.5, putative 
25225000 7,4018 1,1949 
Q4Q873 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative zinc transporter 25212000 7,4016 1,1949 
A4IDS4 
LEADING_SPECIES 
- DO NOT CHANGE! 
40S ribosomal protein SA 25134000 7,4003 1,1946 
E9AGQ7 Multi SPECIES Histone H2B 25050000 7,3988 1,1944 
A4HU57 Multi SPECIES Histone H2B 25050000 7,3988 1,1944 
A4HY42 Multi SPECIES Histone H2B 25050000 7,3988 1,1944 
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A0A088S198 
LEADING_AUTO - 
DO NOT CHANGE! 
Heat shock protein 83 24959000 7,3972 1,1941 
A4H879 Multi SPECIES Tryparedoxin peroxidase 24803000 7,3945 1,1937 
A4H877 Multi SPECIES TRYP1 protein 24803000 7,3945 1,1937 
A4HWJ3 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 40S ribosomal protein S3 24557000 7,3902 1,1930 
A4HTZ8 
LEADING_SPECIES 
- DO NOT CHANGE! 
Oligopeptidase 
bwith=GeneDB:LmjF09.0770 
24421000 7,3878 1,1926 
A4H9T4 
LEADING_SPECIES 
- DO NOT CHANGE! 
Proteasome endopeptidase complex 24333000 7,3862 1,1924 
Q6TDF7 
LEADING_AUTO - 
DO NOT CHANGE! 
70 kDa heat shock protein 23922000 7,3788 1,1912 
A4GVE9 
LEADING_SPECIES 
- DO NOT CHANGE! 
Eukaryotic translation initiation factor 
5A 
23850000 7,3775 1,1910 
A4I1G1 
LEADING_SPECIES 
- DO NOT CHANGE! 
ATP synthase subunit beta 23611000 7,3731 1,1903 
A4HWS2 
LEADING_SPECIES 
- DO NOT CHANGE! 
Protein tyrosine phosphatase-like 
protein 
23549000 7,3720 1,1901 
E9AIM4 
LEADING_AUTO - 
DO NOT CHANGE! 
Contig, possible fusion of 
chromosomes 20 and 34 
23089000 7,3634 1,1887 
A4HSH2 
LEADING_SPECIES 
- DO NOT CHANGE! 
ATPase alpha subunit 22992000 7,3616 1,1884 
Q4QDQ1 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative pyruvate dehydrogenase E1 
component alpha subunit 
22768000 7,3573 1,1877 
Q4QF35 
LEADING_AUTO - 
DO NOT CHANGE! 
Proliferating cell nuclear antigen 22599000 7,3541 1,1872 
A4I115 
LEADING_AUTO - 
DO NOT CHANGE! 
Transketolase 22546000 7,3531 1,1870 
E9ADX4 
LEADING_AUTO - 
DO NOT CHANGE! 
Tryparedoxin 22397000 7,3502 1,1866 
A4HWV1 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative aspartate 
carbamoyltransferase 
22299000 7,3483 1,1862 
E9AHW0 Multi SPECIES Putative 60S ribosomal protein L12 22190000 7,3462 1,1859 
A4I130 Multi SPECIES Putative 60S ribosomal protein L12 22190000 7,3462 1,1859 
A4ICW2 
LEADING_SPECIES 
- DO NOT CHANGE! 
Eukaryotic translation initiation factor 
3 subunit L 
22141000 7,3452 1,1858 
E9AFW0 
LEADING_AUTO - 
DO NOT CHANGE! 
Proteasome subunit alpha type 22054000 7,3435 1,1855 
E9BBD0 
LEADING_AUTO - 
DO NOT CHANGE! 
Lectin, putative 21785000 7,3382 1,1846 
E9AST7 
LEADING_AUTO - 
DO NOT CHANGE! 
Proteasome subunit beta type 21714000 7,3367 1,1844 
A4HVQ0 Multi SPECIES 40S ribosomal protein S4 21692000 7,3363 1,1843 
A4HVQ1 Multi SPECIES Putative 40S ribosomal protein S4 21692000 7,3363 1,1843 
A4ICY0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Stress-inducible protein STI1 
homolog 
21384000 7,3301 1,1833 
A4I7Q0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 21333000 7,3291 1,1831 
A4HZI8 
LEADING_SPECIES 
- DO NOT CHANGE! 
60S ribosomal protein L37a 21279000 7,3280 1,1830 
P36400 Multi SPECIES Cysteine proteinase B 21075000 7,3238 1,1823 
Q05094 Multi SPECIES Cysteine proteinase 2 21075000 7,3238 1,1823 
A4HLC9 Multi SPECIES Tubulin beta chain 20900000 7,3201 1,1817 
A4HLC8 Multi SPECIES Tubulin beta chain 20900000 7,3201 1,1817 
A4HT77 Multi SPECIES Putative 60S ribosomal protein L7a 20811000 7,3183 1,1814 
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A4HT78 Multi SPECIES Putative 60S ribosomal protein L7a 20811000 7,3183 1,1814 
A4I7N3 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative ras-related rab-4 20793000 7,3179 1,1813 
E9BIG7 
LEADING_AUTO - 
DO NOT CHANGE! 
Thimet oligopeptidase, putative 20741000 7,3168 1,1812 
E9AN53 
LEADING_AUTO - 
DO NOT CHANGE! 
GP63, leishmanolysin 20634000 7,3146 1,1808 
P27891 
LEADING_AUTO - 
DO NOT CHANGE! 
Histone H2A.1 20575000 7,3133 1,1806 
A4HLA1 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 20569000 7,3132 1,1806 
A4H5S5 
LEADING_AUTO - 
DO NOT CHANGE! 
Elongation factor-1 gamma 20520000 7,3122 1,1804 
E9AKI9 
LEADING_AUTO - 
DO NOT CHANGE! 
S-methyl-5'-thioadenosine 
phosphorylase 
20503000 7,3118 1,1804 
A4ID21 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 40S ribosomal protein S27-1 20320000 7,3079 1,1797 
A4I3W2 
LEADING_SPECIES 
- DO NOT CHANGE! 
Eukaryotic translation initiation factor 
3 subunit E 
20250000 7,3064 1,1795 
A4HS64 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative ubiquitin-conjugating 
enzyme e2 
20070000 7,3025 1,1789 
A4I1K7 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 19840000 7,2975 1,1781 
A4ID83 
LEADING_SPECIES 
- DO NOT CHANGE! 
Succinate-CoA ligase subunit beta 19824000 7,2972 1,1780 
A4ID08 
LEADING_AUTO - 
DO NOT CHANGE! 
Eukaryotic translation initiation factor 
3 subunit I 
19788000 7,2964 1,1779 
A4HY22 
LEADING_AUTO - 
DO NOT CHANGE! 
Plasma membrane ATPase 19619000 7,2927 1,1773 
Q711P7 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative trypanothione synthetase 19570000 7,2916 1,1771 
A4IBY7 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 19434000 7,2886 1,1766 
Q4Q0A9 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative histidine secretory acid 
phosphatase 
19316000 7,2859 1,1762 
Q4QDF8 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative histone H3 variant 19279000 7,2851 1,1760 
Q8WT31 Multi SPECIES Cysteine proteinase 19202000 7,2833 1,1758 
A4HYH2 Multi SPECIES Cysteine peptidase A (CPA) 19202000 7,2833 1,1758 
A4HFQ7 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 19146000 7,2821 1,1756 
A4HZS1 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 40S ribosomal protein S15 19074000 7,2804 1,1753 
A4I2Y7 
LEADING_AUTO - 
DO NOT CHANGE! 
Glycosomal phosphoenolpyruvate 
carboxykinase, putative 
19028000 7,2794 1,1751 
A4HYI1 
LEADING_SPECIES 
- DO NOT CHANGE! 
Peptidylprolyl isomerase 18939000 7,2774 1,1748 
A4I1L9 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative pyruvate dehydrogenase E1 
beta subunit 
18842000 7,2751 1,1744 
E9AG92 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 18819000 7,2746 1,1744 
E9B6R2 
LEADING_AUTO - 
DO NOT CHANGE! 
Proteasome subunit beta type 18648000 7,2706 1,1737 
A4HJ18 
LEADING_AUTO - 
DO NOT CHANGE! 
TDR1 protein 18510000 7,2674 1,1732 
A4HV26 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 40S ribosomal protein S15A 18472000 7,2665 1,1730 
A4HP21 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative universal minicircle 
sequence binding protein 
18180000 7,2596 1,1719 
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A4I841 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 17935000 7,2537 1,1710 
A4ID74 
LEADING_SPECIES 
- DO NOT CHANGE! 
40S ribosomal protein S24 17933000 7,2537 1,1710 
Q4Q8S3 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 17791000 7,2502 1,1704 
A4IE56 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative oxidoreductase 17719000 7,2484 1,1701 
P23223 
LEADING_AUTO - 
DO NOT CHANGE! 
Leishmanolysin 17636000 7,2464 1,1698 
A4IBR8 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 60S ribosomal protein L23 17432000 7,2413 1,1690 
A4HSZ7 
LEADING_SPECIES 
- DO NOT CHANGE! 
Protein disulfide isomerase 17418000 7,2410 1,1689 
Q4Q6Z5 Multi SPECIES 
Glyceraldehyde-3-phosphate 
dehydrogenase 
17309000 7,2383 1,1685 
Q4Q6Z4 Multi SPECIES 
Glyceraldehyde-3-phosphate 
dehydrogenase 
17309000 7,2383 1,1685 
E9ARK6 
LEADING_AUTO - 
DO NOT CHANGE! 
Citrate synthase 17114000 7,2334 1,1677 
E9B3L2 
LEADING_AUTO - 
DO NOT CHANGE! 
Heat shock protein 83-1 17075000 7,2324 1,1675 
E9B8M5 
LEADING_SPECIES 
- DO NOT CHANGE! 
Proteasome subunit beta type 16932000 7,2287 1,1669 
A4I7P2 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative RNA binding protein 16759000 7,2242 1,1662 
Q4QHH2 Multi SPECIES GP63, leishmanolysin 16224000 7,2102 1,1640 
Q4QHH1 Multi SPECIES GP63, leishmanolysin 16224000 7,2102 1,1640 
Q4QHG9 Multi SPECIES GP63, leishmanolysin 16224000 7,2102 1,1640 
B8YDG1 Multi SPECIES GP63 16224000 7,2102 1,1640 
Q9N9V3 Multi SPECIES Putative ribosomal protein L10 16206000 7,2097 1,1639 
A4HS71 Multi SPECIES Putative 60S ribosomal protein L10 16206000 7,2097 1,1639 
P62884 
LEADING_SPECIES 
- DO NOT CHANGE! 
Guanine nucleotide-binding protein 
subunit beta-like protein 
16001000 7,2041 1,1630 
A4I426 
LEADING_SPECIES 
- DO NOT CHANGE! 
Glutamate dehydrogenase 15985000 7,2037 1,1629 
A4I2C4 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 15795000 7,1985 1,1621 
P14700 
LEADING_AUTO - 
DO NOT CHANGE! 
Membrane antigen containing 
repeating peptides (Fragment) 
15610000 7,1934 1,1612 
A4HFK0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative small GTP-binding protein 
Rab1 
15572000 7,1923 1,1611 
A4IAD2 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 60S ribosomal protein L21 15564000 7,1921 1,1610 
A4IB25 
LEADING_SPECIES 
- DO NOT CHANGE! 
Histone H4 15499000 7,1903 1,1607 
Q5EXB3 
LEADING_AUTO - 
DO NOT CHANGE! 
Hemoglobin receptor 15466000 7,1894 1,1606 
A4I935 
LEADING_SPECIES 
- DO NOT CHANGE! 
Peptidyl-prolyl cis-trans isomerase 15412000 7,1879 1,1604 
E9BHI2 
LEADING_AUTO - 
DO NOT CHANGE! 
Protein phosphatase, putative 15357000 7,1863 1,1601 
E9B099 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative heat-shock protein hsp70 15261000 7,1836 1,1597 
A4HGY1 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative heat-shock protein hsp70 15244000 7,1831 1,1596 
A4H9Q9 
LEADING_SPECIES 
- DO NOT CHANGE! 
Nonspecific nucleoside 
hydrolasewith=GeneDB:LmjF18.1580 
15134000 7,1800 1,1591 
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A4I574 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative aspartyl-tRNA synthetase 15031000 7,1770 1,1586 
A4IBL4 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative cystathione gamma lyase 15003000 7,1762 1,1585 
A0A1E1J358 Multi SPECIES ADP-ribosylation factor, putative 14981000 7,1755 1,1584 
A0A088RXX3 Multi SPECIES ADP-ribosylation factor, putative 14981000 7,1755 1,1584 
A4IDB2 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative translation elongation factor 
1-beta 
14958000 7,1749 1,1583 
A0A1E1IN58 Multi SPECIES 
Putative small GTP binding protein 
rab6-like protein 
14863000 7,1721 1,1578 
A0A088RH69 Multi SPECIES 
Small GTP binding protein rab6-like 
protein 
14863000 7,1721 1,1578 
A4I0C2 Multi SPECIES Acetyl-coenzyme A synthetase 14842000 7,1715 1,1577 
A4I093 Multi SPECIES Acetyl-coenzyme A synthetase 14842000 7,1715 1,1577 
E9AE96 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 14748000 7,1687 1,1573 
A4HWZ0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Sucrose-phosphate synthase-like 
protein 
14734000 7,1683 1,1572 
Q8T6M2 
LEADING_AUTO - 
DO NOT CHANGE! 
Guanosine permease 14696000 7,1672 1,1570 
Q9U4E3 
LEADING_AUTO - 
DO NOT CHANGE! 
ADP-ribosylation factor-like 3A 14634000 7,1654 1,1567 
A4IAU1 Multi SPECIES 40S ribosomal protein S3a-2 14547000 7,1628 1,1563 
A4IAU0 Multi SPECIES 40S ribosomal protein S3a-1 14547000 7,1628 1,1563 
Q4QJG7 
LEADING_AUTO - 
DO NOT CHANGE! 
Trypanothione reductase 14514000 7,1618 1,1561 
E9ACW0 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative heat shock protein DNAJ 14428000 7,1592 1,1557 
A4IAS5 
LEADING_SPECIES 
- DO NOT CHANGE! 
60S ribosomal protein L30 14388000 7,1580 1,1555 
A9LNR9 
LEADING_AUTO - 
DO NOT CHANGE! 
Tryparedoxin peroxidase 14334000 7,1564 1,1553 
A4H8V4 
LEADING_SPECIES 
- DO NOT CHANGE! 
Elongation factor 1-alpha 14289000 7,1550 1,1550 
A4ID12 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative glycyl tRNA synthetase 14283000 7,1548 1,1550 
E9BTH9 
LEADING_SPECIES 
- DO NOT CHANGE! 
Short chain 3-hydroxyacyl-CoA 
dehydrogenase, putative 
14209000 7,1526 1,1547 
A4HS12 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 14148000 7,1507 1,1544 
A4HKH0 Multi SPECIES Superoxide dismutase 13808000 7,1401 1,1526 
A4HKH1 Multi SPECIES Superoxide dismutase 13808000 7,1401 1,1526 
A4ICS4 Multi SPECIES 
Putative ubiquitin/ribosomal protein 
S27a 
13696000 7,1366 1,1521 
A4HW73 Multi SPECIES 
Putative ubiquitin/ribosomal protein 
S27a 
13696000 7,1366 1,1521 
E9AK40 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative spermidine synthase 13618000 7,1341 1,1517 
A4H6Z3 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative NADH:flavin 
oxidoreductase/NADH oxidase 
13527000 7,1312 1,1512 
E9AUR8 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative calpain-like cysteine 
peptidase 
13524000 7,1311 1,1512 
E9ARW7 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative aminopeptidase 13469000 7,1293 1,1509 
A4IAZ8 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative casein kinase 13413000 7,1275 1,1506 
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A0A142BXX3 Multi SPECIES 
6-phosphogluconate dehydrogenase, 
decarboxylating (Fragment) 
13367000 7,1260 1,1504 
A0A142BXX2 Multi SPECIES 
6-phosphogluconate dehydrogenase, 
decarboxylating (Fragment) 
13367000 7,1260 1,1504 
I3VJT5 Multi SPECIES 
6-phosphogluconate dehydrogenase, 
decarboxylating (Fragment) 
13367000 7,1260 1,1504 
Q18L52 Multi SPECIES 
6-phosphogluconate dehydrogenase, 
decarboxylating 
13367000 7,1260 1,1504 
Q18L04 Multi SPECIES 
6-phosphogluconate dehydrogenase, 
decarboxylating 
13367000 7,1260 1,1504 
Q5SDH3 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative small myristoylated protein 4 13217000 7,1211 1,1496 
Q8I496 
LEADING_SPECIES 
- DO NOT CHANGE! 
Hs1vu complex proteolytic subunit-
like 
13207000 7,1208 1,1495 
A4HDR8 
LEADING_SPECIES 
- DO NOT CHANGE! 
Transketolase 13203000 7,1207 1,1495 
A4I8P2 
LEADING_SPECIES 
- DO NOT CHANGE! 
Thiol-dependent reductase 1 13162000 7,1193 1,1493 
A4IB89 Multi SPECIES Putative 60S Ribosomal protein L36 13160000 7,1193 1,1493 
A4HZ73 Multi SPECIES Putative 60S Ribosomal protein L36 13160000 7,1193 1,1493 
A4HWN5 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative ribosomal protein S6 13075000 7,1164 1,1488 
E9BET4 
LEADING_AUTO - 
DO NOT CHANGE! 
Calpain-like cysteine peptidase, 
putative 
13065000 7,1161 1,1488 
A4HHL6 
LEADING_SPECIES 
- DO NOT CHANGE! 
Rab GDP dissociation inhibitor 12988000 7,1135 1,1484 
Q4QDX9 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative 60S ribosomal protein L10a 12928000 7,1115 1,1480 
Q4QIE0 
LEADING_AUTO - 
DO NOT CHANGE! 
Superoxide dismutase 12908000 7,1109 1,1479 
A4I7Q4 
LEADING_SPECIES 
- DO NOT CHANGE! 
60S ribosomal protein L18a 12906000 7,1108 1,1479 
A4I1Q0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 12794000 7,1070 1,1473 
A4I996 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative aminopeptidase 12740000 7,1052 1,1470 
Q4QD68 
LEADING_AUTO - 
DO NOT CHANGE! 
Cysteine peptidase A (CPA) 12736000 7,1050 1,1470 
E9B1Z9 
LEADING_AUTO - 
DO NOT CHANGE! 
GP63-like protein, leishmanolysin-
like protein 
12688000 7,1034 1,1467 
A4H445 Multi SPECIES Surface antigen-like protein 12624000 7,1012 1,1464 
A4H446 Multi SPECIES Surface antigen-like protein 12624000 7,1012 1,1464 
A4H440 Multi SPECIES Surface antigen-like protein 12624000 7,1012 1,1464 
A4H3Y2 Multi SPECIES Surface antigen-like protein 12624000 7,1012 1,1464 
E9AP91 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative lectin 12620000 7,1011 1,1463 
E9BUX4 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 12590000 7,1000 1,1462 
E9ADY9 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative carnitine/choline 
acetyltransferase 
12582000 7,0997 1,1461 
A4ICV5 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative proteasome beta 2 subunit 12464000 7,0957 1,1455 
E9AHL7 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative ADP-ribosylation factor 12447000 7,0951 1,1454 
A4H4D9 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative dipeptidyl-peptidase III 12376000 7,0926 1,1450 
E9AKY4 
LEADING_AUTO - 
DO NOT CHANGE! 
Protein disulfide isomerase 12352000 7,0917 1,1448 
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E9AZH2 
LEADING_AUTO - 
DO NOT CHANGE! 
Proteasome subunit beta type 12337000 7,0912 1,1447 
A4I191 Multi SPECIES RNA-binding protein, putative, UPB2 12286000 7,0894 1,1445 
E9AH94 Multi SPECIES RNA-binding protein, putative, UPB1 12286000 7,0894 1,1445 
A4HYZ5 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 40S ribosomal protein S11 12261000 7,0885 1,1443 
O00912 
LEADING_SPECIES 
- DO NOT CHANGE! 
Histone H4 12223000 7,0872 1,1441 
E9AGX4 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 40S ribosomal protein S23 12165000 7,0851 1,1438 
A4HQG9 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative histidine secretory acid 
phosphatase 
12145000 7,0844 1,1436 
E9AWS6 
LEADING_AUTO - 
DO NOT CHANGE! 
Triosephosphate isomerase 12118000 7,0834 1,1435 
A4I1V1 
LEADING_SPECIES 
- DO NOT CHANGE! 
Adenine phosphoribosyltransferase 12044000 7,0808 1,1431 
E9BBL6 
LEADING_AUTO - 
DO NOT CHANGE! 
Pyrroline-5-carboxylate reductase 11965000 7,0779 1,1426 
A0A1E1IRP4 Multi SPECIES Uncharacterized protein 11957000 7,0776 1,1426 
A0A088RML4 Multi SPECIES Uncharacterized protein 11957000 7,0776 1,1426 
E8NHG6 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative uncharacterized protein 
LmxM_30_0440_1 
11954000 7,0775 1,1425 
E9B2V9 
LEADING_AUTO - 
DO NOT CHANGE! 
Superoxide dismutase 11930000 7,0766 1,1424 
E9AHK3 
LEADING_SPECIES 
- DO NOT CHANGE! 
S-adenosylmethionine synthase 11867000 7,0743 1,1420 
A4HVX3 
LEADING_AUTO - 
DO NOT CHANGE! 
Proteasome subunit alpha type 11839000 7,0733 1,1419 
A4HRR9 
LEADING_SPECIES 
- DO NOT CHANGE! 
Dipeptylcarboxypeptidase 11757000 7,0703 1,1414 
A4HVW1 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 11671000 7,0671 1,1409 
E9AHJ2 Multi SPECIES Putative paraflagellar rod protein 1D 11634000 7,0657 1,1406 
Q66V59 Multi SPECIES Paraflagellar rod protein 1 11634000 7,0657 1,1406 
A4I4N5 Multi SPECIES Putative paraflagellar rod protein 1D 11634000 7,0657 1,1406 
O18699 
LEADING_SPECIES 
- DO NOT CHANGE! 
Cysteine protease 11603000 7,0646 1,1404 
A4HW72 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 11565000 7,0631 1,1402 
A4ICB5 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative prolyl oligopeptidase 11466000 7,0594 1,1396 
E9B3P3 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 11466000 7,0594 1,1396 
A4I4E1 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative guanine deaminase 11359000 7,0553 1,1390 
A4HX65 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 11357000 7,0553 1,1389 
A4HV05 
LEADING_SPECIES 
- DO NOT CHANGE! 
40S ribosomal protein S5 11343000 7,0547 1,1389 
E9BCQ4 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 11332000 7,0543 1,1388 
Q4Q504 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative ribosomal protein L27 11260000 7,0515 1,1383 
A4HTJ5 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative small ubiquitin protein 11221000 7,0500 1,1381 
A4ICK8 
LEADING_SPECIES 
- DO NOT CHANGE! 
Fructose-bisphosphate aldolase 11178000 7,0484 1,1378 
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E8NHC1 
LEADING_AUTO - 
DO NOT CHANGE! 
Proteasome subunit beta type 11054000 7,0435 1,1371 
A4HLW4 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative carboxypeptidase 10882000 7,0367 1,1360 
A4I885 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative cysteine desulfhydrase 10870000 7,0362 1,1359 
Q9BHZ6 Multi SPECIES Elongation factor-1 gamma 10862000 7,0359 1,1358 
A4HU19 Multi SPECIES Elongation factor-1 gamma 10862000 7,0359 1,1358 
A4HU18 Multi SPECIES Elongation factor-1 gamma 10862000 7,0359 1,1358 
A4I3Z9 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 10842000 7,0351 1,1357 
E9AW99 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative uncharacterized protein 10740000 7,0310 1,1350 
Q4QF83 
LEADING_AUTO - 
DO NOT CHANGE! 
NAD-specific glutamate 
dehydrogenase 
10736000 7,0308 1,1350 
O43992 
LEADING_AUTO - 
DO NOT CHANGE! 
40S ribosomal protein S2 10688000 7,0289 1,1347 
E9ACC9 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 10528000 7,0223 1,1336 
A0A088RLI0 
LEADING_AUTO - 
DO NOT CHANGE! 
Histone H2B 10499000 7,0211 1,1334 
A4HVR4 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 10498000 7,0211 1,1334 
E9AYP9 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative uncharacterized protein 10449000 7,0191 1,1331 
A0A1E1J8P0 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative S-adenosylhomocysteine 
hydrolase 
10445000 7,0189 1,1331 
A4HQL6 
LEADING_AUTO - 
DO NOT CHANGE! 
Protein disulfide-isomerase 10442000 7,0188 1,1331 
E9AHB0 Multi SPECIES Putative 60S ribosomal protein L7 10367000 7,0157 1,1326 
A4I1V4 Multi SPECIES Putative 60S ribosomal protein L7 10367000 7,0157 1,1326 
Q4QBL1 
LEADING_AUTO - 
DO NOT CHANGE! 
Farnesyl pyrophosphate synthase 10321000 7,0137 1,1322 
A0A1E1J0K7 Multi SPECIES 40S ribosomal protein S17, putative 10315000 7,0135 1,1322 
A0A088RXB2 Multi SPECIES 40S ribosomal protein S17, putative 10315000 7,0135 1,1322 
A4HMQ9 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative aminopeptidase P 10241000 7,0103 1,1317 
A4I5C0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative adenosine kinase 10235000 7,0101 1,1317 
A4I5Z0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 10164000 7,0071 1,1312 
A4HY61 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 40S ribosomal protein S13 10143000 7,0062 1,1310 
Q4QDX3 
LEADING_AUTO - 
DO NOT CHANGE! 
Probable citrate synthase, 
mitochondrial 
10117000 7,0051 1,1308 
A4HI30 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 4-methyl-5(Beta-
hydroxyethyl)-thiazole 
monophosphate synthesis protein 
10093000 7,0040 1,1307 
A4I890 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative ribosomal protein L27 10091000 7,0039 1,1307 
A4HU23 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 10064000 7,0028 1,1305 
A4H746 
LEADING_AUTO - 
DO NOT CHANGE! 
40S ribosomal protein S12 10051000 7,0022 1,1304 
E9AII6 
LEADING_SPECIES 
- DO NOT CHANGE! 
Contig, possible fusion of 
chromosomes 20 and 34 
10038000 7,0016 1,1303 
A4I067 
LEADING_SPECIES 
- DO NOT CHANGE! 
Pteridine reductase 1 9968900 6,9986 1,1298 
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Q4Q6F6 
LEADING_AUTO - 
DO NOT CHANGE! 
Biotin/lipoate protein ligase-like 
protein 
9954600 6,9980 1,1297 
A4HX73 Multi SPECIES Elongation factor 1-alpha 9950300 6,9978 1,1297 
E9AGP5 Multi SPECIES Elongation factor 1-alpha 9950300 6,9978 1,1297 
A4HT92 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 40S ribosomal protein S9 9923600 6,9967 1,1295 
A4HV19 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 60S ribosomal protein L28 9922600 6,9966 1,1295 
A4HDN8 
LEADING_AUTO - 
DO NOT CHANGE! 
Inhibitor of cysteine peptidase 9877400 6,9946 1,1292 
A4HCH8 
LEADING_AUTO - 
DO NOT CHANGE! 
FPPS protein 9716400 6,9875 1,1280 
E9AEF4 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 9692000 6,9864 1,1278 
E9ACQ0 
LEADING_AUTO - 
DO NOT CHANGE! 
Surface antigen-like protein 9659700 6,9850 1,1276 
A4HXT8 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative 60S ribosomal protein L10a 9620100 6,9832 1,1273 
A4HE56 
LEADING_SPECIES 
- DO NOT CHANGE! 
Aldehyde dehydrogenase, 
mitochondrial 
9561600 6,9805 1,1269 
Q27686 
LEADING_AUTO - 
DO NOT CHANGE! 
Pyruvate kinase 9543900 6,9797 1,1268 
A4I2F5 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative nitrilase 9474400 6,9766 1,1262 
Q4QIX1 
LEADING_AUTO - 
DO NOT CHANGE! 
Protein disulfide isomerase 9325200 6,9697 1,1251 
F8QV42 
LEADING_AUTO - 
DO NOT CHANGE! 
Tubulin beta chain 9321600 6,9695 1,1251 
A4H942 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 9313200 6,9691 1,1250 
A4I1Z8 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 9266800 6,9669 1,1247 
A4I9G0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Small nuclear ribonucleoprotein 
SmD2 
9223300 6,9649 1,1244 
B8Y658 
LEADING_SPECIES 
- DO NOT CHANGE! 
Methylene-tetrahydrofolate 
dehydrogenase/cyclohydrolase 
9209300 6,9642 1,1242 
Q70GE8 
LEADING_AUTO - 
DO NOT CHANGE! 
Thiol-dependent reductase 1 9171100 6,9624 1,1240 
A4I849 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 9114400 6,9597 1,1235 
E9AGX7 
LEADING_SPECIES 
- DO NOT CHANGE! 
T-complex protein 1 subunit delta 9067600 6,9575 1,1232 
E9BQ78 
LEADING_SPECIES 
- DO NOT CHANGE! 
Mitogen activated protein kinase, 
putative 
8964200 6,9525 1,1224 
A4HB47 
LEADING_SPECIES 
- DO NOT CHANGE! 
Contig, possible fusion of 
chromosomes 20 and 34 
8918500 6,9503 1,1220 
A4I412 Multi SPECIES Putative heat-shock protein hsp70 8894100 6,9491 1,1218 
E9AHH1 Multi SPECIES Putative heat-shock protein hsp70 8894100 6,9491 1,1218 
Q4QGD8 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 8874200 6,9481 1,1217 
A4HWC9 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative ribonucleoprotein p18, 
mitochondrial 
8809100 6,9449 1,1211 
A4I2T4 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative arginyl-tRNA synthetase 8701500 6,9396 1,1203 
E9AHP6 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 8670600 6,9380 1,1200 
A4HSP6 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 8649100 6,9370 1,1198 
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A4HFU7 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 8636800 6,9364 1,1197 
Q6QMI0 Multi SPECIES 
Nonspecific nucleoside hydrolase 
(Fragment) 
8601200 6,9346 1,1195 
Q6QMJ1 Multi SPECIES 
Nonspecific nucleoside hydrolase 
(Fragment) 
8601200 6,9346 1,1195 
Q6QMI7 Multi SPECIES 
Nonspecific nucleoside hydrolase 
(Fragment) 
8601200 6,9346 1,1195 
Q2PDC6 Multi SPECIES 
Inosine-uridine preferring nucleoside 
hydrolase 
8601200 6,9346 1,1195 
Q2PDC5 Multi SPECIES 
Inosine-uridine preferring nucleoside 
hydrolase 
8601200 6,9346 1,1195 
Q2PDB9 Multi SPECIES 
Inosine-uridine preferring nucleoside 
hydrolase 
8601200 6,9346 1,1195 
Q2PD97 Multi SPECIES 
Inosine-uridine preferring nucleoside 
hydrolase 
8601200 6,9346 1,1195 
Q2PD96 Multi SPECIES 
Inosine-uridine preferring nucleoside 
hydrolase 
8601200 6,9346 1,1195 
A4I4C9 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative lipophosphoglycan 
biosynthetic protein 
8589400 6,9340 1,1194 
C7EX18 
LEADING_AUTO - 
DO NOT CHANGE! 
Gp63 8559700 6,9325 1,1191 
A4ICD5 
LEADING_SPECIES 
- DO NOT CHANGE! 
Protein disulfide-isomerase 8539900 6,9315 1,1190 
A4H8B2 
LEADING_SPECIES 
- DO NOT CHANGE! 
Proliferating cell nuclear antigen 8539700 6,9314 1,1190 
A4I1F4 
LEADING_SPECIES 
- DO NOT CHANGE! 
Aldehyde dehydrogenase, 
mitochondrial 
8522100 6,9305 1,1188 
Q4QFJ8 
LEADING_AUTO - 
DO NOT CHANGE! 
Inositol-3-phosphate synthase 8477500 6,9283 1,1184 
E9AWR7 
LEADING_AUTO - 
DO NOT CHANGE! 
Malic enzyme 8476600 6,9282 1,1184 
A4HXD8 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 8463000 6,9275 1,1183 
A0A1E1ISN0 Multi SPECIES Putative cystathionine beta-synthase 8460200 6,9274 1,1183 
A0A088RP82 Multi SPECIES Cystathionine beta-synthase 8460200 6,9274 1,1183 
A4ID19 
LEADING_SPECIES 
- DO NOT CHANGE! 
Nascent polypeptide-associated 
complex subunit beta 
8399300 6,9242 1,1178 
A4I7N0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Profilin 8323000 6,9203 1,1172 
A4I082 
LEADING_SPECIES 
- DO NOT CHANGE! 
Aldose 1-epimerase-like protein 8314600 6,9198 1,1171 
A0A0S1M2A5 Multi SPECIES 
Putative spermidine synthase 1 
(Fragment) 
8296200 6,9189 1,1169 
A0A0S1M298 Multi SPECIES 
Putative spermidine synthase 1 
(Fragment) 
8296200 6,9189 1,1169 
A0A0S1M285 Multi SPECIES 
Putative spermidine synthase 1 
(Fragment) 
8296200 6,9189 1,1169 
A4H3X8 Multi SPECIES Putative spermidine synthase 8296200 6,9189 1,1169 
A4IDL0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Tyrosine aminotransferase 8254100 6,9167 1,1166 
A4I3Q8 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative replication factor A, 51kDa 
subunit 
8238700 6,9159 1,1164 
E9BB38 
LEADING_AUTO - 
DO NOT CHANGE! 
Alanine aminotransferase 8238400 6,9158 1,1164 
A4HRT6 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative ribosomal protein L38 8214700 6,9146 1,1162 
A4H635 
LEADING_AUTO - 
DO NOT CHANGE! 
GP63-4 protein 8210400 6,9144 1,1162 
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LEADING_CHECK CASE_CHECK DESC_CHECK iBAQ LOG10 
NORMALISED 
TO LOG10 
AVERAGE 
A4I253 
LEADING_AUTO - 
DO NOT CHANGE! 
Heat shock protein 70-related protein 8198100 6,9137 1,1161 
A9YYK9 Multi SPECIES p4 nuclease (Fragment) 8185800 6,9131 1,1160 
A4I5I0 Multi SPECIES p1/s1 nuclease 8185800 6,9131 1,1160 
E9JUH3 Multi SPECIES Trypanothione reductase (Fragment) 8182100 6,9129 1,1160 
E9JUG5 Multi SPECIES Trypanothione reductase (Fragment) 8182100 6,9129 1,1160 
E9BB84 
LEADING_AUTO - 
DO NOT CHANGE! 
Carboxypeptidase, putative 8178000 6,9126 1,1159 
A4IAG9 
LEADING_SPECIES 
- DO NOT CHANGE! 
Nucleolar protein family a member-
like protein 
8167600 6,9121 1,1158 
Q8I8E1 Multi SPECIES Protein disulfide-isomerase 8159700 6,9117 1,1158 
Q4Q059 Multi SPECIES Protein disulfide-isomerase 8159700 6,9117 1,1158 
E9BG32 
LEADING_AUTO - 
DO NOT CHANGE! 
GDP-mannose pyrophosphorylase 8137900 6,9105 1,1156 
A4HWJ8 
LEADING_AUTO - 
DO NOT CHANGE! 
60S ribosomal protein L6 8124700 6,9098 1,1155 
I3VJK5 Multi SPECIES Fumarate hydratase (Fragment) 8066700 6,9067 1,1150 
A2CIQ7 Multi SPECIES Fumarate hydratase 8066700 6,9067 1,1150 
A2CIQ1 Multi SPECIES Fumarate hydratase 8066700 6,9067 1,1150 
A2CIP4 Multi SPECIES Fumarate hydratase 8066700 6,9067 1,1150 
A2CIN2 Multi SPECIES Fumarate hydratase 8066700 6,9067 1,1150 
A2CIN0 Multi SPECIES Fumarate hydratase 8066700 6,9067 1,1150 
A4H9H8 
LEADING_AUTO - 
DO NOT CHANGE! 
Probable citrate synthase, 
mitochondrial 
8021700 6,9043 1,1146 
A4IBC5 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 7993600 6,9027 1,1143 
A2CIM6 Multi SPECIES 
Glucose-6-phosphate 1-
dehydrogenase 
7927800 6,8992 1,1137 
A2CIL1 Multi SPECIES 
Glucose-6-phosphate 1-
dehydrogenase 
7927800 6,8992 1,1137 
A2CIK1 Multi SPECIES 
Glucose-6-phosphate 1-
dehydrogenase 
7927800 6,8992 1,1137 
A2CIJ8 Multi SPECIES 
Glucose-6-phosphate 1-
dehydrogenase 
7927800 6,8992 1,1137 
A4HVI6 
LEADING_SPECIES 
- DO NOT CHANGE! 
40S ribosomal protein S12 7922800 6,8989 1,1137 
P42865 
LEADING_AUTO - 
DO NOT CHANGE! 
Probable quinone oxidoreductase 7871000 6,8960 1,1132 
A7UFI6 Multi SPECIES Malate dehydrogenase 7838600 6,8942 1,1130 
A4HAC0 Multi SPECIES Malate dehydrogenase 7838600 6,8942 1,1130 
Q1A5Y1 
LEADING_AUTO - 
DO NOT CHANGE! 
Tubulin beta chain (Fragment) 7770400 6,8904 1,1123 
Q9N9V2 Multi SPECIES 
Nascent polypeptide associated 
complex homologue, alpha chain 
7764500 6,8901 1,1123 
A4HS73 Multi SPECIES 
Nascent polypeptide associated 
complex subunit-like protein, copy 1 
7764500 6,8901 1,1123 
A4HS72 Multi SPECIES 
Nascent polypeptide associated 
complex subunit-like protein, copy 2 
7764500 6,8901 1,1123 
P25204 
LEADING_AUTO - 
DO NOT CHANGE! 
40S ribosomal protein S8 7762500 6,8900 1,1123 
E9B3B0 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative chaperonin alpha subunit 7704400 6,8867 1,1117 
Q4QGJ6 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative surface antigen protein 2 7645300 6,8834 1,1112 
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LEADING_CHECK CASE_CHECK DESC_CHECK iBAQ LOG10 
NORMALISED 
TO LOG10 
AVERAGE 
Q2HZY7 Multi SPECIES Elongation factor 2 7632600 6,8827 1,1111 
A4HNM7 Multi SPECIES Elongation factor 2 7632600 6,8827 1,1111 
A4I478 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative thymine-7-hydroxylase 7508000 6,8755 1,1099 
Q4Q276 
LEADING_AUTO - 
DO NOT CHANGE! 
Uncharacterized protein 7437800 6,8714 1,1093 
E9ARS1 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative heat shock protein 7388800 6,8686 1,1088 
A4HCV5 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 7387700 6,8685 1,1088 
A4HXQ3 
LEADING_SPECIES 
- DO NOT CHANGE! 
Glycogen synthase kinase 3 7374100 6,8677 1,1087 
Q9N9V5 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 40S ribosomal protein S33 7367100 6,8673 1,1086 
A4HKX6 
LEADING_SPECIES 
- DO NOT CHANGE! 
Dihydrolipoyl dehydrogenase 7358900 6,8668 1,1085 
A4HCZ3 
LEADING_SPECIES 
- DO NOT CHANGE! 
T-complex protein 1 subunit gamma 7346600 6,8661 1,1084 
Q2PD92 
LEADING_SPECIES 
- DO NOT CHANGE! 
Aspartate aminotransferase 7265000 6,8612 1,1076 
A0A1E1J180 Multi SPECIES 
Aspartyl 
aminopeptidase,putative,metallo-
peptidase, Clan MH, Family M20 
7237900 6,8596 1,1074 
A0A088RY37 Multi SPECIES Aspartyl aminopeptidase, putative 7237900 6,8596 1,1074 
A4ICM4 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative ribosomal protein L24 7176300 6,8559 1,1068 
Q4Q8S1 
LEADING_AUTO - 
DO NOT CHANGE! 
6-phosphogluconolactonase 7162800 6,8551 1,1066 
A4HSS8 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative glutamine synthetase 7136800 6,8535 1,1064 
A4HFS1 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 7075200 6,8497 1,1058 
A4HI66 
LEADING_SPECIES 
- DO NOT CHANGE! 
Importin subunit alpha 7069400 6,8494 1,1057 
A4HUB4 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative ribosomal protein l35a 7035600 6,8473 1,1054 
E9BEP5 
LEADING_AUTO - 
DO NOT CHANGE! 
1,2-dihydroxy-3-keto-5-
methylthiopentene dioxygenase 
7032900 6,8471 1,1053 
A4IA81 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 6980300 6,8439 1,1048 
P42922 
LEADING_SPECIES 
- DO NOT CHANGE! 
60S ribosomal protein L11 6869200 6,8369 1,1037 
E9AKK2 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative dipeptidyl-peptidase III 
(Metallo-peptidase, clan m-, family 
m49) 
6803900 6,8328 1,1030 
E9AYH6 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative uncharacterized protein 6794400 6,8322 1,1029 
A4HUL2 
LEADING_SPECIES 
- DO NOT CHANGE! 
Nucleoside phosphorylase-like 
protein 
6661600 6,8236 1,1015 
E9AGM7 Multi SPECIES Putative nucleoside transporter 1 6651400 6,8229 1,1014 
E9AGM6 Multi SPECIES Putative nucleoside transporter 1 6651400 6,8229 1,1014 
E9AGM5 Multi SPECIES Putative nucleoside transporter 1 6651400 6,8229 1,1014 
A4HWK9 Multi SPECIES Putative nucleoside transporter 1 6651400 6,8229 1,1014 
A4HU05 
LEADING_SPECIES 
- DO NOT CHANGE! 
Uncharacterized protein 6633800 6,8218 1,1013 
A4HHW2 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative 2-hydroxy-3-oxopropionate 
reductase 
6632500 6,8217 1,1012 
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LEADING_CHECK CASE_CHECK DESC_CHECK iBAQ LOG10 
NORMALISED 
TO LOG10 
AVERAGE 
E9AQI0 
LEADING_AUTO - 
DO NOT CHANGE! 
Protein tyrosine phosphatase-like 
protein 
6618900 6,8208 1,1011 
E9AU19 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative kinetoplast-associated 
protein 
6607400 6,8200 1,1010 
Q4QAI0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative IgE-dependent histamine-
releasing factor 
6601000 6,8196 1,1009 
A4ID58 Multi SPECIES Putative ribosomal protein L29 6597900 6,8194 1,1009 
A4ID57 Multi SPECIES Putative ribosomal protein L29 6597900 6,8194 1,1009 
A4HNP0 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative proteasome beta 2 subunit 6574500 6,8179 1,1006 
E9ATD8 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative cysteine synthase 6562000 6,8170 1,1005 
Q4QBF5 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative endoribonuclease L-PSP 
(Pb5) 
6543800 6,8158 1,1003 
E9B6B5 
LEADING_AUTO - 
DO NOT CHANGE! 
Putative aminopeptidase P 6530900 6,8150 1,1002 
A4HSB6 
LEADING_SPECIES 
- DO NOT CHANGE! 
Putative RNA-binding protein 6519300 6,8142 1,1000 
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Data was collected from the Allele Frequency Net Database for the following world 
regions: South and Central America (Table 1), North Africa (Table 2), Western Asia (Table 3), 
South Asia (Table 4).  
Data were retrieved from AFND through a ‘HLA allele freq (Classical)’ search with the 
following filters: i) region name; ii) level of resolution=2-digits; iii) Population standard=Gold 
and Silver (8); iv) show frequencies=only positives 
 
Table 1 Population studies from AFND included in the HLA allele frequency analysis of the South and 
Central America World region. 
World region: SOUTH AND CENTRAL AMERICA 
Population Ethnicity Study 
Sample 
Size 
HLA Loci 
Argentina Buenos Aires Caucasoid HLA 466 
A, B, C, DPB1, DQA1, DQB1, 
DRB1 
Argentina Buenos Aires pop 2 Caucasoid HLA 1216 A, B, DRB1 
Argentina Chiriguano Amerindian HLA 54 A, B, DPB1, DQA1, DQB1, DRB1 
Argentina Chubut Tehuelche Amerindian HLA 23 DRB1 
Argentina Corrientes Mixed HLA 155 A, B, DRB1 
Argentina Cuyo Region Caucasoid HLA 420 A, B, DRB1 
Argentina Gran Chaco Eastern 
Toba 
Amerindian HLA 135 A, B, DPB1, DQA1, DQB1, DRB1 
Argentina Gran Chaco Mataco 
Wichi 
Amerindian HLA 49 A, B, DPB1, DQA1, DQB1, DRB1 
Argentina Gran Chaco Western 
Toba Pilaga 
Amerindian HLA 19 A, B, DPB1, DQA1, DQB1, DRB1 
Argentina Kolla Amerindian HLA 61 DQB1, DRB1 
Argentina La Plata Caucasoid HLA 100 A, B, C, DRB1 
Argentina Mapuche Amerindian HLA 48 DPB1, DQA1, DQB1, DRB1 
Argentina Rio Negro Mapuche Amerindian HLA 34 DRB1 
Argentina Rosario Toba Amerindian HLA 86 A, B, DQA1, DQB1, DRB1 
Argentina Salta Wichi pop 2 Amerindian HLA 19 A, B, DPB1, DQA1, DQB1, DRB1 
Bolivia Aymara Amerindian HLA 102 A, B, DQB1, DRB1 
Bolivia Quechua   HLA 80 DQB1, DRB1, A, B 
Brazil Belem Mixed Mixed HLA 100 B 
Brazil Belo Horizonte Caucasian Caucasoid HLA 95 A, B 
Brazil Central Plateau Xavante Amerindian HLA 74 DPB1, DQA1, DQB1, DRB1 
Brazil Curitiba-Parana Mixed Mixed HLA 264 A, B, C, DRB1 
Brazil Guarani Kaiowa Amerindian HLA 155 DQA1, DQB1, DRB1 
Brazil Guarani M bya Amerindian HLA 93 DQA1, DQB1, DRB1 
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Table 1 (continued) 
Population Ethnicity Study 
Sample 
Size 
HLA Loci 
Brazil Guarani Nandeva Amerindian HLA 86 DQA1, DQB1, DRB1 
Brazil Kaingang Amerindian HLA 235 DQA1, DQB1, DRB1 
Brazil Mato Grosso do Sul Mixed HLA 203 DRB1 
Brazil Minas Gerais State Mixed Mixed HLA 1 A, B, DRB1 
Brazil North East Mixed Mixed HLA 205 DQA1, DQB1, DRB1 
Brazil Parana Afro Brazilian Black HLA 77 A, B, DRB1 
Brazil Parana Cafuzo Mixed HLA 319 A, B, DRB1 
Brazil Parana Caucasian Caucasoid HLA 2775 A, B, DRB1 
Brazil Parana Japanese   HLA 192 A B C 
Brazil Parana Mulatto Mulatto HLA 186 A, B, DRB1 
Brazil Parana Oriental Oriental HLA 33 A, B, DRB1 
Brazil Pernambuco Mixed Mixed HLA 101 A, B, C 
Brazil Piaui Mixed Mixed HLA 21943 A, B, DRB1 
Brazil REDOME Acre Mixed HLA 859 A, B, DRB1 
Brazil REDOME Alagoas Mixed HLA 25349 A, B, DRB1 
Brazil REDOME Amapa Mixed HLA 17,864 A, B, DRB1 
Brazil REDOME Amazonas Mixed HLA 24,129 A, B, DRB1 
Brazil REDOME Bahia Mixed HLA 47399 A, B, DRB1 
Brazil REDOME Ceara Mixed HLA 101217 A, B, DRB1 
Brazil REDOME Espirito Santo Mixed HLA 88,485 A, B, DRB1 
Brazil REDOME Federal District Mixed HLA 29549 A, B, DRB1 
Brazil REDOME Goias Mixed HLA 88,574 A, B, DRB1 
Brazil REDOME Maranhao Mixed HLA 10180 A, B, DRB1 
Brazil REDOME Mato Grosso Mixed HLA 34649 A, B, DRB1 
Brazil REDOME Mato Grosso do Sul Mixed HLA 95667 A, B, DRB1 
Brazil REDOME Minas Gerais Mixed HLA 211275 A, B, DRB1 
Brazil REDOME Para Mixed HLA 72637 A, B, DRB1 
Brazil REDOME Paraiba Mixed HLA 43868 A, B, DRB1 
Brazil REDOME Parana Mixed HLA 341639 A, B, DRB1 
Brazil REDOME Pernambuco Mixed HLA 92332 A, B, DRB1 
Brazil REDOME Piaui Mixed HLA 46140 A, B, DRB1 
Brazil REDOME Rio de Janeiro Mixed HLA 139322 A, B, DRB1 
Brazil REDOME Rio Grande do 
Norte 
Mixed HLA 46603 A, B, DRB1 
Brazil REDOME Rio Grande do Sul Mixed HLA 241329 A, B, DRB1 
Brazil REDOME Rondonia Mixed HLA 54396 A, B, DRB1 
Brazil REDOME Roraima Mixed HLA 4140 A, B, DRB1 
Brazil REDOME Santa Catarina Mixed HLA 106673 A, B, DRB1 
Brazil REDOME Sao Paulo Mixed HLA 800809 A, B, DRB1 
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Table 1 (continued) 
Population Ethnicity Study 
Sample 
Size 
HLA Loci 
Brazil REDOME Sergipe Mixed HLA 7321 A, B, DRB1 
Brazil REDOME Tocantins Mixed HLA 20692 A, B, DRB1 
Brazil Rio Grande do Norte Mestizo Mestizo HLA 12973 A, B, DRB1 
Brazil Rio Grande do Sul Black Black HLA 248 A, B, DRB1 
Brazil Rio Grande do Sul Caucasoid Caucasoid HLA 4428 A, B, DRB1 
Brazil Rio Grande do Sul Mixed Mixed HLA 324 A, B, DRB1 
Brazil Sao Paulo Bauru Mixed Mixed HLA 3542 A, B, DRB1 
Brazil Sao Paulo Mixed Mixed HLA 239 A, B, DQA1, DQB1, DRB1 
Brazil South East Cord Bllod Unknown HLA 11409 A B DRB1 
Brazil South Ribeirao Preto Mixed HLA 184 A, B, DRB1 
Brazil Southeast Campinas Mixed Mixed HLA 99 DRB1 
Chile Easter Island Amerindian HLA 21 A, B, C, DRB1 
Chile Huilliche Amerindian HLA 40 DRB1 
Chile Santiago   HLA 920 A, B, DRB1 
Chile Santiago Mixed Mixed HLA 70 A, B, C, DQB1, DRB1 
Colombia Antioquia Paisa Amerindian HLA 100 DQB1, DRB1 
Colombia Barranquilla   HLA 188 A, B, DRB1 
Colombia Bogota and Medellin 
Mestizo 
Mestizo HLA 65 DQB1, DRB1 
Colombia Guajira Peninsula Wayuu Amerindian HLA 88 DQA1, DQB1, DRB1 
Colombia Jaidukama   HLA 39 A, B, DQB1, DRB1 
Colombia Northwest Tule Amerindian HLA 29 DPB1, DQA1, DQB1, DRB1 
Colombia San Basilio de Palenque   HLA 42 A B DQB1 DRB1 
Colombia Sierra Nevada de Santa 
Marta Arhuaco 
Amerindian HLA 107 DQA1, DQB1, DRB1 
Colombia Sierra Nevada de Santa 
Marta Arsario 
Amerindian HLA 18 DQA1, DQB1, DRB1 
Colombia Sierra Nevada de Santa 
Marta Kogi 
Amerindian HLA 42 DQA1, DQB1, DRB1 
Colombia Wayu from Guajira 
Peninsula 
Wayu HLA 48 A B DQB1 DRB1 
Costa Rica Central Valley Mestizo Mestizo HLA 130 
A, B, C, DQB1, DRB1, DRB3 
DRB4 DRB5 
Cuba Caucasian Caucasoid HLA 70 A, B 
Cuba Mixed Mixed HLA 78 A, B, DQA1, DQB1, DRB1 
Cuba Mixed pop 2 Mixed HLA 189 A, B, C, DRB1 
Cuba Mulatto Mulatto HLA 42 A, B 
Ecuador African Black HLA 58 DPA1, DPB1, DQA1, DQB1 
Ecuador Amazonia Mixed Ancestry   HLA 39 A, B, DQB1, DRB1 
Ecuador Andes Mixed Ancestry   HLA 824 A, B, DQB1, DRB1 
Ecuador Cayapa Amerindian HLA 183 A, DPB1, DQA1, DQB1, DRB1 
Ecuador Coast Mixed Ancestry   HLA 238 A, B, DQB1, DRB1 
Ecuador Mixed Ancestry   HLA 1173 A, B, DQB1, DRB1 
Guatemala Mayan Amerindian HLA 132 A, B, DQB1, DRB1 
Jamaica Black HLA 132 DQA1, DQB1, DRB1 
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Table 2 Population studies from AFND included in the HLA allele frequency analysis for the North Africa 
World region.  
World region: NORTH AFRICA 
Population Ethnicity Study 
Sample 
Size 
HLA Loci 
Algeria pop 2 Arab HLA 106 A, B, C, DQA1, DQB1, DRB1 
Ethiopia Amhara Black HLA 98 DQA1, DQB1, DRB1 
Ethiopia Oromo Black HLA 83 DQA1, DQB1, DRB1 
Morocco Arab HLA 96 A, B, DQA1, DQB1, DRB1 
Morocco Casablanca Arab HLA 100 A, B 
Morocco pop 2 Mixed HLA 110 A, B, DQB1, DRB1 
Morocco Souss Region Arab HLA 98 DQA1, DQB1, DRB1 
Sudan Central Shaigiya Mixed Mixed HLA 36 A, B, C, DRB1 
Sudan East Rashaida Arab HLA 27 A, B, C, DRB1 
Sudan Mixed Mixed HLA 200 A, B, C, DPB1, DQB1, DRB1 
Sudan South Nuba Black HLA 46 A, B, C, DRB1 
Tunisia Arab HLA 100 A, B, C, DPB1, DQA1, DQB1, DRB1 
Tunisia Ghannouch Arab HLA 82 A, B, DQB1, DRB1 
Tunisia pop 3 Arab HLA 104 A, B, DQB1, DRB1 
 
 
Table 3 Population studies from AFND included in the HLA allele frequency analysis for the Western Asia 
World region. 
World region: WESTERN ASIA 
Population Ethnicity Study 
Sample 
Size 
HLA Loci 
Armenia combined Regions Arab HLA 100 A, B, DRB1 
Armenia Ghegharkunik Arab HLA 242 A, B, DRB1 
Armenia living in Iran Arab HLA 85 A, B, DRB1 
Armenia living in Karabakh Arab HLA 445 A, B, DRB1 
Armenia living in Lebanon Arab HLA 368 A, B, DRB1 
Armenia living in USA Arab HLA 233 A, B, DRB1 
Armenia Lori Arab HLA 102 A, B, DRB1 
Armenia Shirak Arab HLA 76 A, B, DRB1 
Armenia Syunik Arab HLA 117 A, B, DRB1 
Armenia Yerevan Arab HLA 445 A, B, DRB1 
Gaza Palestinians Arab HLA 165 A, B, DQB1, DRB1 
Georgia Kurds Kurds HLA 30 A, B, DQB1, DRB1 
Georgia Svaneti Region 
Svan 
Caucasoid HLA 80 A, B, DPB1, DQA1, DQB1, DRB1 
Iran Persian HLA 58 DQA1, DQB1, DRB1 
Iran Baloch Persian HLA 100 A, B, C, DQA1, DQB1, DRB1 
Iran pop 1 Arab HLA 64 A, B 
Iran pop 3 Arab HLA 100 DQB1, DRB1 
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Table 3 (continued) 
Population Ethnicity Study 
Sample 
Size 
HLA Loci 
Iran Royan Cord Blood 
Bank 
Persian HLA 15600 A, B, DRB1 
Iran Tehran Persian HLA 120 C 
Iraq Erbil   HLA 372 A B C DQB1 DRB1 
Israel Arab Arab HLA 109 DQA1, DQB1, DRB1 
Israel Arab   HLA 12301 DRB1, A, B 
Israel Ashkenazi Jews Jew HLA 80 DQA1, DQB1, DRB1 
Israel Ashkenazi Jews   HLA 4625 DRB1, A, B 
Israel Ashkenazi Jews pop 
2 
Jew HLA 132 A, B, DQA1, DQB1, DRB1 
Israel Ethiopian Jews Jew HLA 122 DQA1, DQB1, DRB1 
Israel Iranian Jews Jew HLA 101 DQA1, DQB1, DRB1 
Israel Jews pop 2 Jew HLA 23000 A, B, DRB1 
Israel Libyan Jews Jew HLA 119 DQA1, DQB1, DRB1 
Israel Moroccan Jews Jew HLA 113 A, B, DQA1, DQB1, DRB1 
Israel Non Ashkenazi Jews Jew HLA 80 DQA1, DQB1, DRB1 
Israel Yemenite Jews Jew HLA 76 DQA1, DQB1, DRB1 
Jordan Arab HLA 15141 A, B, DRB1 
Jordan Amman Arab HLA 146 A, B, C, DQA1, DQB1, DRB1 
Iraq Kurdistan Region Kurd HLA 209 A, B, C, DQB1, DRB1 
Lebanon Kafar Zubian Arab HLA 94 DPB1, DQB1, DRB1 
Lebanon Niha el Shouff Arab HLA 61 DPB1, DQB1, DRB1 
Lebanon Yuhmur Arab HLA 82 DPB1, DQB1, DRB1 
Oman Arab HLA 118 A, B 
Saudi Arabia Arab HLA 18 A, B, DPB1, DQB1, DRB1 
Saudi Arabia pop 2 Arab HLA 383 A, B, DQB1, DRB1 
Saudi Arabia pop 4 Arab HLA 499 A, B, C, DQB1, DRB1 
Turkey Ankara Caucasoid HLA 50 DQA1, DQB1, DRB1 
Turkey Istanbul Caucasoid HLA 250 DRB1 
Turkey pop 1 Caucasoid HLA 250 DQA1, DQB1, DRB1 
Turkey pop 2 Caucasoid HLA 228 A, B, DQB1, DRB1 
Turkey pop 3 Caucasoid HLA 50 DQA1, DQB1 
Turkey pop 5 Caucasoid HLA 142 A, B, C 
United Arab Emirates pop 2 Arab HLA 373 A, B, DRB1 
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Table 4 Population studies from AFND included in the HLA allele frequency analysis for the South Asia 
World region. 
World Region: SOUTH ASIA     
Population Ethnicity Study 
Sample 
Size 
HLA Loci 
Bangladesh Dhaka Bangalee Asian HLA 141 A, B, DRB1 
India Andhra Pradesh 
Brahmin 
Asian HLA 98 DRB1 
India Andhra Pradesh Sunni Asian HLA 100 DRB1 
India Bombay Asian HLA 59 DPA1, DPB1, DQA1, DQB1 
India Delhi pop 2 Asian HLA 90 A, B, C 
India Jalpaiguri Toto Asian HLA 40 A, B 
India Kerala Adiya Asian HLA 21 B, C 
India Kerala Hindu Ezhava Asian HLA 24 A, B, C 
India Kerala Hindu Nair Asian HLA 41 A, B, C 
India Kerala Hindu 
Namboothiri 
Asian HLA 40 A, B, C 
India Kerala Hindu Pulaya Asian HLA 16 A, B, C 
India Kerala Kanikkar Asian HLA 22 B, C 
India Kerala Kattunaikka Asian HLA 17 B, C 
India Kerala Kurichiya Asian HLA 10 B, C 
India Kerala Kuruma Asian HLA 15 B, C 
India Kerala Malabar Muslim Asian HLA 34 A, B, C 
India Kerala Malapandaram Asian HLA 10 B, C 
India Kerala Paniya Asian HLA 10 B, C 
India Kerala Syrian Christian Asian HLA 31 A, B, C 
India Lucknow Asian HLA 123 DPB1, DQA1, DQB1, DRB1 
India New Delhi pop 2 Asian HLA 102 DQB1, DRB1 
India North Asian HLA 85 DRB1 
India North Gujarat Asian HLA 338 A, B, C, DQB1, DRB1 
India North pop 2 Asian HLA 72 A, B, C, DQA1, DQB1, DRB1 
India North pop 3 Asian HLA 587 A, B, DRB1 
India Northeast Kayastha Asian HLA 190 DQA1, DQB1, DRB1 
India Northeast Lachung Asian HLA 58 DQA1, DQB1, DRB1 
India Northeast Mathur Asian HLA 155 DQA1, DQB1, DRB1 
India Northeast Mech Asian HLA 63 DQA1, DQB1, DRB1 
India Northeast Rajbanshi Asian HLA 98 DQA1, DQB1, DRB1 
India Northeast Rastogi Asian HLA 196 DQA1, DQB1, DRB1 
India Northeast Shia Asian HLA 190 DQA1, DQB1, DRB1 
India Northeast Sunni Asian HLA 188 DQA1, DQB1, DRB1 
India Northeast Vaish Asian HLA 198 DQA1, DQB1, DRB1 
India Tamil Nadu Chennai Asian HLA 137 DRB1 
India Tamil Nadu Dravidian Asian HLA 156 DRB1 
India Uttar Pradesh Asian HLA 202 DQA1, DQB1, DRB1 
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Table 4 (continued) 
Population Ethnicity Study 
Sample 
Size 
HLA Loci 
Pakistan Baloch Asian HLA 66 A, B, C, DQB1, DRB1 
Pakistan Brahui Asian HLA 104 A, B, C, DQB1, DRB1 
Pakistan Burusho Asian HLA 92 A, B, C, DQB1, DRB1 
Pakistan Kalash Asian HLA 69 A, B, C, DQB1, DRB1 
Pakistan Karachi Parsi Asian HLA 91 A, B, C, DQB1, DRB1 
Pakistan Mixed Pathan Mixed HLA 100 A, B, C, DQB1, DRB1 
Pakistan Mixed Sindhi Mixed HLA 101 A, B, C, DQB1, DRB1 
Sri Lanka Colombo Sinhalese Asian HLA 101 A, B, C, DQB1, DRB1 
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Peptide screening in samples from healed individuals 
- Total PBMC stimulation IFN-γ ELISpot results - 
1st healed donor series (20/09/2017) 
Whole blood samples from 10 healed individuals (Gafsa): TUN1 to 10 
1 blood sample was hemolysed (TUN2) so PBMC were not purified 
HLA-CLASS I peptides: 
- 5 µM each peptide; 
- All solubilized in sterile water (or sodium 
bicarbonate); 
- 14 peptide pools with 7 peptides per pool  
(except I_pool7 and G with 6 peptides); 
- pool ALL_I (49 peptides), I_pool1-7 and  
I_poolA-G. 
HLA-CLASS II peptides:  
- 5 µM each peptide;  
- All solubilized in 10% DMSO + sterile water; 
- 10 peptide pools with 5 peptides per pool (except II_pool5 
and E with 4 peptides);  
- pool ALL_II (24 peptides), II_pool1-5 and II_poolA-E 
Controls: 
PHA 10 µg/mL 
CaniLeish® 10 µg/mL 
TSLA 10 µg/mL 
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 OVERALL RESULTS - CONTROLS 
Non-parametric significance test (Mann-Whitney) 
* p-value < 0.05 
TNTC = spot count 400 
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OVERALL RESULTS - CONTROLS 
Non-parametric significance test (Mann-Whitney) 
* p-value < 0.05 
TNTC = spot count 400 
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OVERALL RESULTS - CONTROLS 
Non-parametric significance test (Mann-Whitney) 
* p-value < 0.05 
TNTC = spot count 400 
 
 
Donor NS TSLA stim CaniLeish® stim 
TUN1 161.5 160,3 287.3 
TUN3 80.2 133* 162.3* 
TUN4 95.3 209* 229.3* 
TUN5 98.8 165,75* 400 (TNTC)* 
TUN6 28.8 192.5 113.5 
TUN7 14.5 42.75 (0.0571) 29.33* 
TUN8 60.2 90.25 213* 
TUN9 39.7 77 102.3* 
TUN10 18.333 400 (TNTC)* 400 (TNTC)* 
 
  
Appendix V.2 
284 
OVERALL RESULTS - Pools ‘ALL’ 
cNS = culture well not stimulated in ELISPOT 
NeverStimulated average in the legend 
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OVERALL RESULTS – HLA-CLASS I Pools 1-7 
cNS = culture well not stimulated in ELISPOT 
NeverStimulated average in the legend 
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OVERALL RESULTS – HLA-CLASS I Pools A-B 
cNS = culture well not stimulated in ELISPOT 
NeverStimulated average in the legend 
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OVERALL RESULTS – HLA-CLASS II Pools 1-5 
cNS = culture well not stimulated in ELISPOT 
NeverStimulated average in the legend 
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OVERALL RESULTS – HLA-CLASS II Pools A-E 
cNS = culture well not stimulated in ELISPOT 
NeverStimulated average in the legend 
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TUN1 
M / Age 33 
1 scar (leg) 
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TUN1 
M / Age 33 
1 scar (leg) 
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TUN3 
M / Age 33 
1 scar (leg) 
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TUN3 
M / Age 33 
1 scar (leg) 
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TUN4 
F / Age 36 
2 scars (nose, wrist) 
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TUN4 
F / Age 36 
2 scars (nose, wrist) 
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TUN5 
M / Age 49 
1 scar (leg) 
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TUN5 
M / Age 49 
1 scar (leg) 
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TUN6 
M / Age 26 
1 scar (leg) 
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TUN6 
M / Age 26 
1 scar (leg) 
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TUN7 
M / Age 51 
5 scars (arm, leg) 
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TUN7 
M / Age 51 
5 scars (arm, leg) 
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TUN8 
M / Age 45 
2 scars (abdomen, foot) 
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TUN8 
M / Age 45 
2 scars (abdomen, foot) 
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TUN9 
M / Age 64 
1 scars (leg) 
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TUN9 
M / Age 64 
1 scars (leg) 
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TUN10 
M / Age 64 
1 scars (leg) 
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TUN10 
M / Age 64 
1 scars (leg) 
 
